20th Euretina Congress
Amsterdam

1–4 October 2020
RAI Amsterdam, The Netherlands

Instructional Course & Symposium
Submission Deadline: December 20 2019

www.euretina.org
<table>
<thead>
<tr>
<th>CONTENTS</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Board &amp; Officers</td>
<td>2</td>
</tr>
<tr>
<td>President's letter</td>
<td>3</td>
</tr>
<tr>
<td>Programme Overview</td>
<td>4</td>
</tr>
<tr>
<td>Surgical Skills Training Course</td>
<td>8</td>
</tr>
<tr>
<td>Scientific Programme – Thursday</td>
<td>11</td>
</tr>
<tr>
<td>Scientific Programme – Friday</td>
<td>35</td>
</tr>
<tr>
<td>Scientific Programme – Saturday</td>
<td>65</td>
</tr>
<tr>
<td>Scientific Programme – Sunday</td>
<td>93</td>
</tr>
<tr>
<td>ePoster Presentations</td>
<td>111</td>
</tr>
<tr>
<td>Video Competition</td>
<td>141</td>
</tr>
<tr>
<td>General Information</td>
<td>148</td>
</tr>
<tr>
<td>Sponsors</td>
<td>150</td>
</tr>
<tr>
<td>Congress Centre Plan</td>
<td>152</td>
</tr>
<tr>
<td>Exhibition Plans</td>
<td>153</td>
</tr>
<tr>
<td>List of Exhibitors &amp; Booth Numbers</td>
<td>154</td>
</tr>
<tr>
<td>Satellite Education Programme</td>
<td>157</td>
</tr>
<tr>
<td>Index</td>
<td>162</td>
</tr>
</tbody>
</table>
**Board Members**

- José García-Arumí (SPAIN)
- Morten la Cour (DENMARK)
- Alistair Laidlaw (UK)
- Edoardo Midena (ITALY)
- Stefan Seregard (SWEDEN)
- Ramin Tadayoni (FRANCE)

**Co-Opted Board Members**

- Pravin Dugel (USA)
- Caroline C.W. Klaver (THE NETHERLANDS)
- Xiaoxin Li (CHINA)
- Yuichiro Ogura (JAPAN)
- Giuseppe Querques (ITALY)

**Programme Committee**

- Sebastian Wolf (SWITZERLAND (CHAIRPERSON))
- Frank G. Holz (GERMANY)
- Morten la Cour (DENMARK)
- Alistair Laidlaw (UK)
- Anat Loewenstein (ISRAEL)
- Ursula Schmidt-Erfurth (AUSTRIA)
- Ramin Tadayoni (FRANCE)
- Jan van Meurs (THE NETHERLANDS)
Dear Colleagues,

It is my pleasure to welcome you, on behalf of the Board of the European Society of Retina Specialists, to the 19th EURETINA Congress in Paris.

The annual congress has experienced tremendous growth in recent years. And with registration numbers reaching over 5,000 delegates, the EURETINA meeting has been firmly established as the largest retina congress in the world.

This year’s programme boasts the highest quality scientific content, with the most esteemed of speakers travelling from across the globe to offer their expert insights. This meeting also hosts the 4th World Retina Day, which reinforces the global appeal and influence of the meeting.

EURETINA has long been committed to education, not just through the meeting itself, but with the establishment of its observership programme, eLearning platform (EURETINA InSight) and online expert interviews (EURETINA Player).

However, this year presented something of a milestone for the society, seeing it invest heavily in the field of Research. The EURETINA Retinal Clinical Research Funding programme launched to members, while a second call opened to fund clinical research to support and develop the medical management of submacular haemorrhage.

The success of the Congress is a culmination of the efforts of each person who has travelled to be here today. I truly hope that, in addition to enjoying the wealth of scientific sessions across the four-day programme, you will allow some time to savour the sights and spirit of Paris, and return home enhanced by the experience.

Yours sincerely,

Sebastian Wolf,
President of EURETINA
PROGRAMME OVERVIEW

Saturday 7 September (World Retina Day)

EURETINA Session 14
7 Deadly Sins in Paediatric Retina Surgery – Yes, No, Maybe

EURETINA Session 15
The EURETINA Guidelines for the Management of Retinal Disease

Symposium
Update in Diabetic Macular Edema

Free Papers 17
AMD & New Drug Treatment & Technology

Course 36
Management of Proliferative Diabetic Retinopathy

Symposium
Retina Surgery in Challenging situations of Ocular Trauma

Course 37
Key Issues for OCT & OCTA Interpretation

Free Papers 18
Vitreoretinal Surgery II

Course 38
Engineering Tools for Ophthalmologists

Course 39
Central Serous Chorioretinopathy: Diagnosis & Treatment

Course 40
Fluorescein, ICG & OCT-Angiography in Macular Diseases

Course 41
New Frontiers & Perspectives in Diabetic Diseases

Course 42
Neovascular AMD: Beyond Anti-VEGF

Free Papers 20
AMD IV

Course 43
Surgical Controversies in Vitrectomy for Retinal Detachment

Course 44
Innovative Technologies & State of the Art on Retinal Imaging

Course 45
Surgical Management for VR Complications

Free Papers 22
Mixed III

Course 46
Uveitis Pearls for the Retina Specialist

Course 47
Diabetic Macular Edema: From Bench to Bedside

Closing Drinks & Abstract Awards
(Foyer Bleu from 14.00)

Sunday 8 September

Amphithéâtre Bleu (Level 2)

Amphithéâtre Havane (Level 3)

Room 252 (Level 2)

Room 342 (Level 2)

Salle Maillot (Level 2)

Room 241 (Level 2)

Room 251 (Level 2)

Room 351 (Level 3)

Speakers’ Corner
Arlequin (Level 3)
SURGICAL SKILLS TRAINING COURSES

Instructors:  I. Krebs AUSTRIA
             K. Krepler AUSTRIA
             U. Stolba AUSTRIA

THURSDAY 5 SEPTEMBER
Room 353 (Level 3)

<table>
<thead>
<tr>
<th>Course No.</th>
<th>Course Name</th>
<th>Course Time</th>
<th>Cost*</th>
</tr>
</thead>
<tbody>
<tr>
<td>01</td>
<td>First Approach to Vitreoretinal Surgery</td>
<td>09.00 – 12.00</td>
<td>€175 (plus VAT)</td>
</tr>
<tr>
<td>02</td>
<td>Combined Surgery with Intraocular Tamponade</td>
<td>13.00 – 16.00</td>
<td>€175 (plus VAT)</td>
</tr>
</tbody>
</table>

FRIDAY 6 SEPTEMBER
Room 353 (Level 3)

<table>
<thead>
<tr>
<th>Course No.</th>
<th>Course Name</th>
<th>Course Time</th>
<th>Cost*</th>
</tr>
</thead>
<tbody>
<tr>
<td>03</td>
<td>Vitrectomy for Complicated Cataract Surgery</td>
<td>09.00 – 12.00</td>
<td>€175 (plus VAT)</td>
</tr>
<tr>
<td>04</td>
<td>Buckle Surgery</td>
<td>12.30 – 15.30</td>
<td>€175 (plus VAT)</td>
</tr>
</tbody>
</table>

Course 01: First Approach to Vitreoretinal Surgery
First steps with 23g techniques explained step by step and practiced on pigs’ eyes.
Participants should have experience in anterior segment microsurgery.

Course 02: Combined Surgery with Intraocular Tamponade
The combined procedure including cataract surgery, IOL implantation,
23g vitrectomy and fluid/gas exchange are demonstrated and practiced on pigs’ eyes.
Participants should have skills in anterior segment surgery or should have participated in Course 1.

Course 03: Vitrectomy for Complicated Cataract Surgery
Surgical repair for dropped lenses or removal of luxated IOLs are explained and practiced on pigs’eyes.
Participants should be skilled in anterior segment surgery or should have participated in Courses 1 or 2.

Course 04: Buckle Surgery
Finding the retinal break and sealing it with radial or oraparallel sponges are explained and practiced on model eyes. No microsurgical experience is required.

*To reserve a place in a Surgical Skills course please go to the Congress registration
THURSDAY, FRIDAY, SATURDAY, SUNDAY

E-POSTER TERMINALS
LOCATION: ARLEQUIN, LEVEL 3

SEE PROGRAMME OVERVIEW FOR SESSION DETAILS
DOWNLOAD THE CONGRESS APP

EURETINA APP

‘euretina 2019’

Any web enabled device

m.euretina.org

Free wi-fi throughout the congress centre

Network Name: EURETINA2019
Password: EYL60:40
THURSDAY 5 SEPTEMBER

08.30 – 18.30

INSTRUCTIONAL COURSE

Posterior Uveitis on the Move: Basics & New Developments

Room 351 (Level 3)

Course Organisers: C.P. Herbort Jr SWITZERLAND
C.E. Pavesio UK

I. Diagnosis, Work-up and Investigational procedures

08.30 C.P. Herbort Jr SWITZERLAND, C.E. Pavesio UK
Introduction

08.35 M. Khairallah TUNISIA
Introduction: Clinical assessment of posterior uveitis

09.00 A. Denniston UK
Investigational work-up of posterior uveitis

09.25 C.P. Herbort Jr SWITZERLAND
Angiography: Stressing the importance of FFA and ICG and why they can’t be replaced by new modalities

10.00 P. Neri ABU DHABI
New imaging modalities including OCTA

10.15 Discussion

10.30 Break

II. Main Entities

IIa. Infectious

10.50 C. Pavesio UK
Toxoplasmosis and other parasites

11.10 A. Abu El Asrar SAUDI ARABIA
Tuberculosis

11.25 N. Jones UK
Viral Retinitis

11.40 M. Westcott UK
Syphilis

11.55 A. Curi BRAZIL
Cat-scratch disease and ocular infections in immunosuppressed patients

IIb1. Non-Infectious

12.10 I. Tugal-Tutkun TURKEY
Behçet’s disease

12.25 C.P. Herbort Jr SWITZERLAND
Choriocapillaritis – MEWDS
APMPPE, multifocal choroiditis

12.50 Cases & Discussion

13.05 Break

IIb2. Non-Infectious

14.00 M. Westcott UK
Seropositive Choroiditis

14.15 I. Tugal Tutkun TURKEY
Stromal choroiditis I: VKH

14.30 A. Abu El Asrar SAUDI ARABIA
Stromal choroiditis II: Sympathetic ophthalmia

14.45 C. Pavesio UK
Stromal choroiditis III: Birdshot retinochoroiditis

15.00 N. Jones UK
Sarcoidosis

15.25 Cases & discussion

16.00 Break

III. Treatment & Complications

16.15 C. Pavesio UK
Local therapies in posterior uveitis

16.35 M. Khairallah TUNISIA
Steroids and immunosuppressives

16.55 A. Denniston UK
Biologics

17.10 – 17.40

Round Table Discussion 1
What is your strategy for the management of uveitic macular edema?

17.40 – 18.10

Round Table Discussion 2
What is the real value of investigations?

18.10 Closing remarks

18.30 End of Course
08.30 – 12.30
INSTRUCTIONAL COURSE
Salle Maillot (Level 2)

Ocular Oncology 1:
Clinical Features & Diagnosis of Intraocular Tumours
Moderators: N. Bechrakis GERMANY
S. Seregard SWEDEN

08.30 N. Bornfeld GERMANY
Small choroidal melanomas and large nevi
08.40 S. Seregard SWEDEN
Unpigmented choroidal tumours
08.50 N. Bechrakis GERMANY
Differential diagnosis of intraocular tumours in opaque media
09.00 H. Heimann UK
Transvitreal biopsy indications. Risk factors and results
09.10 M. Angi ITALY
Tumours and pseudo-tumours of the optic disc
09.20 Discussion

Ocular Oncology 2:
Management of Uveal Melanomas
Moderators: B. Damato UK
L. Zografos SWITZERLAND

09.30 A. Moulin SWITZERLAND
Prognosis and risk factors of uveal melanomas and progress in the management of the metastatic disease
09.40 B. Damato UK
Conservative management of posterior uveal melanomas
09.50 A. Schalenbourg SWITZERLAND
Prevention and treatment of neovascular glaucoma and anterior segment complications following irradiation treatment of uveal melanomas
10.00 A. Joussen GERMANY
Vitreoretinal surgery following irradiation treatment of uveal melanomas (prevention and treatment of toxic tumour syndrome)
10.10 L. Zografos SWITZERLAND
Prevention and treatment of irradiation induced optic neuropathy and maculopathy following conservative management of uveal melanomas
10.20 Discussion

Ocular Oncology 3:
Paediatric Ocular Oncology
Moderators: N. Cassoux FRANCE
F. Munier SWITZERLAND

10.30 N. Cassoux FRANCE
Overview of intraocular tumors in paediatric population
10.40 C. Stathopoulos SWITZERLAND
Multimodal imaging techniques in retinoblastoma and paediatric ocular tumours
10.50 M. Paruleher UK
Retinoblastoma: diagnosis, epidemiology and genetics
11.00 D. Hadjistilianou ITALY
Management of retinoblastoma
11.10 F. Munier SWITZERLAND
Coats’ disease
11.20 Discussion

Ocular Oncology 4:
Vascular Tumours of the Eye
Moderators: V. Cohen UK
L. Desjardins FRANCE

11.30 L. Desjardins FRANCE
Circumscribed choroidal hemangiomas: Diagnosis and management
11.40 J-F. Kiilgaard DENMARK
Diffused choroidal hemangiomas and Sturge-Weber syndrome
11.50 V. Cohen UK
Retinal hemangioblastomas and von Hippel Lindau disease
12.00 M. Sagoo UK
Cavernous haemangiomas and arteriovenous communications (Wyburn-Mason Syndrome)
12.10 R. Aljamal FINLAND
Vasoproliferative pseudo-tumours
12.20 Discussion
12.30 End of course series
**THURSDAY 5 SEPTEMBER**

**08.30 – 10.00**

**INSTRUCTIONAL COURSE 1**

OCT Angiography: How to Understand What We See

Room 252 (Level 2)

Course Organiser: J-F. Korobelnik FRANCE

- 08.30 G. Staurenghi ITALY
  Overview on OCT-A

- 08.42 J. Cunha-Vaz PORTUGAL
  OCT-A in diabetic retinopathy.

- 08.54 N. Eter GERMANY
  OCT-A in AMD

- 09.06 M.B. Rougier FRANCE
  OCT-A and optic disc

- 09.18 J-F. Korobelnik FRANCE
  Quantification in OCT-A: What for?

- 09.30 Discussion

- 10.00 End of course

**08.30 – 10.00**

**INSTRUCTIONAL COURSE 2**

Micropulse Laser Surgery: Advantages & Disadvantages of Micropulse Laser & Other Subthreshold Laser Techniques

Room 342 (Level 3)

Course Organiser: J. Keunen THE NETHERLANDS

- 08.30 J. Keunen THE NETHERLANDS
  Introduction: What’s new in subthreshold laser surgery and what have we learned so far?

- 08.42 V. Chong UK
  Basic principles of micropulse laser and differences to other subthreshold laser techniques

- 08.54 E. Midena ITALY
  New insights of micropulse diode laser in DME

- 09.06 J. Luttrull USA
  Safety of transfoveal subthreshold diode micropulse laser and important new developments on the horizon

- 09.18 J. Keunen THE NETHERLANDS
  The current role of micropulse laser therapy as treatment for chronic central serous chorioretinopathy: Evaluation of the current treatment protocols

- 09.30 J. Keunen THE NETHERLANDS, J. Luttrull USA, E. Midena ITALY, V. Chong UK
  Challenging cases & discussion

- 10.30 End of course
08.30 – 10.00

INSTRUCTIONAL COURSE 3

Macular Dystrophies

Room 352B (Level 3)

Course Organisers: G. Querques ITALY
E. Souied FRANCE

08.30 G. Querques ITALY
Best disease

08.45 C.J. Boon THE NETHERLANDS
Pattern dystrophies

09.00 E. Souied FRANCE
Stargardt disease and FFM

09.15 C.B. Hoyng THE NETHERLANDS
Macular dystrophies mimicking AMD

09.30 B. Leroy BELGIUM
Cone dystrophies

09.45 I. Audo FRANCE
X-linked retinoschisis

10.00 Discussion

10.30 End of course

08.30 – 10.00

FREE PAPER SESSION 1

Imaging I

Amphithéâtre Havane (Level 3)

Chairpersons: C. Dysli SWITZERLAND
Y. Matsui JAPAN

08.30 Y. Matsui, M. Kondo, H. Suimon, A. Ichio,
H. Matsubara, M. Sugimoto, K. Ikesugi JAPAN
Assessment of the effective view angles of
CLRAS 500 and Optos 200Tx ultra widefield
ophthalmoscopes in clinical practice

08.36 R. Hussain MAURITIUS
Diagnostic accuracy of spectral domain optical
coherence tomography in detecting RPE leak in
central serous chorioretinopathy

08.42 R. Abreu Gonzalez, C. Bermudez Perez,
J. Rodriguez Martin, J. Rodrigo Bello,
M. Gil Hernandez SPAIN
Artificial intelligence for the detection of
diabetic retinopathy by means of retinographies
in clinical practice

08.48 R. Dolz Marco, V. Esteve, M. Andreu Fenoll,
R. Gallego Pinazo SPAIN
High magnification images in macular disease

08.54 S. Pignatello, L. Grego, R. Rizzetto, P. Lanzetta ITALY
OCT angiography fundus patterns in a pediatric
population with sickle cell anemia

09.00 S. Abdolrahimzadeh, V. Fencia ITALY
Imaging of choroidal hemangioma and evaluation
of choroidal and outer retinal layer thickness using
spectral domain optical coherence tomography in
Sturge Weber Syndrome

09.06 S. Vujosevic, C. Toma, A. Muraca, E. Torti,
G. Florimbi, S. De Cilla ITALY
Quantitative choriocapillaris evaluation in
intermediate AMD by swept source OCT
angiography

09.12 S. Agarwal Sinha, A. Gonzalez USA
Intravitreal bevacizumab for retinopathy of
prematurity: stratification of low and high risk
fluorescein angiography findings

09.18 T. van Rijssen, L. Hahn, E. van Dijk,
P. Scholz, M. Breukink, E. Souied,
G. Querques THE NETHERLANDS
Change in hyperfluorescent abnormalities on
indocyanine green angiography after half dose
photodynamic therapy or high density subthreshold
micropulse laser in chronic central serous
chorioretinopathy

09.24 V. Kadri, C. Vyas INDIA
2 year experience of using EIDON confocal fundus
imaging on a daily basis

09.30 V. Capuano, R. Sacconi, E. Borelli, A. Miere,
F. Bandello, E. Souied, G. Querques FRANCE
Dimple in the serous pigment epithelial
detachment secondary to neovascular age related
macular degeneration
08.30 – 10.00
FREE PAPER SESSION 2
AMD I
Room 241 (Level 2)

Chairperson: M-S. He, TAIWAN

08.30 M-S. He, F. Chang, H. Lin, J. Wu, T. Hsieh, Y. Lee, TAIWAN
The association between diabetes and age related macular degeneration among the elderly in Taiwan

08.36 A. Abdin, S. Suffo, A. Langenbucher, B. Seitz, GERMANY
Intravitreal ranibizumab versus aflibercept following treat and extend protocol for neovascular age related macular degeneration (2 years follow up)

08.42 A. Balalin, V. Fokin, S. Balalin, S. Tchaikovskaya, RUSSIA
Microperimetry and optical coherence tomography in morphofunctional evaluation of retinal status in patients with wet macular dystrophy

08.48 A. Penwarden, R. Borbara, N. Aggarwal, G. De Salvo, UK
Real life treatment outcomes in patients with polypoidal choroidal vasculopathy: a retrospective cohort study

08.54 A. Clemens, A. Sagkriotis, R. Griner, A. Duras, O. Doyle, T. Wintermantel, U. Chakravarthy, SWITZERLAND
Key confounders for translating results from non interventional trials (NIS) to those observed in randomized controlled trials (RCTs): applying predictive analytics in neovascular age related macular degeneration (nAMD)

09.00 A. Airody, T. Szczerbicki, V. Allgar, L. Downey, H. Baseler, A. Morland, R. Gale, UK
The MATE study: a 24 month, pilot, randomized controlled trial comparing standard care with individualized treat and extend regimen with intravitreal aflibercept for neovascular age related macular degeneration

09.06 C. Tan, S. Lim, L. Tan, L. Ong, Y. Tan, J. Heng, E. Lamoureux, SINGAPORE
The relationship between objectively measured activities of daily living tasks with components of the visual function system in patients with age related macular degeneration: a pilot study

2 year outcomes of intravitreal aflibercept in patients with treatment naïve wet AMD in a swiss routine practice treat and extend regimen: final analysis of the Asteria study

Time to dry analysis of brolucizumab versus aflibercept in patients with neovascular AMD: 96 week data from the HAWK and HARRIER trials
08.30 – 10.00

**CLUB JULES GONIN SYMPOSIUM**

**New Information in Retinal Detachment**

*Amphithéâtre Bordeaux* *(Level 3)*

**Chairpersons:**  B. Aylward *USA*  
T. Wolfensberger *SWITZERLAND*

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Country</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.30</td>
<td>D. Yorston</td>
<td>UK</td>
<td>Retinal detachment</td>
</tr>
<tr>
<td>08.40</td>
<td>A. Kychenthal</td>
<td>CHILE</td>
<td>Paediatric retinal detachment</td>
</tr>
<tr>
<td>08.50</td>
<td>L. Wickham</td>
<td>UK</td>
<td>OCT - redefining round hole pathology</td>
</tr>
<tr>
<td>09.00</td>
<td>S. Wolf</td>
<td>SWITZERLAND</td>
<td>Fluorescence lifetime imaging in retinal detachment</td>
</tr>
<tr>
<td>09.10</td>
<td>T. Wolfensberger</td>
<td>SWITZERLAND</td>
<td>Does the choroid play a role in retinal detachment progression?</td>
</tr>
<tr>
<td>09.20</td>
<td>W. Heriot</td>
<td>AUSTRALIA</td>
<td>Retinal thermofusion in retinal detachment repair</td>
</tr>
<tr>
<td>09.30</td>
<td>Discussion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09.40</td>
<td>End of session</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

09.24  C. Tan, L. Lim, W. Ngo, P. P. C. See, N. Saxena, S. Patil  
*SINGAPORE*  
Predictors of persistent disease activity following loading dose of anti VEGF agents in Asian patients with neovascular age related macular degeneration

09.30  D. Colantuono, A. Miere, V. Capuano, R. Sacconi, E. Borrelli, G. Querques, E. Souied  
*ITALY*  
Quantitative deep capillary plexus analysis in optical coherence tomography angiography: quiescent neovascularization versus intermediate and neovascular AMD

09.36  E. Paroiakis, L. Kontomichos, G. Batsos, S. Fragkopoulou, E. Ktena, A. Chatzirallis, D. Karagiannis  
*GREECE*  
Incidence of subclinical choroidal neovascularization in fellow eyes of unilateral exudative age related macular degeneration using optical coherence tomography angiography

09.42  E. Pilotto, L. Frizziero, E. Longhin, R. Parrozzani, R. Frisina, E. Midena  
*ITALY*  
Geographic atrophy secondary to age related macular degeneration: new insights using a morpho functional approach

09.48  M. Streho, C. Sevin, M. Bovis, V. Caillaux, B. Haouchine, M. Puech  
*FRANCE*  
Effect of intravitreal injections of anti VEGF in nAMD on the peri papillary flow density

10.00  End of session
THURSDAY 5 SEPTEMBER

09.00 – 16.00

INSTRUCTIONAL COURSE

132nd Retinal Detachment Course

Room 251 (Level 2)

09.00  Welcome
   I. Kreissig  GERMANY

1.  Fellow Eye of Retinal Detachment
   Moderators:  I. Kreissig  GERMANY
                F. LaFranco  USA

   1.1  Lattice degeneration and breaks in fellow eye:
        What to do or what not to do?
        S. Mennel  AUSTRIA

2.  Diagnostics: Rhegmatogenous
    Primary Retinal Detachment

   2.1  The 4 rules to find the primary break
        I. Kreissig  GERMANY

   2.2  A detachment without a break: What to try first?
        T. Boeker  GERMANY

3.  Cerclage With Drainage

   3.1  A look at cerclage after 50 years:
        Indications, complications, long-term results
        I. Kreissig  GERMANY

4.  Minimal Segmental Buckling
    with Sponge(S) Without Drainage

   Moderators:  T. Boeker  GERMANY
                S. Mennel  AUSTRIA

   4.1  Indications, optimal tamponaded of break(s),
        video of surgery: complications, long-term
        anatomic and functional results
        F. LaFranco  USA

   4.2  Differential diagnosis of residual fluid
        D. Tognetto  ITALY

11.00  Coffee Break

5.  Gas Operation

   Moderators:  D. Tognetto  ITALY
                J. Schmidt  GERMANY

   5.1  Pneumatic retinopexy for uncomplicated detachments
        J. Schmidt  GERMANY

6.  Primary Vitrectomy

   6.1  Rationale, indications, complications,
        long-term results
        V. Ferrara  ITALY

   6.2  Comparison of 20-, 23-, 25-gauge ppv:
        Indications, complications, results
        J. Schmidt  GERMANY

7.  Minimal Segmental Buckling for
    Complicated Detachments

   7.1  Reoperation: The 4 rules to find the
        undetected break
        I. Kreissig  GERMANY

   7.2  How to minimise the risk of PVR
        A. Sudhalkar  GERMANY

   7.3  PVR-C1/C2 detachments. Try buckling first:
        Long-term anatomic and functional results
        J. Schmidt  GERMANY

12.15  Group Photo
12.30  Break
13.40

8. **AMD**
   **Moderators:** V. Ferrara ITALY, A. Kothari INDIA
   
   8.1 Options for diagnostics: Which and when?  
      A. Kothari INDIA
   
   8.2 Dry macular degeneration: What to do or not to do?  
      T. Boeker GERMANY
   
   8.3 Exudative macular degeneration: Which treatment when to do?  
      F. LaFranco USA
   
   8.4 Discussion of AMD:  
      **Presenter:** T. Boeker GERMANY  
      **Panel:** V. Ferrara ITALY, A. Kothari INDIA, I. Kreissig GERMANY, F. LaFranco USA, S. Mennel AUSTRIA, J. Schmidt GERMANY, A. Sudhalkar GERMANY, D. Tognetto ITALY

9. **Comparison of Present Techniques for Repair of Primary Retinal Detachment**
   
   9.1 Temporary balloon buckle vs. pneumatic retinopexy vs. segmental buckling vs. primary vitrectomy  
      T. Boeker GERMANY

10. **Various**
    
    10.1 Misdiagnosis of retinoschisis  
        V. Ferrara ITALY
    
    10.2 Ambulatory double patching  
        S. Mennel AUSTRIA

11. **Presentations with Quiz**
    **Moderator:** I. Kreissig GERMANY  
    Presentation of Videos of Minimal Segmental Buckling without Drainage:  
    T. Boeker GERMANY, V. Ferrara ITALY, A. Kothari INDIA, F. LaFranco USA, S. Mennel AUSTRIA, D. Tognetto ITALY
    Presentation of Detachment Cases:  
    S. Mennel AUSTRIA
    **Panel:** T. Boeker GERMANY, V. Ferrara ITALY, A. Kothari INDIA, F. LaFranco USA, S. Mennel AUSTRIA, J. Schmidt GERMANY, A. Sudhalkar GERMANY, D. Tognetto ITALY

12. **Distribution of Diplomas**
    16.00 End of course
THURSDAY 5 SEPTEMBER

09.00 – 10.30
EURETINA SESSION 1
Vitreoretinal Surgery
Grand Amphithéâtre (Level 0 & 2)
Chairpersons:  
A. Laidlaw UK
J. García-Arumí SPAIN

09.00  
J.P. Hubschman USA
Lamellar holes: Degenerative versus tractional, pre retinal proliferation, non myopic tractional maculoschisis

09.10  
M. Veckeneer BELGIUM
VMT: pneumatic release vs vitrectomy. Natural history and need for treatment

09.20  
J. García-Arumí SPAIN
Highly myopic maculoschisis and macular holes: natural history, indication for surgery, internal versus external procedures, expected outcome

09.30  
S. Priglinger GERMANY
Macular holes: why do they happen? Tangential traction versus bistable structures, why do they get bigger with time?

09.40  
D. Yorston UK
Macular holes (non highly myopic) Predicting success: visual and anatomical outcome: Which holes are high risk for failure. In which holes should we consider additional procedures

09.50  
S. Rizzo ITALY
Macular hole surgery with adjuncts: review of options and outcomes: Platelets, flaps and amniotic membrane patches

10.00  
D. Steel UK
Retinal patches in macular holes: an inert puncture repair patch or a functioning retinal transplant

10.10  
Panel discussion on macular hole surgery

10.30  
End of session

09.00 – 10.30
EURETINA SESSION 2
Retinal Gene Therapy: Present & Future
Amphithéâtre Bleu (Level 2)
Chairpersons:  
B. Leroy BELGIUM
D. Fischer GERMANY

09.00  
R. MacLaren UK
Gene therapy of CHM and XLRP

09.10  
B. Leroy BELGIUM
Gene therapy of LCA

09.20  
J. Sahel FRANCE
Optogenetics for vision restoration: Foundations of the first clinical trial in rod-cone dystrophies

09.30  
N. Bressler USA
Gene therapy of AMD

09.40  
D. Fischer GERMANY
Gene therapy of ACHM and RP

09.50  
P. Sieving USA
Gene therapy of XLRS

10.00  
G. le Meur FRANCE
Gene therapy of PDE6B-RP

10.10  
Discussion

10.30  
End of session
10.30 – 12.00

SPEAKERS’ CORNER 1

Vascular Diseases & Diabetic Retinopathy

Taking place within the EURETINA Speakers’ Corner (Arlequin, Level 3), the following posters will be presented for 3 minutes each with 2 minutes for discussion and interaction with the audience.

Moderator: S. Zweifel SWITZERLAND

10.30 S. Oruc Dundar, H. Çakmak TURKEY
Analysis of retinal layer thickness and choroidal thickness in diabetic macular oedema treated with ranibizumab or aflibercept

10.35 S. Yu, M. Zinkernagel, S. Wolf, A. Ebner SWITZERLAND
Anterograde optic neuropathy and associated retrograde degeneration after branch retinal vein occlusion

10.40 C. Mitsch, A. Sadeghipour, M. Arikan, M. Fabianska, A. Gleiß, U. Schmidt Erfurth AUSTRIA
Automated detection and quantification of spectral domain optical coherence tomography hyper-reflective foci in eyes with retinal vein occlusion

10.45 D. Hwang, K. Chen, S. Chiou TAIWAN
Changes in systemic oxidative stress in response to intravitreal anti-vegf therapy for patients with retinal vein occlusions

10.50 O. Galvin IRELAND
Educational tool kit for diabetic eye disease

10.55 K. Liston, M. James IRELAND
Evaluating the impact of a new national diabetic retinopathy screening programme on patient knowledge of HbA1c following referral to a regional treatment centre

11.00 M. Kim, S. Woo, K. Park SOUTH KOREA
Increased risk of cancer in patients with retinal vein occlusion: a 12-year nationwide cohort study

11.05 J. Kwon SOUTH KOREA
Intravitreal bevacizumab responsiveness after dexamethasone implants in diabetic macular edema patients previously refractory to intravitreal bevacizumab

Long term effects of pan-retinal photocoagulation in diabetic retinopathy in choroid, retina and in visual field

11.15 A. Amini, A. Nabavi IRAN
Randomized clinical trial of intravitreal Bevacizumab versus intravitreal Bevacizumab combined with Losartan in the treatment of diabetic macular edema

11.20 M. Fenech, D. Seneviratne UK
Real-time data on the clinical outcomes of fluocinolone acetonide (Iluvien) implant use in chronic diabetic macular edema in pseudophakic patients

11.25 D. Wong HONG KONG
Safety and efficacy of combined phacoemulsification and intravitreal triamcinolone injections for diabetic macula edema in high myopes

11.35 A. Willerslev, M. Larsen, I. Munch DENMARK
Spectral-domain optical coherence tomography reveals subtle vascular changes in patients with Waldenström’s macroglobulinemia

11.40 M. Hayashida, H. Imai, S. Honda, M. Nakamura JAPAN
The comparison of reduced fluence photodynamic therapy with modified or conventional irradiation area for central serous chorioretinopathy

11.45 C. Bailey, A. Lotery, G. Menon, J. Talks UK
The impact of prior therapies on visual acuity outcomes achieved with the 0.19 mg fluocinolone acetonide implant – Insights from the UK Medisoft audit study

11.50 S. Bini, T. Torresin E. Pilotto E. Midena ITALY
The quantification of retinal inflammatory biomarkers after treatment of naïve diabetic macular edema

12.00 End of session
THURSDAY 5 SEPTEMBER

11.00 – 12.30

EURETINA SESSION 3

Novelties & Late Breaking Developments in Retina & Technology

Grand Amphithéâtre (Level 0 & 2)

Chairpersons:  
J. García-Arumí SPAIN  
P. Dugel USA  
R. Tadayoni FRANCE

11.00  
E. Midena ITALY  
Quantifying visual function beyond acuity

11.09  
A. Tufail UK  
Big data for retina: perspectives and cautions

11.18  
G. Staurenghi ITALY  
Where do we go with OCTA?

11.27  
K. Rezaei USA  
New gene therapy options for inherited retinal diseases

11.36  
J. García-Arumí SPAIN  
New surgical trends and techniques: From A to Z

Late Breaking Presentations

11.45  
R. Schlingemann THE NETHERLANDS  
Comparing the efficacy of bevacizumab to ranibizumab in patients with a retinal vein occlusion. The BRVO study

11.52  
R. Tadayoni FRANCE  
A Phase 2 Study to evaluate THR-317 in combination with ranibizumab for the treatment of diabetic macular edema

11.59  
P. Dugel USA  
Novel anti-VEGF antibody biopolymer conjugate KSI-301 with potential for extended durability in retinal vascular diseases: First-time results from a Phase 1b study in patients with wAMD, DME and RVO

12.06  
P. Dugel USA  
RGX-314 gene therapy: Interim results of an ongoing Phase I/IIa study to evaluate the safety and tolerability in subjects with neovascular age-related macular degeneration

12.13  
A. Loewenstein ISRAEL  
Real time display of preoperative data during surgery using the head wearable device for ocular surgery

12.20  
S.F. Wolf SWITZERLAND  
Apps to support patients with visual impairment

12.27  
Discussion

12.30  
End of session

11.00 – 12.30

EURETINA SESSION 4

Uveitis/Endophthalmitis Session

Amphithéâtre Bleu (Level 2)

Chairpersons:  
C. Chiquet FRANCE  
J. van Meurs THE NETHERLANDS

11.00  
J. van Meurs THE NETHERLANDS  
Treatment with injections only works well in most: Towards earlier injections

11.15  
A. Chang AUSTRALIA  
Vitrectomy in endophthalmitis

11.30  
C. Chiquet FRANCE  
A series of clinical studies of FRIENDS in France

11.45  
M. Callegan USA  
Endophthalmitis: Novel adjuvant therapeutics and future directions

12.00  
R. Jansen THE NETHERLANDS  
Newer versus older diagnostic techniques in bacterial endophthalmitis

12.15  
Discussion

12.30  
End of session
11.00 – 12.30
SYMPOSIUM
Expected & Unexpected Adverse Effects of the Medical Devices used in Intraocular Surgery
Amphithéâtre Bordeaux (Level 3)
Chairperson: J.C. Pastor SPAIN
11.00 J.C. Pastor SPAIN
Overview of the problem
11.12 R. Coco Martin SPAIN
Chronic and acute toxicity related to perfluorocarbon liquids
11.24 M. Romano ITALY
Toxicity and expected complications of the silicone oil and heavy silicone oil use
11.36 K. Januschowski GERMANY
Toxic effects of stains for ILM: Possible causes and recommended protocols
11.48 M. Spitzer GERMANY
Side effects related to the use of intraocular gases. Recommended protocols
12.00 C. Ruiz-Villar SPAIN
How the network of European agencies works with medical devices alerts
12.12 Discussion
12.30 End of symposium

11.00 – 12.30
FREE PAPER SESSION 3
Mixed I
Amphithéâtre Havane (Level 3)
Chairpersons: D. Steel UK
P. Sen UK
11.00 P. Sen, J. Ramu, S. Sivaprasad, P. Hykin,
U. Chakravarthy, T. Peto UK
Development and validation of grading technique to measure change in retinal non perfusion over time using a step level change
11.06 L. Ramirez Paez, A. Rickmann, P. Szurman,
S. Jung, K. Boden, K. Januschowski GERMANY
SD-OCT based classification of acute submacular hemorrhages due to age related macular degeneration – a retrospective study
11.12 L. Bisorca Gassendorf, K. Boden, P. Szurman,
N. Perez Guerra, S. Becker, S. Jung,
K. Januschowski GERMANY
Tackling postoperative endophthalmitis with an early vitrectomy and intravitreal antibiotics a retrospective study
11.18 M. Forslund Jacobsen, L. Konge, M. Alberti,
M. la Cour, Y. Park, A. Thomsen DENMARK
Robot assisted vitreoretinal surgery improves surgical accuracy compared to manual surgery. A randomized trial
11.24 M. Habib, S. Holden, C. Currie UK
Variation in retinal thickness before and after treatment with the fluocinolone intravitreal implant in people with diabetic macular oedema
11.30 M. Dogramaci, A. Ivanov UK
A novel method to study qualities and parameters of intra ocular forceps
11.36 M. Stopa, A. Gotz Węckowska, J. Mazela,
P. Rakowicz, M. Dalz, M. Pawlak POLAND
One year anatomical and functional outcomes of 27G transconjunctival vitrectomy for advanced retinopathy of prematurity in Poland
11.42 M. Mazzola, R. Smith, R. Rosen ITALY
Choroidal cavern in a 8 year old child with unilateral macular atrophy
11.48 M. Mura, D. Abulon, K. Williams ITALY
Comparison of 3D digitally assisted visualization system with current standard visualization for the removal of vitreous in a preclinical model
11.54 M. Pastore, G. Cirigliano, M. Riccardo,
C. De Giacinto, O. Vattovani, D. Tognetto ITALY
Peripapillary RNFL and retinal layers thicknesses changes after vitrectomy for idiopathic epiretinal membrane
12.00 M. Prieto del Cura, M. Crespo Carballes,
M. Acebes Garcia, J. Garcia Hinojosa SPAIN
Effectiveness of superior inverted internal limiting membrane (ILM) flap in macular hole surgery: Anatomical and functional outcomes
THURSDAY 5 SEPTEMBER

11.00 – 12.30

INSTRUCTIONAL COURSE 4

Geographic Atrophy Secondary in AMD: Key issues on Diagnosis, Classification & Management

Room 252 (Level 2)

Course Organisers: F.G. Holz GERMANY
S. Schmitz-Valckenberg GERMANY

11.00 S. Schmitz-Valckenberg GERMANY
Terminology and imaging

11.15 G. Staurenghi ITALY
CAM report: Towards a severity scale for dry AMD

11.30 F.G. Holz GERMANY
Natural history and biomarkers for geographic atrophy progression

11.45 A. Tufail UK
Current and future clinical management of geographic atrophy patients

12.00 C. Hoyng THE NETHERLANDS
Differential diagnosis of geographic atrophy - Pearls and pitfalls

12.15 Discussion

12.30 End of course
11.00 – 12.30
FREE PAPER SESSION 4
Vitreoretinal Surgery I
Room 241 (Level 2)

Chairpersons: D. Fischer GERMANY
A. Takeyama JAPAN

11.00 A. Takeyama, Y. Imamura, M. Shibata, Y. Komiya, M. Ishida JAPAN
Comparison of idiopathic epiretinal membrane surgery with and without internal limiting membrane staining with Brilliant Blue G

11.06 A. Mavi, S. Yilmaz, R. Avci TURKEY
Evaluation of inner retinal dimples and flap configuration with en face optical coherence tomography angiography after temporal inverted internal limiting membrane flap technique

11.12 C. La Spina, C. Del Turco, G. D’Amico Ricci, D. Giobbio, C. Panico ITALY
Heads up 3d vision system reduces acute phototoxic related autofluorescence changes after macular surgery

11.18 C. Leisser, E. Paschalis, S. Rokidi, M. Ruiss, W. Burgmuller, O. Findl AUSTRIA
Results of fourier transformed infrared spectroscopy of epiretinal membranes after membrane peeling

11.24 T. Baba, M. Kakisu, T. Nizawa, T. Oshitari, S. Yamamoto JAPAN
Regional densities of retinal capillaries and retinal sensitivities after macular hole surgery with internal limiting membrane peeling

11.30 E. Peiretti, G. Giannaccare, M. Pellegrini, M. Braghiroli, C. Lovino ITALY
Dexamethasone implant for the treatment of advanced stages epiretinal membrane

11.36 F. Contieri, F. Contieri Lambiase, A. Sanz Zorrilla, J. Barreiro Lucas, A. Exposito Ordonez, J. Gallardo Galera, E. Ibarra de la Rosa SPAIN
Scleral buckling procedure in the era of pars plana vitrectomy for rhegmatogenous retinal detachment repair

11.42 G. Vartsakis SWEDEN
Residual subretinal fluid following retinal detachment surgery – A literature review

11.48 G. Gonzalez Saldivar, D. Chow MEXICO
Ectopic inner foveal layers classification scheme predicts visual outcomes after epiretinal membrane surgery

11.54 J. Kaluzny, P. Zabel, M. Kaluzna, A. Caillaux POLAND
En face OCT imaging of internal limiting membrane after inverted flap pars plana vitrectomy for full thickness macular hole

12.00 J. Kapetanovic, K. Xue, T. Edwards, T. Meenink, G. Naus, M. de Smet, R. MacLaren UK
First in human clinical trial of robot assisted subretinal drug delivery under local anaesthesia

12.06 J. Zhong, J. Li CHINA
Outcomes and complications of 27 gauge microincision vitrectomy for rhegmatogenous retinal detachment in 43 consecutive cases

12.12 J. Klein, N. Bleidiesl, J. Klaas, N. Feucht, A. Nasseri, C. Lohmann, M. Maier GERMANY
iSD OCT based surgery – long term follow up of conventional membrane peeling compared to inverted flap membrane peeling in patients with full thickness macular hole

12.18 K. Kim, J. Kim SOUTH KOREA
Comparing clinical outcomes of early vitrectomy versus delayed vitrectomy for spontaneous, fundus obscuring vitreous hemorrhage

12.30 End of session
THURSDAY 5 SEPTEMBER

11.00 – 12.30
INSTRUCTIONAL COURSE 6
Pneumatic Retinopexy: Practical Tips, Evidence Base & Role in Contemporary Retinal Detachment Repair
Room 352B (Level 3)
Course Organiser: R. Hillier UK

11.00  R. Hillier UK
Review of the pneumatic retinopexy versus vitrectomy for the management of primary rhegmatogenous retinal detachment outcomes randomized trial (PIVOT) results

11.03  P. Kertes CANADA
Review of the pneumatic retinopexy trial results Practical pearls and pitfalls of pneumatic retinopexy technique

11.06  R. Hillier UK
Principles of intraocular gas

11.09  R. Muni CANADA
Case selection

11.13  E. Mavrikakis GREECE
Surgical technique

11.18  P. Kertes CANADA
Management of complications

11.22  P. Kertes CANADA
Extended indications, the ‘double-bubble’ technique, pneumatic retinopexy for paediatric retinal detachment

11.27  P. Sullivan UK
Pneumatic retinopexy as a ‘rescue’ procedure

11.34  H. Heimann USA
Combining pneumatic retinopexy with scleral buckle

11.41  R. Muni CANADA
Redefining ‘success’ following retinal detachment surgery

Debate: ‘The Best Intervention for Routine Retinal Detachment Repair is…’
Moderator: E. Mavrikakis GREECE

11.48  R. Hillier UK vs J. Kitchens USA
Pneumatic retinopexy vs scleral buckle

11.58  R. Muni CANADA vs P. Sullivan UK
Pneumatic retinopexy vs vitrectomy

12.08  Discussion
12.30  End of course

11.00 – 12.30
INSTRUCTIONAL COURSE 5
Deep Learning Made Simple for Retinal Diseases
Room 342 (Level 3)
Course Organisers: L. Peng USA  D. Ting SINGAPORE

11.00  L. Peng USA
The concept of deep learning

11.12  D. Sim UK
The role of AI in a tele-medicine setting

11.24  T. Wong SINGAPORE
The clinical consideration in applying AI for fundus images

11.36  D. Ting SINGAPORE
The technical consideration in applying AI for fundus images

11.48  P. Keane UK
The clinical consideration in applying AI for OCT images

12.00  J. Ledsam UK
The technical consideration in applying AI for OCT images

12.12  Discussion
12.30  End of course
13.15 – 14.45

THURSDAY 5 SEPTEMBER

INTERACTIVE

SPEAKERS’ CORNER 2

Imaging

Taking place within the EURETINA Speakers’ Corner (Arlequin, Level 3), the following posters will be presented for 3 minutes each with 2 minutes for discussion and interaction with the audience.

Moderator: S. Sadda USA

13.15 C. Tsen TAIWAN
Imaging analysis with optical coherence tomography angiography after primary repair of macula-off rhegmatogenous retinal detachment

13.20 D. Lee TAIWAN
Analysis of macular region in patients with branch retinal vein occlusion using AngioPlex optical coherence tomography angiography

13.25 R. Abreu González, J. Rodrigo Bello, M. Gil Hernández, C. Bermúdez Perez SPAIN
Artificial intelligence, by means of retinographies, for the characterization of the patient.

13.30 M. Fernández Rodríguez, P. Almuiña, J. Novo, M. Gil, M. Rodríguez, G. Samagaio SPAIN
Automatic system for the characterization of diabetic macular edema using optical coherence tomography images

Choroidal thickness estimation based on color fundus photography by means of deep neural network and adaptive binarization image processing in normal eyes and eyes showing central serous chorioretinopathy

13.40 I. Trifanenkova, E. Erokhina RUSSIA
Comprehensive assessment of the fundus vessels by fluorescent angiography and OCT-angiography for active retinopathy of prematurity

13.45 M. Ranjbar, F. Siegfried, M. Rothe, J. Sochurek, J. Freitag, S. Grisanti GERMANY
Evaluating diurnal changes in choroidal sublayer perfusion using optical coherence tomography angiography

Inner macular displacement toward optic disc in eyes after vitrectomy with internal limiting membrane peeling for epiretinal membrane

13.55 A. Maalej, S. Rahma, B. Sakr, R. Riadh TUNISIA
Macula thickness, retinal nerve fiber layer, and ganglion cell-inner plexiform layer in the macular hole

14.00 S. Kabanarou, T. Xirou, Z. Kapsala, E. Dimitriou, P. Theodossiadis, I. Chatziralli GREECE
Multimodal imaging for the assessment of geographic atrophy in patients with ‘foveal’ and ‘no foveal’ sparing

14.05 J. Iturria Soler, I. Hernández de los Reyes, M. García Zamora, J. Ruiz Medrano, J. Ruiz Moreno, M. Sánchez Saez Dehesa SPAIN
OCTA chorioretinal findings of early changes in diabetics patients without diabetic retinopathy

14.10 R. Rasheed UK
OCTA to assess the impact of treatment on choroidal neovascularisation characteristics over time: conclusions and recommendations on image acquisition

Outer retinal involvement in N-methyl-D-aspartate-induced excitatory retinal toxicity model in rabbits assessed by spectral domain optical coherence tomography

14.20 A. Lee, H. Ra, E. Kim, N. Kang, J. Baek South KOREA
Serial follow-up of commotio retinae using ultra-wide field imaging

14.25 H. Sawamura, A. Mitsutake, Y. Nagashima, T. Toda JAPAN
Spectral domain optical coherence tomography and full-field electroretinogram findings in neuronal intranuclear inclusion disease

14.30 E. Aydin, S. Gurakar Ozcift TURKEY
The effect of the smoking on choroidal thickness, central macular vascular and optic disc perfusion

14.35 M. Iglicki, C. Busch, A. Barak, M. Goldstein, J. Nawrocki, A. Loewenstein ARGENTINA
Underdiagnosed optic disk pit maculopathy—Spectral domain optical coherence tomography features for accurate diagnosis

14.45 End of session
THURSDAY 5 SEPTEMBER

14.30 – 16.00
EURETINA SESSION 5
Al in Retina
Grand Amphithéâtre (Level 0 & 2)

Chairpersons: S. Wolf SWITZERLAND
U. Schmidt-Erfurth AUSTRIA

14.30 M. Abramoff USA
Al-based diabetic retinopathy screening in the real world

14.45 U. Schmidt-Erfurth AUSTRIA
Al and OCT imaging: Modern times are here to stay

15.00 P. Keane UK
Is the algorithm superior to the clinician?

15.15 R. Sznitman SWITZERLAND
Machine learning with in-built annotations for clinical support

15.30 R. Tadayoni FRANCE
State-of-the-art OCT-A and its algorithms

15.45 TBC
The ethical and legal issue in digital medicine

16.00 End of session

14.30 – 16.00
INSTRUCTIONAL COURSE 7
Forlini Trauma School
Amphithéâtre Bleu (Level 2)

Course Organisers: M. Forlini ITALY
F. Kuhn USA
A. Nikolakopolous GREECE
V. Reppucci USA

14.30 W. Schrader GERMANY
Decisions in severe ocular trauma: When to reconstruct, give up reconstruction or refer

14.42 P. Sullivan UK
Microsurgical techniques for corneal injuries

14.54 F. Kuhn USA
Vitrectomy in open globe injuries: Do it before it’s too late!

15.06 M. Mura SAUDI ARABIA
Management of post-traumatic complications

15.18 K. Sabti UAE
The use of endoscopy in severe posterior segment trauma

15.30 F. Fayyad JORDAN
Severe trauma in children

15.42 M. Forlini ITALY
Traumatic cataract and iris management.

15.54 A. Nikolakopolous GREECE
Blunt trauma and the lens

16.06 N. Sundaram INDIA
Management of complex pellet ocular trauma

16.18 Discussion

16.30 End of course
14.30 – 16.00

SYMPOSIUM

Vitreoretinal Surgeons' Nightmares!

Amphithéâtre Bordeaux (Level 3)

Chairperson: B. Chanana INDIA

14.30 L. Hattenbach INDIA
Sub-macular haemorrhage during vitrectomy for retinal detachment

14.42 H. Heimann UK
My infusion cannula is not in position: Subretinal or suprachoroidal displacement of infusion cannula

14.54 S-J. Chen TAIWAN
Slippage of giant retinal tear flap: What to do next?

15.06 B. Chanana INDIA
Uncontrolled bleeding during diabetic vitrectomy

15.18 G. Tan SINGAPORE
Intra-operative suprachoroidal haemorrhage: Is there any hope left?

15.30 V. Agrawal INDIA
Globe collapse during vitrectomy: Causes, sequela and management

15.42 Discussion

16.00 End of symposium

14.30 – 16.00

INSTRUCTIONAL COURSE 8

How Can We Improve Functional Outcomes After Vitreoretinal Surgery?

Room 252 (Level 2)

Course Organiser: D. Yorston UK

14.30 N. Strang UK
Beyond visual acuity: Metamorphopsia and aniseikonia and their effect on vision-related quality of life

14.45 P. Tranos GREECE
Vision-related quality of life and vitreoretinal surgery

15.00 D. Charteris UK
Improving functional outcomes in retinal detachment surgery

15.15 D. Yorston UK
Improving functional outcomes in macular surgery

15.30 D. Steel UK
Improving functional outcomes in vitrectomy for diabetic retinopathy

15.45 Discussion

16.00 End of course
THURSDAY 5 SEPTEMBER

14.30 – 16.00
FREE PAPER SESSION 5
Vascular Diseases & Diabetic Retinopathy I
Amphithéâtre Havane (Level 3)
Chairperson: S. Priglinger GERMANY

14.30 J. Do, J. Shin, D. Park SOUTH KOREA
Assessment of hyperreflective foci following bevacizumab or dexamethasone according to duration of macular edema in branch retinal vein occlusion

14.36 J. Garweg, S. Sivaprasad, J. Štefanickova, C. Hoyng, A. Achcar, T. Schmelter, S. Leal SWITZERLAND
A phase 3b, randomized study to compare three dosing regimens of intravitreal aflibercept for diabetic macular edema beyond the first year of treatment: primary outcomes of the violet study

14.42 K. Spooner, A. Fraser Bell, D. Hong, A. Alves AUSTRALIA
Aflibercept in macular oedema secondary to retinal vein occlusion refractory to previous bevacizumab or ranibizumab: 24 week outcomes

14.48 P. Scanlon, I. Stratton, V. Kumar, S. Natha, S. Harsum, S. Kashani, J. Talks UK
Aflibercept in the real world – are the visual outcomes worse in patients with diabetic macula oedema who have had a cataract operation?

14.54 A. Seres, J. Sahni, S. Scheidl, S. Sadikho, M. Pauly Evers, P. Szczesny, R. Weikert HUNGARY
Anatomical and durability outcomes from the BOULEVARD phase 2 trial of faricimab for DME

15.00 P. Corazza, H. Orlans, T. Soomro, J. Kabbani, S. Younis ITALY
Anti VEGF in retinal vein occlusions: real data for long term outcomes

15.06 A. Augustin GERMANY
Area under the curve analysis of visual acuity following treatment with the 0.19 mg fluocinolone acetonide implant: Results from the Retro IDEAL study

15.12 Z. Haskova, F. Arcadu, A. Maunz, J. Willis, F. Benmansour, M. Prunotto USA
Artificial intelligence algorithm that predicts diabetic retinopathy (DR) response to anti VEGF treatment in patients via deep learning (DL)

15.18 S. Sadda, J. Lim, B. Blodi, B. Bode, E. Ipp, C. Regillo USA
Artificial intelligence screening system for diabetic retinopathy: results from a pivotal multi center prospective clinical trial

15.24 C. Busch, M. Iglicki, S. Fraser Bell, D. Zur, M. Lupidi, A. Loewenstein, M. Rehak GERMANY
Baseline predictors for visual outcome in diabetic macular edema with good baseline visual acuity – obtain study

15.30 S. Kabra, A. Kabra INDIA
Clinical and OCT angiography features of post dengue fever retinal vasculopathy

15.36 J. Kim, D. Kim, J. Chae SOUTH KOREA
Clinical outcome of diabetic macular edema patients who lost to follow up for more than 1 year after Anti VEGF injections

15.42 S. Ah Moye, S. Ah Moye, M. Niedzwiecki, P. Zalmay, V. Nguyen, D. Barthelmes, H. Mehta UK
Comparing real world outcomes of intravitreal anti VEGF therapy for macular oedema secondary to central retinal vein occlusion between a Swiss and UK teaching hospital

15.48 I. Pearce, I. Keyzor, N. Kirby, C. Miglio, C. Gray, J. Campbell UK
Real world outcomes with dexamethasone intravitreal implant in the management of retinal vein occlusion in the UK

16.00 End of session
14.30 – 16.00

INSTRUCTIONAL COURSE 9
Understanding Retinal Imaging: A Guide to Clinical Interpretation of OCT, OCTA & Autofluorescence
Room 342 (Level 3)

Course Organiser: A. Pollreisz AUSTRIA

14.30 A. Pollreisz AUSTRIA
Introduction

14.40 T. Ach GERMANY
Anatomy meets clinical imaging - Solving the mysteries behind OCT and autofluorescence signals in health and disease

14.55 A. Pollreisz AUSTRIA
OCT-Angiography – Tips and pearls for quick and accurate image interpretation

15.20 S. Sivaprasad UK
Differential diagnosis of retinal diseases by clinical imaging

15.45 Discussion

16.00 End of course

14.30 – 16.00

INSTRUCTIONAL COURSE 10
Polypoidal Choroidal Vasculopathy: Diagnosis & Treatment
Salle Maillot (Level 2)

Course Organisers: A. Koh SINGAPORE
R. Silva PORTUGAL

14.30 R. Silva PORTUGAL
Introduction

14.35 A. Carneiro PORTUGAL
PVC - An overview

14.45 G. Staurenghi ITALY
PVC - The diagnosis; A multimodal evaluation: FA, OCT, AF, NIA, ICG, OCTA

14.55 M. Falcão PORTUGAL
PVC - The differential diagnosis of PCV: CSC, nAMD, others

15.05 S. Sadda USA
PCV Treatment - Clinical evidence for anti-VEGF monotherapy

15.20 A. Koh SINGAPORE
PCV Treatment - Clinical evidence for combination therapy

15.35 R. Silva SINGAPORE
PCV treatment in a Caucasian population - Results from the ATLANTIC study

15.55 Discussion

16.00 End of course
THURSDAY 5 SEPTEMBER

14.30 – 16.00
FREE PAPER SESSION 6
Imaging & Retinal Dystrophies
Room 241 (Level 2)

Chairpersons: C. Dysli SWITZERLAND
D. Jaggi SWITZERLAND

14.30 D. Jaggi, Y. Solberg, C. Dysli, S. Wolf, M. Zinkernagel SWITZERLAND
Fluorescence lifetime imaging ophthalmoscopy and the influence of oral lutein supplementation on macular pigment: a preliminary study report

The disease course of rhodopsin (RHO) associated retinitis pigmentosa (RP): a follow up study

Optogenetic restoration of vision using breaches

14.48 A. Goyal, A. Giridhar INDIA
Smartphone guided wide field imaging for retinopathy of prematurity in neonatal intensive care unit in a developing country

14.54 N. Sinim Kahraman, A. Oner, B. Gonen, D. Gulmez Sevim, M. Unlu TURKEY
Mesenchymal stem cell implantation in advanced stage retinitis pigmentosa: 6 month results of a phase 2 study

15.00 A. Dias Dos Santos, J. Tavares Ferreira, J. Cunha, M. Alves, A. Papoila, M. Moraes Fontes, R. Proenca PORTUGAL
Choroidal thickness in systemic lupus erythematosus

15.06 C. Dysli, R. Fink, S. Wolf, M. Zinkernagel SWITZERLAND
Influence of lens opacities on fluorescence lifetimes of the retina

15.12 Y. Koyanagi, M. Akiyama, K. Nishiguchi, Y. Momozawa, Y. Kamatani, S. Takata, C. Inai JAPAN
Targeted resequencing of 83 causative genes in 1,204 Japanese patients with retinitis pigmentosa

15.18 Y. Otsuka, A. Oishi, M. Miyata, M. Oishi, T. Hasegawa, S. Numa, A. Tsujikawa JAPAN
Investigating the origin of photophobia in inherited retinal dystrophy

15.24 M. Michl, M. Fabianska, A. Sadeghipour, S. Waldstein, B. Gerendas, U. Schmidt Erfurth AUSTRIA
Automated detection of macular fluid and its space and time related change under anti VEGF therapy

High resolution in vivo retinal imaging with wavefront correctionless full field OCT

15.36 A. Shinojima, E. Bousquet, C. Lavia, A. Gaudric, R. Tadayoni FRANCE
The course of ultra late phase hypofluorescent foci on indocyanine green angiography in patients with central serous chorioretinopathy before and after photodynamic therapy

15.42 A. Papayannis, E. Tsamis, F. Stringa, K. Chwieyczak, S. Vita, M. Battaglia Parodi, P. Stanga ITALY
Swept source optical coherence tomography angiography vitreo retinal segmentation in proliferative diabetic retinopathy

15.48 T. Ong, B. Lam, R. Maclaren USA
Microperimetry as an endpoint in inherited retinal diseases

16.00 End of session
THURSDAY 5 SEPTEMBER

14.30 – 16.00
INSTRUCTIONAL COURSE 11
Concepts in Vitreoretinal Surgery
Room 352B (Level 3)
Course Organisers: A. Grosso ITALY
E. Sigler USA

10.30 A. Grosso ITALY
Introduction

10.40 K. Laud USA
Surgical management of rhegmatogenous retinal detachment

10.50 J. Randolph USA
Traction retinal detachment

11.00 J. Calzada PANAMA
Recurent retinal detachment and proliferate vitreoretinopathy

11.10 V. Ferrara ITALY
Surgical approach to the vitreous base

11.20 M. Romano ITALY
Endoresection of uveal melanoma

11.30 G. Scarpa ITALY
Functional study of retinal detachment repair with multimodal imaging and angio OCT

11.40 E. Sigler USA
Surgical management of exudative macular degeneration

11.50 Discussion

12.00 End of course

15.00 – 16.30
INTERACTIVE
SPEAKERS’ CORNER 3
Mixed I
Taking place within the EURETINA Speakers’ Corner
(Arlequin, Level 3), the following posters will be presented
for 3 minutes each with 2 minutes for discussion and
interaction with the audience.
Moderator: R. Muni CANADA

15.00 C. Georgakopoulos, F. Tsapardoni, K. Kagkelaris,
P. Plotas GREECE
Coats disease under monotherapy with aflibercept;
2-year results

15.05 G. Velis, S. Reddy, S. Mahuli INDIA
A case series of ocular toxocariasis (OT) in a tertiary
eye care center in South India.

15.10 H. Nawase, M. Kawagoe, A. Meguro,
N. Mizuki JAPAN
Analysis of gene expression levels in excessive
light exposed litter mate mice retina reveals the
potential to affect the expression level of myopia
related gene

15.15 H. Noma, M. Shimura JAPAN
Anti-vegf therapy with/without initial steroid
therapy for macular edema in branch retinal vein
occlusion

15.20 S. Xiong, X. Xu CHINA
Choroidal thickness changes and associated factors
in children and adolescents aged 6 to 18 years: a
one-year longitudinal study

15.25 A. Uppuluri, M. Zarbin, N. Bhagat USA
Comorbidities associated with increased risk of
undergoing enucleation in cases of infectious
endophthalmitis

15.30 S. Wong, R. Chhabra, N. Jones UK
Corticosteroid-associated osteonecrosis in patients
with uveitis in a single tertiary referral centre

15.35 M. Figueras Roca, J. Matas, V. Llorens,
J. Zarranz Ventura, A. Adán, B. Molins SPAIN
Diabetic macular edema and uveitic macular edema
analysis of peripheral blood cytokine and growth factor levels

15.40 M. Sun, S. Wiviott, E. Antman, M. Roe,
M. Ohman, M. Neely AUSTRALIA
Intracocular bleeding with dual Antiplatelet therapy using potent P2Y12 inhibitors

15.45 Y. Kim, S. Lee, H. Byeon, J. Kim,
K. Lee SOUTH KOREA
Hyperreflective foci in diabetic macular edema
with serous retinal detachment: association with
dyslipidemia

15.50 C. Lee, E. Yonsei, S. Lee SOUTH KOREA
Multiple evanescent white dot syndrome with
overlapping white dot syndrome

15.55 Z. Szepessy, A. Farkas, J. Németh HUNGARY
Retinal function in patients with adalimumab
Treatment: a microperimetric follow-up
THURSDAY 5 SEPTEMBER

16.00 – 17.00
Opening Ceremony & EURETINA Lecture
Grand Amphithéâtre (Level 0 & 2)

16.00 President’s Welcome
S. Wolf SWITZERLAND (PRESIDENT, EURETINA)

16.10 EURETINA Lecture 2019
Diabetic Retinopathy Today
F. Bandello ITALY

Presentation of Certificate
A. Loewenstein ISRAEL
(GENERAL SECRETARY, EURETINA)

16.40 EURETINA Video Competition Awards
F.G. Holz GERMANY
(INCOMING PRESIDENT, EURETINA)

16.50 Closing Remarks
S. Wolf SWITZERLAND

17.00 End of Ceremony
FRIDAY 6 SEPTEMBER

08.00 – 09.30

EURETINA SESSION 6

The Diabetic Retina

Grand Amphithéâtre (Level 0 & 2)

Chairpersons: A. Loewenstein ISRAEL
E. Midena ITALY
M. Goldstein ISRAEL

08.00 R. Schlingemann THE NETHERLANDS
New insights in the pathophysiology of the diabetic retina

08.08 F. Bandello ITALY
Is OCT-A essential in diabetic eyes?

08.16 U. Schmidt-Erfurth AUSTRIA
Artificial intelligence in diabetic retina

08.24 S. Sivaprasad UK
The management of DME and PDR in 2019

08.32 E. Pilotto ITALY
Laser treatment in 2019

08.40 N. Bressler USA
Recent Lessons from the DRCR network trials

08.48 J. García-Arumí SPAIN
Vitreoretinal interface in diabetes: New perspectives

08.56 P. Hykin UK
LEAVO study

09.04 M. MacCumber USA
Protocol V - DRCR retina network

09.12 R. Schlingemann THE NETHERLANDS
Comparing the efficacy of bevacizumab to ranibizumab in patients with diabetic macular edema. The BRDME study

Moderator: M. Goldstein ISRAEL

09.20 Panel Discussion: Diabetic retinopathy: Clinical cases

09.30 End of session

08.00 – 09.30

EURETINA SESSION 7

Environmental Exposures & Risk of Eye Diseases

Amphithéâtre Bleu (Level 2)

Chairpersons: C.C.W. Klaver THE NETHERLANDS
C. Delcourt FRANCE

08.00 C.C.W. Klaver THE NETHERLANDS
Risk of blindness for smoking

08.12 C. Delcourt FRANCE
Nutritional threats and benefits for the retina

08.24 V. Daïen FRANCE
Systemic drugs and AMD: the good, the bad, and the ugly

08.36 C.J. Boon THE NETHERLANDS
Systemic drugs and CSR: more ugliness?

08.48 K.M. Williams UK
Sun exposure: friend or foe?

09.00 G. Renard FRANCE
The dangers of blue light: True story

09.12 Discussion

09.30 End of session
FRIDAY 6 SEPTEMBER

08.00 – 09.30

SYMPOSIUM

Posterior Segment Complications of Cataract Surgery

Amphithéâtre Bordeaux (Level 3)

Chairperson: B. Chanana INDIA

08.00 B. Chanana INDIA
Management of dropped IOL and nucleus

08.12 L. Verma INDIA
Inadvertent globe perforation during local anaesthesia for cataract surgery and its management

08.24 P.J. Polkinghorne NEW ZEALAND
Retinal detachment in mismanaged cataract surgery: Prevention, etiology, and management

08.36 S. Chawla INDIA
Cystoid macular edema: When and how to treat?

08.48 B. Chanana INDIA
Endophthalmitis: Early detection, differentiation from sterile reaction, and management

09.00 A. Rajendran INDIA
Expulsive haemorrhage: Early detection and management

09.12 Discussion

09.30 End of symposium

08.00 – 09.30

FREE PAPER SESSION 7

Imaging II

Amphithéâtre Havane (Level 3)

Chairpersons: K. Januschowski GERMANY
M. Iglicki ARGENTINA

08.00 M. Iglicki, D. Zur, A. Loewenstein, A. Barak ARGENTINA
Outer retina hyperreflective deposits (ORYD) on spectral domain OCT as a manifestation of sudden desinflammation of the macula in cases of naive diabetic macular edema after pars plana vitrectomy with ILM peeling: the ORYD Study

08.06 M. Tian, C. Tappeiner, M. Zinkernagel, S. Wolf, M. Munk SWITZERLAND
Evaluation of vascular changes in posterior uveitis using swept source wide field optical coherence tomography angiography

08.12 M. Diab, W. Turky EGYPT
Punctate hyperreflective vitreous opacities visualized by handheld spectral domain optical coherence tomography in premature infants screened for retinopathy of prematurity

08.18 M. Mostafa, W. Turkey, M. Al Shehri, S. Milisic SAUDI ARABIA
Diagnosis of inherited retinal degenerations in pediatric patients using the reteval handheld electroretinogram

08.24 O. Klepinina, A. Doga, P. Volodin, E. Pedanova RUSSIA
Features of the chorioretinal structure of the eyes with acute and chronic central serous chorioretinopathy based on EDI OCT

08.30 P. Mece, C. Pett, E. Gofas Salas, J. Sahel, K. Grieve, M. Paques, S. Meimon FRANCE
Adaptive optics image guided precise retinal laser photocoagulation

08.36 I. Mantel, C. Bergin, J. Guidotti, C. Ciller, S. Apostolopoulos, S. De Zanet SWITZERLAND
Automated detection and quantification of pathological fluid in treatment naive neovascular age related macular degeneration using a deep learning approach

08.42 J. Siedlecki, N. Mohr, N. Luft, L. Keidel, B. Schworm, S. Priglinger GERMANY
Impact of flavanol rich dark chocolate on visual function and retinal perfusion measured with optical coherence tomography angiography: a randomized clinical trial

08.48 J. Ruiz Medrano, I. Flores Moreno, M. Garcia Zamora, J. Ruiz Moreno SPAIN
Validation of new ATN classification and grading system for myopic maculopathy

08.54 K. Hess, M. Pfau, M. Wintergerst, F.G. Holz, P. Herrmann GERMANY
Altered foveal avascular zone in patients with Alport Syndrome
08.00 – 09.30

INSTRUCTIONAL COURSE 12

Everything you Need to Know to Start with Ocular Gene Therapy in your Clinics

Room 252 (Level 2)

Course Organiser: D. Fischer Germany

08.00 C. Fasser Switzerland
Introduction of the topic from a patient’s perspective

08.08 Discussion

08.10 D. Fischer Germany
Setting up a gene therapy unit & participating in the patient registry

08.25 Discussion

08.30 J. Kapetanovic UK
Diagnostic challenges, patient selection and surgical pearls for retinitis pigmentosa

08.45 Discussion

08.50 P. Stanga UK
Subretinal gene therapy – Do’s and don’ts in choroideremia and retinitis pigmentosa

09.05 Discussion

09.10 G. Le Meur France
The learnings from the French ocular gene therapy programmes

09.25 Discussion

09.30 End of course
08.00 – 09.30
INSTRUCTIONAL COURSE 13
Diabetic Macular Edema: Classification, Imaging Techniques & Management of Challenging Cases
Room 342 (Level 3)
Course Organisers: N. Davies UK  
                      S. Mann UK

08.00  N. Davies UK  
        Classification and the use of imaging in DME

08.15  S. Mann UK  
        Management ladder: Laser, anti-VEGF therapy and steroids

08.35  M. Mohammed UK  
        Cataract surgery in patients with DME

08.50  A. Laidlaw UK  
        Vitrectomy in patients with DME

09.00  All Presenters  
        4 difficult cases of patients with DME

09.30  End of course

08.00 – 09.30
INSTRUCTIONAL COURSE 14
Recognition of Key Signs on OCT Influencing our Decisions in Daily Practice
Salle Maillot (Level 2)
Course Organisers: A. Ambresin SWITZERLAND  
                   F. Coscas FRANCE

08.00  I. Mantel SWITZERLAND  
        OCT in systemic diseases

08.10  F. Coscas FRANCE  
        OCT in vein occlusions

08.20  Discussion

08.30  L. Zografos SWITZERLAND  
        OCT in adult and paediatric oncology

08.40  F. Behar-Cohen FRANCE  
        OCT in diabetic retinopathy

08.50  Discussion

09.00  A. Ambresin SWITZERLAND  
        OCT in age-related macular degeneration

09.10  J.A. Pournaras SWITZERLAND  
        OCT and surgical interface pathologies

09.20  Discussion

09.30  End of course
FRIDAY 6 SEPTEMBER

08.00 – 09.30

FREE PAPER SESSION 8
Vascular Diseases &
Diabetic Retinopathy II

Room 241 (Level 2)

Chairpersons: J-F. Korobelnik FRANCE
  F. Pici UAE

08.00  F. Pichi, K. Freund, P. Neri, D. Sarraf UAE
  Cilioretinal artery hypoperfusion and its association with paracentral acute middle maculopathy

08.06  S. Fraser Bell, K. Kang, P. Mitchell, J. Arnold, J. Tainton, S. Simony
  AUSTRALIA
  Dexamethasone intravitreal implant in treatment naïve diabetic macular edema – findings from the prospective, multicenter, AUSSIEDEX study

08.12  C. Isanta Otal, F. Bartol Puyal, M. Puzo Bayod, J. Sanchez Monroy, P. Calvo Perez, O. Ruiz Moreno, L. Julio SPAIN
  Diabetes affecting eye and other systems

08.18  K. Locaylocay, K. Duyongco, M. Arroyo, V. Caparas, P. Silva PHILIPPINES
  Dilated smartphone imaging for the detection and grading of diabetic retinopathy

08.24  D. Zur, M. Iglicki, A. Sala Puigdollers, M. Lupidi, Z. Cebeci, C. Busch, A. Loewenstein ISRAEL
  Disorganization of retinal inner layers as a biomarker in patients with diabetic macular edema treated with dexamethasone implant

08.30  J-F. Korobelnik, C. Lu, T. Katz, D. Dhoot, A. Loewenstein, J. Arnold, G. Staurenghi FRANCE
  Effect of baseline subretinal fluid on treatment outcomes in diabetic macular edema: subanalysis of VIVID DME and VISTA DME studies

08.36  I. Marques, D. Alves, T. Santos, A. Santos, C. Lobo, J. Cunha-Vaz PORTUGAL
  Five years progression of diabetic retinopathy (PROGRESS Study). Dr Phenotypes as a predictor of long term progression in diabetic retinopathy

08.42  P. De Boever, S. Lemmens, C. Landtmeters, R. Peeters, A. Simons, J. Vercauteren BELGIUM
  Fractal dimension of the retinal vasculature: age related evolution in the general population and effect of cardiovascular health status

  Gastric bypass surgery reduced the risk for diabetic retinopathy in patients with type 2 diabetes: A nationwide observational study

08.54  D. Maltsev, A. Kulikov, M. Burnasheva, J. Chhablani RUSSIA
  High prevalence of deep retinal capillary ischemic lesions in fellow eyes of patients with unilateral retinal vein occlusion

09.00  D. Castro Farías, R. Matsui Serrano, J. Bianchi Gancharov, U. De Dios Cuadras, F. Graue Riechers, B. Dupas, M. Paques MEXICO
  Indocyanine green angiography for identifying telangiectatic capillaries in diabetic macular edema

09.06  A. Sepetis, E. Karatsai, C. Tossounis, S. Mourtzoukos, S. Taylor, B. Gupta UK
  Long term outcome following fluorocinolone intravitreal implant for the treatment of refractory DMO: Multicenter study

09.12  I. Panchenko UKRAINE
  Mathematical modeling of development and progression of diabetic macular edema in patients with diabetic retinopathy and type 2 diabetes mellitus

09.30  End of session
FRIDAY 6 SEPTEMBER

08.00 – 09.30

SYMPOSIUM

ESASO: Challenging Surgical Cases

Room 251 (Level 2)

Chairpersons: M. Battaglia-Parodi ITALY
B. Corcostegui SPAIN
E. El-Rayes EGYPT
S. Rizzo ITALY

08.00  A. Alqahtani SAUDIA ARABIA
Sub-ILM macular haemorrhage in promyelocytic leukemia management

08.07  S. Sheth INDIA
Internal limiting membrane peeling in unusual situations

08.14  A. Papayannis ITALY
The effect of bevacizumab before vitrectomy for diabetic tractional retinal detachment demonstrated on optical coherence tomography angiography

08.21  F. March de Ribot SPAIN
Bilateral traumatic macular hole

08.28  G.M. Hüning BRAZIL
Secondary iol implantation using net technique

08.35  I. Chowers ISRAEL
Dome-shaped macula and anti-VEGF therapy

08.42  S. Shulman ISRAEL
Multimodal imaging of sickle cell maculopathy

08.49  I. Mallias GREECE
Retina detachment due to unsuccessful cataract surgery

08.56  A. Kothari INDIA
Vitreoretinal surgery in the presence of corneal opacity

09.03  G. Makris GREECE
Vitreoretinal nightmares - A usual day in the OR

09.10  R. Rejdak POLAND
Hybrid 23/27 G bimanual vitrectomy in severe complications of diabetic retinopathy

09.17  Discussion

09.30  End of symposium

08.00 – 09.30

INSTRUCTIONAL COURSE 15

New Insights in Imaging & Therapeutic Strategies for Macular Holes & Myopic Macular Traction Syndrome

Room 351 (Level 3)

Course Organiser: G. Pertile ITALY

08.00  G. Pertile ITALY
Introduction

08.10  F. Bottoni ITALY
What’s new in idiopathic and lamellar macular holes

08.20  A. Polito ITALY
Myopic foveoschisis: Natural history, surgical planning and postoperative outcomes

08.30  G. Prigione ITALY
Inverted ILM flap and transplanted ILM for macular hole: Surgical techniques

08.35  A. Alfano ITALY
The dynamic healing process after surgery for idiopathic and myopic macular hole with inverted flap technique

08.40  C. Mateo SPAIN
My personal tips and tricks dealing with myopic macular holes

08.50  G. Pertile ITALY
Tips and tricks of surgery in high myopic eyes

09.10  Discussion

09.30  End of course
Taking place within the EURETINA Speakers’ Corner (Arlequin, Level 3), the following posters will be presented for 3 minutes each with 2 minutes for discussion and interaction with the audience.

**Moderator:** T. Peto **UK**

10.00  F. Ascaso, O. Esteban, S. Marco, I. López, J. Montoya, E. Ruiz Pesini **SPAIN**
Influence of mitochondrial haplogroups in response to ranibizumab therapy in neovascular age-related macular degeneration

10.05  P. Yoganathan, A. Sagkirotis, A. Kukaswadia, F. Lebeau, V. Gregory **CANADA**
Anti-VEGF persistence and switching in nAMD: Real world analysis from a Canadian claims database

10.10  M. Amirkavi, S. Pallasaho, O. Kaikkonen, H. Andre A. Koskelainen **FINLAND**
Application of ERG-based retinal temperature monitoring method for non-damaging heating therapy of retinal pigment epithelium cells in mice

10.15  D. Rodriguez Feijoo, M. Aldazabal Echeveste, Z. Del Barrio, A. Larrauri Arana, T. Yunes Abumohor, D. Rodriguez Feijoo **SPAIN**
Bringing clinical trials results to real life in nAMD. Results of an advanced intravitreal treatment setting in a public hospital in Spain

10.20  I. Chang, H. Kwak, K. Kim **SOUTH KOREA**
Changes in macular pigment optical density with age in healthy and in patients with dry age-related macular degeneration: A cross sectional study

10.25  A. Sagkirotis, A. Skelly, S. Venkatesan, S. Oyetunde **SWITZERLAND**
Drug utilization and associated visual acuity in patients treated with anti-VEGFs for neovascular age-related macular degeneration (nAMD) in the UK

10.30  N. Daftarian, S. Rohani, M. Rezaei Kanavi, Z. Soheili **IRAN**
Effects of intravitreal connective tissue growth factor neutralizing antibody on the CNV-associated subretinal fibrosis

10.35  E. Gokhale, F. Horner, W. FusiRubiano, R. Chavan **UK**
Eighteen month outcomes of treat and extend regime for AMD with intravitreal aflibercept in clinical setting as compared to results of VIEW1 and VIEW 2

10.40  Y. Gayadine Harricham, A. Barakat, T. Tran **FRANCE**
Four-year outcome of aflibercept therapy for neovascular age-related macular degeneration

10.45  S. Trier, P. Schoonheim, G. Staurenghi **UK**
Geographic atrophy (GA) secondary to neovascular age related macular degeneration (nAMD): Online medical education significantly improves ophthalmologists’ knowledge, competence and confidence

10.50  E. Fournaux, B. Briend, M. Lelez, P. Griffon, F. Rumen, S. Cohen **FRANCE**
National survey on the management and information practices of patients with wet AMD

10.55  N. Patrao, R. Schwartz, P. Hykin, S. Sivaprasad **UK**
Optical coherence tomography – Angiography as a tool for guiding treatment interval between anti-VEGF injections in neovascular age related macular degeneration

11.00  K. Chia **SINGAPORE**
Optical coherence tomography (OCT) findings in lacquer crack haemorrhage (LCH)

11.05  A. Chang, L. Priestman, C. Holmes, P. Said **AUSTRALIA**
Persistence to intravitreal aflibercept therapy in patients with wet age-related macular degeneration engaged with the smartsight support programme

11.10  C. Tan **SINGAPORE**
Polyp evolution over 24 months among patients with polypoidal choroidal vasculopathy

11.15  M. Vadala, G. Guarrasi, A. Casuccio, S. Cillino **ITALY**
Polypoidal choroidal vasculopathy in pachychoroid: Aflibercept and PDT combined therapy

11.20  M. Garcia Mendieta, J. Caminal, A. Filloy **SPAIN**
Swept-source optical coherence tomography (ssOCT) imaging in vitreoretinal interface disorders (VRID) and their role in intravitreal treatment response in wet age-related macular degeneration (AMD)

11.30  End of session
FRIDAY 6 SEPTEMBER

11.00 – 12.00
KEYNOTE LECTURE
Kreissig Lecture
Grand Amphithéâtre (Level 0 & 2)
Chairperson: I. Kreissig GERMANY

Introduction
S. Wolf SWITZERLAND (PRESIDENT, EURETINA)

Keynote
J. Jonas GERMANY
Myopia: Epidemiology, Histology & Clinics

Presentation of Award
I. Kreissig GERMANY

11.00 – 12.30
AFIV SYMPOSIUM
Amphithéâtre Bleu (Level 2)
Chairpersons: M. Goldstein ISRAEL
E. Souied FRANCE

11.00 N. Mathalon ISRAEL
Macular thickness changes following femtosecond laser assisted and conventional phacoemulsification

11.06 E. Souied FRANCE
Pathways from CNV to fibrosis

11.12 I. Chowers ISRAEL
Lines & algorithms – Evidence based fitting of anti-VEGF compound for the individual eye

11.18 F. Amoroso FRANCE
Laser for macular disorders: The revival

11.24 G. Querques ITALY
Colour-coded fundus autofluorescence

11.30 S. Schwartz ISRAEL
Treatment options for sub macular haemorrhage. Intravitreal tPA and pneumatic displacement vs PPV

11.36 R. Tadayoni FRANCE
Epiretinal membrane foveoschisis

11.42 C. Creuzot-Garcher FRANCE
Update on endophthalmitis post IVT

11.48 H. Mechoulam ISRAEL
Geographic considerations in screening criteria for ROP

12.00 S.Y. Cohen FRANCE
Bilateral Coats

12.05 Z. Habot Wilner ISRAEL
Ocular SUSAC in the immunomodulatory treatment era

12.10 S. Soudri ISRAEL
An unusual CRVO in a young patient

12.15 O. Zambrowski FRANCE
Mysterious case

12.20 G. Katz ISRAEL
PDT for chronic atypical or recurrent central serous chorioretinopathy

12.25 Discussion

12.30 End of symposium
11.00 – 12.30
THE EuroVeRsion CASE CONTEST
Amphithéâtre Bordeaux (Level 3)

The EuroVeRsion Case Contest is an international competitive Vitreo Retinal multimedia case presentation symposium. It combines the best elements of educational high quality case presentations by trainee Vitreo Retinal Surgeons with the vital competitive element.

Candidates are competing for two prestigious prizes:

• The EuroVeRsion Jury Prize, awarded on merit by independent judges, and the EuroVeRsion Audience Prize which, like all referenda, depends entirely on how many of your side you can persuade to attend and vote.

• A break from the usual formal EURETINA programme, this infotainment symposium will sort out the true leaders in European Retina. Don’t be on the losing team! European National Retinal Societies have been invited to submit a candidate, from whom the ten best entries have been selected to compete in this final.

Chairpersons: A. Laidlaw UK
S. Lash UK
G. McGowan UK
D. Yorston UK

Judges: K. Krepker AUSTRIA
Y. Le Mer FRANCE
Z. Michalewska POLAND
M. Romano ITALY
S. Saidkasimova UK & IRELAND
M. Veckeneer LOW COUNTRIES
I. Relimpio SPAIN

11.00 – 12.30
FREE PAPER SESSION 9
New Drug Treatment & Technology
Amphithéâtre Havane (Level 3)

Chairpersons: I. Pearce UK
A. Lotery UK

11.00 A. Lotery, S. Sivaprasad, A. Willcox, L. Culliford, C. Rogers, A. Cree, F. Behar Cohen UK
Clinical efficacy of eplerenone for central serous chorioretinopathy – the VICI randomised trial

11.06 R. Nourinia, H. Ahmadieh, A. Hafezi Moghadam, N. Daftarian, A. Daneshtalab, H. Sabbaghi IRAN
Combined intravitreal bevacizumab and fasudil (rock inhibitor) injection versus intravitreal injection of bevacizumab alone for macular edema secondary to central vein occlusion randomized clinical trial

Duration of effect of ocular gene therapy: 4 year follow up data from the phase III voretigene neparvovec trial in patients with biallelic RPE65 mutation associated retinal dystrophy

11.18 L. Kryl, A. Doga, P. Volodin, Y. Yanilikina, D. Buryakov RUSSIA
Efficacy of combined laser surgery in the treatment of horseshoe tears with subclinical retinal detachment

11.24 O. Kaikkonen, T. Turunen, A. Koskelainen FINLAND
Electroretinogram based temperature determination for non damaging retinal laser treatments - a proof of concept with photopic pig ex vivo electroretinogram

11.30 I. Pearce, R. Mohamed, A. Ribeiro UK
Evaluation of baseline characteristics on lesion progression in a large phase 2 clinical trial for geographic atrophy (FILLY study)

11.36 W. Li, H. Fan, Z. Qian, D. Lin, H. Wang CHINA
A new two step anesthesia for microincision vitrectomy surgery: A prospective, randomized clinical trial

11.42 Y. Luo, J. Zhong, L. da Cruz UK
Functional near infra red spectroscopy (fnirs) imaging of primary visual cortex activation in argus® ii retinal prosthesis subjects

11.48 M. Abrishami, M. Abrishami, B. Malaekheh Nikouei, M. Motamed Shariati, B. Khameneh IRAN
Preparation and in vivo evaluation of nanoliposomes containing vancomycin after intravitreal injection in albino rabbits

11.54 A. Praidou, S. Gerovasileiou, C. Antoniadou GREECE
Pseudophakic cystoid macular edema prevention and risk factors; prospective study with a topical non steroidal anti inflammatory drug versus placebo
FRIDAY 6 SEPTEMBER

11.00 – 12.30

INSTRUCTIONAL COURSE 16

How is the Management of Small Pigment Choroidal Tumours

Room 252 (Level 2)

Course Organisers: D.E. Pelayes ARGENTINA, S. Seregard SWEDEN

11.00  E. Midena ITALY
       How is the clinical evaluation and prognostic factors

11.12  T. Kivela FINLAND
       Clinical-pathological aspects

11.24  L. Zografos SWITZERLAND
       Images in SPCT

11.36  N. Bornfeld GERMANY
       How and when the biopsy

11.48  A. Joussen GERMANY
       How and when the surgery

12.00  N. Bechrakis GERMANY
       How is the follow up?

12.12  D.E. Pelayes ARGENTINA, S. Seregard SWEDEN
       Discussion

12.30  End of course

12.00  H. Ocampo COLOMBIA
       Real Life experience with ozurdex in Colombian patients

       The small molecule integrin antagonist THR 687 potently inhibits ocular fibrosis in preclinical models

12.12  A. Aurora, S. Singh, A. Aurora, C. Malik INDIA
       Suprachoroidal injection of triamcinolone using a novel device

12.18  K. Januschowski, A. Rickmann, A. Schulz, P. Szurman GERMANY
       Testing and first clinical results of a hydrogel based artificial vitreous substitute

12.30  End of session
FRIDAY 6 SEPTEMBER

11.00 – 12.30

INSTRUCTIONAL COURSE 17

The Amsterdam Basic Medical Retina Course

Room 342 (Level 3)

Course Organisers:  C.J. Boon THE NETHERLANDS  
                    R. Schlingemann THE NETHERLANDS

Course Topics
- Basics and practical application of OCT, OCT-angiography, fluorescein angiography, indocyanine angiography and fundus autofluorescence
- Diagnosis and practical management of neovascular age-related macular degeneration (AMD) and myopic macular degeneration
- Diagnosis and practical management of central serous chorioretinopathy, atrophic AMD, and macular dystrophies
- Diagnosis and practical management of diabetic macular edema and retinal venous occlusion

15.50  Discussion  
16.00  End of course

11.00 – 12.30

INSTRUCTIONAL COURSE 18

The Multiple Applications of Imaging in Uveitis: Differential Diagnosis, Follow-up, Patient Management & Prognostic Signs

Salle Maillot (Level 2)

Course Organisers:  V. Gupta INDIA  
                    A. Invernizzi ITALY  
                    C. Pavesio UK

11.00  V. Gupta INDIA  
       Traditional techniques interpretation in uveitis (FA, ICG, OCT)

11.10  Discussion

11.15  A. Invernizzi ITALY  
       Novel applications of wide-field OCT/EDI-OCT in the differential diagnosis of Uveitis

11.25  Discussion

11.30  F. Pichi UAE  
       Wide filed imaging techniques

11.40  Discussion

11.45  M. Munk SWITZERLAND  
       The use of OCTA in uveitis: A comparison with conventional angiography techniques

11.55  Discussion

12.00  C. Pavesio UK  
       The importance of the clinical examination and how it guides imaging tests

12.10  Discussion

12.30  End of course
### 11.00 – 12.30

**FREE PAPER SESSION 10**

**AMD II**

**Room 241 (Level 2)**

**Chairpersons:** F. Behar-Cohen **SWITZERLAND**  
M. Zhao **FRANCE**

#### 11.00  
**M. Zhao, E. Gelize, X. Li, A. Arboleda, J. Canonica, F. Jaisser, F. Behar-Cohen** **FRANCE**
Mineralocorticoid receptor invalidation in vascular endothelial cells prevents CNV development

#### 11.06  
**E. van Dijk, L. Hahn, T. Van Rijssen, S. Fauser, S. Downes, C. Hoyng, C. Boon** **THE NETHERLANDS**
Pigment epithelial detachments in chronic central serous chorioretinopathy: effect of half dose photodynamic therapy versus high density subthreshold micropulse laser (PLACE trial report No. 5)

#### 11.12  
**E. Cervera Taulet, A. Acero Pena, Y. Poza Morales, F. Cabrera Lopez, C. Esmerado Appiani, L. Sanchez Lopez, M. Bassaganyas Vilarrasa** **SPAIN**
Effectiveness of intravitreal aflibercept in patients with neovascular age related macular degeneration treated in routine practice – REALE Study

#### 11.18  
**C. Farinha, M. Cachulo, D. Alves, J. Marques, I. Pires, S. Nunes, R. Silva** **PORTUGAL**
Age related macular degeneration prevalence and staging by color fundus photography vs multimodal imaging: the coimbra eye study

#### 11.24  
Phase 2b study of brimonidine dds: potential novel treatment for geographic atrophy

#### 11.30  
**F. Behar-Cohen, I. Mantel, E. Gelize, F. Jaisser, C. Rivolta, J. Canonica, M. Zhao** **FRANCE**
Pharmacological antagonism of mineralocorticoid receptor exerts VEGF independent anti angiogenic effects: Implication for wet AMD

#### 11.36  
**F.G. Holz, P. Dugel, C. Jhaveri, C. Wykoff, R. Singh, J. Alam, R. Hamilton** **GERMANY**
Visual and expanded anatomical outcomes for brolucizumab versus aflibercept in patients with neovascular AMD: 96 week data from HAWK and HARRIER

#### 11.42  
**G. Reiter, R. Told, L. Baumann, S. Sacu, U. Schmidt Erfurth, A. Poliireisz** **AUSTRIA**
Quantitative autofluorescence for the prediction of lesion growth in advanced age related macular degeneration with solitary geographic atrophy

#### 11.48  
**H. Kang, C. Lee, E. Choi, S. Lee** **SOUTH KOREA**
Pachydrusen, choroidal vascular hyperpermeability, and punctate hyperfluorescent spots in polypoidal choroidal vasculopathy

#### 11.54  
**I. Kilic, W. Freeman** **TURKEY**
The effect of vitrectomy on the progression of dry age related macular degeneration

---

#### 12.00  
**J. Stewart, C. Awh, P. Campochiaro, D. Marcus, C. Regillo, M. Wieland, G. Barteselli** **USA**
Optimization of the port delivery system with ranibizumab (PDS) implant insertion procedure in the ladder phase 2 trial

#### 12.06  
**J. Lok, S. Mohamed, C. Tsang** **HONG KONG**
Real world data on endophthalmitis after intravitreal anti vascular endothelial growth factor injections with or without topical antibiotic prophylaxis

#### 12.12  
**J. Wang, H. Weng** **T AIWAN**
Comparison of one year outcome of photodynamic therapy in combination with intravitreal aflibercept or ranibizumab for polypoidal choroidal vasculopathy

#### 12.18  
**Y. Le Mer, S. Mohand Said, M. Muqit, J. Sahel, D. Palenker** **FRANCE**
One year results with PRIMA, a photovoltaic wireless subretinal implant for advanced atrophic Dry Age related Macular Degeneration

#### 12.30  
End of session
FRIDAY 6 SEPTEMBER

11.00 – 12.30

SYMPOSIUM

Innovations in Ophthalmology: Spotlight on Artificial Intelligence Applications

Room 251 (Level 2)

Chairperson: T. Aslam UK

11.00  T. Aslam UK
Beyond deep learning – Limitations and alternatives in AI

11.15  K. Balaskas UK
AI in ophthalmology – From computer science to real-world

11.30  U. Schmidt-Erfurth AUSTRIA
AI in early and advanced disease

11.45  A. Tufail UK
What validation do we need for an AI algorithm before clinical deployment?

12.00  P. Keane UK
Crossing the AI chasm

12.15  Discussion

12.30  End of symposium

11.00 – 12.30

INSTRUCTIONAL COURSE 19

Submacular Haemorrhages in AMD: A Practical Guide to Management

Room 351 (Level 3)

Course Organiser: D. Steel UK

11.00  G. McGowan UK
Epidemiology, mechanisms of visual loss, risk factors and classification

11.10  Z. Koshy UK
Anti VEGFs alone?

11.20  W. Heriot AUSTRALIA
Pneumatic displacement technique

11.30  J. Hillenkamp GERMANY
Vitrectomy and subretinal TPA/anti VEGF

11.40  D. Yorston UK
Results, complications and limitations - How do the two techniques compare?

11.50  T. Jackson UK
Tiger; a pan European RCT of SMH in AMD

12.30  End of course
12.00 – 13.00

AMSTERDAM RETINA DEBATE

Grand Amphithéâtre (Level 0 & 2)

Chairperson: S. Lesnik-Oberstein THE NETHERLANDS

Debate 1:
Cryo versus Laser

12.00  For: R. Hussain UK
Against: P. Sullivan UK

Debate 2:
Uveitis Always Needs Extensive Investigations

12.30  For: E. de Carvalho UK
Against: L. Faia USA

12.15 – 13.45

SPEAKERS’ CORNER 5

Mixed II

Taking place within the EURETINA Speakers’ Corner (Arlequin, Level 3), the following posters will be presented for 3 minutes each with 2 minutes for discussion and interaction with the audience.

Moderator: F. March de Ribot SPAIN

12.15
B. Burgos Blasco, M. Jimenez Santos, C. Narvaez Palazón, F. Saenz Frances, E. Santos Bueso SPAIN
Multimodal imaging in optic nerve melanocytoma: optical coherence tomography angiography and other findings

12.20
B. Mushtaq, H. Palmer UK
3 Hospitals, 3 Years, 96 Eyes: Real-world response rates in diabetic macular oedema (DMO) for patients treated with the 0.2 µg/day fluocinolone acetonide (FAc; ILUVIEN®) implant

12.25
B. McKay, H. Krema, D. Weisbrod CANADA
A case of multifocal presumed solitary circumscribed retina astrocytic proliferation lesions in the same eye

12.30
O. Makri, A. Pallikari, P. Plotas, C. Georgakopoulos GREECE
A late onset of bilateral choroidal metastases from clear cell renal cell carcinoma

12.35
E. Paroikakis, D. Karagiannis, V. Peponis, L. Kontomihos, E. Ktena, I. Chatziralli GREECE
Aniridia lens scleral fixation using Gore-Tex sutures: A novel approach

12.40
B. Pessoa, J. Beirão, S. Monteiro, J. Figueira, A. Meireles, P. Menéres PORTUGAL
Changes in ganglionar cell layer thickness measured using optical coherence tomography following treatment with a 0.19 mg fluocinolone acetonide implant in vitrectomized and nonvitrectomized eyes with diabetic macular edema

12.45
I. Panova, E. Gyuntner, E. Samkovich RUSSIA
Clinical and instrumental criteria for the risk of choroidal melanoma metastasis

12.50
O. Sorour, N. Mehta, P. Braun, I. Gendelman, J. Duker, N. Waheed EGYPT
Comparison of visual and anatomic outcomes of sustained anti-VEGF treatment versus double anti-VEGF switching in the treatment of persistent diabetic macular edema

12.55
M. Diab EGYPT
Determining the tractional forces on vitreoretinal interface using computer simulation and animal models to elucidate the retinal hemorrhage patterns in abusive head trauma

13.00
N. Ucgun, Z. Yazar TURKEY
Hydrophilic acrylic intraocular lens optic opacification in vitrectomized diabetic eyes
13.05  R. Hogg, T. Peto, I. Young, D. Wright, F. Kee, U. Chakravarthy  UK
Reticular pseudo drusen using multi-modal retinal imaging in a population based aging cohort: The NICOLA Study

13.10  A. Cuna, E. Interlandi  ITALY
Retinal optical coherence tomography angiography in transsynaptic retrograde degeneration

13.15  Y. Kim, D. Moon, H. Park, O. Kwon  SOUTH KOREA
Short-duration multiple-session subthreshold micropulse yellow laser(577-nm) for chronic central serous chorioretinopathy

13.20  M. Karpoor, M. Mundy, Y. Yang, N. Narendran  UK
Success rate of decision making to extend in the treat and extend ranibizumab regimen for neovascular age related macular degeneration

13.25  S. Liew, K. Curtin  IRELAND
The effect of haemodialysis on visual acuity and retinal structure in patients with end-stage renal disease

13.30  M. Mostafa, M. Al Shehri, S. Milisic  SAUDI ARABIA
Validation of the 9-rop modified retinopathy of prematurity screening criteria

13.35  A. Safi  BELGIUM
Yasunari nodules: a new marker of neurofibromatosis type 1 for ophthalmologists

13.40  Discussion

13.45  End of session

14.30 – 16.00

SYMPOSIUM

RETINATech: Where Surgery Meets Technology

Amphithéâtre Bleu (Level 2)

Chairpersons:  T. Rossi  ITALY
T. Hassan  USA

14.30  T. Rossi  ITALY
Welcome and introduction

14.32  C. Awh  USA
New devices for vitreoretinal surgery

14.40  T. Hassan  USA
Advancements in surgical sterility

14.48  C. Eckardt  GERMANY
Closure of sclerotomies in difficult cases

14.56  P. Stalmans  BELGIUM
Two year experience with a digital microscope for eye surgery

15.04  P. Dugel  USA
Advances in visualization in VR surgery: Science fiction or science fact

15.12  S. Charles  USA
Advances in digital visualisation

15.20  T. Rossi  ITALY
New vitrectomy probes

15.28  D. Steel  UK
The fluidics of beveled tips

15.36  M. De Smet  THE NETHERLANDS
Macular hole surgery: The pros and cons of a robotic approach

15.44  S. Rizzo  ITALY
Ultrasound vitrectomy: Preliminary results with a new device

15.52  Discussion

16.00  End of symposium
14.30 – 16.00

**SYMPOSIUM**

**Tackling Subretinal Haemorrhage: What is New?**

*Amphithéâtre Bordeaux (Level 3)*

**Chairpersons:** K. Januschowski **GERMANY**  
J. van Meurs **THE NETHERLANDS**  
K. van Willekens **BELGIUM**

14.30  **K. Januschowski** **GERMANY**  
OCT-based classification and outlook

14.42  **A. Couturier** **FRANCE**  
Case presentations, what would you do?

14.54  **K. van Willekens** **BELGIUM**  
Evidence based data? Where is the evidence?

15.06  **J. van Meurs** **THE NETHERLANDS**  
Is there a role for RPE patches?

15.18  **T. Jackson** **UK**  
Introducing a randomised controlled trial

15.30  Discussion

16.00  End of symposium

14.30 – 16.00

**INSTRUCTIONAL COURSE 20**

**Troubleshooting VR Surgical Snags & Techniques for ILM Peeling – OR Tricks Unplugged in Video Tutorial!**

*Room 252 (Level 2)*

**Course Organisers:** R.R. Reddy **INDIA**  
D. Singh **INDIA**

14.30  **R.R. Reddy** **INDIA**  
Sclerotomies related snags in hypotony or choroidal detachment or bullous retinal detachment and interface vitrectomy

14.38  Discussion

14.42  **J. Singh** **INDIA**  
Managing visualisation snags (fogging, Air in AC, IOL decentration)

14.50  Discussion

14.52  **A. Jhinja** **INDIA**  
Managing ora – Adding buckle and peripheral indentation

15.00  Discussion

15.02  **D. Singh** **INDIA**  
Less common manoeuvres – Working under silicone oil, subretinal TPA injection and managing silicone oil in AC

15.10  Discussion

15.14  **P. Aristodemou** **CYPRUS**  
Combining phaco and vitrectomy – Tricks to minimize snags

15.22  Discussion

15.26  **S. Gupta** **INDIA**  
Getting ready for ILM Peeling – Visualizing systems, lenses, dyes and forceps

15.34  **A. Jhinja** **INDIA**  
ILM Peeling – Basics of technique

15.42  **R.R. Reddy** **INDIA**  
ILM Flaps; Inverted, temporal & free flaps for Macular hole – Tips for success

15.50  Discussion

15.54  **D. Singh** **INDIA**  
ILM peel in retinal detachment, disc anomalies and diabetic retinopathy – Modifications in technique

16.00  End of course
FRIDAY 6 SEPTEMBER

14.30 – 16.00
FREE PAPER SESSION 11
Uveitis

Amphithéâtre Havane (Level 3)

Chairperson: C. Chiquet FRANCE

14.30  X. Liu, S. Kelly, G. Montesano, S. Bryan, R. Barry, A. Denniston, D. Crabb UK
Evaluating the impact of uveitis on visual field progression using large scale real world data

14.36  B. Pershin, A. Smirnova, V. Makhmutov RUSSIA
Treatment of cytomegalovirus retinitis: intravitreal injections of antiviral agents controlled by polymerase chain reaction of aqueous humor in a real time inivroment

14.42  C. Pavesio, W. Tucker, C. Heinz UK
Prevention of relapse of recurrent non infectious uveitis affecting the posterior segment of the eye (NIU PS) with a single 0.18 mg fluocinolone acetonide (FAc) implant – the efficacy and safety outcomes at 3 years

14.48  C. Chiquet, S. Boissett, J. Kosacki, P. Cornut, G. Thuret, R. Hubanova, M. Maurin FRANCE
Specific PCR and quantitative real time PCR in ocular samples from acute and delayed onset postoperative endophthalmitis

Reliability of an OCT based vitreous inflammation score in uveitis

15.00  G. Velis, B. MS, S. Bhandari INDIA
Analysis of polymerase chain reaction (PCR) results in presumed ocular tuberculosis (TB) with treatment response

15.06  J. Ma, N. Carrell, C. Baker CANADA
Ocular manifestations of disseminated mycobacterium chimaera infection after cardiothoracic surgery

15.12  P. Dhoble, B. S, A. Khodifad, G. Velis INDIA
Case series of ocular toxoplasmosis in a tertiary eye care centre in India

15.18  S. Minaker, R. Kohly CANADA
Asymmetric presentation and fundus autofluorescence in non paraneoplastic autoimmune retinopathy (npair): a case series

15.24  S. Ajamil Rodanes, F. Bosello, M. Westcott UK
Unilateral idiopathic neuroretinitis: a retrospective review of 7 cases

15.30  X. Wu, Y. Chen, T. Jonsdottir, A. Tasiopoulou, N. Al Qassimi, S. Lightman, O. Tomkins Netzer UK
Endophthalmitis management, microbiological patterns, and outcomes over 12 years

15.36  D. Bhojwani, A. Sudhalkar, S. Vasavada, V. Vasavada, A. Vasavada, V. Vasavada, S. Srivastava INDIA
Managing uveitic cataract: intravitreal dexamethasone implant Vs systemic steroids, a comparative clinical case series

15.42  K. Belkhadir, N. Boutimzine, A. Amazouzi, S. Tachfouiti, M. Laghmari, O. Cherkaooui MOROCCO
Retinal vasculitis during Bechet’s disease: when everything goes wrong

15.48  F. Pichi, P. Neri, A. Invernizzi, H. Sen, C. Shields UAE
Vasoproliferative tumors in intermediate uveitis

16.00  End of session
14.30 – 16.00
INSTRUCTIONAL COURSE 21
Macular Surgery: Decision Making in Daily Practice
Room 342 (Level 3)
Course Organisers: F. Bottoni ITALY
R. Schumann GERMANY

14.30 J. van Meurs THE NETHERLANDS
Vitreoretinal interface – Vitreoschisis and vitreous cortex remnants in macular surgery and beyond

14.38 Discussion

14.42 S. Priglinger GERMANY
Vitreomacular traction – Is traction resolution all that matters for visual function response?

14.50 Discussion

14.54 H. Hoerauf GERMANY
Epiretinal gliosis – Vitrectomy postponed but not abandoned

15.02 Discussion

15.06 M. Figueroa SPAIN
Myopic traction maculopathy – New insights in disease progression and surgical management

15.14 Discussion

15.18 R. Tadayoni FRANCE
Lamellar macular holes, premacular membrane foveoschisis and macular pseudohole – New classification of the international lamellar macular hole study group

15.26 Discussion

15.30 R. Schumann GERMANY
Lamellar macular defects – Clinical course, prognostic factors and surgical intervention

15.38 Discussion

15.42 F. Bottoni ITALY
Full-thickness macular holes – Is an inverted flap procedure the better choice?

15.50 Discussion

16.00 End of course

14.30 – 16.00
INSTRUCTIONAL COURSE 22
Artificial Intelligence for Diabetic Retinopathy Screening
Salle Maillot (Level 2)
Course Organisers: A. Grzybowski POLAND
L. Schmetterer AUSTRIA
D. Ting SINGAPORE

14.30 A. Grzybowski POLAND
AI for DR Screening in Europe

14.40 M. Abramoff USA
AI for DR screening in USA

14.50 G. Tan SINGAPORE
AI for DR screening in Singapore

15.00 D. Ting SINGAPORE
AI for DR screening in Africa

15.10 P. Ruamviboonsuk THAILAND
AI for DR screening in Thailand

15.20 L. Schmetterer AUSTRIA
Potential challenges in AI application for DR screening in the clinical setting

15.40 Discussion

16.00 End of course
FRIDAY 6 SEPTEMBER

14.30 – 16.00
FREE PAPER SESSION 12
Retinal Dystrophies
Room 241 (Level 2)

Chairperson: D.E. Pelayes ARGENTINA

Two year experience with Argus II retinal prosthesis in France: safety, postoperative anatomical findings, functional performances and satisfaction

14.36 A. Khan, E. Abdelkader, Z. Yasir, O. Radadi, R. Khandekar, S. Nowlaty, P. Schatz SAUDI ARABIA
Analysis of retinal structure and function in cone dystrophy with supernormal rod response

14.42 B. Ballios, R. Kohly, R. Muni, D. Weisbrod, T. Wright, P. Yan CANADA
Oguchi disease: Widefield imaging and clinical characterisation of a novel GRK1 mutation

14.48 C. Lovino, A. Au, A. Hilely, S. Violanti, E. Peiretti, M. Gorin, D. Sarraf ITALY
Evaluation of the choroid in eyes with retinitis pigmentosa and cystoid macular edema

14.54 H. Dezhagah, H. Sajjadi, M. Abtahi IRAN
High intracranial pressure in retinitis pigmentosa (RP)

Optical coherence tomography grading of retinopathy associated with bardet biedl syndrome

15.06 K. Stingl, L. Kuehlewein, M. Kempf, E. Zrenner, B. Wilhelm, C. Kelbsch, K. Stingl GERMANY
Objective evaluation of rod visual field in patients with USH2A and PDE6A retinitis pigmentosa

Preserved cone photoreceptors and choroidal thickness analysis using high resolution retinal imaging in female carriers of choroideremia

15.18 L. Hahn, N. Wesseling, M. van Schooneveld, M. van Genderen, R. Florijn, J. ten Brink THE NETHERLANDS
Long term follow up, clinical and genetic spectrum of patients with juvenile X linked retinoschisis

15.24 N. Sinim Kahraman, A. Oner TURKEY
The therapeutic effect of subtenon injection of autologous platelet rich plasma in retinitis pigmentosa

Intravitreal injection of non expanded autologous bone marrow derived mononuclear cells for retinitis pigmentosa

15.36 S. Strong, A. Kalitzeos, T. Peto, S. Degli Esposti, W. Xing, C. Bunce, M. Michaelides UK
A prospective exploratory study to assess the safety and efficacy of aflibercept in cystoid macular oedema associated with retinitis pigmentosa

15.42 M. Simunovic, N. Avery, Z. Mammo AUSTRALIA
Threshold versus intensity functions in two colour perimetry

15.48 J. Kim, I. Kim, J. Lee SOUTH KOREA
Outer retinal tubulation in chronic central serous chorioretinopathy

16.00 End of session
14.30 – 16.00
INSTRUCTIONAL COURSE 23
Retinal Vein Occlusion: From Pathophysiology to Treatment
Room 251 (Level 2)
Course Organisers: S. Sivaprasad UK
I. Chatziralli GREECE
14.30 I. Chatziralli GREECE
Epidemiology, risk factors, pathophysiology of RVO
14.45 S. Sivaprasad UK
Imaging and prognosis in RVO
15.00 P. Hykin UK
LEAVO study
15.15 B. Blodi USA
SCORE 2 study
15.30 A. Loewenstein ISRAEL
Results of steroids / laser treatment
15.45 Panel discussion
Clinical cases
16.00 End of course

14.30 – 16.00
INSTRUCTIONAL COURSE 24
Pathology & Interventions in the Suprachoroidal Space
Room 351 (Level 3)
Course Organiser: S. Saidkasimova UK
14.30 S. Saidkasimova UK
Anatomy, physiology and pathophysiology
14.40 E. Feron BELGIUM
Suprachoroidal haemorrhage management
14.50 A. Laidlaw UK
Choroidal effusions and ocular hypotony management
15.00 P. Szurman GERMANY
Suprachoroidal buckling for peripheral breaks
15.10 E. El-Rayes EGYPT
Suprachoroidal macular buckling
15.20 S. Saidkasimova UK
Suprachoroidal approach to subretinal drug delivery
15.30 L. Au UK
Suprachoroidal glaucoma devices
15.40 P. Allen AUSTRALIA
Suprachoroidal retinal implant
15.50 Discussion
16.00 End of course
FRIDAY 6 SEPTEMBER

15.00 – 16.30  
INTERACTIVE

SPEAKERS’ CORNER 6

Vitreoretinal Surgery

Taking place within the EURETINA Speakers’ Corner (Harlequin, Level 3), the following posters will be presented for 3 minutes each with 2 minutes for discussion and interaction with the audience.

Moderator: T. Aslam  UK

15.00  I. Chatziralli, E. Dimitriou, T. Xiou, I. Gkizis, S. Kabanalou, P. Theodossiadis GREECE
OCT biomarkers as predictive factors for postoperative visual acuity in patients with epiretinal membrane treated with vitrectomy

15.05  M. Arimatsu, H. Hasebe, N. Matsuoka, E. Ueda, T. Fukuchi JAPAN
25g vitrectomy and internal limiting membrane peeling with and without fovea sparing for myopic foveoschisis

15.10  X. Lumi, S. Petrovic Pajic SLOVENIA
Autologous neurosensory retinal transplant in patients with macular hole

15.15  J. Verhoeckx, R. Wubbels, J. van Meurs, K. van Overdam THE NETHERLANDS
Prophylactic laser treatment to decrease the incidence of retinal detachment in fellow eyes of idiopathic giant retinal tears

15.20  M. Kim, S. Park, K. Park, S. Woo SOUTH KOREA
Different mechanistic association of myopia with rhegmatogenous retinal detachment between young and elderly patients

15.25  Y. Nariai, R. Sakurai, A. Tanikawa, M. Horiguchi JAPAN
Effect of illumination on visual acuity measurement in patients with epiretinal membrane

15.30  A. Tetsumoto, M. Hayashida, K. Otsuka, A. Miki, M. Nakamura JAPAN
Effectiveness of the intentional lamellar macular hole formation for the treatment of refractory cystoid macular edema

15.40  H. Takagi, T. Jujo, A. Shiono JAPAN
Impact of hemi-temporal ILM peeling on superficial retinal displacement in macular hole surgery

15.45  M. Brinkmann, M. Becker, S. Michels SWITZERLAND
Influence of vitrectomy and maculapexing on abnormalities of the central foveal bouquet in eyes with epiretinal membranes

15.50  N. Cheung, T. Wong, C. Cheng, S. Lee, E. Wong SINGAPORE
Macular hole in Singapore epidemiology of eye disease study

15.55  H. Terashima, N. Matsuoka, E. Ueda, T. Togano, T. Fukuchi JAPAN
Prediction of postoperative visual function based on inner layer structure of preoperative epiretinal membrane

16.00  V. Yarmak, V. Markovich BELARUS
Pseudophakic retinal detachment: the role of scleral buckling in our days

16.05  H. Yang, K. Kim SOUTH KOREA
Retinal hemorrhage after sub-tenon’s anesthesia in patients with pathologic myopia: a case-series

16.10  E. Reifsneider, K. Boden, H. Lägel, P. Szurman GERMANY
Sclerotomy leakage in transconjunctival small-gauge pars plana vitrectomy is affected by direction of the sclerotomies

16.15  M. Kutubi, N. Narendran, Y. Yang, K. Balaggan UK
Six months follow up data of ultrastructural and visual outcomes of large subfoveal haemorrhages treated with Pneumatic displacement and intravitreal Tissue Plasminogen Activator.

16.20  I. Chatziralli, E. Dimitriou, G. Theodossiadis, A. Chatzirallis, D. Kazantzis, P. Theodossiadis GREECE
Treatment of macular edema after pars plana vitrectomy for idiopathic epiretinal membrane using intravitreal dexamethasone implant: long-term outcomes

16.30  End of session
15.00 – 16.00
KEYNOTE LECTURE
Gisbert Richard Lecture
Grand Amphithéâtre (Level 0 & 2)
Chairperson: S. Wolf SWITZERLAND

Welcome
F.G. Holz GERMANY

Keynote
G. Pertile ITALY
Surgery in Exudative AMD: Functional and Physiopathological Implications

Presentation of the Award
G. Richard GERMANY

16.30 – 18.00
EURETINA SESSION 8
Decision Making in Challenging Cases
Grand Amphithéâtre (Level 0 & 2)

Chairpersons:
A. Gaudric FRANCE
A. Tufail UK
H. Vingerling THE NETHERLANDS
M. Zinkernagel SWITZERLAND

16.30 M. Zinkernagel SWITZERLAND
Are we able to predict reactivation after therapy cessation in patients with neovascular AMD

16.40 S. Vujosevic ITALY
What to do with a DME which does not dry after 6 months of continuous anti-VEGF treatment

16.50 R. Tadayoni FRANCE
Should we operate on lamellar macular holes?

17.00 R. Spaide USA
What is the best way to image the choriocapillaris with optical coherence tomography angiography? Techniques and pitfalls

17.10 A. Tufail UK
Should we inject a quiescent CNV in a fellow eye of a treated neovascular AMD patient?

17.20 H. Vingerling THE NETHERLANDS
Should we induce CNV in AMD to protect from atrophy?

17.30 R. Dolz Marco SPAIN
Why is it important to differentiate myopic choroidal neovascularisation from idiopathic multifocal choroiditis, or punctuate inner choroidopathy?

17.40 Y. Ikuno JAPAN
Should we operate myopic foveoschisis with significant macular thickening before vision drop?

17.50 M. Tedja THE NETHERLANDS
Should we treat young children with myopia?

18.00 End of session
FRIDAY 6 SEPTEMBER

16.30 – 18.00
EURETINA SESSION 9

Tumours
Amphithéâtre Bleu (Level 2)

Chairpersons:
S. Seregard SWEDEN
J-F. Kiilgaard DENMARK
H. Heimann UK

16.30 T. Kivela FINLAND
Are small pigmented lesions dangerous?

16.42 J-F. Kiilgaard DENMARK
OCT follow up of small lesions

16.54 H. Heimann UK
CHRPE what to do?

17.06 A. Joussen GERMANY
Endoresection of uveal melanoma

17.18 B. Damato USA
Endoresection of choroidal melanoma without neoadjuvant radiotherapy

17.30 A. Shain USA
The genetics of metastatic uveal melanoma

17.42 Discussion

18.00 End of session

16.30 – 18.00
SYMPOSIUM

The State-of-Art Artificial Intelligence Technologies for Retinal Diseases

Amphithéâtre Bordeaux (Level 3)

Chairpersons:
D. Ting SINGAPORE
P. Keane UK

16.30 T. Wong SINGAPORE
AI in Retina: Where are we now? What’s next?

16.42 D. Ting SINGAPORE
From development to clinical integration of AI into a national DR screening programme

16.54 N. Bressler USA
AI for AMD detection and prediction using fundus photographs

17.06 S. Sadda USA
AI for wide field imaging for DR

17.18 P. Keane UK
The state-of-art deep learning systems for retinal conditions on OCTs

17.30 U. Schmidt-Erfurth AUSTRIA
Deep learning in optical coherence tomography for age-related macular degeneration

17.40 Discussion

18.00 End of symposium
<table>
<thead>
<tr>
<th>Time</th>
<th>Course Organiser</th>
<th>Location</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>16.30</td>
<td>E. Miserocchi</td>
<td>ITALY</td>
<td>Update on diagnosis of uveitis</td>
</tr>
<tr>
<td>16.45</td>
<td>M. Funk</td>
<td>AUSTRIA</td>
<td>Imaging in uveitis: When to do and what to do</td>
</tr>
<tr>
<td>17.00</td>
<td>U. Pleyer</td>
<td>GERMANY</td>
<td>New developments in treatment and surgery in uveitis</td>
</tr>
<tr>
<td>17.15</td>
<td>J. De Boer</td>
<td>THE NETHERLANDS</td>
<td>Paediatric uveitis: how to approach diagnosis and management in children with uveitis</td>
</tr>
<tr>
<td>17.30</td>
<td></td>
<td></td>
<td>Discussion</td>
</tr>
<tr>
<td>18.00</td>
<td></td>
<td></td>
<td>End of course</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Course Organiser</th>
<th>Location</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>16.30</td>
<td>P. Sullivan</td>
<td>UK</td>
<td>Introduction</td>
</tr>
<tr>
<td>16.32</td>
<td>P. Sullivan</td>
<td>UK</td>
<td>Complications of scleral buckling</td>
</tr>
<tr>
<td>16.44</td>
<td>A. Laidlaw</td>
<td>UK</td>
<td>Retinal trauma during vitrectomy</td>
</tr>
<tr>
<td>16.56</td>
<td>C. Pavesio</td>
<td>UK</td>
<td>Uveitis and vitrectomy</td>
</tr>
<tr>
<td>17.08</td>
<td>A. Laidlaw</td>
<td>UK</td>
<td>Complications of diabetic vitrectomy</td>
</tr>
<tr>
<td>17.20</td>
<td>P. Sullivan</td>
<td>UK</td>
<td>Intraocular haemorrhage during vitrectomy</td>
</tr>
<tr>
<td>17.32</td>
<td></td>
<td></td>
<td>Discussion</td>
</tr>
<tr>
<td>18.00</td>
<td></td>
<td></td>
<td>End of course</td>
</tr>
</tbody>
</table>
**FRIDAY 6 SEPTEMBER**

**16.30 – 18.00**

**FREE PAPER SESSION 13**

**Mixed II**

**Amphithéâtre Havane (Level 3)**

Chairpersons:  
F. Bandello **ITALY**  
Z. Abdelmoneim Abdou **EGYPT**

**16.30**  
Z. Abdelmoneim Abdou, A. Howaidy **EGYPT**  
Comparison of aflibercept versus ranibizumab in patients with myopic choroidal neovascularization

**16.36**  
B. Kucuk, S. Akkaya, E. Sirakaya **TURKEY**  
Evaluation of thiol/disulfide homeostasis as a novel tool for the assessment of oxidative stress in patients with retinopathy of prematurity

**16.42**  
B. Jacobsen, A. Shah, S. Aggarwal, A. Shakoor **USA**  
Prevalence of retinal diseases and associated risk factors in an African population from Mwanza, Tanzania

**16.48**  
C. Del Turco, C. La Spina, G. D’Amico Ricci, E. Belcastro, C. Panico **ITALY**  
Eye injuries in an Italian urban population study II: the ten year report of the eye emergency department of Torino

**16.54**  
D. Taylor, L. Jones, L. Edwards, D. Crabb **UK**  
What are the readability levels of patient reported outcome measures used in common ophthalmological conditions?

**17.00**  
E. Vounotrypidis, J. Meyer, R. Liegl, R. Schuhmann, S. Priglinger, A. Wolf **GERMANY**  
Impact of epiretinal membrane stage and OCT biomarkers on resolution of persistent post operative cystoid macular edema after vitrectomy

**17.06**  
F. Bandello, L. D’Angiolella, M. Bianco, C. Bennison, B. Lescruwaet, L. Mantovani **ITALY**  
Cost effectiveness of ocirplasmin for the treatment of vitreomacular traction with or without full thickness macular hole in Italy

**17.12**  
B. Schworm, J. Siedlecki, F. Hagenau, K. Kortum, S. Priglinger, N. Luft **GERMANY**  
Response of secondary choroidal neovascularization in chronic central serous chorioretinopathy to an extended upload of anti VEGF agents

**17.18**  
F. Dikkaya, S. Karaman Erdur **TURKEY**  
Comparison of choroidal thickness between high hyperopic and low hyperopic children

**17.24**  
G. Gonzalez Saldivar, D. Chow **MEXICO**  
Comparison of simulated surgical skills using different camera aperture settings for digitally assisted vitreoretinal surgery

**17.30**  
H. Zhang, Z. Liu **CHINA**  
Comparison of the effect of intravitreal conbercept and ranibizumab on aqueous humor cytokines in macular edema secondary to central retinal vein occlusion

**17.36**  
S. Fraser Bell, P. Mitchell, K. Kang, J. Tainton, S. Simonyi **AUSTRALIA**  
Dexamethasone intravitreal implant in diabetic macular edema refractory to anti vascular endothelial growth factor therapy – a subgroup analysis of the phase 4, open label, non randomized, prospective AUSSIEDEX study

**17.42**  
J. Verhoeckx, L. Smid, K. Vermeer, J. Martinez, S. Yzer **THE NETHERLANDS**  
Exploring the clinical spectrum of perifoveal exudative vascular anomalous complex

**17.48**  
J. Cunha-Vaz, I. Marques, D. Alves, T. Santos, A. Santos, C. Lobo, M. Durbin **PORTUGAL**  
Characterization of disease progression in the initial stages of retinopathy in diabetes type 2. A two year longitudinal study

**18.00**  
End of session
**FRIDAY 6 SEPTEMBER**

**16.30 – 18.00**

**INSTRUCTIONAL COURSE 27**

*Best Practice & Novel Approaches to the Management of Macular Haemorrhage*

*Salle Maillot (Level 2)*

**Course Organisers:**
- C.F. Arndt **FRANCE**
- L.O. Hattenbach **GERMANY**

16.30  **S. Bopp** **GERMANY**
How to classify macular haemorrhages - Impact on clinical decision making

16.45  **N. Feltgen** **GERMANY**
When and how should we use anti-VEGF monotherapy in the management of macular haemorrhage?

17.00  **C. Arndt** **FRANCE**
Agony of choice or clear thing? Advantages and disadvantages of surgical drainage in subretinal macular haemorrhage

17.15  **L.O. Hattenbach** **GERMANY**
How to reduce risks and improve outcomes in macular haemorrhage - Minimally invasive and digitally assisted surgical techniques

17.30  **B. Parolini** **ITALY**
Autologous choroidal RPE patch transplantation in haemorrhagic age-related macular degeneration - Surgical techniques and drawbacks

17.45  Discussion

18.00  End of course

**16.30 – 18.00**

**INSTRUCTIONAL COURSE 28**

*Stepping into the Future: How to Safely Adopt New Surgical Techniques*

*Room 251 (Level 2)*

**Course Organisers:**
- S. Saidkasimova **UK**
- L. Wickham **UK**

16.30  **L. Wickham** **UK**, **D. Yorston** **UK**
How to safely innovate my surgical practice

16.45  **L. Wickham** **UK**
Challenges of changing to 27G surgery

17.00  **S. Lash** **UK**, **A. Chandra** **UK**
Scleral capture intraocular lenses

17.15  **D. Steel** **UK**
ILM flap surgery for macular holes

17.30  **S. Saidkasimova** **UK**
Suprachoroidal buckle

17.45  Discussion

18.00  End of course
FRIDAY 6 SEPTEMBER

16.30 – 18.00

FREE PAPER SESSION 14

Tumours & Anterior Posterior Segment Surgery

Room 241 (Level 2)

Chairpersons: P. Stavrakas GREECE
G. Barcat UK

16.30 G. Barcat, J. Tripp, K. Van Keer, S. Overall, R. Ling UK
Real World retrospective study evaluating the incidence of endophthalmitis following use of intravitreal injection therapy (IVT) of anti vascular endothelial growth factor (anti VEGF) agents aflibercept and ranibizumab, vial vs pre filled syringe (PFS)

Genomic characteristics of paired choroidal melanoma samples obtained before and after proton beam irradiation in patients undergoing endoresection

16.42 D. Bhojwani, S. Vasavada, V. Vasavada, A. Sudhalkar, A. Vasavada INDIA
Safety profile and clinical outcomes of scleral fixed IOLs using a novel nonbiodegradable suture

16.48 G. Deak, D. Goldstein, L. Jampol AUSTRIA
Vertical hyperreflective lesions: an OCT finding in vitreoretinal lymphoma

16.54 H. Khaqan PAKISTAN
Outcomes of intravitreal melphalan for vitreous seeding resistant to systemic chemotherapy or intra arterial chemotherapy in retinoblastoma

17.00 I. Seibel, D. Eckstein, A. Riechardt, O. Zeitz, A. Boker, C. Brockmann, A. Joussen GERMANY
Radiation induced optic neuropathy – observation versus intravitreal treatment

17.06 L. Vigues Jorba, R. Morwani Morwani, D. Lorenzo Parra, J. Caminal Mitjana, G. Fernandez Cosmen, M. Baradad Jurjo SPAIN
Survival in small melanocytic lesions with risk factors initially monitored until growth

17.12 M. Baradad Jurjo, Á. Fernandez Vega Gonzalez, D. Lorenzo Parra, L. Arias Barquet, J. Caminal Mitjana SPAIN
Concordance between ultrasonography and swept source optical coherence tomography in the measurement of melanocytic choroidal tumors

17.18 M. Batur, M. Ozer, S. Tekin TURKEY
Effect of reduced production of aqueous humor on bacterial growth potential in rabbit eyes

17.24 M. Tunc, K. Oysul, E. Ataseven Akkas TURKEY
Cyberknife radiotherapy of small, medium and large uveal melanoma: effects of tumor size and fractionization on radiation induced complications

17.30 O. Scannell, V. O’Neill, M. Dunne, C. Baily, M. Cunningham, N. Horgan IRELAND
Quality of life in uveal melanoma patients

17.36 P. Dhoble, J. Jayakumar INDIA
Sub Tenon’s versus retrobulbar anesthesia in vitreoretinal surgeries: a prospective randomised study

17.42 R. Parrozzani, L. Frizziero, S. Trainiti, E. Pilotto, E. Midena ITALY
Identification and classification of macular morphologic biomarkers related to visual acuity in radiation maculopathy: a multimodal imaging study

17.48 S. Aslanis, D. Epstein SWEDEN
Anterior subconjunctival triamcinolone acetonide injection for the treatment of postoperative cystoid macular edema

18.00 End of session
16.30 – 18.00

EVICR.NET SYMPOSIUM

Room 351 (Level 3)

Chairpersons: J. Cunha-Vaz PORTUGAL
              H. Scholl SWITZERLAND

16.30  H. Scholl SWITZERLAND
       What’s new in retina and EVICR.net’s contributions in Europe

16.40  F.G. Holz GERMANY
       MACUSTAR – An IMI2 study on AMD outcomes

16.50  H. Scholl SWITZERLAND
       Treatment of retinal dystrophies: New developments

17.00  B. Lorenz GERMANY
       EVICR.net and the European reference network on rare eye diseases

17.10  J. Cunha-Vaz PORTUGAL
       Imaging biomarkers for diabetic retinal disease – The recognised study

17.20  C. Martinho PORTUGAL
       EVICR.net update

17.30  Roundtable on Innovation in Retinal Diseases Management
       Moderators:
       F. Asmus GERMANY
       A. Clemens SWITZERLAND
       J. Cunha-Vaz PORTUGAL
       M. Durbin USA
       F.G. Holz GERMANY
       H. Scholl SWITZERLAND
       T. Otto GERMANY

18.00  End of symposium
YOURS provides a platform to ensure that issues and focus points of Young Retina Specialist are heard. Sign up for free Membership (under 40s) at the EURETINA Resource Centre (Exhibition Hall, Level 2) or online.

Don’t miss the Young Retina Specialists Day

Saturday 7th September 2019
10.00 – 17.15
Amphithéâtre Havane (Level 3)

Programme Outline

YOURS Symposium: New Developments in Retinal Research & Treatment
Organisers: D. Fischer GERMANY, Y. Subhi DENMARK, L. Kuehlewein GERMANY

YOURS Science Slam
Organisers: C.J. Boon THE NETHERLANDS, C. Dysli SWITZERLAND, E. van Dijk THE NETHERLANDS

YOURS Mystery Cases
Organisers: E. de Carvalho UK, R. Mastropasqua ITALY

Ophthalmologica Lecture 2019
Keynote Presentation: R. Dolz Marco SPAIN
From Histology to Multimodal Imaging in AMD

For more information go to www.euretina.org/yours
Saturday
7 September
**SATURDAY 7 SEPTEMBER**

08.00 – 09.30

**EURETINA SESSION 10**

**RETINAWS 3D**

Grand Amphithéâtre

**Chairperson:** K. Rezaei USA

This dynamic 3D session consists of video presentations describing challenging cases and unexpected events during retinal surgery.

The aim is for faculty to share their experiences to predict, treat and prevent unexpected outcomes during surgery. Attendees will gain a knowledge of a variety of unexpected and complicated events during surgery.

**Faculty:**
- F. Balta ROMANIA
- E. Balli BELGIUM
- K. El Sabti UAE
- F. Fayyad JORDAN
- J. García-Arumí SPAIN
- K. Kadonosono JAPAN
- S. Priglinger GERMANY
- S. Rizzo ITALY
- R. Tadayoni FRANCE

08.00 – 09.30

**FREE PAPER SESSION 15**

**AMD III**

**Amphithéâtre Havane (Level 3)**

**Chairpersons:**
- P. Mitchell AUSTRALIA
- S. Natarajan INDIA

08.00


Efficacy of intravitreal aflibercept administered using treat and extend regimen over 2 years in patients with neovascular age related macular degeneration: 1 year Aries results

08.06

J. Ehlers, J. Clark, A. Uchida, N. Figueiredo, L. Lunasco, J. Reese, X. Meng USA

Higher order optical coherence tomography (OCT) fluid burden assessment: Analysis from the OSPREY trial

08.12

K. Hatz, M. Guichard, P. Rossouw SWITZERLAND

Correlation between different visual acuity measurements and patient self reported vision related quality of life in bilateral neovascular AMD

08.18

K. Teo, G. Cheung, A. Gan, N. Saxena, S. Patil SINGAPORE

The impact of compliance on the 12 month outcomes in the treatment of neovascular age related macular degeneration. An experience in a co payment healthcare system

08.24

K. Spooner, S. Fraser Bell, M. Cozzi, D. Monteduro, A. Invernizzi, G. Staurenghi, A. Chang AUSTRALIA

Comparison of macular atrophy in eyes with neovascular age related macular degeneration treated with VEGF inhibitors using a treat and extend or a pro re nata regimen: Four year results of the manex study

08.30


The effectiveness of intravitreal aflibercept in routine clinical practice in patients with treatment naïve neovascular age related macular degeneration (nAMD): GALAXY – An integrated pooled analysis of two studies from different healthcare systems

08.36

L. Sauer, C. Komanski, A. Vitale, E. Hansen, C. Calvo, P. Bernstein USA

Fluorescence lifetime imaging ophthalmoscopy (FLO) in AMD

08.42

M. Sand Sivertsen, M. Moe, O. Jorstad NORWAY

A cluster of 48 cases of symptomatic silicone droplets following intravitreal anti VEGF: Injections addressed by switching to silicone free syringes

08.48

M. de Luz Cachulo, M. Oliveira, C. Farinha, T. Rodrigues, J. Marques, I. Pires, R. Silva PORTUGAL

Macular atrophy in Anti VEGF treated neo vascular AMD: Incidence and risk factors

08.54

M. Krogh Nielsen, S. Jandorf, K. Sørensen, T. Sørensen DENMARK

Low health literacy levels in patients with chronic retinal disease
08.00 – 16.00

INSTRUCTIONAL COURSE

Genetics of Retinal Disease

Room 251 (Level 2)

Course Organisers: C. Hoyng THE NETHERLANDS
C.C.W. Klaver THE NETHERLANDS
C.J. Boon THE NETHERLANDS

Part I: Genetics of Inherited Retinal Dystrophies

08.00 C.C.W. Klaver THE NETHERLANDS
General introduction of genetics of retinal dystrophies

08.15 B. Leroy BELGIUM
Electrofysiological testing in RD

08.30 J. Klevering THE NETHERLANDS
Retinitis pigmentosa, the clinical spectrum

08.45 B. Leroy BELGIUM
Syndromes associated with RP

09.00 C.C.W. Klaver THE NETHERLANDS
Usher syndrome

09.15 D. Fischer GERMANY
Choroideremia

09.30 C. Hoyng THE NETHERLANDS
Stargardt disease

09.45 C.J. Boon THE NETHERLANDS
Best disease

10.00 Morning Break

10.30 L. Hahn THE NETHERLANDS
x-linked retinoschisis

10.45 A. Thiadens THE NETHERLANDS
Cone dystrophies

Part II: Emerging Therapies in RD

11.00 C.J. Boon THE NETHERLANDS
General introduction in therapeutic approaches in RD

11.15 B. Leroy BELGIUM
Gene therapy in RPE65

11.30 D. Fischer GERMANY
Gene therapy in Choroideremia

11.45 C. Hoyng THE NETHERLANDS
Therapies in Stargardt disease

12.00 D. Fischer GERMANY
Gene therapy in achromatopsia

12.15 R. Collin THE NETHERLANDS
Antisense oligonucleotide therapy in retinal disease

12.30 Break for Lunch

Part III: Various

13.30 V. Verhoeven THE NETHERLANDS
Genetic testing and its consequences

14.00 Discussion

16.15 End of session
10.00 – 17.15
YOUNG RETINA SPECIALISTS (YOURS) DAY 2019
Amphithéâtre Havane (Level 3)

10.00 – 11.30
New Developments in Retinal Research & Treatment
Organisers: D. Fischer GERMANY
L. Kuehlewein GERMANY
Y. Subhi DENMARK

10.00  K. Januschowski GERMANY
Testing and fist clinical results of a hydrogel-based artificial vitreous substitute

10.14  L. Sauer USA/GERMANY
Fluorescence lifetime imaging ophthalmoscopy (FLIO) in MacTel

10.28  R. Schwartz UK
“I can see your halo”

10.42  A. Daruich Matet FRANCE
Iron is neurotoxic in retinal detachment and transferrin confers neuroprotection

10.56  T. Kurmann SWITZERLAND
Expert-level automated biomarker identification in optical coherence tomography scans

11.10  D. Bacherini ITALY
“OCT angiography in macular hole”

11.24  Discussion

11.30 – 11.45 Break

11.45 – 12.45 YOURS Science Slam
Organisers: C.J. Boon THE NETHERLANDS
C. Dysli SWITZERLAND
E. van Dijk THE NETHERLANDS

11.45  L. Cehofski DENMARK
The mystery of retinal vein occlusion – Untangling molecular mechanisms through animal models and proteomics

11.51  I. Kilic ISRAEL
Game of the membrane

11.56  M. Forslund Jacobsen DENMARK
Robot-assisted vitreoretinal surgery: Rise of the machines?

12.02  S. Halim UK
Demystifying the black box: scratching the surface of deep learning in modern diabetic retinopathy screening

12.08  S. Numa JAPAN
The AI-detective: Can Mr. Watson elucidate the causative genes of retinitis pigmentosa?

12.14  B. Elora Higgins UK
Dude, where’s my car? Novel tasks assessing everyday visual function in people with age-related macular degeneration

12.20  J. Ten Berge THE NETHERLANDS
The eye under attack: Autoimmunity in uveitis and other choriorretinal disorders

12.26  S. Kunzel THE NETHERLANDS
Reading report - Can we predict patients’ reading abilities?

12.32  J. Brinks THE NETHERLANDS
Steroids and central serous chorioretinopathy: A human-based model

12.45 – 14.15 Break for Lunch

14.15 – 15.00 Mystery Cases I

14.15  A. Willerslev DENMARK
A mystery

14.26  R. Anjos PORTUGAL
The drowning bull

14.37  R.A. Sonmez TURKEY
That’s too coincidental to be a coincidence

14.49  M. Forlini ITALY
Mysterious vision loss in a teenager

15.00 – 15.30
Ophthalmologica Lecture
R. Dolz Marco SPAIN
From Histology to Multimodal Imaging in AMD

15.30 – 16.15
Mystery Cases II
Organisers: E. de Carvalho UK
R. Mastropasqua ITALY

15.30  A. Liu USA
Retinal evaluation after cataract surgery

15.41  L. del’Arti ITALY
That’s bilateral!

15.52  S. Kamar THE NETHERLANDS
An island of vision in an atrophic fundus

16.03  M. Khattab GERMANY
Unilateral RP, really?

16.15 – 17.15
Networking Reception
10.00 – 11.30

SPEAKERS’ CORNER 7

Imaging & Retinal Dystrophies

Taking place within the EURETINA Speakers’ Corner (Arlequin, Level 3), the following posters will be presented for 3 minutes each with 2 minutes for discussion and interaction with the audience.

10.00  S. Strong, A. Quartilho, A. Kalitzeos, M. Michaelides  UK
A retrospective cohort study exploring whether an association exists between spatial distribution of cystoid spaces in cystoid macular oedema secondary to retinitis pigmentosa and response to treatment with carbonic anhydrase inhibitors.

10.05  S. Costa, A. Grangeia, R. Santos Silva, S. Estrela Silva, F. Falcão Reis  PORTUGAL
A novel homozygous frameshift variant in the cellular retinaldehyde-binding protein 1 gene (RLBP1) causes retinitis punctata albescens

10.10  M. Prieto del Cura, M. Crespo Carballes, J. Garcia Hinojosa, L. Rebolledo Lara  SPAIN
A rare presentation of pigmented paravenous retinochoroidal atrophy

10.15  O. Fayzrakhmanova, E. Larina  RUSSIA
Changes in the morphology of the macula in epiretinal fibrosis

10.20  S. Kasbia, N. Boonarpha, T. Aslam  UK
Choroidal thickness measurements using enhanced depth imaging OCT: The feasibility of automatic analysis in central serous retinopathy

10.25  Y. Wang, Y. Oh, J. Rullo, S. Sharma  CANADA
Evaluating changes in scleral quadrant thickness following repeated intravitreal injections of anti-vascular endothelial growth factor agents

10.30  A. Vagge, P. Cirafici, V. Testa, H. Orlans, C. Traverso, M. Nicò  ITALY

10.35  A. Karalezli, S. Sul, A. Kaderli  TURKEY
Evaluation of macular microvascularity and choriocapillaris after pneumatic retinopexy

10.40  K. Nam, S. Ahn, B. Lee, J. Oh  SOUTH KOREA
Features of the choriocapillaris and choroidal vessels on 4 different optical coherence tomography angiography devices

10.45  O. Galvin  IRELAND
Impact of inherited retinal disease in Ireland and UK

10.50  L. Barbano, V. Pagliei, E. Verrecchia, F. Martelli, L. Ziccardi, B. Falsini  ITALY
Macular impairment in Fabry disease: a morpho-functional assessment by swept-source OCT angiography and focal electroretinography

10.55  R. Burggraaf Sánchez de las Matas, J. Zarco Bosquet, A. Soriano Lafarga, A. Estrela Sanchis  SPAIN
Macular pattern dystrophy in maternally inherited diabetes and deafness (MIDD): 7 years progression, clues and implications of diagnosis

11.00  M. Haruta, S. Yoshida  JAPAN
Macular retinoschisis associated with glaucomatous optic neuropathy: Response to topical carbonic anhydrase inhibitor and trabeculectomy

11.05  N. Mandal  UK
Multimodal imaging of late-onset retinal degeneration

11.10  J. Baek, S. Kwon  SOUTH KOREA
OCT angiography of persistent hyaloid artery(pha): a case report

11.15  S. Kadayıfçilar, A. İşkay Çolpak, G. Yağcın Çakmaklı, A. Bilgiç, B. Elibol, B. Eldem  TURKEY
Retinal and choroidal findings in autosomal recessive Parkinson’s disease are similar to those in idiopathic Parkinson’s disease

11.20  M. Maglíyah, A. Saif Addin  SAUDI ARABIA
Rpe65 mutation in three siblings with lca resulting in variable phenotypic features

11.30  End of session
11.00 – 12.30

**EURETINA SESSION 11**

**AMD**

**Grand Amphithéâtre (Level 0 & 2)**

**Chairpersons:**
- P. Mitchell, **Australia**
- F.G. Holz, **Germany**
- G. Staurenghi, **Italy**

11.00  P. Mitchell, **Australia**  
AMD real world management and outcomes

11.10  P. Dugel, **USA**  
New pharmacologic agents for neovascular AMD therapy

11.20  F. Sennlaub, **France**  
Complement and immunomodulatory therapy in AMD

11.30  G. Staurenghi, **Italy**  
Classifying and staging atrophy in AMD

11.40  U. Chakravarthy, **UK**  
Apl-2 treatment for geographic atrophy

11.50  R. Finger, **Germany**  
Subthreshold laser treatment approaches for intermediate AMD

12.00  G. Cheung, **Singapore**  
Choroidal thickness and AMD manifestations

12.10  A. Loewenstein, **Israel**  
PDS with long-acting drug delivery

12.20  Discussion

12.30  End of session

---

11.00 – 12.30

**SYMPOSIUM**

**Retinal Pigment Epithelium & Choroid: A Functional Unit in Healthy & Affected Eyes**

**Room 351 (Level 3)**

**Chairpersons:**
- F. Bandello, **Italy**
- F. Coscas, **France**
- G. Querques, **Italy**
- E. Souied, **France**

11.00  I. Audo, **France**  
Imaging the RPE metabolism

11.10  R. Sacconi, **Italy**  
Imaging the choroid and its aging

11.20  F. Behar-Cohen, **France**  
RPE in health and diseases: Imaging and pathology correlations

11.30  E. Borrelli, **Italy**  
Choroid and diabetes

11.40  F. Coscas, **France**  
RPE in AMD

11.50  S. Sadda, **USA**  
The choroid in AMD

12.00  S. Sivaprasad, **UK**  
RPE detachments (CSCR and others)

12.10  I. Meunier, **France**  
RPE in retinal dystrophies

12.20  L. Zografos, **Switzerland**  
Imaging the RPE in oncology

12.30  End of symposium
13.15 – 14.45 INTERACTIVE

SPEAKERS’ CORNER 8

Mixed III

Taking place within the EURETINA Speakers’ Corner (Arlequin, Level 3), the following posters will be presented for 3 minutes each with 2 minutes for discussion and interaction with the audience.

Moderator: M. Munk SWITZERLAND

13.15 M. Elashry, H. Hasan UK
Improving the medical management of patients with sight-threatening diabetic retinopathy using point of care HbA1c

13.20 S. Babiker, Z. Cheng, I. Pearce UK
Audit on the utility of Optical coherence tomography angiography in detection of choroidal neovascularisation in age related macular degeneration

13.25 D. Cha, H. Ku, H. Yu SOUTH KOREA
Comparison of clinical results between 4-point scleral fixation of intraocular lenses with Gore-Tex suture and 2-point fixation with Prolene suture

13.30 I. Hernandez de los Reyes, A. Gomez Fernandez, M. Garcia Zamora, I. Flores Moreno, E. Casado Lopez de la Franca, J. Ruiz Moreno SPAIN
Data analysis of intravitreal therapy in wet age-related macular degeneration through the light retinal blindness platform

13.35 N. Daftarian, F. Suri, H. Ahmadieh, M. Rezaei Kanavi, Z. Soheili IRAN
Effects of intravitreal connective tissue growth factor neutralizing antibody on the epiretinal membrane formation; an experimental study

13.40 M. Alotaibi, H. Alkatan, D. Edward, I. Kozak SAUDI ARABIA
Immunohistochemical characterization of subretinal bands in proliferative vitreoretinopathy

13.45 E. Pearce, S. Sivaprasad UK
Improvements in deep haemorrhages and IRMA are maintained within four months of receiving intravitreal aflibercept injections

13.50 M. Jimenez Santos, J. Ruiz Medrano, A. Valverde Megias SPAIN
Influence of eye dominance in peripapillary retinal nerve fiber layer and outer retinal layers in a pediatric population

13.55 H. Taylan Sekeroglu, J. Karakaya TURKEY
Is fixation prevalence a potential indicator of macular function?: A pilot study

14.00 H. Chien TAIWAN
Kaempferol suppresses cell migration through the activation of the ERK signaling pathways in ARPE-19 cells

14.05 M. Woronkowicz, A. Webster UK
Long-term outcomes of intravitreal anti-VEGF treatment for choroidal neovascularization secondary to pseudoxanthoma elasticum

14.10 I. Velasque, M. Dominguez, E. Fourmaux, L. Rosier, C. Seguy FRANCE
LUX study : contribution of a heads-up three-dimensional high dynamic range visualization system with a low light sensitive camera to a significant decrease of the endoillumination during ocular surgeries, compensated by the brightness of the screen

14.15 L. Jones, L. McDonald, P. Jones, D. Crabb UK
Sight: the most valuable sense?

14.20 M. Kuze, M. Kataoka, Y. Fukuda, T. Morita JAPAN
The effect of blue light filter on electrical response of intrinsically photosensitive retinal ganglion cells

14.25 S. Ozdogan Erkul TURKEY
The real-life comparison of clinical and anatomical results of neovascular age related macular degeneration patients with good and bad follow-up according to the number of median visits in Turkey. Bosphorus retina study group report 4

14.30 W. Fusi Rubiano, E. Gokhale, R. Chavan UK
Twelve month outcomes comparing different anti-VEGF treatment regimens for the treatment of AMD in a UK NHS Trust

14.35 C. Hazel, C. Fulcher, F. Ghanchi UK
Vision outcomes in patients with central serous chorioretinopathy (CSCR) – A real-life study

14.45 End of session
SATURDAY 7 SEPTEMBER

14.30 – 16.00

EURETINA SESSION 12
Research Session
Grand Amphithéâtre (Level 0 & 2)
Chairpersons: M. la Cour DENMARK
R. MacLaren UK

14.30  B. Lam USA
RPGR gene therapy
14.45  M. Pennesi USA
Choroideremia gene therapy
15.00  P. Barale FRANCE
Luxturna gene therapy
15.15  R. MacLaren UK
CRISPR gene therapy
15.30  U. Schmidt-Erfurth AUSTRIA
Artificial intelligence in retinal decision making
15.45  Discussion
16.00  End of session

15.00 – 16.30

INTERACTIVE

SPEAKERS’ CORNER 9
VR Surgery & New Drug Treatment & Technology
Taking place within the EURETINA Speakers’ Corner (Arlequin, Level 3), the following posters will be presented for 3 minutes each with 2 minutes for discussion and interaction with the audience.

15.00  H. Ra SOUTH KOREA
Efficacy of the inverted internal limiting membrane flap technique with perfluorocarbon liquid-mediated selective staining for large macular hole repair
15.05  K. Shinoda, M. Shibuya, J. Makita, T. Shoji, H. Ohno, H. Matsumoto JAPAN
3D heads up surgery under low light intensity conditions: New high sensitivity HD camera for ophthalmologic microscopes
15.10  N. Gan SINGAPORE
A case series of sub-ILM (internal limiting membrane) hemorrhages and their evolution: When to intervene?
15.15  S. Kohsuke, S. Yoshiaki, S. Ryota, T. Atsuxiro, H. Masayuki JAPAN
A novel wide-angle B-mode echogram to find abnormality in eyeball shape in patients with Marfan syndrome
15.20  V. Chaudhary, A. Lee, J. Barbosa, G. Isaza CANADA
A review evaluating telemedicine screening for retinopathy of prematurity
15.25  N. Matsuoka, H. Terashima, T. Fukuchi JAPAN
Change of the internal limiting membrane peeling area after vitrectomy for idiopathic macular hole
15.30  C. Tatyana, N. Arbenyeva RUSSIA
Detection of ocular ischemic syndrome in patients with chronic ischemic neuropathy
15.35  B. Kim, O. Kwon, H. Yu SOUTH KOREA
Evaluation of the safety and efficacy of R:GEN laser treatment in patients with Central Serous Chorioretinopathy
15.40  D. Abulon USA
Fluid flow performance 27 gauge dual cutters
15.45  E. Kacerik, M. Codenotti, F. Bandello ITALY
Intraoperative increased cohesion with TWIN blue dye during vitreoretinal surgery
15.50  S. Trier, P. Schoonheim UK
Online medical education can significantly improve ophthalmologists’ knowledge on emerging therapies for neovascular age related macular degeneration (nAMD) and aid early adoption into clinical practice
15.55  S. Chiu UK
Outcomes in primary macular hole surgery with 23-gauge, 25-gauge, and 27-gauge pars plana vitrectomy (PPV)
16.00  N. Yudina, I. Trifanenkova, E. Erohina, M. Tereshchenkova  
RUSSIA  
Place episcleral circular buckling in the treatment of retinal detachments with cicatrical retinopathy of prematurity

16.05  T. Sato, L. Hernandez Aya, J. Sacco, M. Orloff, F. Engler, N. Little  
USA  
Redirected t cell mediated lysis in patients with metastatic uveal melanoma with gp100-directed tcr imcgp100: Overall survival findings

16.10  N. Khan  
UK  
The implementation of day 1 post-operative vitrectomy telephone follow-up consultations by clinic nursing staff

16.15  A. Serhiienko, K. Tkachuk  
UKRAINE  
Modeling of silicone oil emulsification under posterior retinal tamponade

16.20  M. Lam  
FRANCE  
Epiretinal membrane foveoschisis in low myopic eyes

16.30 – 18.00  
EURETINA SESSION 13  
Myopia Update 2019: Pathogenesis, Diagnosis & Treatment  
Grand Amphithéâtre (Level 0 & 2)

Chairpersons:  
Y. Ogura  
JAPAN  
R. Tadayoni  
FRANCE

16.30  R. Tadayoni  
FRANCE  
Myopic traction maculopathies made easy

16.40  K. Ohno-Matsui  
JAPAN  
Ultra-wide field OCT imaging for pathologic myopia

16.50  G. Cheung  
SINGAPORE  
Correlation of aqueous molecular factors and fundus changes in highly myopic eyes

17.00  A. Grzybowski  
POLAND  
Atropine to prevent myopia progression

17.10  R. Spaide  
USA  
Underdiagnosed inflammation in myopic choroidal neovascularization

17.20  W.K. Lee  
SOUTH KOREA  
Macular hole development after myopic maculoschisis repair

17.30  B. Parolini  
ITALY  
MTM Italian staging system: From classification to treatment

17.40  Discussion

16.00  End of session
SATURDAY 7 SEPTEMBER

16.30 – 18.00
INSTRUCTIONAL COURSE 29
AI in the Retina: Deep Learning for the Ophthalmologist
Amphithéâtre Bleu (Level 2)
Course Organiser: U. Schmidt-Erfurth AUSTRIA
16.30 M. Abramof USA
Understanding and using AI in retinal imaging
16.42 B. Gerendas AUSTRIA
Automated diabetes screening in Europe
16.54 U. Schmidt-Erfurth AUSTRIA
Understanding retinal disease by AI
17.06 H. Bogunovic AUSTRIA
AI for personalized therapy and prognosis
17.18 A. Sadeghipour AUSTRIA
AI in retina has already arrived: AI-tools ready to use
17.30 J. Roider GERMANY
OCT and AI at home
17.42 Discussion
18.00 End of course

16.30 – 18.00
INSTRUCTIONAL COURSE 30
OCT-Angiography in Clinical Practice from the OCTANE (OCT Angiography Network) Study Group: Real-World Experience & Challenges
Amphithéâtre Bordeaux (Level 3)
Course Organiser: K. Balaskas UK
16.30 R. Gale UK
How to interpret OCTA- a systematic approach
16.40 I. Pearce UK
OCT-A in retinal vein occlusions
16.50 G. Staurenghi ITALY
OCTA in geographic atrophy
17.00 F. Ghanchi UK
Experience with different commercially available OCT-A devices, relative strengths and weaknesses
17.10 J. Talks UK
OCT-A in diabetic maculopathy, role for assessing perfusion and association with visual function
17.20 S. Sivaprasad UK
OCT-A in wet AMD, diagnostic accuracy and role for assessing response to treatment
17.30 T. Aslam UK
Artificial intelligence for the interpretation of OCTA
17.40 Discussion
18.00 End of course
16.30 – 18.00

FREE PAPER SESSION 16

Vascular Diseases & Diabetic Retinopathy III

Amphithéâtre Havane (Level 3)

Chairpersons:  
M. Zarbin  USA  
C. Dot  FRANCE

16.30  
C. Dot, J-F. Korobelnik, V. Dainen, C. Faure,  
R. Tadayoni, A. Giocanti Auregan, P. Massin  FRANCE  
Real world use of intravitreal aflibercept injections in diabetic macular edema: 1 year interim results of APOLLON

16.36  
A. El Asrar, G. Mohammad, E. Allegaert,  
A. Ahmad, M. Siddiquei, K. Alam,  
P. Gikandi  SAUDI ARABIA  
Matrix metalloproteinase 14 is a biomarker of angiogenic activity in proliferative diabetic retinopathy

16.42  
A.R. Santos, D. Alves, T. Santos, I. Marques,  
L. Mendes, M. Durbin, J. Cunha Vaz  PORTUGAL  
Multimodal imaging of the initial stages of diabetic retinopathy: different disease pathways in different patients

16.48  
R. Schwartz, A. Lamin, M. Gikka, C. Sys, B. Pal  UK  
Long term follow up of patients with type 1 idiopathic macular telangiectasia

16.54  
U. Schmidt-Erfurth, T. Bertelmann,  
K. Johnson, T. Katz, B. Gerendas, J. Arnold,  
J-F. Korobelnik  AUSTRIA  
Outcomes of baseline central macular ischemia in patients with diabetic macular edema treated with intravitreal aflibercept or laser

17.00  
M. Vieira, A. Campos, H. Arruda, J. Santos,  
J. Sousa  PORTUGAL  
Prognostic factors of functional response in major branch retinal vein occlusion

17.06  
M. Lukic, P. Patel, R. Hamilton, R. Rajendram  UK  
Real life anatomical and visual acuity outcomes in treatment naive patients treated with intravitreal aflibercept for diabetic macular oedema; 36 months results

17.12  
B. Oliveira Lopez, M. Brizido, A. Basilio,  
J. Rodrigues, M. Ribeiro, M. Miranda  PORTUGAL  
Real world effectiveness and safety study of fluocinolone acetonide intravitreal implant in persistent diabetic macular edema: A comparison of outcomes based on early versus late switching following an insufficient response to prior therapies

17.18  
S. Ah Moye, P. Zalmay, M. Theodorsson,  
V. Nguyen, M. Harris, H. Mehta  UK  
Real world outcomes in patients with macular oedema secondary to branch retinal vein occlusion receiving intravitreal anti VEGF therapy in a UK public hospital setting

17.24  
P. Zalmay, S. Ah Moye, V. Nguyen, Z. Elhousseini,  
M. Harris, H. Mehta  UK  
Real world outcomes in patients with macular oedema secondary to central retinal vein occlusion receiving intravitreal anti VEGF therapy in a UK public hospital setting

17.30  
C. Angguri Putri, F. Quhill  UK  
Comparison of intraoperative intravitreal dexamethasone implant (OZURDEX®) versus perioperative intravitreal anti vascular endothelial growth factor (VEGF) in patients with diabetic macular edema (DME) undergoing cataract surgery

17.36  
P. Massin, L. Kodikjian, A. Creuzot Garcher,  
C. Creuzot Garcher, J. Girmens, C. Delcourt,  
F. Fajnkuchen  FRANCE  
Real world outcomes with ranibizumab (RBZ) 0.5 mg initiation in French patients with visual impairment due to diabetic macular edema: 36 month results of the BOREAL DME study

17.42  
F. Bandello, C. Riemann  ITALY  
The USER Study: Long term outcomes of patients with diabetic macular edema switched from dexamethasone implant to 0.2 µg/day fluocinolone acetonide implant

17.48  
S. Minaker, R. Mason, M. Lee, Y. Lee,  
R. Muni  CANADA  
Changes in aqueous and vitreous inflammatory cytokine levels in retinal vein occlusion: A systematic review and meta analysis

18.00  
End of session
16.30 – 18.00
INSTRUCTIONAL COURSE 31 3D
Surgical Videos In 3D, Latest Indications & Evolution on Digital Viewing Eye Surgery
Room 252 (Level 2)
Course Organisers:
- A. Nikolakopoulos GREECE
- C. Riemann USA
- V. Ferrara ITALY
- T. Aaberg USA
Faculty:
- S. Rizzo ITALY
- J.A. Pournaras SWITZERLAND
- M. Mura THE NETHERLANDS
- K. Kadonosono JAPAN
- M. Figueroa SPAIN
- D. Chow CANADA
- Y. Oshima JAPAN
- C. Awh USA
- E. Paroikakis GREECE
- A. Maia BELGIUM
- E. Parikakis GREECE
- F. Balta ROMANIA
- A. Franklin USA

16.30 – 18.00
OPHTHALMOLOGY INNOVATIONS SUMMIT (OIS) SYMPOSIUM
Room 342 (Level 3)
Chairpersons:
- E. Cunningham USA
- M. Munk SWITZERLAND

16.30
E. Cunningham USA
Introduction

Panel:
- E. Cunningham USA
- M. Munk SWITZERLAND
- S. Wolf SWITZERLAND
- F.G. Holz GERMANY
- A. Loewenstein ISRAEL
- P. Dugel USA
- D. Sauer GERMANY
- J. Edwards USA
- K. Nahen GERMANY

Presentations:
- K. Rolsted DENMARK
- M. Munk SWITZERLAND
- M. de Smet THE NETHERLANDS
- J. Kumm USA
- S. Bekkali UK

18.00 End of symposium
### INSTRUCTIONAL COURSE 32
**Scleral Buckling for Rhegmatogenous Retinal Detachment: Mastering a Dying Art!**

**Salle Maillot (Level 2)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Country</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>16.30</td>
<td>B. Chanana</td>
<td>INDIA</td>
<td>Indications and basic principles of scleral buckling</td>
</tr>
<tr>
<td>16.40</td>
<td>L. Verma</td>
<td>INDIA</td>
<td>Technique of conventional scleral buckling surgery</td>
</tr>
<tr>
<td>16.50</td>
<td>H. Heimann</td>
<td>UK</td>
<td>Cryotherapy: Principles/procedure and advantages/disadvantages</td>
</tr>
<tr>
<td>17.00</td>
<td>M. Zinkernagel</td>
<td>SWITZERLAND</td>
<td>Sub-retinal fluid drainage: Indications, dry tap and different techniques</td>
</tr>
<tr>
<td>17.10</td>
<td>J. Chhablani</td>
<td>INDIA</td>
<td>Complications of scleral buckling surgery</td>
</tr>
<tr>
<td>17.20</td>
<td>B. Chanana</td>
<td>INDIA</td>
<td>Role of scleral buckling in the modern era and endoillumination-assisted scleral buckling</td>
</tr>
<tr>
<td>17.30</td>
<td></td>
<td></td>
<td>Discussion</td>
</tr>
<tr>
<td>18.00</td>
<td></td>
<td></td>
<td>End of course</td>
</tr>
</tbody>
</table>

### INSTRUCTIONAL COURSE 33
**Proliferative Vitreoretinopathy, Surgical Management & Improved Techniques**

**Room 241 (Level 2)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Country</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>16.30</td>
<td>B. Corcostegui</td>
<td>SPAIN</td>
<td>Risk factors in proliferative vitreoretinopathy</td>
</tr>
<tr>
<td>16.42</td>
<td>E. El Rayes</td>
<td>EGYPT</td>
<td>Vitreomacular interface epiretinal membranes management</td>
</tr>
<tr>
<td>16.54</td>
<td>T. Wolfensberger</td>
<td>SWITZERLAND</td>
<td>Retinomy retinectomy in PVR: When and how</td>
</tr>
<tr>
<td>17.06</td>
<td>J. García-Arumí</td>
<td>SPAIN</td>
<td>Membrane peeling: Staining and PFCL: Viscodissection in closed funnel</td>
</tr>
<tr>
<td>17.18</td>
<td>S. Rizzo</td>
<td>ITALY</td>
<td>Endotamponades in PVR Membrane peeling: Staining and PFCL: Viscodissection in closed funnel</td>
</tr>
<tr>
<td>17.30</td>
<td></td>
<td></td>
<td>Discussion</td>
</tr>
<tr>
<td>18.00</td>
<td></td>
<td></td>
<td>End of course</td>
</tr>
</tbody>
</table>
SATURDAY 7 SEPTEMBER

16.30 – 18.00
INSTRUCTIONAL COURSE 34
Advances in the Management of Complex Paediatric Retinal Diseases
Room 351 (Level 3)

Course Organiser: S. Agarwal-Sinha USA

16.30 S. Agarwal-Sinha USA
Introduction

16.31 W. Wu TAIWAN
Persistent fetal vasculature and its management

16.41 H. Kondo JAPAN
Management of Stickler syndrome: Diagnosis, surgery and prophylaxis

16.51 S. Kusaka JAPAN
Surgical treatment for severe Coats disease

17.01 S. Iyer USA
Surgical management in paediatric trauma

17.11 S. Agarwal-Sinha USA
Current and potential pathogenesis and therapeutics in retinopathy of prematurity

17.21 S. Kusaka JAPAN
Anti-VEGF treatment and/or vitrectomy for severe ROP

17.31 W.C. Wu TAIWAN
Macular structures, optical components, and visual acuity in preschool children after intravitreal bevacizumab or laser photocoagulation for type 1 ROP

17.41 H. Kondo JAPAN
Diagnosis of FEVR and related disorders, genetics and clinical features

17.51 S. Kusaka JAPAN
Surgery of FEVR: When and how?

18.00 End of course

16.30 – 18.00
INSTRUCTIONAL COURSE 35
Use & Safety of Oil & Liquid Devices in Vitreoretinal Surgery
Room 251 (Level 2)

Course Organisers: A. Chandra UK
J. Smith UK

16.30 P. Banerjee UK
Physical properties of silicone oils and perfluorocarbon liquids

16.45 H. Menz GERMANY
Production and safety standards of silicone oils and perfluorocarbon liquids

17.00 A. Chandra UK
Use of oils and PFCL: Indications and videos

17.15 R. Henderson UK
Toxicity issues of PFCL

17.30 J. Smith UK
Toxicity issues of silicone oil

17.45 Discussion

18.00 End of course
Euretina
Winter Meeting

Vilnius 2020

20–21 March | Lithuania

www.euretina.org
EURETINA is committed to reducing waste, lowering carbon emissions and using sustainable and ethically sourced congress materials.
WORLD RETINA DAY

Saturday 7 September
08.00 – 09.30

**FRENCH RETINA SOCIETY SYMPOSIUM**

**Novel Imaging Biomarkers for Retinal & Choroidal Diseases Using Optical Coherence Tomography-Angiography**

**Amphithéâtre Bleu (Level 2)**

Chairpersons:  
J. Uzzan FRANCE  
G. Soubrane FRANCE

08.00  
H. Oubraham FRANCE  
Biomarkers of the growth of choroidal neovascularization under anti-VEGF therapy in AMD with OCT-angiography

08.10  
F. Behar-Cohen FRANCE  
OCT-angiography in central serous chorioretinopathy and neovascular complications

08.20  
L. Zografos SWITZERLAND  
OCT-angiography of the iris in ocular oncology

08.30  
M. Mauger-Faysse FRANCE  
OCT-angiography in "the other diseases"

08.40  
F. Coscas FRANCE  
Volume rendering of OCT-angiography data

08.50  
J. Uzzan FRANCE  
OCT-angiography of the choroid: A challenge?

09.00  
C. Pournaras SWITZERLAND  
OCT-A guided focal (Navilas) macula laser photocoagulation

09.10  Discussion

09.30  End of symposium

08.00 – 09.30

**EUROPEAN ACADEMY OF OPHTHALMOLOGY (EAO) SYMPOSIUM**

**Hot Topics in Retina 2019**

**Amphithéâtre Bordeaux (Level 3)**

Chairpersons:  
F. Bandello ITALY  
A. Grzybowski POLAND

08.00  
U. Schmidt-Erfurth AUSTRIA  
Recent developments in dry AMD

08.10  
A. Loewenstein ISRAEL  
Recent developments in AMD

08.20  
F. Bandello ITALY  
Recent developments in DR

08.30  
G. Querques ITALY  
Recent developments in OCT imaging

08.40  
E. Midena ITALY  
Recent developments in laser therapy

08.50  
A. Grzybowski POLAND  
Recent developments in artificial intelligence use in retinal diseases

09.00  Discussion

09.30  End of symposium
SATURDAY 7 SEPTEMBER

08.00 – 09.30
SPANISH VITREORETINAL SOCIETY (SERV) SYMPOSIUM
Diagnostic & Therapeutic Utility of the New Imaging Technologies in Retino-Choroidal Pathology
Room 252 (Level 2)

Chairpersons: J. García-Arumí SPAIN
J.M. Ruiz-Moreno SPAIN

08.00  A. García-Layana SPAIN
Quiescent choroidal neovascularization. What is that suggesting to us?

08.10  L. Arias Barquet SPAIN
Update on wide-field imaging in retino-choroidal pathology

08.20  J. García-Arumí SPAIN
OCTA in choroidal nevus and melanomas. Is it helpful?

08.30  J.M. Ruiz-Moreno SPAIN
ATN classification of myopic maculopathy based in multimodal imaging study by SS-OCT and OCTA

08.40  M.S. Figueroa SPAIN
New OCT classification of ERM

08.50  M.I. López SPAIN
Update on OCT biomarkers and their contribution to individualized therapy in diabetic macular edema

09.00  F. Gómez-Ulla SPAIN
Contribution of OCT-angiography to the foveaplan diagnosis

09.10  I. Jürgens SPAIN
New developments in intraoperative OCT

09.20  Discussion

09.30  End of symposium

08.00 – 09.30
SINGAPORE SOCIETY SYMPOSIUM
PCV: Current Understanding and Evolving Concepts
Room 342 (Level 3)

Chairpersons: G. Cheung SINGAPORE
C. Tan SINGAPORE
C. Lye Ang SINGAPORE

08.00  T. Wong SINGAPORE
Overview of current understanding in PCV

08.12  K. Teo SINGAPORE
Real world outcome of PCV treatment from a multinational data-base

08.24  G. Staurenghi ITALY
Aneurysmal vs polypoidal: SD-OCT insights

08.36  R. Spaide USA
Choroid and polypoidal disease

08.48  W.K. Lee SOUTH KOREA
Outer retinal and choroidal changes and neovascularization development in fellow eye

09.06  A. Invernizzi ITALY
Case discussion

09.14  Y. Yew Sen SINGAPORE
Case discussion

09.22  W. Kiong Ngo SINGAPORE
Case discussion

09.30  End of symposium
SATURDAY 7 SEPTEMBER

08.00 – 09.30
EVER SYMPOSIUM
Progress in the Management of Cystoid Macular Edema
Salle Maillot (Level 2)

Chairpersons: C. Creuzot-Garcher FRANCE
C. Pournaras SWITZERLAND

08.00 M. Paques FRANCE
Multimodal imaging of cystoid macular edema

08.10 A. Gaudric FRANCE
Progress on the management of diabetic cystoid macular edema

08.20 C. Creuzot-Garcher FRANCE
Management of the cystoid macular oedema related to an intraocular inflammation

08.30 L. Zografos SWITZERLAND
Cystoid macular edema in ocular oncology: Pathogenesis and management

08.40 C.J. Pournaras SWITZERLAND
Progress in the management of cystoid macular edema with laser photocoagulation

08.50 E. Philippakis FRANCE
Surgical approaches for the management of cystoid macular edema

09.00 Discussion

09.30 End of symposium

08.00 – 09.30
APVRS SYMPOSIUM
Challenging Cases on Medical & Surgical Retina
Room 241 (Level 2)

Chairpersons: A. Chang AUSTRALIA
A. Koh SINGAPORE
P. Ruamviboonsuk THAILAND

08.00 A. Chang AUSTRALIA
Surgical management of subretinal haemorrhage in Polypoidal choroidal vasculopathy

08.09 T. Lai HONG KONG
Challenging cases of myopic maculopathy

08.18 T. Das INDIA
Post cataract surgery endophthalmitis after intracameral antibiotic and comparative efficacy of intracameral cefuroxime and moxifloxacin in endophthalmitis prophylaxis in India

08.27 M. Ohji JAPAN
A challenging case of diabetic macular edema

08.36 A. Koh SINGAPORE
“Seeing Stars”

08.45 S.Y. Yu SOUTH KOREA
Yellow depigmented ring with submacular fluid

08.54 S.J. Sheu TAIWAN
Refractory macular edema in ocular tuberculosis

09.03 H. Terasaki JAPAN
Challenging in diagnosis and treatment for CNV in hereditary retinal diseases

09.12 P. Ruamviboonsuk THAILAND
Submacular fluid and glaucoma

09.21 Discussion

09.30 End of symposium
08.00 – 09.30
EGVRS SYMPOSIUM
Challenges in Macular Surgery
Room 351 (Level 3)

Chairpersons: S. Sheta EGYPT
K. Elrakhawy EGYPT

08.00 S. Sheta EGYPT
Vitrectomy for X-linked juvenile foveoschisis

08.07 S. Embabi EGYPT
Macular dragging and retinal detachment in an adult with FEVR

08.14 K. Elrakhawy EGYPT
Management of macular folds after vitrectomy for retinal detachment (RD)

08.21 M. Tawfik EGYPT
Subretinal escape of PFCL through the fovea during vitrectomy for RD

08.28 S. Sheta EGYPT
Traumatic macular tear

08.35 S. Elbaha EGYPT
Ultimate challenge in failed macular hole surgery

08.42 S. Embabi EGYPT
Autologous retinal transplant for tractional macular break post endogenous endophthalmitis

08.49 H. Hamza EGYPT
Pneumatic displacement of submacular hemorrhage: How to play it safe

08.56 S. Elbaha EGYPT
Autologous choroidal graft in huge submacular CNV

09.03 M. Tawfik EGYPT
Detach to treat submacular hard exudates in DME

09.10 H. Hamza EGYPT
Submacular cyst

09.17 Discussion

09.30 End of symposium

11.00 – 12.30
MEDITERRETINA SYMPOSIUM
Amphithéâtre Bleu (Level 2)

Chairpersons: A. Nikolakopoulos GREECE
F. Fayyad JORDAN
Y. Le Mer FRANCE

The aim of this session is to report the latest results in diabetic retinopathy follow-up changes that have been made recently. Followed by the update of treatment options in anti-VEGF and laser and the current surgical innovation for the proliferative retinopathy complications.

Participants:
E. Bali BELGIUM
F. Boscia ITALY
G. Fasolino ITALY
M. Forlini ITALY
E.R. Khaled EGYPT
L. Mavroudis EGYPT
K. Nikolakopoulos SWITZERLAND
C. Papadopoulou GREECE
G. Ripantelli ITALY
T. Rotsos GREECE

12.30 End of symposium
11.00 – 12.30

**JAPANESE VR SOCIETY SYMPOSIUM**

From RCT to Registry & AI, the Present & the Future

**Room 252 (Level 2)**

**Chairpersons:**
- Y. Ogura  **JAPAN**
- T. Sakamoto  **JAPAN**
- K. Kadonosono  **JAPAN**

11.00  **F. Gomi**  **JAPAN**
Fujisan study

11.10  **T. Sakamoto**  **JAPAN**
JRVS retinal detachment registry

11.20  **A. Itoh**  **JAPAN**
AI guided surgery

11.30  **M. Miyake**  **JAPAN**
JAPAN JOI registry

11.40  **T. Yasukawa**  **JAPAN**
AI assisted detection and monitoring system for macular diseases

11.50  **H. Tabuchi**  **JAPAN**
AI based monitoring

12.00  **R. Tadayoni**  **FRANCE**
AI for diabetic retinopathy

12.10  **J-F. Korobelnik**  **FRANCE**
Real world evidence of VEGF

12.20  **A. Koh**  **SINGAPORE**
Everest study

12.30  End of symposium

**VRSI SYMPOSIUM**

Conquering Complex Surgical Scenarios: Pearls & Pitfalls

**Amphithéâtre Bordeaux (Level 3)**

**Chairpersons:**
- A. Rajendran  **INDIA**
- S. Chawla  **INDIA**
- G. Anantharaman  **INDIA**

11.00  **G. Anantharaman**  **INDIA**
Dealing with diabetic detachments

11.10  **S. Boral**  **INDIA**
Submacular surgeries and haemorrhage evacuation

11.20  **S. Natarajan**  **INDIA**
Taming traumatised detachments, IOFBs and expulsives

11.30  **P. Bhende**  **INDIA**
Paediatric retinal detachments - No child’s play

11.40  **A. Rajendran**  **INDIA**
Tackling PVR – Peripheral and posterior

11.50  **S. Chawla**  **INDIA**
ILM Play – Holes, pits, myopic foveoschisis

12.00  **H. Murthy**  **INDIA**
Uveitic detachments - Endophthalmitis, effusions & parasites

12.10  **R. Narayanan**  **INDIA**
Endoscopic vitrectomy, intraoperative OCT, 3D Surgery – New frontiers

12.20  Discussion

12.30  End of symposium
### TAIWAN RETINAL SOCIETY SYMPOSIUM

**From Bench to Bedside & Big Data**

**Room 342 (Level 3)**

**Chairpersons:** S.J. Sheu TAIWAN  
S.J. Chen TAIWAN  
J.H. Liu TAIWAN

#### Basic Science & Image

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Country</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>11.00</td>
<td>C.H. Yang TAIWAN</td>
<td>Basic fibroblast growth factor: A new target for the treatment of diabetic retinopathy</td>
<td></td>
</tr>
<tr>
<td>11.08</td>
<td>A. Kashani USA</td>
<td>Retinal capillary structure and function in diabetic retinopathy: Insights from OCT angiography based studies</td>
<td></td>
</tr>
<tr>
<td>11.22</td>
<td></td>
<td>Discussion</td>
<td></td>
</tr>
</tbody>
</table>

#### Clinical Treatment

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Country</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>11.30</td>
<td>A. Loewenstein ISRAEL</td>
<td>Update of treatment on diabetic macular edema</td>
<td></td>
</tr>
<tr>
<td>11.38</td>
<td>S. Ni Chen TAIWAN</td>
<td>Diabetic macular edema with macular pucker: Vitrectomy or anti-VEGF agents?</td>
<td></td>
</tr>
<tr>
<td>11.46</td>
<td>C.M. Yang TAIWAN</td>
<td>Discussion</td>
<td></td>
</tr>
</tbody>
</table>

#### Big Data

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Country</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>12.00</td>
<td>T. Sakamoto JAPAN</td>
<td>Real world data of diabetic retinopathy</td>
<td></td>
</tr>
<tr>
<td>12.08</td>
<td>D.E. Hwang TAIWAN</td>
<td>Diabetic macular edema in Taiwan pearls from nationwide databank</td>
<td></td>
</tr>
<tr>
<td>12.16</td>
<td>D.C. Tsai TAIWAN</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>12.30</td>
<td></td>
<td>End of symposium</td>
<td></td>
</tr>
</tbody>
</table>

### MEXICAN RETINA SOCIETY SYMPOSIUM

**Mexican Retina Association: Retina & Macular Surgery Approach**

**Salle Maillot (Level 2)**

**Chairperson:** F. Graue MEXICO

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Country</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>11.00</td>
<td>A. Ramirez-Estudillo MEXICO</td>
<td>Residual oedema in epiretinal membrane surgery</td>
<td></td>
</tr>
<tr>
<td>11.08</td>
<td>S. Rojas-Juarez MEXICO</td>
<td>Autologous retinal transplant in large macular holes</td>
<td></td>
</tr>
<tr>
<td>11.16</td>
<td>S. Hernandez-Da Mota MEXICO</td>
<td>Autofluorescence imaging in diabetic macular edema</td>
<td></td>
</tr>
<tr>
<td>11.24</td>
<td>J. Gonzalez-Cortes MEXICO</td>
<td>Packing&quot; techniques in macular hole surgery: Mexican experience</td>
<td></td>
</tr>
<tr>
<td>11.32</td>
<td>F. Graue-Wiechers MEXICO</td>
<td>Diabetic tractional retinal detachment: Current management</td>
<td></td>
</tr>
<tr>
<td>11.40</td>
<td>V. Morales-Canton MEXICO</td>
<td>Best options in sutured intraocular lenses</td>
<td></td>
</tr>
<tr>
<td>11.48</td>
<td>R. Cano-Hidalgo MEXICO</td>
<td>Epiretinal membranes: To peel or not to peel</td>
<td></td>
</tr>
<tr>
<td>11.56</td>
<td>P. Rodriguez Valdes MEXICO</td>
<td>Treatment strategies for DME antiVEGF non-responders: When and where to go next</td>
<td></td>
</tr>
<tr>
<td>12.04</td>
<td>M.A. Martinez-Castellanos MEXICO</td>
<td>Radiofrequency surgery in grade 5 ROP</td>
<td></td>
</tr>
<tr>
<td>12.12</td>
<td>J.L. Guerrero-Naranjo MEXICO</td>
<td>Conventional macular hole surgery: Current status</td>
<td></td>
</tr>
<tr>
<td>12.20</td>
<td></td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>12.30</td>
<td></td>
<td>End of symposium</td>
<td></td>
</tr>
</tbody>
</table>
11.00 – 12.30  
**SYMPOSIUM OF THE ECUADORIAN RETINA AND VITREOUS SOCIETY**

**Management of Special Clinical & Surgical Cases**

Room 241 (Level 2)

**Chairpersons:**  
G. Gabela ECUADOR  
N. Matamoros ECUADOR

11.00  
**E. Velastegui** ECUADOR  
Cataract and diabetes

11.10  
**G. Miotto** ECUADOR  
Paediatric macular hole: Management alternative

11.20  
**J.D. Carpio** ECUADOR  
27 g vitrectomy in retinal detachment cases

11.30  
**C. Abdala** COLOMBIA  
SS-OCT after macular hole surgery

11.40  
**A. Almeida** ECUADOR  
Treatment of ROP: Experience with Pascal yellow multipot laser

11.50  
**P. Flor** ECUADOR  
Retinal arterial macroaneurysms

12.00  
**D.E. Pelayes** ARGENTINA  
OCT - A in the treatment of diabetic macular edema as a predictor of visual acuity results

12.10  
**N. Matamoros** ECUADOR  
Second surgery in reopened macular holes

12.20  
**G. Gabela** ECUADOR  
Treatment of diabetic proliferative retinopathy: Anti-VEGF alone vs panretinal photocoagulation in a country in development

12.30  
End of symposium

14.30 – 16.00  
**MACULA SOCIETY SYMPOSIUM**

**Amphithéâtre Bleu** (Level 2)

**Chairpersons:**  
P. Dugel USA  
M. Zarbin USA

14.30  
P. Keane UK  
AI for screening vision threatening retinal disease: DR, nAMD

14.40  
P. Rosenfeld USA  
Treatments for GA (update on current clinical trials)

14.50  
P. Dugel USA  
New treatments for nAMD

15.00  
F.G. Holz GERMANY  
Brolucizumab: where does it fit in?

15.10  
M. Zarbin USA  
Treatment of diabetic retinopathy with anti-VEGF therapy: When should we intervene?

15.20  
R. MacLaren UK  
Update on gene therapy

15.30  
M. Humayun USA  
Update on cell-based therapy for GA and nAMD

15.40  
R. Tadayoni FRANCE  
Intraoperative OCT: When to use it?

15.50  
S. Rizzo ITALY  
Applications of human amniotic membrane grafts for macular disease

16.00  
End of symposium
14.30 – 16.00

GERMAN RETINA SOCIETY SYMPOSIUM

Controversies in the Management of Retinal Diseases

Amphithéâtre Bordeaux (Level 3)

Chairpersons: H. Helbig GERMANY
               F.G. Holz GERMANY
               D. Pauleikhoff GERMANY

14.30  D. Pauleikhoff GERMANY
       Treatment of exudative AMD, a resolved problem?

14.45  A. Joussen GERMANY
       Laser treatment of proliferative diabetic retinopathy, an old fashioned method?

15.00  B. Mazinani GERMANY
       After the viper study, is there still an indication for an encircling buckle

15.15  A. lappa GERMANY
       Should liquid silicone be banned?

15.30  F. Schaub GERMANY
       PVR, avoidable? Treatable?

15.45  Discussion

16.00  End of symposium

14.30 – 16.00

EUROLAM SYMPOSIUM

Management of Infrequent Cases of Vitreoretinal Diseases

Room 252 (Level 2)

Chairpersons: F. Bandello ITALY
               F. Graue MEXICO
               D.E. Pelayes ARGENTINA

14.30  A. Loewenstein ISRAEL
       Clinical case report

14.39  R. Cano MEXICO
       Fibrinoid central serous chorioretinopathy

14.48  G. Richard GERMANY
       A very unusual reason for severe inflammation of the eye

14.57  A. Joussen GERMANY
       Tips and tricks on endoresection

15.06  S. Seregard SWEDEN
       Infrequent ocular oncology case

15.15  S. Gotzaridis GREECE
       Amazing vitreoretinal procedures

15.24  G. Gabela ECUADOR
       Complex retinal detachment

15.33  C. Abdala COLOMBIA
       Retinal angioma, surgical management

15.42  C. Meyer SWITZERLAND
       Subretinal fluid application to close persisting large macular holes

15.51  F. March De Ribot SPAIN
       Anterior segment challenging approach in retina surgery

16.00  End of symposium
SATURDAY 7 SEPTEMBER

14.30 – 16.00

IFAN SYMPOSIUM

Retinal Imaging Cases for Discussion with A Panel & Audience

Room 342 (Level 3)

Chairpersons: M. van Schooneveld THE NETHERLANDS
J. Chhablani INDIA
P. Jaki SLOVENIA

14.30 J. Keunen THE NETHERLANDS
Two unusual retinal cases at the oncology service

14.38 J. Chhablani INDIA
Retinal case

14.46 P. Jaki SLOVENIA
Retinal case

14.54 A. Cahuzac FRANCE
Non described retinopathy in young adults

15.02 A. Leys BELGIUM
A challenging macular case

15.10 M. Van Schooneveld THE NETHERLANDS
Acute unilateral visual loss in a 17-year old as a result of an autosomal recessive condition

15.18 M. Van Schooneveld THE NETHERLANDS
Two ladies with a late RP-like condition

15.26 Discussion

16.00 End of symposium

14.30 – 16.00

SYMPOSIUM

Symposium for Retinal Specialists from 15 Independent States
(Former USSR)

Room 351 (Level 3)

Chairpersons: S. Saidkasimova UK/UZBEKISTAN
M. Bikbov BASHKORTOSTAN
A. Laidlaw UK
B. Malyugin RUSSIA
A. Shpak RUSSIA
A. Zolotaryev RUSSIA

14.30 Rapid fire presentations
15.05 A. Shpak RUSSIA
OCT changes following macular hole surgery

15.15 M. Bikbov BASHKORTOSTAN
Epidemiology of retinal disease in Ural region

15.25 B. Malyugin RUSSIA
Anterior segment meets posterior segment

15.35 S. Saidkasimova UK
Retinal detachment and suprachoroidal buckling

15.45 A. Laidlaw UK
Management of proliferative diabetic retinopathy

15.55 A. Zolotaryev RUSSIA
TBC

16.00 End of symposium
14.30 – 16.00

KOREAN RETINA SOCIETY SYMPOSIUM

Meeting the Challenges in the Diagnosis & Treatment of Retinal Disorders

Room 241 (Level 2)

Chairpersons: D.I. Ham SOUTH KOREA
               J. Oh SOUTH KOREA

14.30 J.H. Song SOUTH KOREA
Endoilluminator phototoxicity and foveal light-saving vitrectomy for epiretinal membrane removal

14.40 D.I. Ham SOUTH KOREA
Macular folds following retinal detachment surgery

14.50 J.Y. Lee SOUTH KOREA
Stem cell therapies for geographic atrophy of age-related macular degeneration

15.00 J. Young Shin SOUTH KOREA
Controversies in the management of diabetic retinopathy

15.10 E.S. Kim SOUTH KOREA
OCTA in silent type 1 CNV

15.20 J. Baek SOUTH KOREA
Choroidal morphology and clinical outcome in polypoidal choroidal vasculopathy

15.30 J. Oh SOUTH KOREA
CSC with CNV versus pachychoroid neovasculopathy

15.40 C.S. Lee SOUTH KOREA
Management of chronic central serous chorioretinopathy

15.50 Discussion

16.00 End of symposium

14.30 – 16.00

AMERICAN SOCIETY OF RETINA SPECIALISTS (ASRS) SYMPOSIUM

Salle Maillot (Level 2)

Chairpersons: C. Awh USA
               P.J. Ferrone USA

14.30 P.J. Ferrone USA
Understanding the Ang/TIE2 pathway in retinal vascular diseases

14.39 K.A. Rezaei USA
Adaptation to a disruptive new surgical technology

14.48 C. Awh USA
Update on genetic testing and the AREDS formulation

14.57 B.D. Kupperman USA
Neuroprotection for retinal diseases

15.06 T.S. Hassan USA
Is it necessary to peel ILM during retinal detachment repair?

15.15 A. Tufail UK
Big data and retinal disorders

15.24 P.K. Kaiser USA
Next generation anti-VEGF agents

15.33 F. Boscia ITALY
Update on treatments for central serous retinopathy

15.42 S. Rizzo ITALY
Multimodal imaging of macular hole surgery with amniotic membrane

15.51 C. Regillo USA
Port delivery system for wet AMD—Phase 2 results and Phase 3 study designtimodal imaging of macular hole surgery with amniotic membrane

16.00 End of symposium
Closing Reception

Including Best Free Paper & Poster Awards for the 19th EURETINA Congress

Sunday 8 September
14.00, Foyer Bleu (Level 2)
SUNDAY 8 SEPTEMBER

08.30 – 10.00
SYMPOSIUM
Update in Diabetic Macular Edema
Amphithéâtre Bleu (Level 2)

Chairpersons: F. Bandello ITALY
F. Graue MEXICO
A. Grzybowski POLAND

08.30  D.E. Pelayes ARGENTINA
SS angio OCT in DME

08.42  A. Loewestein ISRAEL
Steroids in the treatment of DME

08.54  E. Midena ITALY
The role of different lasers in DME

09.06  G. Gabela ECUADOR
Surgical management of corneal opacity in cases of vitrectomy in DME

09.18  R. Cano MEXICO
DME and vitreoretinal interface alterations

09.30  A. Grzybowski POLAND
Anti-VEGF in the treatment of DME

09.42  Discussion

10.00  End of symposium

08.30 – 10.00
INSTRUCTIONAL COURSE 36
Understanding the Management of Proliferative Diabetic Retinopathy

Room 252 (Level 2)

Course Organisers: A. Laidlaw UK
M. Mohamed UK

08.30  A. Laidlaw UK
Welcome & introduction

08.42  L. Downey UK
Pathophysiology of proliferative diabetic retinopathy

08.54  S. Mann UK
Medical risk factors for progression of diabetic retinopathy

09.06  S. Mann UK
Classification of diabetic retinopathy, follow up/screening intervals at each stage

09.18  M. Mohamed UK
PRP: When to start, where to do it, how much to do and when to stop

09.30  N. Davies UK
Evidence for anti-VEGF drugs: Is PRP redundant?

09.42  A. Laidlaw UK
Vitrectomy in proliferative diabetic retinopathy: Vitreous haemorrhage and traction

09.54  Discussion

10.00  End of course
SUNDAY 8 SEPTEMBER

08.30 – 10.00

FREE PAPER SESSION 17

AMD & New Drug Treatment & Technology

Amphithéâtre Havane (Level 3)

Chairpersons: P. Dugel USA
S. Degli Esposti UK

08.30 S. Degli Esposti, E. Boulanger Schemama, J. Martel, M. Taiel, B. Katz, J. Sahel UK
A phase 1/2 optogenetic retinal gene therapy clinical trial for non syndromic retinitis pigmentosa (PIONEER study)

08.36 E. Souied FRANCE
Efficacy and safety of abicipar compared with ranibizumab in the treatment of neovascular age related macular degeneration: Results from the cedar and sequoia phase 3 clinical trials

08.42 H. Ocampo COLOMBIA
OTS APP: Improving the ocular trauma management

08.48 M. Abrishami, M. Abrishami, B. Malaekheh Nikouei, N. Mosallaei, A. Mahmoudi IRAN
Solid lipid nanoparticles improve the diclofenac availability in vitreous after intracocular injection

08.54 Y. Nakamura, Y. Matsuda, Y. Nonaka, S. Futakawa, K. Akita, M. Fujiwara, Y. Ali JAPAN
Anti angiogenic and anti scarring dual action of an anti fibroblast growth factor 2 aptamer in animal models of retinal disease

09.00 M. Ozturk TURKEY
Based on the real life data of Turkey: one year results of treatment with anti vascular endothelial growth factor for exudative age-related macular degeneration in eyes with different baseline visual acuity. bosphorus retina study group, report 6

09.06 V. Sarao, D. Veritti, P. Lanzetta ITALY
One year efficacy of anti vascular endothelial growth factor agents in patients with neovascular age-related macular degeneration: A meta analysis and meta regression

09.12 P. Almuina Varela, P. Santos, M. Gil, M. Rodriguez, M. Abraldes, F. Gomez Ulla, M. Rodriguez SPAIN
Correlation of OCT A and angiography in the diagnosis and classification of neovascular complexes in nAMD

09.18 M. Gillies AUSTRALIA
Outcomes of suspending VEGF inhibitors for neovascular age-related macular degeneration when lesions have been inactive for 3 months

09.24 T. Laforest, M. Künzi, L. Kowalczuk, I. Mantel, F. Behar Cohen, C. Moser SWITZERLAND
Cellular resolution retinal pigment epithelium imaging with transscleeral optical phase imaging (TOPI)

09.30 P. Kaiser, D. Boyer, J. Heier, G. Jaffe, J. Kornfield, B. Kuppermann, H. Quiroz Mercado USA
Safety and efficacy of risuteganib in non exudative age related macular degeneration – Primary results from a phase 2 study

09.36 P. Lanzetta, M. Ohji, J-F. Korobelnik, P. Wojciechowski, M. Palarczyk, D. Janer, C. Tuckmantel ITALY
Efficacy and treatment burden of intravitreal aflibercept vs. ranibizumab treat and extend regimens at 24 months: network meta analysis incorporating individual patient data meta regression and matching adjusted indirect comparison

09.42 M. Singer, S. Kiss, C. Wykoff, A. Patel, L. Bennett, S. Abeysinghe, J. Campbell USA
Analysis of the relationship between anatomic control and visual acuity outcomes with anti-VEGF therapy: A post hoc analysis of catt study data

09.48 P. Dugel, J. Velazquez Martin, D. Do, J. Naor, D. Beutelspacher, J. Ehrlich, V. Perlroth USA
Extended durability in exudative retinal diseases using a new class of molecules: Novel anti VEGF antibody biopolymer conjugate KSI 301: first time results of the phase 1b study in patients with wAMD, DME and RVO

10.00 End of session
08.30 – 10.00
**INTERNATIONAL SOCIETY OF OCULAR TRAUMA (ISOT) SYMPOSIUM**
Retina Surgery in Challenging Situations of Ocular Trauma

**Room 342** (Level 3)

Chairpersons:  
D.E. Pelayes **ARGENTINA**  
S. Natarajan **INDIA**  
W. Schrader **GERMANY**

08.30  
**F. March de Ribot** **SPAIN**  
Traumatic macular hole

08.42  
**C. Abdala** **COLOMBIA**  
IOL sutured in traumatic lens luxation to vitreous

08.54  
**G. Gabela** **ECUADOR**  
Iris suture in ocular trauma cases

09.06  
**H. Yan** **CHINA**  
Innovating in trauma surgery

09.18  
**T. Wolfensberger** **SWITZERLAND**  
Clinical case management

09.30  
**T. Nikolakopulos** **GREECE**  
Blunt ocular trauma surprises

09.42  
Discussion

10.00  
End of symposium

08.30 – 10.00
**INSTRUCTIONAL COURSE 37**
Key Issues for OCT & OCT-Angio Interpretation

**Salle Maillot** (Level 2)

Course Organisers:  
G. Staurenghi **ITALY**  
A. Tufail **UK**  
A. Gaudric **FRANCE**

08.30  
**G. Staurenghi** **ITALY**  
Basics of OCT and OCT-A interpretation and nomenclature

08.55  
**A. Tufail** **UK**  
Neovascular age related macular degeneration

09.20  
**A. Gaudric** **FRANCE**  
Central serous chorioretinopathy, macular edema

09.45  
Discussion

10.00  
End of Course
08.30 – 10.00

FREE PAPER SESSION 18
Vitreoretinal Surgery II
Room 241 (Level 2)
Chairpersons:  S. Sheta EGYPT
               M. Iglicki ARGENTINA

08.30  M. Iglicki, D. Zur, A. Lavaque, M. Ozimek, J. Chhablani, C. Busch, A. Loewenstein ARGENTINA
       Biomarkers and predictors for functional and anatomic outcomes for small gauge pars plana vitrectomy and peeling of the internal limiting membrane in naive diabetic macular edema

08.36  M. Lanza, A. Sorgente, F. Sorgente, M. Mensorio, C. Irregolare, A. Lovine, L. Zeppa ITALY
       To evaluate safety and efficacy of a 3D visualization system for vitreoretinal surgery

08.42  P. Shakhabutdinova, D. Shkvorchenko, I. Sharafetdinov RUSSIA
       Two port pars plana endovitreal surgery technique without endoillumination, using 3D visualization system ngenuity alcon

08.48  P. Szurman, R. Constantine, K. Blot, B. Lescrauwaet, A. Khanani GERMANY
       Effectiveness of ocriplasmin in real world settings and clinical trials: A systematic literature review

08.54  P. Koelbl, C. Lingenfelder, S. Kupferschmid, F. Koch, M. Hessling GERMANY
       Endoillumination poses a higher hazard to the retina than expected due to standards missing the consequences of the eye anatomy

09.00  R. Avci, A. Mavi Yildiz, S. Yilmaz TURKEY
       Internal limiting membrane (ILM) peeling versus temporal inverted ILM flap technique in large macular holes

09.06  S. Balalin, H. Nesterova, A. Zotov, A. Akhmedov RUSSIA
       Surgical treatment of retinal detachment with vitreal cavity air tamponade: a practice survey

09.12  S. Sheta EGYPT
       Vitrectomy outcomes for X linked retinoschisis

09.18  S. Freissinger, K. Kortum, S. Priglinger, A. Wolf GERMANY
       Therapy of intravitreal medical therapy associated retinal detachment

09.24  S. Donati, P. Della Valle, E. Premi, M. Mazzola, L. Lo Presti, C. Azzolini ITALY
       Lamellar Macular Holes: the role of microperimetry in functional assessment

09.30  S. Guenther, S. Guenther, D. Vogt, F. Hagenau, A. Wolf, S. Priglinger, R. Schumann GERMANY
       Clinicopathological comparison of idiopathic and traumatic macular holes

09.36  S. Ganekal INDIA
       Sustained release intravitreal dexamethasone (Ozurdex®) implant as a surgical adjuvant in high risk proliferative vitreoretinopathy

09.42  Y. Chen TAIWAN
       Repeated intravitreal injections of antivascular endothelial growth factor in patients with neovascular age related macular degeneration may increase the risk of ischemic optic neuropathy

09.48  C. Chiquet, J. Kosacki, M. Gallice, J. Labarere, F. Aptel, K. Palombi FRANCE
       Multifocal electroretinography and spectral domain OCT in macula off rhegmatogenous retinal detachment. A prospective cohort study

10.00  End of session
SUNDAY 8 SEPTEMBER

08.30 – 10.00
INSTRUCTIONAL COURSE 38
Engineering Tools for Ophthalmologists
Room 251 (Level 2)

Course Organisers:  I. Eames UK  
M. Zouache USA

08.30  I. Eames UK  
Research methodology and modelling in ophthalmic engineering.

08.42  M. Zouache USA  
Transport processes in the retina: From blood flow to intracellular transport

08.54  M. Zouache USA  
Energetics and retinal metabolism

09.06  I. Eames UK  
Retinal solid mechanics: Deformation of the retina in health and disease

09.18  M. Zouache USA  
Analyzing large datasets: Application to retinal OCT images

09.30  I. Eames UK, M. Zouache USA  
Questions and answers

09.42  Discussion

10.00  End of course

08.30 – 10.00
INSTRUCTIONAL COURSE 39
Central Serous Chorioretinopathy: Diagnosis & Treatment
Room 351 (Level 3)

Course Organiser:  C.J. Boon THE NETHERLANDS

08.30  J. Chhablani INDIA  
Diagnosis of CSC

08.40  T. Theelen THE NETHERLANDS  
OCT and OCT angiography aspects of CSC

08.50  C.J. Boon THE NETHERLANDS  
Differential diagnosis of CSC

09.00  C.J. Boon THE NETHERLANDS  
Genetics and pathophysiology of CSC

09.10  S. Yzer THE NETHERLANDS  
Neovascularization and polypoidal choroidal vasculopathy in CSC

09.20  S. Fauser GERMANY  
Micropulse laser treatment in CSC

09.30  C.B. Hoyng THE NETHERLANDS  
Photodynamic therapy in CSC

09.40  G. Querques ITALY  
Other treatments for CSC

09.50  Discussion

10.00  End of course
SUNDAY 8 SEPTEMBER

09.45 – 11.15

SPEAKERS’ CORNER 10

Vasc Diseases & Diabetic Retinopathy II

Taking place within the EURETINA Speakers’ Corner (Arlequin, Level 3), the following posters will be presented for 3 minutes each with 2 minutes for discussion and interaction with the audience.

Moderator: P. Ruamviboonsuk THAILAND

09.50  A. Hall, J. Eells, E. Liedhegner USA
670nm photobiomodulation modulates bioenergetics and oxidative stress in an in vitro model of diabetic retinopathy

09.55  M. Shibuya, K. Ueyama, S. Yoneya JAPAN
Correlation of retinal vein caliber with retinal oxygen saturation level in patients with central retinal vein occlusion

10.00  M. Latalska, E. Kosior Jarecka, M. Winiarczyk, J. Mackiewicz POLAND
Efficacy and safety of micropulse laser treatment in chronic central serous chorioretinopathy-one-year results

10.05  J. Nassaralla, A. Nassaralla, M. Hage, A. Nassaralla BRAZIL
Efficacy of ranibizumab plus aflibercept therapy with dexamethosone intravitreal injection in patients with diabetic macular edema

10.10  S. Gudsoorkar, A. Cowdry UK
Micropulse laser in diabetic macular oedema: Is it effective and safe?

Observation of ranibizumab treatment in real-life conditions - Interim analysis of 630 German patients with retinal vein occlusion (RVO) from the observational, non-interventional PACIFIC-study

10.20  G. Murphy, V. Lodhia UK
Ozurdex in macular oedema associated with retinal vein occlusion - real world 3 year data from Eastbourne

10.25  S. Kabanarou, E. Boutouri, I. Gkizis, G. Bontzos, P. Theodossiadis, I. Chatziralli GREECE
Pre-operative use of intravitreal dexamethasone implant in patients with refractory diabetic macular edema undergoing cataract surgery.

10.30  S. Gajree, M. Gupta UK
Real world experience of intravitreal dexamethasone implant (ozurdex) in diabetic macular oedema

Real-world evidence of the effectiveness of intravitreal aflibercept in patients with diabetic macular oedema in United Kingdom: Baseline Characteristics of the DRAKO study

10.40  S. Husein, T. Yap, S. Younis UK
Real-world outcomes of intravitreal dexamethasone implants in the treatment of macular oedema after retinal vein occlusion

Supernormal flicker ergs in eyes with central retinal vein occlusion: clinical characteristics, prognosis, and effects of anti-vegf agent

10.50  C. Lin, J. Wang, C. Yang, C. Yang, T. Ho, C. Chiu TAIWAN
Three loading dose plus treat-and-extend regimen with ranibizumab for diabetic macular edema – Tricenter one-year real-world results

10.55  M. Islam, D. Jack Fu, J. Huemer, D. A. Sim, P. A. Keane UK
Three-year visual acuity outcomes in patients with macular oedema following retinal vein occlusion treated with anti-vegf therapy - a retrospective cohort study

11.00  R. Kawasaki, K. Nishida JAPAN
Type 2 diabetes patients treated for diabetic retinopathy are at more than double the risk of renal failure needing hemodialysis: a real-world healthcare claims database in Japan

11.05  R. Zainullin, T. Gilmanshin RUSSIA
Combined surgical treatment for diabetic macular edema

11.15  End of session
10.30 – 12.00

**EURETINA SESSION 14**

7 Deadly Sins in Paediatric Retina Surgery: Yes, No, Maybe

**Amphithéâtre Bleu** *(Level 2)*

Chairpersons:  
- C.K. Patel **UK**  
- W.C. Lam **HONG KONG**

10.30  
- **C. Wong** **UK**  
  Lens injury in paediatric vitrectomy

10.40  
- **W.C. Lam** **HONG KONG**  
  Surgical entry into the vitreous cavity in retinoblastoma

10.50  
- **W.C. Wu** **TAIWAN**  
  Injecting anti-VEGF into the paediatric vitreous

11.00  
- **E. El Rayes** **EGYPT**  
  Management for rhegmatogenous retinal detachment in rare genetic syndromes

11.10  
- **P. Salvanos** **NORWAY**  
  Video or images: Morning Glory Retinal Detachment

11.20  
- **E. Carreras** **SPAIN**  
  Video or images: Complex paediatric VR case 2 Lessons Learned

11.30  
- **M. Menghini** **SWITZERLAND**  
  Complex paediatric VR case: Lessons Learned

11.40  
- Discussion

12.00  
- End of session

10.30 – 12.00

**FREE PAPER SESSION 19**

**Imaging III**

**Amphithéâtre Havane** *(Level 3)*

Chairperson:  
- G. Tan **SINGAPORE**

10.30  
- **Y. Solberg**, **B. Moller**, **S. Wolf**, **M. Zinkernagel** **SWITZERLAND**  
  Fluorescence lifetimes in patients with hydroxychloroquine retinopathy

10.36  
- **D. Jaggi**, **Y. Solberg**, **C. Dysli**, **S. Wolf**, **M. Zinkernagel** **SWITZERLAND**  
  Retinal detachment and fluorescence lifetime imaging ophthalmoscopy

10.42  
- **D. Monteduro**, **M. Cozzi**, **S. Parrulli**, **G. Staurenghi** **ITALY**  
  Topographic detection and characterization of drusen and subretinal drusenoid deposits: Contribution of retromode modality in a multimodal imaging approach

10.48  
- **E. Peiretti**, **J. Chhablani**, **D. Parameswarappa**, **M. Pellegrini**, **G. Giannaccare**, **C. Lovino** **ITALY**  
  Retinal pigment epithelium apertures in chronic central serous chorioretinopathy

11.00  
- **E. Kim**, **K. Kim**, **S. Yu** **SOUTH KOREA**  
  Foveal avascular zone and microvascular changes on OCTA after macula off rhegmatogenous retinal detachment repair

11.06  
- **G. Tan**, **T. Wong**, **Y. Bee** **SINGAPORE**  
  Retinal vascular geometric changes in pre-diabetes

11.10  
- **G. Manayath**, **R. Ranjan**, **N. C K**, **N. Venkatapathy** **INDIA**  
  Exudative variant of non proliferative type 2 macular telangiectasia: role of anti VEGF therapy

11.18  
- **H. Khalid**, **J. Huemer**, **R. Rajendram**, **P. Keane** **UK**  
  Systematic evaluation of ischemic retinal vein occlusions for early detection and characterization of neovascularisation using ultrawide field OCT angiography

11.24  
- **H. Hasan**, **G. Smith**, **N. Shah**, **A. Abumattar** **UK**  
  Prediction of Hydroxychloroquine retinopathy using logistic regression method

11.30  
  Choriocapillaris, sattler and haller layer thicknesses in central serous chorioretinopathy after PDT

11.36  
- **B. Poignet**, **B. Bodaghi**, **D. Saadoun**, **S. Bonnin** **FRANCE**  
  Takayasu arteritis and retinal microanevrysms: Ultra widefield imaging contribution
11.42  
C. Lampert Monte Francisconi, D. Ta Kim, V. Juncal, J. Qian, K. Brosh, D. T Wong, R. Muni  CANADA
Foveal avascular zone area analysis using OCT angiography after pneumatic retinopexy for macula off rhegmatogenous retinal detachment repair

11.48  
C. Dysli, S. Thiele, J. Reiniger, P. Muller, F.G. Holz, W. Harmening  SWITZERLAND
High magnification module – photoreceptor resolved imaging without adaptive optics

12.00  
End of session

10.30 – 12.00

**INSTRUCTIONAL COURSE 40**

**Fluorescein, ICG and OCT-Angiography in Macular Diseases – Interpretation & Comparison with Other Imaging Modalities**

**Room 252 (Level 2)**

**Course Organisers:**  
D. Pauleikhoff  GERMANY  
G. Staurenghi  ITALY

10.30  
D. Pauleikhoff  GERMANY
Multimodal imaging in macular diseases – A great concept and challenge

10.45  
S. Wolf  SWITZERLAND
Specific possibilities of different imaging tools (FA, ICG and OCT-A) in macular diagnostic

11.00  
G. Staurenghi  ITALY
The role of FA and ICGA in differential diagnosis in the angio-OCT era

11.15  
A. Tuffail  UK
OCT-A and SD-OCT during anti-VEGF-therapy in exudative AMD

11.30  
F. Sallo  UK
Multimodal imaging in macular diagnostics: MacTel type 2

11.45  
Discussion

12.00  
End of course
10.30 – 12.00
FREE PAPER SESSION 20
AMD IV
Room 241 (Level 2)

Chairperson: M. Zouache USA

10.30  P. Kertes, T. Sheidow, G. Williams, M. Greve, I. Galic, M. Lahaie CANADA
CANTREAT study 24 month results: The ability to extend treatment and associated visual outcomes in the treat and extend group

10.36  R. Forte, F. Coscas, R. Serra, D. Cabral, D. Colantuono, E. Souied FRANCE
Long term follow up of quiescent choroidal neovascularization associated with age-related macular degeneration or pachychoroid

10.42  S. Kunzel, M. Pfau, P. Möller, L. Goerd, S. Schmitz Valckenberg, F.G. Holz, M. Fleckenstein GERMANY
Determinants of quality of life in geographic atrophy secondary to age-related macular degeneration

Assessment of ellipsoid zone reflectivity by optical coherence tomography in eyes at high risk for development of late stage AMD over time

10.54  S. Chandra, S. Sivaprasad, D. Menon UK
10 year outcome of anti-VEGF therapy in neovascular AMD

11.00  S. Simakurthy, A. Kumar, S. Mohanty, T. Seth INDIA
Evaluation of the role of autologous bone marrow derived mononuclear cells in advanced dry AMD

11.06  S. Bailiff, M. Weber, M. Dominguez, F. Coscas, C. Faure, L. Kodjikian, S. Cohen FRANCE
Impact of intravitreal aflibercept dosing regimens in treatment naïve patients with neovascular age-related macular degeneration: 2 year interim results of rainbow

11.12  S. Young, M. Anderson, S. Borooah, A. Armbrrecht, P. Cackett UK
10 year mortality and clinical outcomes in patients with neovascular age related macular degeneration treated with intravitreal anti VEGF (vascular endothelial growth factor) injections

11.18  T. Davies, T. Makanjuola, Z. Koshy UK
To what extent do patients with exudative age-related macular degeneration, treated out with current UK guidelines, gain improvement in visual acuity (VA)?

7 year outcomes of anti VEGF treatment in exsudative age-related macular degeneration

The efficacy and safety of brolucizumab compared with aflibercept in polypoidal choroidal vasculopathy: 24 month results from the HAWK study

11.36  U. Chakravarthy, E. Kap, N. Pillai, A. Syntosi, A. Sagkriotis UK
Association between changes in anatomical, functional outcomes and physicians’ decisions to treat patients with licensed anti-VEGFs for neovascular age related macular degeneration (nAMD) in the UK

11.42  V. Cipriani, L. Lores Motta, A. Moore, P. Morgan, A. den Hollander, P. Bishop, S. Clark UK
Factor H related protein 4 drives complement activation in age-related macular degeneration

12.00  End of session
10.30 – 12.00
INSTRUCTIONAL COURSE 41
New Frontiers & Perspectives in Diffuse DME
Room 342 (Level 3)
Course Organisers:  M. la Cour DENMARK
D.E. Pelayes ARGENTINA
10.30  F. Bandello ITALY
Evaluation and prognostic factors
10.40  M. Battaglia Parodi ITALY
Multimodal diagnostic tools in DME
10.50  R. Cano MEXICO
Angio SS OCT D DME
11.00  M. Larsen DENMARK
New trends pharmacotherapy in D DME
11.10  F. Graue MEXICO
Surgical management, when the surgery?
11.20  F. Fayad JORDAN
DME surgical management
11.30  F. March SPAIN
Combining lines in DME and proliferative diabetic retinopathy
11.40  M. la Cour DENMARK
D.E. Pelayes ARGENTINA
Discussion
12.00  End of course

10.30 – 12.00
INSTRUCTIONAL COURSE 42
Neovascular AMD: Beyond Anti-VEGF
Salle Maillot (Level 2)
Course Organiser:  I. Mantel SWITZERLAND
10.30  I. Mantel SWITZERLAND
Refractory neovascular AMD - How to differentiate the individual need
10.40  R. Schlingemann SWITZERLAND
Pigment epithelium detachment or tear in nAMD
10.50  A. Ambresin SWITZERLAND
Aneurysmal type 1 neovascularisation
11.00  J. Pournaras SWITZERLAND
Massive haemorrhage in nAMD
11.10  T. Wolfensberger SWITZERLAND
Vitreomacular traction in nAMD
11.20  S. Zweifel SWITZERLAND
Cataract surgery in nAMD during anti-VEGF treatment
11.30  Y. Louati SWITZERLAND
Glaucoma patient with nAMD and anti-VEGF treatment
11.40  Discussion
12.00  End of course
## SUNDAY 8 SEPTEMBER

### 10.30 – 12.00
**INSTRUCTIONAL COURSE 43**

**Surgical Controversies in Vitrectomy for Retinal Detachment**

**Room 251 (Level 2)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Country</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.30</td>
<td>R. Tadayoni</td>
<td>FRANCE</td>
<td>Biomarkers of prognosis in retinal detachment surgery</td>
</tr>
<tr>
<td>10.36</td>
<td>T. Williamson</td>
<td>UK</td>
<td>Posturing modalities</td>
</tr>
<tr>
<td>10.42</td>
<td>J. García-Arumí</td>
<td>SPAIN</td>
<td>Pearls for the management of intraretinal/subretinal PVR</td>
</tr>
<tr>
<td>10.48</td>
<td>S. Rizzo</td>
<td>ITALY</td>
<td>Giant retinal tears: My way</td>
</tr>
<tr>
<td>10.54</td>
<td>C. Mateo</td>
<td>SPAIN</td>
<td>When gas and when oil. How do I choose?</td>
</tr>
<tr>
<td>11.00</td>
<td>Y. Le Mer</td>
<td>FRANCE</td>
<td>Management of epiretinal membrane/macular hole in retinal detachment surgery</td>
</tr>
<tr>
<td>11.06</td>
<td>P. Stanga</td>
<td>UK</td>
<td>Update on management of optic pit maculopathy</td>
</tr>
<tr>
<td>11.12</td>
<td>G. Pertile</td>
<td>ITALY</td>
<td>Retinal detachment in trauma. Any different?</td>
</tr>
<tr>
<td>11.18</td>
<td>F. Patell</td>
<td>ITALY</td>
<td>Combined rhegmatogenous and tractional RRD. How to treat</td>
</tr>
<tr>
<td>11.24</td>
<td>M. Moussa</td>
<td>EGYPT</td>
<td>Management of retinal detachment in inflammatory diseases</td>
</tr>
<tr>
<td>11.30</td>
<td>E. Bali</td>
<td>BELGIUM</td>
<td>Prevention of peroperative complication in vitrectomy for retinal detachment surgery</td>
</tr>
<tr>
<td>11.36</td>
<td>P. Stavrakas</td>
<td>GREECE</td>
<td>Real life scenarios managed by the experts-Interactive discussion of cases</td>
</tr>
<tr>
<td>11.42</td>
<td></td>
<td></td>
<td>Discussion</td>
</tr>
<tr>
<td>12.00</td>
<td></td>
<td></td>
<td>End of Session</td>
</tr>
</tbody>
</table>

### 10.30 – 12.00
**INSTRUCTIONAL COURSE 44**

**Innovative Technologies & State of the Art on Retinal Imaging**

**Room 351 (Level 3)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Country</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.30</td>
<td>R. Dolz Marco</td>
<td>SPAIN</td>
<td>Introduction</td>
</tr>
<tr>
<td>10.36</td>
<td>M. Lupidi</td>
<td>ITALY</td>
<td>Hemodynamics of the choroid</td>
</tr>
<tr>
<td>10.49</td>
<td>M. Munk</td>
<td>SWITZERLAND</td>
<td>Distinguishing the underlying pathology of CME using SD-OCT in daily clinic</td>
</tr>
<tr>
<td>11.02</td>
<td>P. Keane</td>
<td>UK</td>
<td>Artificial intelligence, present and future applications</td>
</tr>
<tr>
<td>11.15</td>
<td>S. Mrejen</td>
<td>FRANCE</td>
<td>Central serous chorioretinopathy and the pachychoroid spectrum</td>
</tr>
<tr>
<td>11.28</td>
<td>S. Yzer</td>
<td>THE NETHERLANDS</td>
<td>Pathologic myopia</td>
</tr>
<tr>
<td>11.41</td>
<td>R. Dolz-Marco</td>
<td>SPAIN</td>
<td>Tomographic features on AMD</td>
</tr>
<tr>
<td>11.54</td>
<td></td>
<td></td>
<td>Discussion</td>
</tr>
<tr>
<td>12.00</td>
<td></td>
<td></td>
<td>End of course</td>
</tr>
</tbody>
</table>
12.30 – 14.00

**EURETINA SESSION 15**

The EURETINA Guidelines for the Management of Retinal Disease: The Next Steps

**Amphithéâtre Bleu (Level 2)**

**Chairpersons:**
- U. Schmidt-Erfurth  **AUSTRIA**
- A. Loewenstein  **ISRAEL**

12.40  **R. Spaide**  **USA**  
Drug dosing with anti-VEGF agents, a new form of meta-analysis

12.40  **A. Loewenstein**  **ISRAEL**  
How to manage diabetic disease in population and individuals

12.50  **U. Schmidt-Erfurth**  **AUSTRIA**  
Is AI taking over the retina?

13.00  **C.C.W. Klaver**  **THE NETHERLANDS**  
Of mice and men: Conclusions from genetics

13.10  **F. Bandello**  **ITALY**  
Are we done with vein occlusion?

13.20  **R. Tadayoni**  **FRANCE**  
Why benchmarking in macular surgery is needed

13.30  Discussion

14.00  End of session

12.30 – 14.00

**FREE PAPER SESSION 21**

Vascular Diseases & Diabetic Retinopathy IV

**Amphithéâtre Havane (Level 3)**

**Chairperson:**  **S. Yzer**  **THE NETHERLANDS**

12.30  **S. Karaman Erdur, F. Dikkaya**  **TURKEY**  
The effect of duration on retinal and choroidal thicknesses in children with hypertension

12.36  **P. Dugel, B. Berger, M. Fineman, A. Khanani, S. Patel**  **USA**  
Results of a phase 1, open label, dose escalation study of THR 149 in patients with diabetic macular oedema (DME)

Smartphone based fundus imaging in diabetic retinopathy screening in low and middle income countries: Evaluation of four different devices

Social deprivation as a risk factor for the incidence of retinal vein occlusion

12.54  **P. Bodhankar, D. Sheth, D. Anantharaman, D. Chandra, M. Gopalakrishnan**  **INDIA**  
Surgical treatment of diabetic maculopathy in patients with type 2 diabetes mellitus: Long term results

13.00  **K. Hatz, M. Guichard, C. Tuerksever, C. Pruente, A. Behrndt**  **SWITZERLAND**  
Spectral domain optical coherence tomography (SD OCT) based morphometric response of intravitreal dexamethasone implant for diabetic macular edema (DME)

13.06  **I. Panchenko**  **UKRAINE**  
System of classification and automatic reference of diabetic retinopathy based on artificial intelligence in developing countries

13.12  **J. Valdez Lopez, J. Arroyo Gonzalez**  **MEXICO**  
Ten year incidence and progression of diabetic retinopathy in type 1 and type 2 diabetes mellitus in France and its impact on screening strategy: the OPHDIAT study A retrospective study based on a screening program

13.18  **V. Rajendran, R. Khan, R. Raman, S. Mahato**  **INDIA**  
Ten year outcomes of conventional panretinal photocoagulation in eyes with proliferative diabetic retinopathy
Treat and extend protocol with aflibercept for cystoid macular edema secondary to central retinal vein occlusion – an 18 month prospective cohort study

13.36  E. Linton, C. Baily, A. Stone  UK
Treatment of diabetic macular edema: real world outcomes from a dedicated UK injection unit

Treatment outcomes achieved with the intravitreal 0.19 mg fluocinolone acetonide implant in clinical practices  Interim results from the prospective IDEAL registry study in Germany

13.48  H. Lai, R. Chan, S. Tsang, T. Woo, A. Lai, R. Lam, C. Yuen  HONG KONG
Two year treatment outcomes of subthreshold micropulse yellow (577 nm) laser for diabetic macular edema

14.00  End of session
12.30 – 14.00
FREE PAPER SESSION 22
Mixed III
Room 241 (Level 2)

Chairperson: S. Yzer THE NETHERLANDS

12.30 K. Romdhane, M. Zola, A. Matet Daruich, A. Matet, C. Elalouf, F. Behar Cohen, I. Mantel FRANCE
Predictors of treatment response to anti VEGF for choroidal neovascular membrane secondary to chronic central serous chorioretinopathy

12.36 A. Wolf, P. Wiedemann, S. Rizzo, J. Crespi Vilimelis, T. El Kashab, T. Raber GERMANY
Ocriplasmin in clinical practice: results from a European prospective drug utilisation study (TULIP)

12.42 A. Couturier, V. Mané, C. Lavia, R. Tadayoni FRANCE
Decorrelated cysts in diabetic macular edema

12.48 A. Özturk Oner, N. Sinim Kahraman, H. Hekmat, M. Unlu TURKEY
Correlation between optical coherence tomography and multifocal electroretinogram findings in patients with chronic central serous chorioretinopathy who underwent photodynamic therapy

12.54 K. Vutipongsatorn, T. Yoshida, X. Li, K. Cao, K. Ohno Matsui UK
Constructing murine model of posterior staphyloma through targeted disruption of bruch’s membrane

13.00 L. Mengyu, Z. Jie, d. Wentao CHINA
A three year follow up report on different treatment schemes for retinopathy of prematurity in stage 4A

13.06 L. Goh, V. Kirthi, J. Harvey, T. Jackson UK
Incidence of fingolimod associated macular oedema (fAMO): an observational study

13.12 N. Relano Barambio, P. Romero Aroca, J. de la Torre, A. Valls, D. Puig SPAIN
Validation of a deep learning algorithm for diabetic retinopathy lecture in a population of diabetes mellitus patients

13.18 R. Guthoff, I. Handoko, P. Albrecht, M. Ringelstein, O. Aktas, G. Geerling GERMANY
Macular and optic disc head morphology on OCT and correlation with visual acuity in patients with non arteriitic anterior ischemic optic neuropathy

13.24 S. Ganekal INDIA
Chandelier endoilluminator assisted modified scleral buckle for Rhegmatogenous retinal detachment

Clinical and morphological outcomes of early idiopathic epiretinal membranes (IERM) surgery

13.36 S. Agarwal Sinha, S. Amin, J. Guevara, A. Gonzalez, C. Bolch, W. Smith USA
Efficacy of aflibercept treatment and its long term effect on the physiological angiogenesis in the mouse model of oxygen induced retinopathy of prematurity

13.42 V. Juncal, M. Bamakrid, C. Francisconi, J. Farah, A. Kherani, R. Muni CANADA
Ranibizumab and aflibercept levels and its impact on vascular endothelial growth factor in human breast milk following intravitreal injection

13.48 V. Thoguluva INDIA
Eplerenone in the treatment of chronic central serous chorioretinopathy with cystoid macular degeneration

14.00 End of session
**SUNDAY 8 SEPTEMBER**

**12.30 – 14.00**

**INSTRUCTIONAL COURSE 46**

**Uveitis Pearls for the Retina Specialist**

**Room 251 (Level 2)**

**Course Organisers:**
- D. Grewal, USA
- M. Munk, SWITZERLAND

12.30  W. Tucker, UK
- An algorithmic approach for uveitis diagnosis

12.45  M. Munk, SWITZERLAND
- Using imaging to monitor disease activity and treatment response

13.00  S. Sharma, USA
- Local treatment options in uveitis

13.15  P. Lin, USA
- Systemic treatment options in uveitis

13.30  D. Grewal, USA
- Surgical planning and vitreoretinal surgical approaches in uveitis

13.45  Discussion

14.00  End of course

**12.30 – 14.00**

**INSTRUCTIONAL COURSE 47**

**Diabetic Macular Edema: from Bench to Bedside**

**Room 351 (Level 3)**

**Course Organisers:**
- A. Joussen, GERMANY
- E. Midena, ITALY

12.30  A. Joussen, GERMANY
- The multifactorial pathophysiology of diabetic macular edema: The paradigms for a new treatment approach

12.45  T. Peto, UK
- Present and future perspectives of screening diabetic macular edema: The prevention of a blinding condition

13.00  E. Pilotto, ITALY
- The role of multimodal imaging modalities in the diagnosis of diabetic macular edema

13.15  E. Midena, ITALY
- The real personalized treatment of diabetic macular edema

13.30  S. Sivaprasad, UK
- Lessons in practice: Special clinical cases to improve the clinical approach to diabetic macular edema

13.45  Discussion

14.00  End of course
Have your registration fees reimbursed! Send us your photos from the Congress and mention @EURETINA or use #EURETINA19 to enter the draw.

Connect with EURETINA during the meeting by following us on:
An online space to **learn** in your **own time** and place

**Developed**
in conjunction with EURETINA course presenters

**Forums**
to connect and discuss with other members

**Interactive**
and assessed, including animations and videos to challenge and engage

**Accredited**
earn CME credits and learn about the latest techniques

Visit our Resource Centre
Booth 228, Exhibition Hall, Level 2
ePoster Presentations & Video Competition
AMD

A. Arrigo, M. Battaglia Parodi, F. Romano, E. Aragona, C. Di Nunzio, F. Bandello ITALY
Towards a quantitative optical coherence tomography angiography classification of choroidal neovascularization secondary to age-related macular degeneration

R. Aydin, H. Topcu, G. Erdogan, O. Artunay TURKEY
Treatment of choroidal neovascularization secondary to central serous chorioretinopathy

K. Bae, J. Lee, H. Kim, Y. Shin, S. Kang SOUTH KOREA
Optical coherence tomography angiography biomarkers of neovascular activity during treatment of exudative age-related macular degeneration using a “treat-extend-stop” protocol

S. Balci, N. Yenerel TURKEY
The choroidal vascularity index decreases in intermediate age-related macular degeneration

The real life after clinical trials in neovascular age-related macular disease: Long term follow up, a case series

I. Bubnova, M. Budzinskaya, A. Plyukhova, A. Shelankova RUSSIA
Influence of IOP indices rise after intravitreal injections from corneal biomechanical properties

A. Cabrera Marenco, T. Ortiz Basso, S. Cura, C. Challiol ARGENTINA
Long-term outcomes of late treatment with repeated intravitreal injections of aflibercept and/or bevacizumab in patients with different neovascular membranes who partially responded to previous bevacizumab injections

A. Chandrasekera SRI LANKA
Relationship between macula pigment optical density and visual performances in patients with Drusen maculopathy

A. Chandrasekera SRI LANKA
Dry age-related macular degeneration associations with: Systemic disorders

P. Corazza, S. Younis, J. Kabbani, M. Nicolò, C. Traverso ITALY
Real life comparison between PRN regime and treat and extend in patients treated for retinal angiomatous proliferation with ranibizumab

A. Cusamano, B. Falsini, E. Giardina, R. Cascella, J. Sebastiani, J. Marshall ITALY
Retinal functional changes in treated and fellow eyes following nano-pulse laser treatment for intermediate AMD: An epigenetic effect?

M. Dalalishvili, C. Takchidi, T. Kasminina, G. Kachalina RUSSIA
Laser technologies for treatment “dry” form of age-related macular degeneration.

Y. Derradji, M. Sherif, A. Safi, I. Mantel SWITZERLAND
Seven-year outcome of the observe-and-plan regimen with intravitreal injections of anti-VEGF for exudative age-related macular degeneration: The real life results

N. Dhingra, M. Pavel, R. Yadav UK
Two year results using fixed dosing regimen for neovascular age-related macular degeneration in real world setting

P. Dionisios, O. Makri, Z. Kapsala, A. Mani, C. Georgakopoulos GREECE
Evaluation of pain during intravitreal ranibizumab injections

S. Donati, W. Messina, E. Pozzi, A. Colombo, L. Premoli, C. Metrangolo, C. Azzolini ITALY
Exudative AMD and anti VEGF therapy in real life setting: Clinical results and quality of treatment

J. Eells, A. Hall, B. Abroe, E. Liedhegner, C. Tedford USA
The development of photobiomodulation for the treatment of dry age-related macular degeneration

O. Fayzrakhmanova, R. Fayzrakhmanov, E. Larina, O. Pavlovskiy RUSSIA
Dynamics of changes in morphometric parameters of foveolar zone in the formation of active fibrovascular membrane

Expected efficacy after intravitreal dexamethasone implant in DME

Final visual acuity correlation with need of intravitreal injections re-treatment in real life after clinical trials in naïve neovascular age-related macular disease: A subgroup analysis

W. Fusi-Rubiano, E. Gokhale, F. Horner, R. Chavan UK
Twelve month outcomes of patients switched from Ranibizumab to Aflibercept for treatment of wet AMD in a UK NHS Trust

R. Gaber, Q. You, M. Allam, I. Kılıç, A. Meshi, W. Freeman EGYPT
High-dose high-frequency aflibercept for recalcitrant neovascular age-related macular degeneration

J. Garweg, P. Traina, R. Garweg, C. Gerhardt, I. Pfister SWITZERLAND
Stability in successfully treated neovascular age-related macular degeneration: Should we stop or should we go?

C. Georgakopoulos, O. Makri, A. Pallikari, K. Kagkelaris, P. Plotas, A. Emmanuil GREECE
Effect of intravitreal injection of aflibercept on cardiovascular risk parameters in patients with age related macular degeneration

M. Gillies, D. Barthelmes AUSTRALIA
Ten-year treatment outcomes of neovascular age-related macular degeneration

M. Grassi, C. Furino, N. Recchimurzo, G. Alessio ITALY
Retinal vessel analysis on octa immediately after anti-VEGF intravitreal injection

M. Grassi, C. Furino, N. Recchimurzo, G. Alessio ITALY
A new model for management of intravitreal injection (IVI): Bari Policlinico real-world experience

A. Hadi Al-Hassany UK
New patho-physiological and OCT classification of exudative age-related macular degeneration
A. Hamoud, G. Almeida, A. Malik UK
Affiblercept treatment for neovascular age related macular degeneration resistant to ranibizumab

D. Hipolito-Fernandes, M. Elisa Luis, M. Vieira, M. Noronha, R. Anjos, R. Flores, L. Vieira PORTUGAL
Neovascular age-related macular degeneration with low vision at baseline: A real-life study

B. Horsman, D. El Gasim USA
Choroidal neovascular membranes modified by micropulse laser

P. Hujanen, H. Uusitalo Järvinen, A. Tuulonen FINLAND
Anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration: 10-year real-life data

A. Invernizzi, V. Nguyen, K. Teo, D. Barthelmes, A. Fung, A. Vincent, M. Gillies ITALY
Five-year real-world outcomes of occult and classic choroidal neovascularization: Data from the fight retinal blindness! Project

Y. Ishimaru, I. Maruko, A. Kagoure Katakura, T. Yokoyama, H. Arakawa, T. Iida JAPAN
Changed in choroidal vascular structures in eyes with chronic central serous chorioretinopathy after half-dose photodynamic therapy

I. Jamiołkowska, M. Figurska, M. Rękas POLAND
Choroidal thickness changes in patients with exudative age-related macular degeneration treated with aflibercept in one year follow-up.

C. Kalogeropoulos, K. Kotsis, D. Kalogeropoulos GREECE
Intravitreal gas injection and tissue plasminogen activator for the management of submacular hemorrhage due to age-related macular degeneration

Z. Kapsala, G. Bontzos, D. Pagoulatos GREECE
Short-term response to intravitreal anti-VEGF treatment of first compared to second eye

K. Kataoka, K. Asai, Y. Tsunekawa, Y. Ito, H. Terasak Japan JAPAN
Three-year outcomes of a treat-and-extend regimen with intravitreal aflibercept injections for neovascular age-related macular degeneration

N. Kocak, M. Kaya, B. Akbulut, F. Atas, T. Ozturk, S. Kaynak TURKEY
The effects of cataract surgery in eyes with nonexudative age-related macular degeneration

A. Korol, T. Kustryn, I. Nasinnyk, A. Nevksa, O. Zadorozhnyy UKRAINE
5-year outcomes of aflibercept treatment for neovascular age-related macular degeneration in routine clinical practice

V. Kotamarthi, O. Arshad, A. Asghar, R. Vellaniparambil, T. El Khashab UK
Late onset of pseudophakic cystoid macular oedema in eyes receiving treatment with intra-vitreal anti-VEGF for neovascular AMD

V. Kotamarthi, A. Hafeez, R. Vellaniparambil, T. El Khashab, V. Antoniou UK
Outcomes and factors to consider before switching anti-VEGF therapy in neovascular AMD

M. Krogh Nielsen, T. Bjerregaard, C. Molbech, Y. Subhi, T. Sørensen DENMARK
Patients with neovascular AMD and lack of response to anti-VEGF treatment have a complex systemic chemokine receptor profile

R. Laiginhas, D. Cabral, M. Falcão PORTUGAL
Early reduction of choroidal neovascularization lesion size predicts long-term visual acuity gains in the comparison of age-related macular degeneration treatment trials (CATT)

P. Lanzetta, M. Ohji, J. Korobelnik, B. Smela Lipińska, P. Szawara, D. Janer, C. Tuckmantel ITALY
Clinical evidence among patients with wet age-related macular degeneration treated with intravitreal aflibercept and ranibizumab: A systematic literature review

Clinical outcome of switching from ranibizumab to aflibercept in the treatment of neovascular age-related macular degeneration

B. Lewke, T. Ishizuka, S. Sonntag, S. Grisanti, R. Brinkmann, Y. Miura GERMANY
Fluorescence lifetime imaging ophthalmoscopy in mouse models of age-related macular degeneration

J. Luttrull USA
Slowed progression of age-related geographic atrophy following subthreshold diode micropulse laser

A. Maalej, A. Khaliloui, R. Choura, R. Foued, O. Yassine, R. Riadh TUNISIA
Correlation between macular structure and function in neovascular macular degeneration treated with aflibercept intravitreal injections

Aflibercept and blood coagulation parameters in treatment naive patients with age related macular degeneration

G. Manayath, R. Ranjan, S. Vidhate, N. Venkatapathy INDIA
Photodynamic therapy: Induced acute exudative maculopathy. Incidence, clinical features and long-term outcomes

I. Mantel, S. Kasser SWITZERLAND
Distinguishing the anti-VEGF sensitivity of so called refractory fluid in anti-VEGF treated neovascular age-related macular degeneration

J. Marques, J. Providência, M. Raimundo, C. Farinha, I. Pires, M. Cachulo, R. Silva PORTUGAL
OCT angiography metrics predict early functional improvement in neovascular age-related macular degeneration

J. Marshall, A. Hussain UK
Retinal rejuvenation therapy (2RT) for early intervention AMD

A. Marta, R. Vieira, A. Abreu, S. Monteiro, M. Furtado, M. Lume PORTUGAL
Atrophy associated with AMD after antiangiogenic therapy

J. Meira, J. Carneiro, M. Carolina, M. Falcão, S. Gonçalves Correira, F. Falcão Reis, A. Carneiro PORTUGAL
Effectiveness of treat-and-extend versus pro re nata regimens in the treatment of neovascular age macular degeneration: A real world comparison
G. Montesano, G. Ometto, J. Terheyden, A. Binns, D. Crabb UK
Quantification of two dimensional progression velocity in geographic atrophy and its relationship with autofluorescence at the borders

I. Mylona, I. Tsinopoulos GREECE
Effect of time interval between anti-VEGF injections on visual acuity in the treatment of neovascular age-related macular degeneration

I. Mylona, I. Tsinopoulos GREECE
Effect of time interval between anti-VEGF injections on central retinal thickness in the treatment of neovascular age-related macular degeneration

Y. Nakano, K. Kataoka, J. Takeuchi, Y. Ito, H. Terasaki JAPAN
Microvascular changes in polypoidal choroidal vasculopathy assessed by optical coherence tomography angiography in response to anti-vascular endothelial growth factor

R. Nourinia, H. Ahmadieh, M. Rezaei, M. Salar Behzadi IRAN
Intravitreal injection of zoledronic acid in rat model of choroidal neovascularization

H. Olga, O. Huzun, N. Khramenko, A. Nevskay, Y. Rostel, A. Krivoruchko UKRAINE
Laser therapy and long-term nutrient therapy in the treatment of patients with dry AMD

Natural history of quiescent choroidal neovascularization

T. Ozturk, K. Kasal, M. Kaya, N. Kocak, S. Kaynak TURKEY
Wrinkled pigment epithelium detachment: A novel biomarker for better anatomic and functional outcomes

Y. Park, J. Kim SOUTH KOREA
Spontaneous total serous retinal detachment following geographic atrophy associated with age-related macular degeneration: Case report

J. Park, W. Lee SOUTH KOREA
The efficacy of Ranibizumab monotherapy in PCV patients with previous history of multiple PDTs

A. Parrado Carrillo, M. Figueras Roca, R. Casaroli Marano, D. Barthelmes, M. Gillies, J. Zarranz Ventura SPAIN
Big data and intravitreal therapy: comparison of treatment-naive vs previously treated neovascular age-related macular degeneration (nAMD) eyes. Barcelona’s cohort of the fight retinal blindness project

M. Pavel, R. Yadav, N. Dhingra UK
Efficacy of fixed bimonthly ranibizumab versus aflibercept in eyes with neovascular age-related macular degeneration—results of a 12-month retrospective study

E. Pedanova, A. Doga, A. Mayorova, I. Gorshkov RUSSIA
12-month results of aflibercept treatment in Caucasian patients with resistant polypoidal choroidal vasculopathy

E. Pedanova, O. Klepinina, I. Gorshkov RUSSIA
Pachychoroid neovasculopathy – comparative efficacy of anti-VEGF agents loading doses (short-term results)

A. Plyukhova, M. Budzinskaya, P. Sorokin, M. Afanasieva RUSSIA
The risk of retinal pigment epithelium tear after anti-VEGF therapy in patients with wet AMD

J. Providência, M. Raimundo, J. Marques, C. Farinha, M. Cachulo, I. Pires, R. Silva PORTUGAL
Applicability of a fully non-invasive diagnosis methodology in neovascular AMD

L. Quagliato, N. Rodrigues, T. Figueiredo, V. Falcão, M. Almeida, T. Carvalho, G. Paula BRAZIL
Brazilian Amazon region ophthalmologic research: Retinal diseases in the riverside population

A. Ramos Valencia BOLIVIA
Therapeutic response and development of taquifilaxia with intravitreal injection of ziv-aflibercept in neovascular age related macular degeneration

N. Rubio Alvarez, C. Arruabarrena Sanchez, M. Teus Guezala SPAIN
8 years follow-up on naïve exudative age-related macular degeneration treated with intravitreal anti-VEGF therapy in real life

R. Sacconi, E. Borrelli, F. Bandello, G. Querques ITALY
Choriocapillaris impairment in the progression of geographic atrophy: 1-year follow-up

N. Sahinoglu-Keskem, F. Batıoğlu TURKEY
Effect of fundus autofluorescence patterns on progression rates of geographic atrophy

F. Sampaio, C. Teixeira, R. Carvalho, B. Vieira, R. Gonçalves, J. Moreira, S. Pereira PORTUGAL
Effect of cataract surgery in exsudative age related macular degeneration

L. Sararols Raysam, M. Guarro, M. Oliveras, G. Londoño, N. Barriga, L. Flores SPAIN
Comparison of visual acuity results, OCT characteristics and patient burden before and after 12 months of treatment protocol implantation and intravitreal clinic optimization in our medical retina unit

M. Sasaki, S. Harada, Y. Kawasaki, K. Tsubota, T. Takebayashi, Y. Nishihashi, R. Kawasaki JAPAN
Dietary patterns and their associations with early age-related macular degeneration in a Japanese population

N. Sayin, M. Erdogan, K. Sarici, S. Bayramoglu, A. Ozkaya TURKEY
Short-term real life efficacy outcomes for a treat and extend anti-vascular endothelial growth factor regimen in eyes with neovascular age related macular degeneration: Up to six month follow up

N. Semenova, V. Akopyan, V. Sulimov, A. Sulimov, A. Stulova RUSSIA
The machine learning method for anti-VEGF treatment prognosis in patients with neovascular age-related macular degeneration: Preliminary results

N. Semenova, A. Stulova, V. Akopyan RUSSIA
Choroidal thickness as a predictor of the anti-VEGF therapy efficacy in neovascular age-related macular degeneration

T. Shaimov, I. Panova, V. Shaimova RUSSIA
Non-invasive diagnosing criteria of polypoidal choroidal vasculopathy
M. Sherif, M. Sherif, Y. Derradji, A. Safi, I. Mantel SWITZERLAND
Longterm results of pigment epithelium detachments in neovascular age-related macular degeneration treated with anti-VEGF in an observe-and-plan regimen

N. Silva, J. Heitor, A. Marta, A. Abreu, M. Furtado, M. Lume PORTUGAL
Visual and morphologic outcomes in patients submitted to thirty or more intravitreal injections for neovascular age-related macular degeneration

Peripheral nurse-led macula service including intravitreal injections under remote consultant supervision in Aberdeen, Scotland: Safety and patient satisfaction

R. Sonmez, C. Koutsiouki, R. Hamilton, R. Rajendram TURKEY
Spontaneous and treatment induced retinal pigment epithelium(RPE) tear in exudative age-related macular degeneration

Y. Suo, J. Zhang CHINA
Mining for genes related to choroidal neovascularization based on the shortest path algorithm and protein interaction information

S. Theodoropoulou, A. Reyman, G. Parisi, S. Salvatore, A. Ross, C. Bailey UK
12-month clinical outcomes of a hybrid treat-and-extend regimen with aflibercept for neovascular age-related macular degeneration in a real life setting

S. Theodoropoulou, A. Reyman, G. Parisi, S. Salvatore, A. Ross, C. Bailey UK
24-month clinical outcomes of a treat-and-extend regimen with aflibercept for wet age-related macular degeneration in a real life setting

Hypoxia inhibits subretinal inflammation resolution in age related macular degeneration

O. Trunova RUSSIA
Results of Aflibercept administered in patients with wet AMD, complicated by giant pigment epithelium detachment (PED) of retina

C. Turksever, K. Hatz SWITZERLAND
A cross sectional study assessing the perifoveal and peripapillary vessel density in nAMD after longterm compared to recently started anti-VEGF treatment: Pilot study

S. Upadhye, D. Manayath, D. Sarvanan, V. Narendran, S. Mokadam INDIA
Outer retinal tubulation as an indicator for poor visual prognosis in choroidal neovascular membrane

A. Vachiberidze, N. Labauri GEORGIA
Different surgical approaches to remove subfoveal blood in hemorrhagic AMD: A comparative study

A. Vardarinos, A. Iron, A. Al Janabi, E. Sprogis, N. Gupta UK
Long term real world outcomes of a treat and extend regimen with aflibercept for age related macular degeneration

E. Vounotrypidis, J. Siedlecki, A. Athanasiou, A. Hillenmayer, C. Wertheimer, S. Priglinger, A. Wolf GERMANY
In vitro simulated stereotactic radiotherapy therapy on different cell lines

I. Wong, R. Wong, C. Ko, F. Yip, C. Tsang, S. Mohamed, N. Fung HONG KONG
A 10-year retrospective review of the real-life use of anti-VEGF in patients with age related macular degeneration in Hong Kong

H. Yang, J. Youm, K. Kim SOUTH KOREA
Diagnostic efficacy of optical coherence tomography angiography (OCT-A) in detecting choroidal neovascularization (CNV)

S. Younis, P. Corazza, T. Soomro, H. Orlans, J. Kabbani UK
Age related macular degeneration: Long terms results from real world data

A. Zafar, A. Pitalia, A. Sylvester, S. Mahmood, T. Aslam UK
Anti-VEGF therapy: Right timing or right frequency?

Anterior/Posterior Segment Surgery

D. Balakrishnan, A. Oli INDIA
Peripheral iridectomy for preventing iris related complications in glued intraocular lens surgery in children

C. Bernal, M. Rodriguez Maqueda, M. Ruiz Miguel, A. Hernandez Martinez, J. Cubero, D. Ruiz Casas, J. Zarranz Ventura SPAIN
Management of aphakia: Spanish national multicenter study of retropupillary iris-claw lens implantation and pars plana vitrectomy

B. Bolek, A. Wylegala, R. Mazur, E. Wylegala POLAND
Ultrasound ciliary plasty: Influence on retinal thickness

A. El Habbak, M. Awwad EGYPT
Combined phacoemulsification and intra-vitreal bevacizumab injection for prophylaxis of macular edema in diabetic patients

V. Evgrafov, G. Kudasheva, I. Medvedev RUSSIA
Influence of intravitreal aflibercept on diabetic macular oedema after phacoemulsification

R. Fayzrakhmanov, E. Larina, O. Fayzrakhmanova, O. Pavlovskiy RUSSIA
Surgical treatment of subpigmental neovasuglyarization

M. He, W. Tsai TAIWAN
Double decentered lens in an eye

L. Hejsek CZECH REPUBLIC
Intraoperative intraocular pressure fluctuation during standard phacoemulsification in real human patients

I. Ianilkina, L. Kryl, P. Volodin, D. Buryakov, E. E. Tolstukhina RUSSIA
The laser surgery of avulsed retinal vessel syndrome associated with vitreal tractions
Diabetic Retinopathy

A. Abu El Asrar, A. Ahmad, E. Bittoun, M. Siddiqui, G. Mohammad, A. Mousa, G. De Hertogh, SAUDI ARABIA
Differential expression and localization of human tissue inhibitors of metalloproteinases in proliferative diabetic retinopathy

E. Ahumada Felix, I. Espinosa Soto, G. González Saldívar, J. Ramírez Estudillo, MEXICO
Pain perception in patients treated with intravitreal Ozurdex with different types of anesthesia in diabetic macular edema

M. Akdogan, Y. Ustundag, M. Sabaner, TURKEY
The relationship biochemical and hematological parameters in patients with age-related macular degeneration and diabetic retinopathy

A. Ale-Chilet, M. Barraso, T. Hernández, C. Oliva, A. Adán, J. Zarranz Ventura, SPAIN
Smoking alters the perivascular vasculature: OCT-A study in diabetes type-1 patients: 1 year follow-up

M. Alonso Plasencia, R. Abreu González, M. Alberto Pestano, M. Gómez Culebras, SPAIN
Retinal vascular density map is better correlated with function than retinal vascular perfusion density map

T. Araújo, T. Araújo, D. Wanderley, C. Carvalho, P. Costa, C. Maia, S. Penas, PORTUGAL
Performance analysis of specialists and automatic methods in diabetic retinopathy screening

S. Asghar, M. Razzaq, UK
Real world outcomes reported in diabetic macular oedema (DMO) from a district hospital in south west (SW) England, following the use of 0.2 µg/day fluocinolone acetonide (FAc; ILUVIEN) intravitreal implant

A. Avunduk, S. Ozen, TURKEY
Evaluation of effect of panretinal photocoagulation on ocular blood flow in patients with diabetic retinopathy by dynamic contour tonometry

O. Ayranç Osmanbasoğlu, S. Ozdoğan Erkul, TURKEY
Does panretinal laser therapy has an effect on macular edema treatment? Real life data

D. Barthelmes, A. Biechl, S. Bandhari, M. Gillies, SWITZERLAND
Two-year outcomes of ranibizumab treatment for diabetic macular edema

K. Belkhadir, S. Jouahri, S. Moutamani, N. Bennani, B. Benhammou, O. Cherkaoui, MOROCCO
The management of type 1 diabetes: A challenge for developing countries

J. Bonnar, O. Earley, T. Peto, UK
Audit on progression of diabetic retinopathy following cataract extraction by phacoemulsification

P. Brito, J. Costa, C. Barbosa Matos, S. Costa, J. Correia Pinto, R. Silva, PORTUGAL
Systemic and ocular factors as predictors of anatomic response categories in diabetic macular edema treated with bevacizumab: Early, late or no significant response

I. Careba, I. Careba, S. Padroni, FRANCE
Visual and anatomical outcomes for patients switched from ranibizumab to aflibercept intravitreal injections for diabetic macular edema

M. Carrión Donderis, M. Figueras, A. Sala Puigdollers, B. Sanchez Dalmau, A. Adán, J. Zarranz Ventura, SPAIN
Automated diabetic macular edema screening in primary care with spectral domain optical coherence tomography (SD-OCT)

J. Castro De Sousa, PORTUGAL
Analysis of the real-world effectiveness and safety of fluocinolone acetonide (FAc) 190 µg intravitreal implant in patients with persistent diabetic macular edema: A comparison between monotherapy and treatment combined with adjuvant therapies

S. Chandra, J. Sheth, A. Giridhar, S. Sivaprasad, UK
Complex interplay between ocular perfusion pressure and choroidal thickness in diabetic retinopathy

Y. Chang, TAIWAN
Intraocular vascular endothelial growth factor and cytokines in diabetic macular edema
V. Chaudhary, J. Qian, A. Sothivannan, N. Barbosa CANADA
Assessing the extent of diabetic retinopathy in an inpatient psychiatric population

X. Chen, Y. Xu, Y. Qu, J. Gao, X. Chen, K. Liu, X. Xu CHINA
Correlation of retinal layer changes with vision gain in diabetic macular edema during conbercept treatment

Efficacy of intravitreal 0.19µg/day fluocinolone acetonide in eyes with centre involving diabetic macular edema: Real world data up to 36 months

J. Chhablani, D. Durandhar, S. Singh, N. Sahoo, A. Goud, M. Lupidi INDIA
Identifying central serous chorioretinopathy biomarkers in coexisting diabetic retinopathy: A multimodal imaging study

Leucine-rich G protein-coupled receptor-5 is significantly increased in the aqueous humor of human eye with proliferative diabetic retinopathy

A. Chronopoulos, L. Hattenbach GERMANY
Switching therapy for refractory diabetic macular edema: 12 and 24 month results with intravitreal fluocinolone acetonide implant (ILUVIEN)

S. Costa, C. Valente, F. Falcão Reis, M. Falcão PORTUGAL
Cytokines and growth factors as predictors of severity and response to intravitreal treatment in diabetic macular edema

Intravitreal ranibizumab injections have no influence on retinal vascular caliber in patients with diabetic macular edema

M. Diaz de Aguilar Osona, M. Sanchez Garcia, D. Angel Pereira, I. Rodriguez Talavera, R. Falcon Roca SPAIN
Experience with OZURDEX on naive patients with diabetic macular edema

L. Dipiotti, S. Pignatto, P. Lanzetta ITALY
Ocular complications of diabetes and optical coherence tomography angiography macular features in a paediatric population with Nls diabetes mellitus

Subthreshold yellow micropulse laser for treatment of diabetic macular edema: Comparison between fixed and variable treatment regimen

L. Duarte, A. Laiqinhas, A. Barros, R. Soares, A. Rocha, J. Chibante Pedro PORTUGAL
Significance of ellipsoid integrity status in the outcome of diabetic macular edema treated with fluocinolone acetonide intravitreal implant (Iluvien®)

J. Eells, S. Gopalakrishnan, T. Connor, K. Stepien, J. Carroll, V. Williams, J. Kim USA
670 nm photobiomodulation as a therapy for diabetic macular edema

S. El Emam, M. Mostafa Abou El Atta, H. El Koumi, M. Abd El Lateef EGYPT
Swept source optical coherence tomography angiography in proliferative diabetic retinopathy

F. El Zawahry, H. Hamza, A. Abdel Baky EGYPT
Yellow micropulse laser 577-nm vs. infrared diode micropulse laser 810-nm for the treatment of diabetic macular edema

Combination of intravitreal bevacizumab and erythropoietin versus intravitreal bevacizumab alone for refractory diabetic macular edema

I. Erbahecic Timur, Ö. Sancat, N. Üğürül TURKEY
Relationship between presence of foveal bulge in optical coherence tomographic images and visual acuity after anti-VEGF therapy for diabetic macular edema

M. Erdoğan, K. Sarici, S. Bayramoglu, N. Sayin TURKEY
Real-life outcomes with intravitreal dexamethasone implant (OZURDEX®) treatment in diabetic macular edema

L. Faes, L. Bachmann, M. Schmid, M. Thiell SWITZERLAND
The diagnostic accuracy of the patient self-test Alleye to detect diabetic macular edema

M. Fenech, T. El Khashab, D. Seneveratn UK
Real time data on the clinical outcomes of fluocinolone acetonide (lluvien) implant use in chronic diabetic macular oedema in pseudophakic patients

A. Filloy Rius, E. Solé Forteza, C. Perálvarez Conde, M. Castro Diaz, SPAIN

D. Fu, C. Kern, J. Huemer, K. Kortuem, K. Balaskas, D. Sim, P. Keane UK
Real-life visual outcomes in patients receiving anti-VEGF treatment for diabetic macular edema in a tertiary referral center

S. Gajree, S. Chakrabart, M. Gupta UK
Real world experience of flucinolone acetonide implant (ILUVIEN) in persistent diabetic macular oedema

S. Ganekal INDIA
Correlation of ganglion cell complex and retinal nerve fiber layer thickness in diabetic patients and age matched normal

Macular microvascular changes after intravitreal bevacizumab injection in diabetic macular edema

M. Guma SAUDI ARABIA
Intravitreal aflibercept for proliferative diabetic retinopathy

M. Hussain, G. Panos, T. Adewoyin UK
Safety and effectiveness of 0.7 mg intravitreal dexamethasone implant (OZURDEX®) for the treatment of chronic diabetic macular edema (DMO) in an ethnically-diverse population with complex co-morbidities

C. Isanta Otal, F. Bartol Puyal, M. Puzo, J. Sánchez Monroy, Ó. Ruiz Moreno, P. Calvo Pérez, L. Pablo Julve SPAIN
Retinal thickness in diabetic patients treated with intravitreal corticoid

B. Ivanovska Adjievska, S. Boskurt, N. Gineva, C. Kara USA
Severe proliferative diabetic retinopathy – Functional and anatomic outcomes after pars-plana vitrectomy
K. Jeong **SOUTH KOREA**
Choroidal thickness in and outside of vascular arcade in diabetic retinopathy eyes using spectral-domain optical coherence tomography

W. Jia **CHINA**
Change of choroidal thickness of non-proliferative diabetic retinopathy and macular edema under different grade

M. Kalanov, M. Bikbov **RUSSIA**
The effectiveness of internal limiting membrane peeling at proliferative diabetic retinopathy

V. Karabas, E. Onder Tokuc, I. Uslubas, H. Kose **TURKEY**
Effect of unilateral dexamethasone implant injection on fellow untreated eye by in patient with diabetic macular edema

M. Karliychuk, P. Bezditko **UKRAINE**
Frequency of different stages of diabetic retinopathy depending on type and stage of diabetic optical neuropathy

M. Karpoor, A. Bhatnagar **UK**
Frequency of different stages of diabetic retinopathy depending on type and stage of diabetic optical neuropathy

A. Kazennov, A. Chuprova, Y. Kuvaytseva, I. Kazennova **RUSSIA**
Efficacy of anti-VEGF drugs before surgical treatment in patients with proliferative diabetic retinopathy complicated by diabetic macular edema

A. Khudyakov, V. Rudenko **RUSSIA**
The analysis of the results of surgical treatment of proliferative diabetic retinopathy

K. Kim, E. Kim, S. Yu **SOUTH KOREA**
Longitudinal changes in retinal vasculature after panretinal photocoagulation in diabetic retinopathy by swept-source OCT Angiography

A. Kononov, E. Klyushnikova, N. Mitrofanova, V. Motyleva, N. Marova **RUSSIA**
Surgical treatment of traction retinal detachment associated with proliferative diabetic retinopathy without tamponade substances

A. Korkmaz, M. Zengin, O. Kartı, B. Yuksel, T. Kusbeci **TURKEY**
The effects of baseline optical coherence tomography biomarkers on the visual improvement of naïve diabetic macular edema patients after year pro re nata regimens of intravitreal ranibizumab, aflibercept, and dexamethasone implant treatments

T. Kotsur, A. Izmaylov **RUSSIA**
Anatomical and functional results of subthreshold high density laser coagulation (810 nm): The complex instrumental evaluation

N. Koyluoglu, A. Batman, M. Canat, S. Erol, E. Çil Şen, D. Yıldız, F. Yener Öztürk **TURKEY**
The evaluation of idx-dr as a screening test for the diabetic retinopathy in an endocrinology clinic

P. Larrañaga-Fragoso, H. Laviers, C. Mckechnie, H. Zambarakji **UK**
Surgical outcomes of vitrectomy surgery for proliferative diabetic retinopathy in patients with abnormal renal function

F. Laureano, M. Canastro, P. Reis, A. Correia, K. Cheles **PORTUGAL**
ILUVIEN®, the long acting steroid for diabetic macular edema treatment: An efficacy and safety retrospective analysis

C. Lavia, A. Couturier, A. Erginay, B. Dupas, R. Tadayoni, A. Gaudric **FRANCE**
A reduced vessel density in the superficial and deep plexuses in diabetes results in different changes in thickness in corresponding retinal layers

G. Le Guern, J. Marie Louise, A. Couturier, B. Dupas, A. Erginay, R. Tadayoni **FRANCE**
Evaluation of retinal perfusion in diabetic retinopathy before and after panretinal photocoagulation using optical coherence tomography angiography

H. Liu, X. Chen **CHINA**
Altered vitreous microRNA expression profile after intravitreal conbercept in proliferative diabetic retinopathy

Combined phacoemulsification and dexamethasone intravitreal implant (ozurdex®) for diabetic macular edema: A prospective study

X. Ma, S. Chen **CHINA**
Study on the treatment of proliferative diabetic retinopathy by intracanal injection of conbercept combined with 23G vitrectomy

C. Madeira, M. Lopes, R. Laiginhias, J. Neves, V. Rosas, F. Falcão Reis, M. Falcão **PORTUGAL**
Serum 25-hydroxyvitamin D levels and diabetic retinopathy in type 1 diabetes patients: An association?

Lifestyle factors and diabetic retinopathy

D. Maltev, A. Kulikov, M. Burnasheva, J. Cحاблاني **RUSSIA**
Structural en face optical coherence tomography imaging for identification of leaky microaneurysms in diabetic macular edema

S. Mamorta, H. Hasan, N. Shah **UK**
Real world data from the use of OZURDEX in pseudophakic, treatment naïve patients with diabetic macular edema

S. Mano, J. Prates Canelas, S. Vaz Pereira **PORTUGAL**
Real-world outcomes of the dexamethasone intravitreal implant in pharmacological treatment-naïve patients with diabetic macular edema

F. Mdanat, Z. Madanat, M. Safi, M. Mookhtiar **UK**
Bevacizumab intravitreal injections in managing proliferative diabetic retinopathy: Real life experience

C. Menezes, F. Vale, S. Azevedo **PORTUGAL**
Individualized posology and optimized outcomes in diabetic macular edema patients treated with intravitreal dexamethasone implant (DEX/OZURDEX): naïves vs non-naïves

R. Molina-pallete, A. Fernandez Santodomingo, P. Martinez Lopez Corell, L. Ramos Gonzalez, P. Udaondo **SPAIN**
Is choroidal thickness a predictive factor of response in DME patients?
L. Mondal, S. Pramanick, India
Do red blood cells (RBCs) resist the response to anti-vascular endothelial growth factor agent (anti-VEGF) in diabetic retinopathy (DR)

W. Ngo, C. Tan, Singapore
Effect of intravitreal anti-vascular endothelial growth factor therapy on macular perfusion in eyes with diabetic macular edema

B. Ning, A. Stone, UK
Retrospective review of the management and outcomes of patients presenting with rubeotic glaucoma

K. Nishida, S. Hirokazu, R. Kawasaki, K. Nishida, Japan
Simulation of panretinal photocoagulation based on the muller cell densities

A. Nosirova, A. Nosirova, P. Yakushev, V. Kolesnik, Russia
Outcome after retinal endolaser photocoagulation for diabetic retinopathy complicated by hemophthalmos: Applying of intraoperative fluorescein angiography

C. Oliveira-Ferreira, M. Dias, J. Tavares Ferreira, A. Rocha Sousa, F. Falcao Reis, Portugal
Choroidal thickness and urinary albumin excretion in type 2 diabetic patients without retinopathy

E. Onder Tokuc, I. Uslubas, V. Karabas, Turkey
The effects of intravitreal dexamethasone implant in diabetic macular edema refractory to ranibizumab therapy

P. Papandreou, M. Toma, UK
Two year follow up of treatment with aflibercept in diabetic macular edema previously refractory to ranibizumab: Intravitreal therapy and/or intravitreal dexamethasone implant: Real life data

S. Pereira, C. Teixeira, T. Maio, J. Moreira, F. Sampaio, Portugal
Long term efficacy and safety outcomes of the 0.2 μg/day fluocinolone acetonide (FAc) implant (ILLUVIEN®) in eyes with chronic and recurrent diabetic macular edema

B. Pessoa, L. Malheiro, C. Coelho, J. Figueira, A. Meireles, J. Beirão, Portugal
Intravitreal ranibizumab or aflibercept after bevacizumab in chronic and recurrent diabetic macular edema treatment

B. Pessoa, I. Carneiro, C. Coelho, J. Figueira, A. Meireles, J. Beirão, Portugal
OCT analyses in patients with persistent diabetic macular edema after bevacizumab therapy

D. Petrichkov, V. Pavlov, Russia
Correlation OCT biomarkers with primary response on anti-VEGF therapy

M. Polito, C. Eandi, G. Tosi, Y. Le mer, M. Varano, D. De Geronimo, M. Parravano, Italy
Characteristics of diabetic macular edema recurrence according to different baseline OCT patterns in patients treated with dexamethasone implant
F. Sermet, F. Sermet, B. Eldad, L. Karabas, G. Yilmaz, N. Unlu, F. Oner TURKEY
SALUTED-D - a randomized, open-label non-inferiority study to compare safety and efficacy of labeled versus wait and extend regimen of lucentis® (ranibizumab) in Turkish patients with visual impairment due to diabetic macular edema

P. Sim, A. Al Nahrawy, R. Feng, S. Younis, T. Richardson, E. Posner, R. Akshikar UK
Changes in retinal layer morphology following intravitreal Ozurdex therapy for diabetic macular edema

S. Simpson, Y. Chen, H. Madi, J. Smith, A. Kotagiri, D. Steel, M. Habib UK
Comparing the efficacy of intravitreal 0.19µg/day fluocinolone acetonide in vitrectomised and non-vitrectomised eyes with centre involving diabetic macular oedema: Real-world data from 24 and 36 months follow-up

A. Solis-Vivanco, A. Hidalgo Bravo, M. Valdés Flores MEXICO
Analysis of differential expression of miRNAs in vitreous and serum derived from Mexican diabetic patients with retinal micro-angiopathies compared to idiopathic macular diseases

The possible role of thyroid hormones on the color vision pathway in early diabetes: In vivo and postmortem data

I. Taskintuna, M. Abdalla Elsayed, P. Schatz, I. Kozak SAUDI ARABIA
Evaluation of intravitreal bevacizumab injections in treating recurrent vitreous hemorrhage following pars plana vitrectomy for diabetic vitreous hemorrhage

K. Torres, J. Sanchez, A. Ramirez, A. Hernandez, F. Del valle MEXICO
Incidence of visual improvement in patients with diabetic macular edema treated with antiangiogenic with and without disorganization of the retinal inner layers

Widefield optical coherence tomography angiography in diabetic retinopathy

T. Tran, E. Ali, S. Baillif, E. Fourmaux, J. Uzzan, S. Milazzo, L. Kodjikian FRANCE
Afibbercept intravitreal injection for diabetic macular edema in vitrectomized eyes

K. Tsoulosis, T. Islam, V. Konidaris, S. Banerjee GREECE
Fluocinolone acetonide (ILUVIEN®) intravitreal implant for diabetic macular edema: The Leicester experience of extended follow-up period up to three years after implantation

P. Udaondo, C. Hernandez Pascual, M. Mesquida, E. Nogoeke, R. Simo SPAIN
OCT biomarkers of response to intravitreal therapy in diabetic macular edema

N. Uğurlu, E. Erdal, S. Malekghasemi TURKEY
Preparation and characterization of carbonic anhydrase inhibitor-loaded nanoparticles intended for treatment of diabetic macular edema

H. Vaidya, R. Raman INDIA
Real life visual and anatomical outcome of management of diabetic macular edema in vitrectomized eyes

Diabetic macular ischemia: Angio-OCT measurement compared to fluorescein angiography

W. Vasquez, G. Rivera, E. Baques PERU
Implant of dexamethasone (OZURDEX) vs aflibercept (wetlia) as start therapy in pseudophakic diabetic macular edema naive patients

E. Von Weidebach, P. Ishida, C. Moreira Junior, C. Moreira Neto, B. Camisa BRAZIL
Anatomic changes of the retina after green, yellow and red laser photoagulation in spectral domain OCT

J. Wang, C. Chiu, D. Lee TAIWAN
Comparison of intravitreal anti-vascular endothelial growth factor agents in one eye and dexamethasone implant in contralateral eye in patients with bilateral treatment-naive diabetic macular edema

R. Zainullin, M. Bikbov, T. Gilmanshin, K. Kudoyarova RUSSIA
Epidemiology diabetic retinopathy in a Russian population

Imaging

A. Abdel-Kader, A. Farag, A. El-Nahry EGYPT
Multimodal imaging in a case of Neurofibromatosis type 1 associated with atypical congenital hamartoma of the retinal pigment epithelium and optic chiasm glioma

M. Aboushussein, A. Soliman EGYPT
Measurement of choroidal thickness in cases of high refractive errors

D. Alex, A. Giridhar, M. Gopalakrishnan INDIA
Choroidal vascularity indices and coexisting morphological changes in polyoid choroidal vasculopathy (PCV): A comparative analysis between two treatment strategies

F. Al-Mamouri JORDAN
Evaluation of macular circulation in patient with sudden visual loss secondary to behcet’s perifoveal vasculitis by (retinal flow) swept-source optical coherence tomography angiography map

A. Al-Saedi, A. Al-Marshood, M. Rubio Caso, R. Khandekar, F. AlMarek, V. Semidey UK
Normative values for choroidal thickness among healthy saudi subjects using enhanced-depth optical coherence tomography imaging. A prospective cross-sectional study

N. Arumuganathan, N. Arumuganathan, I. Beck, K. Fasler, S. Zweifel SWITZERLAND
Acute and subacute changes in retinal and choroidal blood flow following intravitreal anti-VEGF injections

K. Asma, A. Maa lej, R. Choura, Y. Oueslati, R. Rannen TUNISIA
Evaluation of choroidal thickness in amblyopic eyes using enhanced depth imaging optical coherence tomography

S. Benaoun, N. Abroug, I. Sallem, I. Jerbi, E. Saihi, M. Khairallah TUNISIA
En face OCT findings in laser pointer maculopathy: A report of three cases
P. Gurav-Khadke, K. Ramasamy, N. Kannan, K. Kumar, P. Shah INDIA
RAP: Decoding its birth in one eye and weird presentation in other eye

F. Hagenau, B. Schworm, L. Keidel, S. Priglinger, R. Schumann GERMANY
Comparison of automated and manual choroidal thickness measurements in swept source vs. spectral domain optical coherence tomography

A novel method for detecting and monitoring hydroxychloroquine maculopathy

Optical coherence tomography angiography in myopic choroidal neovascularization to predictive anti-vascular endothelial growth factor treatment outcomes

G. Querques ITALY
C. Iovino, E. Peiretti, R. Sacconi, G. Caminiti, Optical coherence tomography angiography study

F. Arango COLOMBIA
A. Hoyos, J. Arias, M. Parra, L. Martinez, R. Sanchez, F. Arango COLOMBIA
Characterization of pachychoroid disease spectrum through optical coherence tomographic angiography (OCT-A)

E. Interlandi, F. Pellegrini, G. Ciancia, A. Cuna ITALY
Chiasmal optic neuritis: An optical coherence tomography study

E. Interlandi, F. Pellegrini, A. Cuna, C. Silvestrin ITALY
Optical coherence tomography angiography (OCTA) in hellp syndrome-related hypertensive choroidopathy

A. Iovino, E. Peiretti, R. Sacconi, G. Caminiti, G. Querques ITALY
Optical coherence tomography angiography features of PCV secondary to chronic CSC

B. Kashyap, S. Azad, R. Chawla INDIA
Swept source OCT and OCT angiography characteristics of choroidal osteoma with or without neovascularisation

L. Keidel, L. Keidel, B. Schworm, N. Luft, C. Priglinger GERMANY
Spectral-domain optical coherence tomography findings in choroidal neovascularization to predictive anti-vascular endothelial growth factor treatment outcomes

R. Kiçiç, H. Soyalıç, O. Polat TURKEY
Does allergic rhinitis have any effect on choroidal thickness?

H. Kılınç Hekimsoy, H. Kılınç Hekimsoy, M. Şekeroğlu, A. Koçer, A. Akdoğan TURKEY
Analysis of retinal and choroidal microvasculature in systemic sclerosis: An optical coherence tomography angiography study

R. Kim, M. Kim, Y. Park SOUTH KOREA
Choroidal structural evaluation in central serous chorioretinopathy by clinical features using choroidal vascularity index

Y. Kim, J. Kim SOUTH KOREA
Optical coherence tomography angiography findings of macular chorioretinal membrane secondary to spontaneous closure of traumatic macular hole: A case report

C. Kucukerdonmez, E. Cinar, B. Yuce, M. Zengin TURKEY
Evaluation of retinal and choroidal microvascular changes in healthy pregnant women using optical coherence tomography angiography

C. Kucukerdonmez, E. Cinar, B. Yuce, M. Zengin TURKEY
The effect of nicotine on macular microcirculation in healthy subjects

C. Lampert Monte Francisconi, R. Hillier, V. Juncal, T. Felfeli, L. Giavedoni, D. T Wong, R. Muni CANADA
Association of baseline OCT features with visual outcomes following retinal detachment repair: Post-hoc analysis of the pivot trial

A. Lentzschi, R. Siggel, C. Spital, S. Liakopoulos GERMANY
Improvement of sensitivity for CNV detection on spectral-domain OCTA en face images using projection artifact removal, manual modification of segmentation lines as well as OCTA B-scans with flow information

V. Likhachevskaia, V. Krasilnikava, A. Kuzmenkov BELARUS
The influence of IT-technology in the diagnostic accuracy of diabetic retinopathy by collective intelligence

M. Lupidi, F. Cardillo Piccolino, C. Cagini, D. Fruttini, M. Nicolò, T. Fiore, C. Eandi ITALY
Chronic central serous chorioretinopathy and choroidal neovascularization: A stress/rest optical coherence tomography-angiography study

S. Mabrouk, H. Zgolli, O. Fekih, A. Ben Youssef, I. Zeghal, L. Nacef TUNISIA
Tomographic data of macular neuroretinal lesions in the rhegmatogenous retinal detachment with macula off: Predictors of long term functional outcomes

S. Mahmah, N. Haouari, R. Bennour, F. Ouagoughi, M. Terahi ALGERIA
Paracentral acute middle maculopathy: One case report

D. Maltsev, A. Kulikov, D. Maltsev, J. Chhablani RUSSIA
Characterization of choroidal nevi with dark field infrared scanning laser ophthalmoscopy

M. Menke, A. Baston, S. Trachaler SWITZERLAND
Intra-observer reproducibility of OCT-A vessel density (perfusion) and foveal avascular zone measurements in patients with non-proliferative diabetic retinopathy and in healthy controls

Y. Miura, S. Sonntag, E. Seifert, B. Lewke, S. Grisanti, R. Brinkmann GERMANY
Fluorescence lifetime imaging ophthalmoscopy on rabbits in vivo after irradiation with single laser pulses in the 5-50 µs time regime

S. Mondal, S. Mandal INDIA
Modification of treatment decision based on ultra wide field imaging in presumed tubercular posterior uveitis

Changes in choroidal structure and circulation after a caffeine intake in healthy subjects

A. Nawar EGYPT
Unusual complication of anti VEGF

V. Nereo, T. Kiseleva, T. Okhotsimskaya, M. Ryabina, V. Fadeeva RUSSIA
OCT-angiography and ultrasound doppler in assessment of ocular blood flow in diabetic macular edema
A. Olate-Perez, A. Olate Perez, C. Oliva, T. Hernandez, Z. Chu, R. Wang, J. Zarranz Ventura SPAIN
Differences in vascular density measurements with three different commercial optical coherence tomography angiography (OCTa) devices (cirrus, spectralis and triton)

H. Ozdemir, M. Sekeroglu TURKEY
The effect of topical tropicamide and phenylephrine on macular and peripapillary microvasculature: An optical coherence tomography angiography study

L. Pace, F. Corvi, M. Cozzi, G. Staurenghi ITALY
Choroidal neovascularization detection using optical coherence tomography angiography versus dye based imaging modalities in geographic atrophy

C. Preziosa, M. Pellegrini, F. Corvi, G. Staurenghi ITALY
Extended field imaging optical coherence tomography angiography (EFI-OCTA) for the study of retinal and choroidal changes after radiation therapy for choroidal melanoma

C. Ramoul, C. Ramoul, K. Laboudi, M. Afriat, A. Denoyer, C. Arndt FRANCE
Impaired mf ERG is associated with suspected cone loss on adaptive optics in patients treated with Hydroxychloroquine

M. Rehak, A. Bauer, C. Busch, P. Wiedemann GERMANY
Correlation between blood pressure and macular perfusion measured by oct angiography

H. Riaz Esfahani, F. Ghassemi, B. Masoomian IRAN
Tamoxifen induced pachychoroid pigment epitheliopathy with reversible changes after drug discontinuation

J. Ruiz-Medrano, M. Sanchez Dehesa, J. Ruiz Moreno SPAIN
En face swept-source OCT imaging of the choroidal structure of AMD patients

S. Sadiq, K. Iqbal PAKISTAN
Sensitivity and specificity of optical coherence tomography angiography to detect choroidal neovascularization

M. Sagong, G. Ryu, D. Park, J. Lee, J. Van Hemert SOUTH KOREA
Quantitative analysis of choroidal vascular area and density in central serous chorioretinopathy: UWF indocyanine green angiography study

A. Sala-Puigdollers, M. Figueras Roca, C. Alba Linero, A. Moll, J. Zarranz Ventura, A. Adan SPAIN
Changes on the optical coherence tomography angiography (OCT-A) in newly diagnosed type 1 diabetes patients: one year follow-up

A. Sethia, A. Giridhar, M. Gopalakrishnan, A. Goyal INDIA
Morphological features and associated macular pathologies in patients with focal choroidal excavation (FCE)

T. Shaimov, V. Shaimova, A. Galin RUSSIA
OCT-based indications for preventive laser photocoagulation of peripheral retinal tears

S. Simakurthy, D. Shanmugam, D. Ramanjulu, D. Mishra INDIA
Hyperreflective dots in optical coherence tomography may prompt a change in treatment.

J. Simão, J. Bernardes, M. Raimundo, C. Farinha, M. Cachulo, I. Pires, R. Silva PORTUGAL
Macular telangiectasia type 1 (MacTel1): A qualitative and quantitative OCTA characterization

Long-term effect of half-fluence photodynamic therapy on fundus autofluorescence in acute central serous chorioretinopathy

S. Syed, S. Pocker, V. Sharma, N. Jones, J. Ashworth, L. Steeples UK
Multimodal imaging in interferon-beta retinopathy

I. Szalai, E. Bosnyák, T. Miklós, Z. Nagy, J. Tian, D. DeBuc, G. Somfai HUNGARY
Retinal morphological changes due to intensive physical exercise in healthy young adults and sportsmen

C. Tan, L. Lim, D. Ting SINGAPORE
Multicolour imaging for the detection of polypoidal choroidal vasculopathy and age-related macular degeneration

C. Tendo, N. George UK
A Laser accident

B. Thalanki Shankarnarayan, S. Pagliarini UK
OCT diagnosis of systemic disease

A. Timsit, E. Bousquet, M. Irmela, E. Martine, F. Behar Cohen FRANCE
Phenotype of central serous chorioretinopathy in female patients with central serous chorioretinopathy

P. Topcu Yilmaz, S. Comcali, Z. Aslar, Y. Maras, M. Alp TURKEY
Optical coherence tomography angiography in systemic lupus erythematosus

S. Vaz-Pereira, H. Proença PORTUGAL
Foveal neovascularization in proliferative diabetic retinopathy

R. Venkatesh, S. Sinha, A. Mohan, N. Yadav INDIA
Newer indices for predicting macular hole closure in idiopathic macular holes

R. Venkatesh, K. Jain, S. Gadde, N. Yadav INDIA
Relevance of multispectral reflectance imaging in type 2 macular telangiectasia

L. Vieira, S. Crisostomo, J. Cardigos, D. Hipólito Fernandes, M. Luís, R. Anjos, R. Flores PORTUGAL
Tamoxifen-induced choriotelial changes: An optical coherence tomography and optical coherence tomography angiography study

P. Viggiano, E. Borrelli, I. Toto, F. Evangelista, I. Matropasqua ITALY
Eyelashes artifact in ultra-widefield optical coherence tomography angiography

P. Volodin, E. Ivanova, A. Fomin, E. Polyakova RUSSIA
Spectral OCT-angiography in en face mode in detecting morphological changes of the retinal pigment epithelium before and after selective micro-pulse laser exposure in patients with central serous chorioretinopathy
G. Yilmaz, G. Tanriasik, I. Akkoyun, E. Yaman Pinarci TURKEY Optic coherence tomography angiography (OCTA) findings of the patients with idiopathic juxtapfoveal telangiectasia type 2 (UT type 2)

P. Zabel, J. Kaluzny, K. Zabel, M. Kaluzna, A. Lamkowski, D. Jaworski POLAND Correlation of microperimetry and standard automated perimetry with retinal vessel density in optical coherence tomography angiography in primary open-angle glaucoma

J. Zarranz-Ventura, A. Alé Chilet, M. Barraso, T. Hernandez, C. Oliva, A. Adán SPAIN Retinal nerve fiber layer thickness is correlated with foveal vessel density and perfusion density assessed by optical coherence tomography angiography (OCTA) in type I diabetes mellitus: A large scale prospective OCTA study

F. Zicarelli, M. Pellegrini, C. Preziosa, G. Staurenghi ITALY Active treatment versus observation in peripheral exudative retinopathy: A multimodal imaging study


S. Zweifel, J. Gunzinger, J. Baur, B. Ibrahim, D. Straumann, A. Pangalu, F. Nietnispach SWITZERLAND Detection of retinal arterial (micro-)emboli after transcather aortic valve implantation using OCTA and fluorescence angiography

Intraocular Tumours

A. Alcantara Santillana, M. Díaz Granda, A. Garrido Hermosilla, B. Domínguez García, L. Coca Gutierrez, M. Gessa Sorroche, A. Medina Tapia SPAIN Retinal capillary hemangioma: The importance of early diagnosis and treatment

P. Arede, M. Cordeiro, C. Bruxelas, C. Fernandes, F. Vaz PORTUGAL Follow-up and management of a solitary retinal capillary hemangioblastoma

D. Bueso Ponce, C. Abdala, S. Vidal, J. Unigarro, C. Salgado, P. Cabal COLOMBIA Combined vitrectomy, retinectomy and enucleation of retinal capillary hemangioblastoma

J.M. Caminal, J. Ruiz Medrano, A. Gorro Miro, M. Biarnes, R. Rodríguez Leor, D. Lorenzo, L. Arias SPAIN Optical coherence tomography angiography study of radiation maculopathy after brachytherapy treatment for uveal melanoma

O. D’Anna, J. Coca Robinot, J. García Martínez, M. Asencio Durán SPAIN Casual finding on magnetic resonance imaging (MRI) of serous retinal detachment secondary to choroidal hemangioma in a patient with an arterio-venous cerebral malformation: Case report

M. De Frutos Lezaur, M. Ruiz Miguel, L. Ruiz Hernandez SPAIN First report of choroidal neovascularization in paediatric patient with tuberous sclerosis

R. De Jesus, A. Veloso PHILIPPINES Choroidal osteoma in a middle aged female

L. Grajewski, C. Kneifel, I. Ciernik, C. Keßler, L. Krause GERMANY Comparison of the recurrence rate following adjuvant brachytherapy with Strontium90 or Ruthenium106 after excision of conjunctival melanoma

A. Hopkins, A. Archana, R. Gale UK Ocular manifestations of testicular lymphoma

P. José, F. Teixeira, R. Barão, F. Pinto PORTUGAL Ultrasonographic features of choroidal metastasis

T. Kaga, T. Mori, Y. Mitamura, Y. Sugioaka, S. Tokiwa JAPAN Subretinal endoscopic surgery for metastatic choroidal tumor: A case report

A. Karamaounas, A. Sideri, D. Brouzas, I. Georgalas, P. Petrou GREECE Diagnostic vitrectomy for intraocular lymphoma

S.H. Kim, S.E. Kim, S. Kim, C. Lee SOUTH KOREA A case report of unusual ciliary body tumor

N. Larysa, Z. Katsiaryna, T. Dmitrii BELARUS Combined treatment of patients with slightly pigmented forms of choroidal melanoma in stages I and II

R. Liegl, L. Demberg, C. Fuerweger, A. Wolf, A. Muacevic, S. Priglinger, P. Foerster GERMANY Vascular integrity assessment using optical coherence tomography angiography following choroidal melanoma treatment using cyberknife

R. Loginov, A. Doga, D. Magaramov, I. Gorshkov, V. Yarovaya, E. Korobov, A. Yarovoy RUSSIA How to treat retinal vasoproliferative tumours?

V. Matuskova, P. Hornackova, L. Zlamalikova, K. Liskova, M. Uher, E. Vlkoza CZECH REPUBLIC Uveal melanoma: First cytogenetic testing of chromosome 3 loss in Czech Republic

N. Misawa, M. Tagami, S. Noma Ishikura, S. Honda, S. Kase, S. Honda JAPAN Epiretinal membranes due to vasoproliferative retinal tumours treated with vitrectomy and cryotherapy

A. Mohammad-Zadeh, S. Aghabaklou, N. Ghassembaglou, IRAN Radiation effect on the optic nerve observed in eyes enucleated after failed choroidal melanoma Iodine 125 brachytherapy

C. Oliveira-Ferreira, J. Tavares Ferreira, V. Fernandes, E. Camisa, T. Bragança, F. Falcao Reis PORTUGAL Bilateral choroidal metastasis from neuroendocrine lung cancer

E. Paroikakis, G. Batsos, E. Ktena, L. Kontomihos, A. Chatzirallis, D. Karagiannis GREECE Epiretinal membranes due to vasoproliferative retinal tumours treated with vitrectomy and cryotherapy

J. Providência, C. Fonseca, J. Casalta, T. Teixeira, P. César, J. Fernandes, R. Proença PORTUGAL Intravitreal bevacizumab in the management of radiation retinopathy following brachytherapy for choroidal melanoma

M. Puech, N. Abraham, K. Hawa, V. Caillaux FRANCE OCT-Angiography and choroidal pigmented lesions
Clinical and pathomorphological features of uveal melanoma

E. Samkovich, I. Panova, E. Gyuntner  
RUSSIA

Robotic assisted radiosurgery (cyberknife) for the treatment of vasoproliferative tumours

V. Schmelter, C. Fuerweger, L. Demberg, S. Priglinger, A. Muacevic, P. Foerster, R. Liegl  
GERMANY

Choroidal metastasis: A diagnostic dilemma in today's era

J. Teope, R. Jarin  
PHILIPPINES

Cyberknife in treatment of retinal vasoproliferative tumor

V. Yarovaya, A. Yarovoy, B. Malyugin, A. Zaretsky  
RUSSIA

Prognostic biopsy of choroidal melanoma: Results and genetic findings

X. Zhu, J. Liang  
CHINA

Miscellaneous

D. Abulon  
USA

The impact of vitrectomy probe design on pulsatile motion during aspiration

K. Agarwal, D.C Parameshwarappa  
INDIA

Novel retinal manifestation of poretti-boltshauser syndrome: A case report

K. Agarwal, S. Mohan, S. Jalali  
INDIA

Familial exudative vitreo-retinopathy in infants: Variations in clinical presentations and treatment outcomes

N. Agustin, M. Arroyo, D. Santiago  
PHILIPPINES

A case of aggressive posterior retinopathy of prematurity who developed post intravitreal anti-VEGF injection endophthalmitis in one eye treated in a tertiary hospital in the Philippines

C. Akkin, C. Degirmencı, S. Nalcaci, F. Afrashi, S. Yarimada  
TURKEY

Choroidal vascularity index in patients with chronic central serous chorioretinopathy

M. Al Qassab, A. Wedrich, S. Strin  
AUSTRIA

Analysis of the endophthalmitis rate among patients receiving intravitreal injections at the Department of Ophthalmology in Graz: ten years analysis.

H. Al-Muhtaseb, G. Tsokolas, P. Lotery, A. Jalil  
UK

Macular photochemical injury secondary to the process of gold melting

M. Al-Otaibi, B. Al Qahtani, A. Omair  
SAUDI ARABIA

Retinopathy of prematurity (ROP) prevalence and risk factors in a tertiary hospital in Riyadh, Saudi Arabia

A. Al-Shamrani, A. Al Kharashi, P. Schatz, E. Abdelkader  
SAUDI ARABIA

Outcomes of argon laser photocoagulation in non-resolving central serous chorioretinopathy: A prospective interventional study

E. Al-Yamaç Sukgen, S. Cevher, B. Ozelbaykal, M. Mert  
TURKEY

Clinical characteristics of morning glory syndrome and its associated problems

F. Ascaso, O. Esteban, M. Martinez, L. Lavilla, S. Marco, C. Marcuello  
SPAIN

Retinal and choroidal thicknesses measured with swept-source optical coherence tomography (SS-OCT) in patients with down syndrome

E. Babaei Mazraeno, M. Abrishami, A. Eslampoor, E. Babaei, M. Roknizadeh, M. Abrishami  
IRAN

Refractive and biometric outcomes following single intravitreal bevacizumab

P. Baptista, L. Malheiro, D. José, M. Macedo, M. João Furtado, M. Lume  
PORTUGAL

Structural and microperimetric function in patients with central serosal chorioretinopathy submitted to photodynamic therapy: Long-term evaluation

H. Behboudi, A. Ashraf, S. Sarmadi  
IRAN

Epidemiological, outcome and relative factors of Terson’s syndrome in patients with subarachnoid hemorrhage

N. Borah, D. Phukan, D. Agarwala  
INDIA

Post partum acute loss of vision

M. Boukhil, S. Moutamani, N. Boutimzine, O. Cherkaoui  
MOROCCO

A case report on Corticotherapy inducing decompensation of Diffuse retinal pigment epitheliopathy

M. Bragheeth  
KUWAIT

Efficacy and safety of YAG laser Vitreolysis for management of symptomatic vitreous floaters

B. Burgos-Blasco, C. Valor Suarez, F. Moreno Morillo, B. Vidal Villegas, M. Jimenez Santos  
SPAIN

Poppers maculopathy: Report of two cases in Spain

E. Casas Maroto, N. Olivier Pascual, R. Arroyo Castillo, S. Romeo Villadóniga, S. Rubio Cid  
SPAIN

Spontaneous suprachoroidal hemorrhage: Expect the unexpected

O. Cejudo-Corbalan, M. Medina Baena, A. Gómez Verdejo, A. Perez Aranda, M. Huertos Carrillo, J. García Pulido  
SPAIN

Massive hemorrhagic choroidal detachment in a patient treated with rivaroxaban

L. Ceklic  
BOSNIA AND HERZEGOVINA

Hydroxychloroquine retinopathy in patient with systemic lupus erithematosus

S. Celik Dulger, M. Teke  
TURKEY

Comet lesions and peau d’orange as early diagnostic findings in a patient with pseudoxanthoma elasticum

B. Costa, D. Ramos, Â. Carneiro, V. Rosas, F. Falcão Reis, M. Falcão  
PORTUGAL

Topical antibiotic prophylaxis role in preventing endophthalmitis after intravitreal injection

A. Cuna, F. Pellegrini, E. Interlandi  
ITALY

Optical coherence tomography angiography findings in optic nerve sheath meningioma
M. De Guia, P. Villa, J. Bautista **PHILIPPINES**
Treatment with intravitreal injection of bevacizumab in late-onset choroidal neovascularization secondary to congenital rubella: A case report

J. De Jesus, A. Gomes Da Rocha, R. Staudt Geraldes, R. Laijnhias, M. Matias, J. Chibante Pedro **PORTUGAL**
The eye evolution in the CHARGE syndrome

**R. De Jesus, A. Veloso** **PHILIPPINES**
Occupational laser injury

J. Dolar-Szczasny, A. Święch Zubilewicz **POLAND**
Macular integrity assessment and fixation analysis in chronic central serous choriotreinopathy

A. Dotan, R. Ehrlich, D. Weinberger, A. Sternfeld **ISRAEL**
Nd:YAG capsulotomy is associated with sustained IOP elevation in patients treated with anti-VEGF injections

P. Eymard, E. Bousquet, M. Gerardy, L. Bouys, R. Tadayoni, J. Bertherat, F. Behar Cohen **FRANCE**
Multimodal imaging in patients with Cushing’s syndrome, searching for pachychoroid

A. Fonseca, A. Bhargava, S. Pal, P. Shroff **INDIA**
Intravitreal injections: A patient’s perspective

M. Garcia-Zamora, E. Almazán Alonso, I. Hernández de los Reyes, I. Flores Moreno, J. Ruiz Medrano, J. Ruiz Moreno **SPAIN**
Multimodal imaging in different anatomical and functional findings in posterior pole after blunt ocular trauma

G. Godinho, T. Madeira, R. Silva, E. Brandão, Á. Carneiro, F. Falcão Reis, J. Beato **PORTUGAL**
Longitudinal structural characterization of the retinal effects of hydroxychloroquine treatment

D. Granada, J. Jacinto Bautista **PHILIPPINES**
Bilateral persistent hyperplastic primary vitreous in a filipino infant presenting with nystagmus: A case report

M. Guma **SAUDI ARABIA**
Intravitreal aflibercept injections in the treatment of sickle cell retinopathy

J. Hanhart, Y. Weill, M. Becker Cohen, S. Revel Vilk, L. Wasser, N. Hussiniovitch, A. Zimran **ISRAEL**
Retinal thinning in Gaucher patients as a predictive test for developing Parkinson’s disease

T. Hidalgo Diaz, N. Rachwani Parshotan, A. Gilveti Puche **SPAIN**
Optic nerve head drusen in a child: A 3-year follow-up study with optical coherence tomography

D. Hipolito-Fernandes, M. Elisa Luis, D. Maleita, M. Vieira, G. Neri Pires, P. Ferreira, R. Anjos **PORTUGAL**
Central serous choriotreinopathy in a patient with hydroxycioroquine retinopathy: A case report

A. Hopkins, A. Airody, R. Gale **UK**
An unusual case of intradural haemangioma of the optic nerve mimicking optic neuritis

H. Huang **CHINA**
Hydraulical transmission of rapid increasing intracranial pressure to optic nerve head drives angiorrhexisand bleeding into vitreous

C. Isanta Otal, F. Bartol Puyal, M. Puzo Bayod, J. Sánchez Monroy, Ó. Ruiz Moreno, P. Calvo Pérez, L. Pablo Júlvez **SPAIN**
effects of photodynamic therapy on retinal pigmentary epithelium

C. Isanta Otal, F. Bartol Puyal, M. Puzo Bayod, J. Sánchez Monroy, P. Calvo Pérez, Ó. Ruiz Moreno, L. Pablo Júlvez **SPAIN**
Influence of systemic diseases and their treatments on choroidal thickness

A. Jossy, N. Kasturi, R. Babu K, S. Parchand **INDIA**
Refractive outcomes following laser photoagulation with frequency doubled Nd:YAG laser (532 nm-GREEN LASER) in severe retinopathy of prematurity

Z. Kapsala, D. Pagoulatos **GREECE**
Incidence of hemorrhage after intravitreal injections in patients treated with oral anticoagulants

M. Khan, S. Sidra **PAKISTAN**
TK estimation of target intraocular pressure (IOP) in open angle glaucoma

S. Kivanc, B. Akova **TURKEY**
Case series of retinitis sclerotopetaria

H. Kolli, S. Sreekanthan **UK**
Cytomegalovirus and herpes simplex 2 retinitis: A rare presentation in a patient receiving obintuzumab for chronic lymphocytic leukemia

A. Kouri, A. Koidou, G. Vartzelis, J. Datseris **GREECE**
Intravitreal Bevacizumab to treat peripapillary choroidal neovascular membrane in a teenage girl with chronic intracranial hypertension

J. Krecicka, M. Słowiń, R. Kaczmarek, A. Turno Kręcicka **POLAND**
Harada disease in Polish population: Unlikely, yet possible!

S. Kuo, Y. Lin, H. Lin **TAIWAN**
Ophthalmic sequelae of dengue fever: A case report

K. Locaylocay, G. Mercado, C. Samaniego **PHILIPPINES**
Ocular complications of a delayed diagnosis of incontinentia pigmenti in a Filipino female: A case report

C. Madeira, G. Godinho, M. Falcão, E. Brandão, T. Bragança, A. Carneiro, J. Beato **PORTUGAL**
Characterization of retinal thickness in healthy eyes with short- and long-term hydroxychloroquine use

M. Magliyah, W. Al Zamil **SAUDI ARABIA**
Favourable outcome in retinal macrovessel-related choroidal neovascularization

P. Maitra, K. N **INDIA**
Piecing the puzzle of a vanishing submacular mass: A case report

A. Maitray, V.TP, S. Sen **INDIA**
Endogenous serum cortisol levels and anxiety assessment in patients with polypoidal choroidal vasculopathy(PCV): A new insight into pathogenesis

A. Maitray, A. Maitray, K. N **INDIA**
Subthreshold micropulse yellow laser and eplerenone drug therapy in chronic central serous chorioretinopathy: A comparative study
I. Malov RUSSIA
Analysis of the results of YAG laser hyaloidotomy in the treatment of premacular hemorrhages

J. Marques, A. Abreu, N. Silva, R. Vieira, I. Barbosa, A. Meirelles, J. Melo Beirão PORTUGAL
Management of recurrent macular edema in Irvine-Gass Syndrome with fluorocinolone acetonide intravitreal implant: A case series

M. Mazzola, B. Powell, G. Landa, R. Smith ITALY
Multimodal imaging of bilateral pigmented paravenous chorioretinal atrophy elucidates primary choriocapillary involvement

M. Mazzola, L. Premoli, C. Metrangolo, J. Cattaneo, S. Donati, C. Azzolini ITALY
Petaloid foveal hemorrhage in a young patient with high myopia

A. Meidani, P. Kosmidis, T. Paraskevopoulos, A. Kouroupaki, D. Pagoulatos, GREECE
Benign intracranial hypertension induced in a male patient by oral administration of moxifloxacin

A. Meshksar, M. Afarid, A. Meshksar, A. Salehi, M. Safarpour IRAN
Evaluation of the effect of topical interferon α2b as a complementary treatment of macular edema of patients with diabetic retinopathy: A double blind placebo controlled randomized clinical trial study

G. Miura, R. Hashimoto, T. Baba, S. Yamamoto JAPAN
A case of prolonging retinal outer layer dysfunction induced by sildenafil overdose

I. Mogollón Giralt, I. Rosa Pérez, A. De la Hoz Polo, M. Roca Cabau, L. Sanjuán Riera, M. Viso Garrote, P. Fernández Pérez SPAIN
Case report: Rare chloroquine maculopathy

J. Montero-Moren, C. Gonzalez Uruena, M. Fernandez Munoz, I. Llorente Gonzalez, J. Ruiz Moreno SPAIN
Chorioretinal atrophy in highly myopic eyes with choroidal neovascularization treated by intravitreal anti-VEGF drugs

K. Mousavi, J. Mousavi Facundo, C. Facundo Molas SPAIN
Effect of tacrolimus on retinal ganglion cells thickness in kidney transplantation patients

S. Moutzouri, P. Bostantzis, E. Kanonidou GREECE
Giant cell arthritis with normal erythrocyte sedimentation rate: a diagnostic challenge

M. Mozo Cuadrado, L. Tabuenca Del Barrio, E. Compains Silva, P. Plaza Ramos, A. Dávila Flores, R. Abárizuza Cortaire SPAIN
Choroidal rupture secondary to ocular blunt trauma with airbag

K. Mun, J. Jang SOUTH KOREA
An unusual case of central serous chorioretinopathy and recurrence of polyoidal choroidal vasculopathy in postmenopausal women receiving hormone replacement therapy

M. Oli, M. Fomina, M. Parkepp ESTONIA
Acute retinal pigment epithelitis (Kril’s disease): Case report

F. Onder, E. Varol, D. Karaca TURKEY
Infiltrative optic neuropathy

S. Ozcaliskan, O. Artunay TURKEY
Long-term outcomes of intravitreal ranibizumab for the treatment of idiopathic choroidal neovascularization

A. Papazacharia, E. Kanonidou GREECE
A 38-year old woman with reported repaired eyesight: An “impressionable exaggerator” with functional visual loss

S. Pastor-Idoate, I. Zabalza, R. Coco, Y. Lantigua, J. Perez Castrillon, A. Dueñas Laita, J. Pastor Jimeno SPAIN
Visual pathway alterations after a severe acute occupational elemental mercury poisoning: Report of a series of 29 cases

I. Perente, I. Yilmaz TURKEY
Intravitreal ranibizumab in treatment of proliferative type 2 idiopathic juxtapfoveal telangiectasia

N. Rassu, S. Pignatto, L. Grego, P. Lanzetta ITALY
Optic nerve hypoplasia, corpus callosum agenesis, congenital cataract and lissencephaly in an infant with a novel COL4A1 mutation

S. Riaz PAKISTAN
Frequency of hepatitis B and C in previously unscreened patients admitted for elective cataract surgery

K. Rittenhouse, S. Ezzine, T. Eissig, D. Janer, T. Katz, J. Arbour USA
Investigating molecular features of aflibercept and brolucizumab to clarify clinical results through pharmacokinetic simulations

N. Rodriguez MEXICO
Structural and functional measurements with macular OCT and microperimetry in presymptomatic patients with myotonic dystrophy type 1

J. Ruiz-Moreno, F. De Andrés Nogales, I. Oyagüez, J. Ruiz Medrano SPAIN
Cost-consequence analysis of extended loading dose from 3 to 6 months of anti-VEGF treatment in diabetic macular edema patients

P. Sandhu, N. Cronbach, A. Higham, M. Bindra UK
Are patients undergoing retinal laser informed about the legal implications of their treatment concerning driving as mandated by the United Kingdom (UK) driver and vehicle licensing agency (DVLA)?

G. Şatırtav, A. Gündoğan, H. Kerimoğlu, M. Okka TURKEY
The neutrophil-to-lymphocyte, lymphocyte-to-monocyte and platelet-to-lymphocyte ratios in retinopathy of prematurity

S. Scholtz, B. Hohberger, L. MacMorris, F. Kroghmann, G. Auffarth GERMANY
Under pressure for more than 2000 years: Glaucoma in antiquity

S. Sekeroglu, E. Gündoğan, H. Kermioglu, M. Okka TURKEY
The neutrophil-to-lymphocyte, lymphocyte-to-monocyte and platelet-to-lymphocyte ratios in retinopathy of prematurity

M. Sevik, F. Çam, A. Aykut, Ö. Şahin TURKEY
The effect of giving birth on retina and choroid in a patient with preeclampsia

M. Sekeroglu, E. Yuksel, S. Doguizi TURKEY
Functional and anatomical results of standard and half dose photodynamic therapy in chronic central serous chorioretinopathy

P. Shah, N. Kannan, K. Ramasamy INDIA
Case series of adult onset coat’s disease
M. Shimura, M. Imazeki, O. Kotake JAPAN
Long term visual prognosis of one-step and two-step reconstruction of traumatic rupture of eyeball

E. Sirakaya, Z. Duru, B. Küçük TURKEY
Monocyte-to-high density lipoprotein ratio as a marker of inflammation in patients with central serous chorioretinopathy

C. Skevas, S. Dulz, M. Spitzer GERMANY
Prognostic factors and reliability of the ocular trauma score in association with retinal detachment after open globe injury

R. Sonmez TURKEY
Successful treatment of subhyaloid hemorrhage in two cases with hematologic malignancies

T. Soomro, P. Corazza, J. Kabbani, S. Younis UK
Real world outcomes of ranibizumab, bevacizumab and aflibercept for treating myopic choroidal neovascularisation in a UK centre: A 10-year review

Ciliary body cyst with atypical vitreous chamber location: Clinical features and diagnostic difficulties

A. Stamate, M. Dragomir, M. Zemba ROMANIA
Valsalva retinopathy after strenous coughing

A. Taracena Velasquez, J. Gonzalez Cortes, C. Azuara Azuara, G. Esparza Benavente, A. Del Pozo Perez, J. Garza Chavarria GUATEMALA
Idiopathic macular hole closure after development of an epiretinal macular membrane

M. Targonska, N. Lewczuk, J. Boguslawska, A. Zdebik, A. Kowal Lange POLAND
How an ophthalmologist can save someones life: Susac syndrome: Case presentation

H. Vaidya, S. Moosa, V. Khetan INDIA
Profile of central serous chorioretinopathy in women

R. Venkatesh, N. Yadav, A. Pereira, T.MB, K. Jain INDIA
Torpedo retinopathy

M. Viso, I. Rosa SPAIN
Complications associated with the treatment of a macular edema in a patient undergoing two surgeries to repair an ocular perforation

E. Viteri, I. Gaibor Santos, J. Alvernia, D. Jaramillo, P. Camacho, P. Lopez Jaramillo, V. Galvis ECUADOR
Retinal optical coherence tomography angiography and cardiovascular risk markers: A population study in Latin-America

J. Vanguas, J. Diaz Bernal, I. Baquero Aranda SPAIN
Choroidal thickness in Susac Syndrome detected by SD-OCT

New Drug Treatment & Technology

C. Azzolini, A. Falco, V. Tartaglia, L. Premoli, C. Metrangolo, E. Premi, S. Donati ITALY
Evaluation of EUMEDA web platform in retina diseases

M. Bayzulaeva, A. Doga, D. Shkvorchenko, L. Kryl, D. Buryakov RUSSIA
The assessment of combined laser and microinvasive surgery efficiency in local rhegmatogenous retinal detachment treatment

S. Carrillo Cristancho, C. Macía Badia, C. Barnes Ruz, E. Cantal Badía, P. De Miguel Simó SPAIN
Predisposing factors for chronic use of intravitreal dexamethasone implant

N. Choudhry, S. Jiang CANADA
Real-world visual outcomes after YAG vitreolysis for vitreous opacities (VOYAGE)

A. Fonseca, A. Bhargava, P. Shroff INDIA
Suprachoroidal triamcinolone acetonide: Simplified!

S. Gruchociak, M. Afriat, A. Denoyez, Z. Djerada, A. Arndt FRANCE
Treatment of vitreomacular traction with intravitreal air or gas injection

L. He CHINA
Challenge and outcome of silicone oil filled foldable capsular vitreous body implantation in severe traumatic eyes

M. João, J. Costa, L. Queirós, M. Falcão, K. Sousa PORTUGAL
Visual and anatomic outcomes of 532nm micropulse laser in chronic central serous chorioretinopathy

S. Kumashiro, T. Shiba, T. Komatsu, T. Matsumoto, T. Kobayashi, Y. Hori JAPAN
Choroidal thickness and choroidal blood flow after 1/3 PDT in eyes with chronic central serous chorioretinopathy

J. Lee, A. Kim, W. Son SOUTH KOREA
Exosomal microRNA profiling in aqueous humor of central serous chorioretinopathy by next-generation sequencing

B. Leroy, S. Russell, A. Maguire, J. Bennett, D. Chung, K. Reape, K. High BELGIUM
Vision-dependent activities of daily living after ocular gene therapy: Visual function questionnaire responses in the voretigene neparvovec phase 3 trial

S. Mokadam, S. Upadhye, N. Mathivanan, S. Mokadam, S. Mokadam, M. Joglekar, P. Dhande INDIA
Our experience with injection razumab (bio-similar intravitreal ranibizumab)

M. Mostafa, W. Turky, M. Al Shehri, S. Milisic SAUDI ARABIA
Interleukin-8 as an emerging therapeutic target for angiogenic retinopathies

A. Oner, N. Sinim Kahraman, Z. Gonen, D. Sevim, M. Unlu TURKEY
Mesenchymal stem cell implantation in patients with optic atrophy

G. Spicer, T. McCulley, J. Pei, P. Sidiropoulos, J. Best, J. Stone, S. Unizony USA
Visual impairment in patients with giant cell arteritis treated with tocilizumab in real-world clinical practice
Retinal Dystrophies

M. Al-Abri, A. Al Hinai, S. Al Zuhaibi, A. Ganesh, A. Al Ghafri, K. Al Thihli
Oman
Normal electro-oculography in a young Omani male with genetically confirmed best disease complicated by choroidal neovascularization

A. Al-Shamrani, O. Raddadi, P. Schatz, O. Brandau, C. Bergmann, E. Abdelkader
Saudi Arabia
Coquille d’oeuf in young patients affected with Pseudoxantoma Elasticum

C. De Nicola, G. Ferro, E. Erroi, F. Evangelista, R. D’aloisio, L. Toto, L. Mastropasqua
Italy
Widefield optical coherence tomography angiography in retinitis pigmentosa

D. Dizdar, M. Sevik, A. Aykut, Ö. Şahin
Turkey
A neuronal ceroid lipofuscinoses patient first presenting with eye symptoms

M. El-Sayyed, A. Marinescu
UK
A lady with sjögren-larsson syndrome showing macular telangiectasia and crystalline maculopathy

K. Or, S. Idil, E. Ozmert
Germany
Comparison of contrast sensitivity in retinitis pigmentosa patients with a visual acuity better than low vision range and low vision range without being legally blind

D. Mucciolo, V. Murro, A. Sodi, D. Giorgio, G. Virgili, S. Rizzo
Italy
Long Term-follow-up of CNV with and without pattern dystrophy in patients affected with Pseudoxantoma Elasticum

I. Kazennova, A. Kazennov
Russia
Treatment of acute central serous chorioretinopathy (CSC) based on Anglo-OCT data

I. Kazennova, A. Kazennov
Russia
Treatment of acute central serous chorioretinopathy (CSC) based on Anglo-OCT data

G. Lahaie Luna, Y. Wang, D. Almeida, Y. Strube
Canada
Pigmented paravenous retinochoroidal atrophy in an infant with thalassemia trait: A case report and literature review

C. Madeira, G. Godinho, E. Brandão, A. Magalhães, R. Silva, Á. Carneiro, S. Estrela Silva
Portugal
Choroideremia in a 14yo boy: A novel mutation variant:: Case report

Italy
Coquille d’oeuf in young patients affected with Pseudoxantoma Elasticum

Italy
Long Term-follow-up of CNV with and without pattern dystrophy in patients affected with Pseudoxantoma Elasticum

I. Musallam
Israel
Vibro-chemical neuromodulation as a novel treatment for retinitis pigmentosa: Short term results

K. Nowomiejska, L. Kuehlewein, K. Stingl, F. Nasser, S. Kohl, R. Rejdak, E. Zrenner
Poland
Fundus autofluorescence patterns in BEST1 mutations

E. Ozmert, U. Arslan, S. Demirel, F. Sermet
Turkey
Efficacy of yellow-wavelength micropulse laser in cases with cystoid macular edema secondary to retinitis pigmentosa: Preliminary clinical results

E. Rebele Neves, M. Oliveira, R. Silva, J. Marques
Portugal
Multimodal retinal imaging of autosomal recessive bestrophinopathy

A. Sideri, T. Paraskevopoulos, A. Karamaounas, I. Georgalas, T. Rotts
Greece
Central areolar choroidal dystrophy and hearing loss

V. Vaclavik Ooi
Switzerland
Novel compound heterozygote mutations in CYP2U1 can cause maculopathy with or without neurological signs of hereditary spastic paraplegia HSP56. Comparison with other syndromic maculopathies

C. Vyas, V. Kadri, R. Chandra
India
Deeply pigmented clumps with surrounding hypo-pigmented haloes at fovea: A novel clinical find in Familial exudative vitre- retinopathy(FEVR)
Uveitis

M. Abrishami, M. Hoseini, N. Shoeibi, M. Azimizadeh, IRAN
Presumed sympathetic ophthalmia after scleral buckling surgery: A case report

N. Abroug, M. Khairallah, S. Zina, H. Zouara, R. Messaoud, M. Khairallah, TUNISIA
Profile of occlusive retinal vasculitis in a referral center in Tunisia, North Africa

Post fever retinitis: Features on optic coherence tomography angiography

H. Agrawal, M. Tyagi, R. Pappuru, INDIA
Optical coherence tomography angiography for inflammatory CNVM: Associated various patterns of neo-vascular network and change in size and pattern of network after intra-vitreal anti-VEGF injection

H. Agrawal, M. Tyagi, R. Pappuru, INDIA
Inflammatory CNVM: Clinical features and presentations and response to anti-VEGF monotherapy

S. Ajamil Rodanes, W. Tucker, UK
Detection of varicella zoster virus (VZV) in vitreous cavity: Case of difficult medical-surgical management

Dexamethasone implant (ozurdex™) for non-infectious uveitis affecting the posterior segment (NIU-PS) in the United Kingdom (UK) – 12-month follow-up data with efficacy and safety outcomes

Occlusive retinal vasculitis in Sydney: A study of 67 eyes of 42 patients

P. Amat Peral, P. Amat Peral, C. De la Vega Galiana, SPAIN
Detection of varicella zoster virus (VZV) in vitreous cavity: Case of difficult medical-surgical management

A. Asal, A. Al Zayani, I. Khunji, A. Ahmed, G. Al Arrayed, BAHRAIN
Healthy young adult with unilateral idiopathic frosted branch angiitis FBA

H. Ben Amor, M. Romdhane, H. Zouara, M. Mefteh, S. Attia, M. Khairallah, TUNISIA
Characteristics of uveitis presenting for the first time in the elderly: Data from North Africa

N. Berker, P. Ozdal, M. Karatepe, C. Karahan, TURKEY
Acute retinal necrosis: Analysing the etiologic risks, risk factors, ocular features and treatment methods

M. Bohn, C. Pavesio, M. Sagoo, UK
Sympathetic ophthalmia after ruthenium plaque brachytherapy for iris melanoma

N. Celik, G. Auffarth, R. Max, GERMANY
Behçet uveitis in Caucasian and Mediterranean patients living in Germany

H. Chawla, K. Winthrop, E. Suhler, INDIA
Clinical profile of ocular tuberculosis in a low endemic country

H. Chawla, V. Vohra, A. khan, E. Agrawal, INDIA
Suprachoroidal triamcinolone in tubercular choroiditis: A case report

L. Cheng, T. Niu, H. Jin, X. Xu, CHINA
HC23, a novel targeting peptide, inhibits inflammation and regulates teff/treg balance in experimental autoimmune uveitis

D. Colombero, E. Ladeveze, G. Filosa, G. Bercovich, ARGENTINA
Multicolor scanning laser imaging in active ocular toxoplasmosis

J. Corredores, M. Halpert, R. Amer, ISRAEL
Endogenous endotheliitis as the first morbidity sign of disseminated invasive methicillin-resistant staphylococcus aureus infection

D. Cugley, N. Szczepan, L. Lim, AUSTRALIA
Tofacitinib associated cytomegalovirus retinitis

E. Esen, S. Sizmaz, N. Demircan, TURKEY
Patterns of childhood uveitis: Tertiary referral center experience in Southern Turkey

E. Gijon, B. Garcia Tomas, I. Yago, J. Marin Sanchez, SPAIN
Multimodal imaging in a case of bilateral multifocal choroiditis secondary to methicillin-sensitive staphylococcus aureus sepsis

M. Hasanreisoglu, M. Halim, M. Hassan, A. Segawa, M. Yilmaz, M. Ertop, Z. Aktas, TURKEY
Effect of fundus fluorescein angiography on semi-automated aqueous flare measurements

P. José, I. Leal, PORTUGAL
Ocular Bartonellosis: three different presentations

K. Kang, S. Kim, SOUTH KOREA
The anti-inflammatory effect of tectorigenin in a mouse experimental autoimmune uveitis (EAU) model

M. Kechida, S. Zina, I. Cherni, H. Ben Amor, S. Attia, M. Khairallah, TUNISIA
Temporal trends in ocular manifestations of Behçet disease: Comparative study between 1995 and 2017

I. Khizhnyak, P. Irina, B. Ernest, S. Elena, RUSSIA
Corticosteroid prevention of macular edema and inflammation in uveitic patients undergoing phacoemulsification. Dex-implant alone vs Subtenon triamcinolone acetate with pulse-therapy

S. Khochtali, M. Romdhane, I. Ouazzani, N. Abroug, S. Attia, M. Khairallah, TUNISIA
Optical coherence tomography findings in healed peripapillary toxoplasmic retinochoroiditis

L. Koh, R. Agrawal, SINGAPORE
Case report: Fluorescein angiogram and optical coherence tomography findings in macula cytomegalovirus retinitis

C. Koutsiouki, C. Pavesio, A. Rees, G. Holder, A. Robson, M. Westcott, UK
Baseline prognostic factors in patients with birdshot retinochoriopathy (BRC)

I. Ksiaa, S. Smaoui, M. Kechida, M. Mefteh, S. Meddeb, M. Khairallah, TUNISIA
Alternating bilateral dense preapillary vitreous exudate associated with peripapillary retinal infiltrate revealing Behcet’s uveitis: A case report
P. Kumar, A. Farrag, C. Lim, B. Kapoor UK
Efficiency and clinical outcomes of mycophenolate mofetil use in patients with intermediate uveitis

C. Lim, A. Farrag, P. Kumar, B. Kapoor UK
Syphilitic uveitis: Manifestations and treatment outcomes: Leicester experience

P. Maitra INDIA
Role of antecedent cystoid macular edema (CME) in epiretinal membrane (ERM) development in patients with anterior uveitis

S. Mandal INDIA
Role of antecedent cystoid macular edema (CME) in epiretinal membrane (ERM) development in patients with anterior uveitis

F. March De Ribot, A. March de Ribot, C. Batlle, T. Torrent, S. Ayats, F. Escalada SPAIN
CMV retinitis associated with thymoma

C. Mariotti, M. Nicolai, P. Pelliccioni, V. Pirani ITALY
Combined therapy in choroidal neovascular membrane secondary to multifocal choroiditis: Long-term visual and anatomical outcomes

S. Medjidova, E. Kasimov, G. Rustambekova, I. Abbasova AZERBAIJAN
Etiology and biological features of post-traumatic endophthalmitis causars

S. Moutzouri, A. Michonidou, S. Morales, C. Sanchez, E. Mantelli CHILE
Characterization of patients with intermediate uveitis (UI) in the department of inflammatory diseases and uveitis in the ophthalmology service of hospital del Salvador

R. Neumann ISRAEL
Suprachoroidal injection of CLS-TA improves clinical outcomes in the treatment of noninfectious uveitis regardless of the uveitis anatomic subtype: Results of the phase 3 PEACTREE study

M. Olivera, S. Pablo, M. Capella Elizalde, J. Nadal SPAIN
Pars plana vitrectomy for diagnosing an undetermined uveitis in children: a case report

S. Pockar, M. Ahmed, R. Chhabra, N. Jones, L. Steeples UK
Optical coherence tomography Pre-clinical detection of second eye involvement in necrotising herpetetic retinitis

A. Praidou, N. Lathouris, T. Topalidis GREECE
Juvenile idiopathic arthritis-associated uveitis: Importance of screening, diagnosis and monitoring in children

Evaluating a patient self-assessment tool for patients with birdshot chorioretinopathy: The birdshot chorioretinopathy patient reported outcome and experience measure (birdshot-POEM)

C. Radovanovic, A. Denniston, A. Folkard, A. Price, X. Liu, C. Arthur UK
Establishing a UK-wide registry and biobank for birdshot chorioretinopathy

A. Saatci, S. Ipek, Z. Ayhan, F. Oner TURKEY
Anti-VEGF treatment in eyes with inflammatory type choroidal neovascular membranes

P. Schwemmer, J. Díaz, M. Alhayek SPAIN
Pars plana vitrectomy in pediatric pars planitis

C. Sjoholm Gomez De Liaño, M. Henriquez Recine, F. Sanchez Carnerero Casas, L. Velez Delgado, J. Argaya Amigo SPAIN
Vasculitis and branch retinal artery occlusion caused by Toxoplasmosis

B. Stern, R. David, R. Amer, I. Antebi, M. Matanis, O. Lagstein, H. Mechoulam ISRAEL
BRAF inhibitor induced granulomatous panuveitis

B. Stern, R. Amer, I. Antebi, M. Matanis, O. Lagstein, R. David, H. Mechoulam ISRAEL
Inflammatory induced posterior uveitis following MMRV vaccination

J. Than, J. Ho, N. Shah, R. Akshikar UK
A case of panuveitis presenting with giant retinal tear and detachment in an immunocompetent young South Asian man

G. Velis, M. Balamurugan, A. Khodiafad, S. Mahuli INDIA
A case series of acute retinal necrosis (ARN) in a tertiary eye care centre in South India

R. Wakfie Corieh, A. Guijarro Alaña, E. Guzmán Almagro, N. Muñoz Sanz, E. Carreño Salas, J. Serrano de la Iglesia SPAIN

Y. Wang, A. Ralhan, S. Baxter, J. Gonder, R. Bal CANADA
Bilateral acute retinal necrosis following Shingrix vaccine in a locally immunosuppressed host

J. Young, S. Pockar, N. Jones, R. Chhabra, L. Steeples UK
Multimodal imaging in influenza A maculopathy

**Vascular Diseases & Diabetic Retinopathy**

M. Abouhussein EGYPT
Switching to aflibercept for persistent diabetic macular edema resistant to bevacizumab

Two year result of intravitreal Aflibercept in macular edema secondary to CRVO with a modified TAND & E regimen in real life conditions

Wide-field fluorescein angiography as diagnostic basis of peripheral retinal ischemia

M. Aky, E. Carini, O. Ali EGYPT
combination of intravitreal ranibizumab injection and laser treatment for macular edema secondary to retinal artery macroaneurysm
M. Amini, M. Nowroozzadeh, Iran
Incidence of systemic vascular accidents within 4 weeks after intravitreal injection of bevacizumab

C. Arndt, V. Chandra, M. Afriat, France
Dexamethasone implant for refractory macular edema in adult Coat’s disease

K. Asma, A. Maalej, S. Bouchoucha, N. Rmili, R. Rannen, Tunisia
Combined cilioretinal artery and central retinal vein occlusion after using follice-stimulating hormone (FSH)

K. Aso, H. Masahara, R. Hashimoto, R. Yamazaki, K. Yata, M. Ubuka, T. Maeno, Japan
Efficacy of a combination of arteriovenous sheathotomy without vitrectomy and anti-VEGF injections in the treatment of BRVO

A. Aykut, Y. Ece, M. Sevik, S. Ozlem, Turkey
Disorganization of the retinal inner layers (DRIL) after intravitreal dexamethasone implant (OZURDEX) for macular edema due to retinal vein occlusion

N. Borah, D. Phukan, D. Agarwala, India
Eale’s disease in patients of southeast Asian descent in India

E. Chalkiadaki, S. Mplounas, C. Flwrou, K. Andreanos, C. Koutsandrea, Greece
An atypical case of acute retinal and choroidal ischaemia after cranioplasty

I. Chang, J. Lee, K. Kim, South Korea
Bevacizumab versus combined bevacizumab-dexamethasone implant for the treatment of branch retinal vein occlusion macular edema

J. Chaves, M. Raimundo, C. Farinha, I. Pires, M. Cachulo, J. Marques, R. Silva, Portugal
Long-term functional and anatomical outcomes following retinal vein occlusion (RVO)

H. Cho, Y. Shin, E. Hong, H. Lim, M. Seong, South Korea
Quantitative evaluation of hard exudates in diabetic macular edema after short-term intravitreal triamcinolone, dexamethasone implant or bevacizumab injections

J. Costa, M. Joao, P. Brito, N. Gomes, Portugal
Anatomic and visual outcomes and risk factors analysis of phacoemulsification cataract surgery in patients with non-proliferative diabetic retinopathy

S. Dawson, M. Qureshi, S. Al Husainy, UK
Comparing lucentis (ranibizumab) and eylea (afibercept) for macular oedema secondary to central retinal vein occlusion

P. De Boever, B. Buvels, T. Van Craenendonck, N. Gerrits, A. Shuaib, R. Malik, Belgium
Retinal vessel network complexity changes in relation to the cardiometabolic phenotype in participants in the Qatar BioBank

E. Dogan, E. Celek, N. Ozkan, G. Alagöz, Turkey
Outcomes of intravitreal dexamethasone implant for the treatment of serous macula detachment secondary to retinal vascular occlusion

D. Espiritu, M. Arroyo, Philippines
A rare case of ophthalmic artery occlusion in a young male with myeloproliferative disorder

R. Fayzrakhmanov, O. Pavlovsky, O. Fayzrakhmanova, E. Larina, Russia
Changes in immunological parameters in the neovascular membrane of the retina

R. Fayzrakhmanov, O. Fayzrakhmanova, Russia
Effect of implant with dexamethasone on macular edema with retina venous occlusion

C. Fernandes, C. Bruxelas, P. Silva, M. Patricio, A. Cabugueira, F. Vaz, Portugal
Retinopathy as diagnostic clue for multiple myeloma

G. Fernandez Sanz, S. Llorente Gonzalez, C. Berrozo, Villabona, M. Saenz de Viteri, A. Garcia Layana, Spain
Perifoveal exudative vascular anomalous complex (PEVAC)

R. Figueiredo, T. Morais Sarmento, J. Garrido, M. Marques, T. Almeida, J. Carvalho, S. Carrasquinho, Portugal
Applicability of the ROscore as a predictive algorithm for early detection of retinopathy of prematurity

K. Frederiksen, M. Nielsen, J. Vestergaard, I. Munch, R. Kawasaki, P. Teto, S. Serensen, Denmark
Retinal vascular oxygen saturation in branch retinal vein occlusion

G. Garay Aramburu, A. Gomez Moreno, H. Urcola Carrera, Spain
Ocular invasion from arterial embolism in Rhino-orbital mucormycosis

G. Godinho, T. Madeira, J. Beato, E. Brandao, F. Falcão Reis, S. Penas, Portugal
Evaluation of peripapillary choroidal thickness in patients with central retinal vein occlusion and branch retinal vein occlusion and its relationship with visual impairment and retinal thickness

A. Grigoreva, T. Iureva, A. Shchuko, Russia
Hypoestrogenemia in the pathogenesis of myopic chorioretinal neovascularization

G. Harb, W. Harb, G. Chidiac, Lebanon
Outcomes of combination therapy using aflibercept and dexamethasone intravitreal implant for macular edema secondary to retinal vein occlusion

T. Hegde, India
A rare case of migrating retinal worm: Story unraveled

E. Hidalgo, D. Moreno, M. Rayon, J. Huerta, Peru
Raceemose hemangiomas: Case report

S. Hidayatzadeh, A. Shahmaliyeva, Azerbaijan
Pseudo-pseudo-foster-kennedii (clinical case)

C. Idrobo, C. Suscena, Ecuador
Post delivery retinal detachment and uveal effusion like syndrome in a hypertensive pregnant patient

M. Jimenez Santos, C. Valor, B. Burgos, C. Calvo, J. Donate Lopez, Spain
Real-life efficacy and safety of intravitreal OZURDEX in naive versus refractory central vein occlusion
S. Jimenez-prada De Miguel, J. Lopez Lopez **SPAIN**
Loss of monocular visual acuity as the only sign of malignant blood hypertension

M. João, R. Leite, S. Guimarães **PORTUGAL**
Retinal vein and artery occlusion in a pediatric patient

P. José, F. Teixeira, F. Caiado de Sousa, R. Rosa **PORTUGAL**
Risk factors for retinopathy of prematurity

H. Kanar, A. Arsan, B. Kanar **TURKEY**
Can SD-OCT findings be as a predictor for end organ damage in systemic hypertension?

S. Kaynak, M. Kaya, T. Ozturk, V. Bolluk, Z. Ayhan, N. Kocak **TURKEY**
Intravitreal ranibizumab and dexamethasone implant injections as primary treatment of diabetic macular edema: Simultaneously double protocol

Long-term follow-up changes of central choroidal thickness after anti-vascular endothelial growth factor therapy in patients of central retinal vein occlusion-related macular edema, with or without systemic hypertension

T. Kiseleva, A. Gavrilenko, N. Pak, A. Kuklin **RUSSIA**
Long-term effects of the carotid artery surgery on visual functions and ocular hemodynamics

T. Kiseleva, V. Neroxov, V. Tankovskiy, V. Vasilchenko **RUSSIA**
Prognostic significance of retinal veins occlusion for the development of cerebral vascular diseases in patients with hypertension and atherosclerosis

T. Kiseleva **RUSSIA**
Ultrasound doppler and OCT-angiography in assessment of ocular blood flow in diabetic macular edema

O. Kolenko, E. Sorokin, N. Khodjaev, N. Pomytkina, A. Fil, I. Pashentsov **RUSSIA**
The effect of endothelial dysfunction on macular blood flow in pregnant women with preeclampsia during pregnancy and in the postnatal period

I. Ksiaa, K. Maaloul, Z. Gharbi, S. Smaoui, R. Messaoud, M. Khairallah **TUNISIA**
Patterns of optic disc changes in children with Sickle cell disease

B. Marc, P. Romero Aroca, M. Mercado Gonzalez, A. Bautista Perez, R. Navarro Gil **SPAIN**
Smoking as a risk factor for recurrent vitreous haemorrhage in patients with proliferative diabetic retinopathy

I. Prieto **SPAIN**
Hyperbaric oxygen therapy in the treatment of retinal artery occlusion: A retrospective study

X. Liu, J. Jovanovic, D. Kokona, M. Zinkernage, A. Ebneter **CHINA**
Microglia depletion mediated retinal ganglion cell survival in branch retinal vein occluded mice

A. Lopes, S. Henriques, C. Vendrell, L. Colaço, F. Silva, I. Prieto **PORTUGAL**
Patterns of optic disc changes in children with Sickle cell disease

T. Loureiro, D. Lopes, A. Vide Escada, N. Campos **PORTUGAL**
Systematic lupus erythematosus retinopathy in a 20-year-old female

T. Loureiro, D. Lopes, A. Vide Escada, N. Campos **PORTUGAL**
Patterns of optic disc changes in children with Sickle cell disease

M. Luis, D. Maleitta, M. Vieira, D. Hipólito Fernandes, N. Moura Coelho, R. Anjos, R. Flores **PORTUGAL**
When the patient hides the answer: A case report of a radiation retinopathy

X. Ma, A. Sun **CHINA**
Comparison of short-term efficacy between conbercept and ranibizumab for treatment of myopic choroidal neovascularization

X. Ma, D. Yang **CHINA**
Epidemiological study of retinopathy of prematurity in dalian and short-term efficacy of anti-VEGF therapy

X. Ma, F. Tang, X. Qin, J. Lu, P. Song, M. Li **CHINA**
Optical coherence tomography predictors of short-term visual acuity in eyes with macular edema secondary to retinal vein occlusion treated with intravitreal conbercept

I. Malinouskaya, I. Zaborovski, L. Stolyarova, Z. Glonti **BELARUS**
Time-domain OCT and OCT-Angiography in the efficiency assessment of the antiangiogenic therapy

S. Mano, J. Prates Canelas, S. Vaz Pereira **PORTUGAL**
Accuracy of general ophthalmologists in detecting idiopathic juxtapoveolar retinal telangiectasia

S. Mano, J. Prates Canelas, S. Vaz Pereira **PORTUGAL**
Idiopathic juxtapoveolar retinal telangiectasia: Retrospective case series from a tertiary hospital

B. García Tomás, M. Riquelme Cano **SPAIN**
Outcomes from the treatment of naïve macular edema after branch retinal vein occlusion with ranibizumab

R. Martinez Diaz, Á. De Casas Fernández, S. Abenza Baizea, J. Bermúdez Pío Rendón, B. García Tomás, M. Riquelme Cano **SPAIN**
Outcomes from the treatment of naïve macular edema after branch retinal vein occlusion with ranibizumab
ePOSTER PRESENTATIONS

Anatomical and functional response of chronic central serous chorioretinopathy to either mineralcorticoide or subthreshold laser

I. Martusevich, O. Krivosheina RUSSIA
Early RVO treatment with aflibercept in combination with further laser photoacoagulation

M. Medina-Baena, O. Cejudo Corbalán, S. Astorga Moreno SPAIN
Paracentral acute middle maculopathy (pamm): A pathological entity or a clinical phenomenon associated with other processes

T. Morais Sarmento, R. Figueiredo, J. Garrido, A. Rebelo, J. Carvalho, A. Candeias PORTUGAL
A starving bubble

S. Morikawa, F. Okamoto, Y. Sugiura, T. Murakami, T. Hiraoka, T. Oshika JAPAN
Stereopsis following intravitreal ranibizumab for branch retinal vein occlusion

M. Mozo Cuadrado, L. Tabuenca Del Barrio, E. Compains Silva, D. Aliseda Pérez de Madrid SPAIN
Type 2 idiopathic macular telangiectasia (MacTel 2): A case report

K. Nishida, H. Sakaguchi, R. Kawasaki, K. Nishida JAPAN
Arteriovenous crossing near the fovea in congenital retinal macrovessel

H. Ocampo, M. Rincon COLOMBIA
Retinal artery occlusion preceded occlusion of the central vein of the retina. Importance of educating in visual self-check. Report of a case

Y. Okamoto, A. Kato, F. Okamoto, M. Saito, Y. Miyazono, T. Oshika JAPAN
Short-term course of intraocular pressure following intravitreal injection of bevacizumab for retinopathy of prematurity

Y. Okawa, A. Kogure Katakura, Y. Ishimaru, T. lida JAPAN
Changes in retinal blood flow after repeated intravitreal Ranibizumab injection in eyes with branch retinal vein occlusion.

H. Olga, O. Huzun, N. Khramenko, N. Konovalova, O. Peretyagin UKRAINE
Neuroprotectors for optic nerve with glaucomatous optic neuropathy

B. Oliveira Lopes, M. Brizido, A. Basilio, J. Rodrigues, M. Ribeiro, M. Miranda PORTUGAL
Beyond the clinical trials: Real-life outcomes of intravitreal dexamethasone implant (DEX/OZURDEX) for the treatment of diabetic macular edema and retinal vein occlusion

A. Ophir ISRAEL
Update on pars plana vitrectomy in diffuse diabetic macular edema when traction is undetected

S. Ozdogan Erkul, O. Ayrranci Osmanbasoglu TURKEY
Early versus late timing of adjuvant intravitreal dexamethasone implant therapy to ranibizumab in diabetic macular edema: Real life data

A. Ozkaya, H. Tarakcioglu TURKEY
Aflibercept versus ranibizumab in diabetic macular edema associated with subretinal detachment

I. Papandreou, A. Tourmouzis GREECE
Reactivation of eales disease after 38 years: A case report

A. Papazacharia, S. Moutzouri, D. Balatsoukas, E. Kanonidou GREECE
An interesting case of atypical unilateral IRVAN syndrome in a 44-year-old male patient

O. Pavlovskiy, R. Fayzrakhmanov, E. Larina RUSSIA
Analysis of the structural parameters of the retina with Central retinal vein occlusion

Coats’ disease adult woman onset

M. Qureshi, S. Dawson, S. Al Husainy UK
A comparison of Intravitreal dexamethasone injection (OZURDEX) versus Lucentis (ranibizumab) versus eylea (aflibercept) for macular oedema secondary to branch retinal vein occlusion

M. Ratkovic, A. Pidro CROATIA
Short-term and long-term results after intravitreal bevacizumab therapy for macular edema in branch retinal vein occlusion

M. Rehak, C. Busch, C. Jochmann, P. Wiedemann GERMANY
Long time real-life results following treatment with dexamethasone or fluocinolone acetonide intravitreal implant in patients with diabetic macular edema

Comparison of a pro re nata treatment regimen with ranibizumab and a treat & extend treatment regimen with aflibercept in patients with retinal vein occlusions

N. Sahinoglu-Keskek, H. Canan, B. Torer, G. Yilmaz, I. Akkoyun TURKEY
Anti-VEGF treatment in cases of Zone-1 aggressive retinopathy of prematurity

J. Sambricio, B. De Lucas Viejo, A. De Pablo Cabrera SPAIN
Multimodal imaging of a case of peripapillary pachychoroid syndrome

J. Sambricio, B. De Lucas Viejo, A. De Pablo Cabrera SPAIN
Treatment of macular telangiectasias type 1 with intravitreal dexamethasone implant after refractory treatment with anti-VEGF injections

A. Sepetis, A. Theodorakis, T. Koutresi, B. Clarke, G. Farantzos, G. De Salvo UK
Safety and efficacy of dexamethasone intravitreal implant for the treatment of macular oedema secondary to branch retinal vein occlusion
P. Shah, K. Ramasamy, N. Kannan, H. Balakrishnan INDIA
Rare case of CRAO in young post FESS

N. Shekerinov, J. Nivitchka Kjaeva, M. Golubovic, V. Dimovska Jordanova USA
Intravitreal Bevacizumab treatment: Different therapeutic approaches for diabetic macular edema

W. Shao Chi TAIWAN
Evaluation and comparison of the central macula thickness, retinal nerve fiber layer and axial length in healthy pregnant and healthy non-pregnant women

A. Shchuko, V. Bukina, T. Iureva, A. Borisova RUSSIA
Tactics of management of patients with retinal arterial macroaneurism

H. Tapia Quijada, C. Mantolan Sarmiento, D. Angel Pereyra, I. Rodriguez Talavera SPAIN
Retinal macroaneurysm with different presentations

H. Tapia Quijada, C. Mantolan Sarmiento, I. Rodriguez, Talavera, D. Angel Pereyra SPAIN
Unilateral central vein occlusion as debut of the G20210A mutation in the prothrombin gene: A case report

F. Teixeira, R. Marques, S. Mano, P. Jose, R. Couceiro, F. Pinto PORTUGAL
Vascular complications of optic nerve head Drusen

N. Unlü, M. Acar, G. Uney TURKEY
Long term follow-up in patient with radiation retinopathy

P. Vassileva, Y. Kirilova, A. Petkova BULGARIA
Anti-VEGF treatment in crvo: Beyond anti-angiogenesis

Pachychoroid neovasculopathy in familiar relatives

A. Vural TURKEY
Comparison of vascular outgrowth rate in infants treated with intravitreal bevacizumab or aflibercept monotherapy for retinopathy of prematurity

Y. Wong, C. Kanawati UK
Comparing the efficacy of intravitreal lucentis, eylea and ozurdex for patients with macular oedema following a retinal vein occlusion in a single centre

Z. Xu, A. Auzuara Blanco, A. Knox, J. Silvestri, T. Peto UK
Neovascular glaucoma: Understanding methodology for improving outcomes: A clinical audit for future quality improvement

J. Yanguas, I. Baquero Aranda, J. Diaz Bernal, I. Garcia Basterra SPAIN
Papillophlebitis in a young pregnant woman with coexisting factor V Leiden an prothrombin G20210A mutations

S. Younis, P. Corazza, T. Soomro, H. Orlans, J. Kabbani UK
Diabetic macular oedema: Real life results of intravitreal injection of anti-VEGF

I. Zabarovski, T. Imshanetskaya, L. Stolyarova, M. Zalinyan BELARUS
The efficacy of micropulse laser therapy for central serous chorioretinopathy

M. Zola, A. Ambresin, F. Munier SWITZERLAND
Bilateral vascular anomalies in Coats’ disease suggest concurrent retinal vascular disease

Vitreoretinal Surgery

A. Abdel Hadi EGYPT
Evaluation of vitrectomy with planned foveal detachment as surgical treatment for refractory diabetic macular edema with or without vitreo-macular interface abnormality

M. Abdejalil, H. Ibttisam, B. Meriem, A. Mounia MOROCCO
At a situation during unusual retinal detachment: an unusual tamponade

I. Akkoyn, C. Öztürk, G. Yilmaz, S. Cezairioglu TURKEY
Pediatric rhegmatogenous retinal detachment: Clinical characteristics and surgical outcomes

I. Akkoyn, Z. Ersoy, M. Karadas, G. Yilmaz, A. Tugcu TURKEY
Vitreous syneresis after intravitreal injection of ranibizumab in treatment of ROP

M. Al-Abri OMAN
Autologous internal limiting membrane (ILM) transplantation technique as a useful procedure for macular hole surgery: Retrospective case series

C. Almeida, A. Marta, N. Ferreira, M. Angelina PORTUGAL
Surgical management of massive retinal bleeding from ruptured retinal arterial macroaneurysms: Outcomes and complications

U. Altynbaev, A. Lebedeva, L. Altynbaeva RUSSIA
Immunomorphological features of idiopathic epiretinal membranes complicated by lamellar macular hole.

M. Aly, F. Patelli, L. Colombo, T. Nuzzo EGYPT
27 gauge 3D vitrectomy for treatment of lamellar macular hole

K. Ananikas, P. Stavvakas, A. Androu, K. Ananikas GREECE
Paracentral acute middle maculopathy following surgically induced branch retinal artery occlusion during vitrectomy for vitreous hemorrhage

R. Anguita, R. Moya, V. Saez, A. Salinas, R. Kobus, C. Nazar, R. Marniquez UK
Intraocular foreign body: Prognosis factors and visual outcomes

E. Anikina, J. Fajardo Sanchez, P. Sullivan UK
Terson’s syndrome and the high incidence of retinal breaks

C. Aras, O. Ozuyazgan, D. Ucar, F. Senturk TURKEY
Retinal debridement for the treatment of retinal detachment due to acute retinal necrosis

J. Arias, R. Hoyos, F. Arango, R. Alcantara, R. Sanchez COLOMBIA
Plasma rich in growth factors, recurrent macular hole, macular hole closure, swept source: Optical coherence tomographic – angiography

C. Arndt, C. Wambergue, V. Chandra, M. Afriat FRANCE
Does triamcinolone assisted membrane peeling reduce post-operative macular edema?

A. Arsan, S. Kanar, A. Hacisalihoğlu, S. Aki TURKEY
Evaluation of peroperative and postoperative discomfort in 23-gauge pars plana vitrectomy
O. Artunay, R. Aydin, S. Ozcaliskan, G. Erdogan, I. Perente TURKEY
Pars plana vitrectomy combined with scleral buckle versus vitrectomy alone for primary repair of rhegmatogenous pediatric retinal detachment

C. Azzolini, G. Porta, G. Millefanti, G. Micheloni, A. Conti, F. Simonelli, S. Donati ITALY
In vitro characterization of Müller cells genes involved in proliferative vitreoretinopathy

G. Batsos, E. Christodoulou, E. Christou, G. Vartholomatos, M. Stefaniotou GREECE
Cytometry flow analysis of vitreous cytokines from patients with rhegmatogenous retinal detachment and the correlation with clinical characteristics

M. Benzerroug, B. Briend, S. Coisy, B. Boussion, C. Mazit FRANCE
A comparative prospective study of 27 gauge versus 25 gauge vitrectomy for posterior segment disease

J. Bernardes, M. Raimundo, J. Figueira PORTUGAL
Ectopic inner foveal layers: Redefining visual prognosis in eyes with idiopathic epiretinal membranes

F. Castillo Capponi, S. Grixolli, P. Diaz, M. Balboa, L. Broc, A. Sabala, X. Valdeperas SPAIN
Functional outcome and surgical complications after pars plana vitrectomy in 15 cases of terson syndrome

M. Cereda, S. Parrulli, F. Zicarelli, F. Bottoni, G. Staurenghi ITALY
Long term results of ILM peeling: Are they really stable?

Postoperative epiretinal membrane after internal limiting membrane peeling during pars plana vitrectomy for rhegmatogenous retinal detachment

L. Chehade, B. Guo, W. Chan, J. Ghilhotra AUSTRALIA
Medium-term tamponade with vitrectomy and perfluorodecalin for the management of complex retinal detachments

Y. Chen, D. Steel, A. Nasrulloh, O. Boguslaw, M. Habib, C. Geenen, I. Wilson UK
Macular hole morphology and measurement using an automated three dimensional image segmentation algorithm

N. Cheung, Y. Lee, N. Liu SINGAPORE
Surgical outcomes of 25-gauge vitrectomy for primary rhegmatogenous retinal detachment with air tamponade

S. Chiu, K. Spiteri Cornish UK
Comparison of the outcomes in primary macular hole surgery with 23-gauge, 25-gauge, and 27-gauge pars plana vitrectomy (PPV)

I. Corcóstegui, I. Herrera, J. Sancristóbal, G. Castiella, J. Araiz, A. Bilbao, V. Freire SPAIN
Assessment of the need for systematic internal limiting membrane peeling during retinal detachment surgery in eyes without high risk of proliferative vitreoretinopathy

D. Dat, H. Bui Viet, T. Nguyen Thu VIETNAM
Result of inverted internal limiting flap technique for large primary macular hole

A. De Pablo Cabrera, J. Sambricio, L. Moreno Garcia, B. de Lucas Viejo SPAIN
Surgical management of submacular hemorrhage: A case series

Pneumatic retinopexy: Should we take the risk?

P. Dionisios, Z. Kapsala, O. Makri, A. Mani, C. Georgakopoulos GREECE
Comparison of intraocular pressure using Goldmann applanation tonometry versus non-contact tonometry in eyes with high-viscosity silicone oil

S. Donati, P. Della Valle, M. Mazzola, E. Premi, L. Lo Presti, C. Azzolini ITALY
Lamellar macular holes: Morphological and functional assessment

A. Dotan, Y. Weinberger, A. Sternfeld, N. Hadar Cohen, R. Ehrlich, M. Tennant ISRAEL
Is scleral buckle combined with pneumatic retinopexy a better procedure than scleral buckle alone?

S. Dowlut, K. Fotis, A. Chandra, N. Karia UK
Can near vision testing within first 1 week of macula hole repair with intraocular gas be a predictor for hole closure?

P. Drakou, E. Mavrikakis, A. Charonis GREECE
The retinal microvasculature in patients with macular microdisplacement after retinal detachment repair: An OCT-A study

M. Elwan, A. Abd Elghafar, S. Hagras, W. Abou Samra, S. Saleh EGYPT
Long-term outcome of internal limiting membrane peeling with and without foveal sparing in myopic foveoschisis

O. Eski Yucel, M. Kalyoncu TURKEY
Outcomes of primary vitrectomy versus scleral buckling in rhegmatogenous retinal detachment

A. Fonseca, A. Bhargava, S. Pal, P. Shroff INDIA
All probe vitrectomy: For cases of complex proliferative diabetic retinopathy

N. Fung HONG KONG
A series of ILM transposition for chronic and persistent macula hole by tuck technique

C. García Arumi, F. Peralta Iturburu, R. Martín Pujol, J. García Arumi SPAIN
Comparison of anatomical and visual outcomes between idiopathic and myopic macular hole using the internal limiting membrane or inverted internal limiting membrane flap technique

R. Giannini, L. Zompatori, G. Cuozzo, T. Mascaro, A. Mauro ITALY
Episcleral buckling surgery for retinal detachment recurrence, after initial failure of pars plana vitrectomy (PPV) and silicone oil tamponade

J. Giralt, A. Olate SPAIN
27-gauge vitrectomy for simultaneous rescue and sutureless transcleral fixation of dislocated intraocular lens (IOL)
L. Goh, L. Motta, T. Jackson, UK
Myopic macular hole detachment associated with intravitreal ocriplasmin

N. Grubnyk, T. Krasnovid, UKRAINE
Role of retinotomy in management of traumatic retinal detachment, complicated by subretinal fibrosis

I. Hajji, S. Belghmaidi, M. Ait El Jazzer, M. Bagueri, A. Moutaouakkil, MOROCCO
Modification of refraction after pars plana vitrectomy

Characteristics of improvement of visual acuity in the eyes with good visual prognosis after surgical macular hole closure

M. Hassani, M. Khalil, EGYPT
Autologous retinal graft in retinal detachment associated with large macular hole

M. Hassani, EGYPT
Autologous retinal graft: The escape

K. Heksch, J. Nemes, HUNGARY
Macular retinoschisis and retinal fold formation following vitrectomy for traumatic retinal detachment: A case report

D. Hipolito-Fernandes, M. Elisa Luis, R. Serras Pereira, C. Xavier, N. Moura Coelho, L. Costa, J. Branco, PORTUGAL
Acute bilateral vision loss in acute myeloid leukemia: A rare clinical report

Y. Hu, K. Feng, Z. Ma, CHINA
Multivariate analysis of intractable hypotony after vitrectomy in open globe injuries

Y. Hzardzhan, V. Fokin, L. Boriskina, S. Balalin, M. Guro, A. Balalin, RUSSIA
Analysis of YAG-vitreolysis efficacy and safety in cases of vitreous opacity

A. Iakimov, S. Kuzmin, V. Zaika, T. Lureva, RUSSIA
Tactics of patient management with perforation of the eyeball and orbit foreign body (clinical case)

T. Imshenetskaya, V. Yarmak, V. Markevich, G. Vashkevich, I. Zabarouski, BELARUS
Endoillumination-assisted scleral buckling surgery: our results

A. Irannejad, D. Abulon, USA
How a beveled tip impacts flow around the probe

N. Ito, T. Baba, S. Yamamoto, JAPAN
Idiopathic uveal effusion developed proliferative retinopathy after scleral resection surgery

K. Januszkowsc, k. Heleiwa, L. Ramirez Paez, P. Szurman, GERMANY
Efficacy of combined administration of preoperative intravitreal and intraoperative subretinal recombinant tissue plasminogen activator in the management of acute hemorrhagic age-related macular degeneration: A prospective study

V. Juncal, T. Shicheng Jin, M. Bamakrid, Q. Paracha, C. Francisconi, R. Muni, CANADA
Real-world evidence for pneumatic retinopexy in patients with primary rhegmatogenous retinal detachment meeting pivot trial criteria

V. Kadri, INDIA
Surgical challenges of vitrectomy in eyes with pre existing multifocal intraocular lenses (MFIOL)

C. Karaca, TURKEY
Autologous transplantation of extrafoveal peeled internal limiting membrane grafts in patients with naive large macular holes: A new surgical approach

M. Karimov, L. Akhundova, T. Aliyeva, AZERBAIJAN
Results of pars plana vitrectomy for macular holes associated with proliferative diabetic retinopathy

B. Kashyap, P. Venkatesh, S. Azad, R. Chawla, INDIA
Learning curve of scleral buckling surgery-a retrospective analytical study

O. Kayikcioglu, H. Mayali, M. Altinisik, A. Yildirim, S. Ilker, TURKEY
Surgical results of stage 3-4 large macular holes

O. Kayikcioglu, M. Alntisik, A. Yldirim, E. Kurt, TURKEY
Surgical results of large macular holes

S. Kerci, T. Aydin, Ö. Kartı, M. Zengin, T. Küsbeci, TURKEY
Effect of internal limiting membrane peeling on macular structure and metamorphopsia scores in idiopathic epiretinal membrane surgery

M. Khalil, EGYPT
Combined surgical peripheral iridectomy with vitrectomy in patients with posterior synechiae secondary to rhegmatogenous retinal detachment with choroidal detachment

M. Khalil, EGYPT
Shake hands technique using two forceps for complete removal of subretinal bands

M. Khan, S. Sidrah, PAKISTAN
Characteristics and epidemiology of rhegmatogenous retinal detachment (RRD) in Pakistan

H. Khaqan, U. Imtiaz, A. Rehman, PAKISTAN
Amniotic membrane graft for treatment of giant refractory macular holes

H. Khaqan, U. Imtiaz, A. Rehman, PAKISTAN
Early experience of foldable capsular vitreous body (FCVB)

C. Kim, S. Woo, K. Park, SOUTH KOREA
Clinical and anatomical factors related with functional and structural outcome of vitrectomy in myopic traction maculopathy

N. Kislitinsa, S. Novikov, S. Kolesnik, A. Kolesnik, M. Veselkova, RUSSIA
Anatomical features of vitreomacular interface in patients with large chronic stage 3-4 idiopathic macular holes

J. Klaas, N. Feucht, M. Pettenkofer, J. Klein, C. Lohmann, M. Maier, GERMANY
A look behind the bubble: Visualization of the vitreomacular interface in eyes treated with pneumatic vitreolysis using SD-OCT imaging in prone position

A. Kleymenov, V. Kazaykin, M. Matevosyan, G. Chashchin, RUSSIA
Relevance of retina drying on the basis of investigation and calculation of geometric dimensions of an intraocular fluid drop formed on the retina surface during macular hole surgery
T. Kurskaya, A. Malafeyev, E. Kozina, S. Yuri, D. Latigan RUSSIA
Experience of surgical treatment and rehabilitation of patients with postoperative endophthalmitis

E. Larina, R. Fayzrakhmanov, O. Pavlovskiy RUSSIA
Features of macular rupture reoperation using an introverted flap

E. Larina, R. Fayzrakhmanov, O. Pavlovskiy RUSSIA
The influence of various surgical treatment techniques on the morphology of an unclosed macular hole with a negative anatomical result

H. Liu, X. Chen CHINA
Intravitreal conbercept versus ranibizumab as a preoperative adjunct to vitrectomy for preventing recurrent vitreous hemorrhage in proliferative diabetic retinopathy

E. Lomukhina, A. Chuprov RUSSIA
Surgical treatment of complicated optic pit

P. Lyskin RUSSIA
Microinvasive non-surgical treatment of vitreomacular traction

P. Lyskin, I. Makarenko, M. Zgoba RUSSIA
Perspective for the treatment of macular holes without peeling of the inner limiting membrane

S. Mabrouk, H. Zgolli, O. Fekih, F. Hamza, I. Malek, L. Nacef TUNISIA
An optical coherence tomography study of the macula before and after successful pars plana vitrectomy in patients with diabetic tractional macular detachment

S. Mabrouk, H. Zgolli, O. Fekih, A. Abdejelil, A. Chebbi, L. Nacef TUNISIA
Post-operative results of posterior vitrectomy in giant tear retinal detachments: About 15 cases

S. Mabrouk, H. Zgolli, O. Fekih, M. Laadheri, I. Zeghal, L. Nacef TUNISIA
Inverted internal limiting membrane flap and ILM peeling technique in large macular holes: A comparative study

C. Madeira, P. Neves Cardoso, G. Godinho, S. Perestelo, J. Meira, F. Falcão Reis, M. Falcão PORTUGAL
Scleral fixation intraocular lenses using Gore-Tex suture: Clinical outcomes

C. Mariotti, M. Nicolai, V. Pirani, P. Pellecicroni ITALY
Comparison between 25-gauge and 27-gauge 3D visualization system-assisted vitrectomy in macular surgery

M. McKenna, P. Severn, J. Bandyopadhyay, A. Gibson UK
Military style grab-bags: To expedite the treatment of urgent sight threatening opthalmic conditions presenting out of hours

H. Menz, J. Dresp, N. Feltgen, H. Hoerauf, T. Lechner, D. Menz, B. Müller GERMANY
Tracing the cause of toxic batches of perfluorooctane

Z. Michalewska, J. Nawrocki POLAND
Complex treatment of endophthalmitis after intravitreal injections with immediate vitrectomy and consecutive anti-VEGF injections

Z. Michalewska, J. Nawrocki POLAND
Vitrectomy with the inverted ILM flap technique in eyes with full-thickness macular hole coexisting with AMD

S. Mokadam, V. Raja, S. Upadhye, I. Constable INDIA
Primary vitrectomy with 360 degrees laser as surgery for rhegmatogenous RD

M. Nabih, M. Azab, A. Khattab, I. Mohalal EGYPT
A comparative study of the results of vitrectomy for repair of non complex rhegmatogenous retinal detachment with & without the use of perfluorocarbon liquids

K. Ohta, S. Aoto, N. Senda, E. Fukui JAPAN
Comparisons of metamorphopsia and stereopsis after macular hole surgery with and without internal limiting membrane peeling

F. Okamoto, Y. Moriya, Y. Sugiura, S. Morikawa, T. Oshika JAPAN
Changes in stereopsis and optical coherence tomography findings after macular hole surgery

C. Oliveira-Ferreira, M. Azvedo, A. Roca, M. Silva, J. Breda, A. Rocha Sousa, F. Falcao Reis PORTUGAL
Unexplained vision loss after intraocular silicone oil removal: Retrospective study

B. Onal Gunay, G. Erdogan, M. Gunay TURKEY
Rebaund diabetic macular edema following pars plana vitrectomy with internal limiting membrane peeling surgery: 51-months results

E. Panagiotou, T. Giannopoulos, S. Panagiotou GREECE
Natural history of idiopathic epiretinal membrane on the island of Limnos

I. Papasavvas, A. Ambresin, V. Chatzistergiou, J. Vaudaux, J. Pournaras SWITZERLAND
OCT-angiography (OCTA) analysis of macular microvascular alterations after vitrectomy for idiopathic epiretinal membrane (ERM)

Y. Park, J. Kim SOUTH KOREA
The change of fixation using microperimetry after successful idiopathic macular hole surgery

S. Parrulli, F. Bottoni, M. Cereda, I. D’agostino, M. Cigada, G. Staurenghi ITALY
Idiopathic full thickness macular holes larger than 450 µm: Traditional ILM peeling vs inverted ILM flap

Epiretinal membrane removal in an Argus II implanted eye: Histological characteristics and functional results

O. Pavlovskiy, R. Fayzrakhmanov, E. Larina RUSSIA
Long-term results of the closure of macular hole with preservation of ILM

E. Philippakis, A. Couturier, R. Thouvenin, R. Tadayoni FRANCE
Best imaging modalities for visualization of epiretinal membranes and comparison to intraoperative blue staining

V. Ponomarchuk, N. Umanets UKRAINE
Peculiarities of vitrectomy and morphological changes in the epiretinal membrane after intravitreal aflibercept in patients with severe proliferative diabetic retinopathy

V. Potapova, A. Zotov RUSSIA
Decision on surgical option in the treatment of macular rupture
A. Sachdev, C. Cristian, J. Pakiteeri, S. Trelore and visual outcomes, a case-series

Postoperative endophthalmitis: causative microorganisms

A. Qureshi, A. Jalil, N. Patton, S. Charles, F. Dhawahir Scala, G. Turner, T. Ivanova
Outcomes of suprachoroidal haemorrhage drainage surgery: The 10-year Manchester experience

R. Rana-Rahman, D. Steel, I. Klassen, J. Rees
The effect of internal limiting membrane (ILM) cleaning on epiretinal membrane formation after vitrectomy for proliferative diabetic retinopathy

C. Rao, M. Sharma, P. Sudhi, M. Bhende
To study the surgical and functional outcome of vitrectomy for retinal detachment (RD) secondary to cytomegalovirus retinitis (CMVR) in patients with acquired immune deficiency syndrome (AIDS)

R. Rejdak, T. Chorągiewicz, K. Nowomiejska, M. Toro
Cataract surgery combined with micro-incision vitrectomy with the 3D viewing systems

V. Rudenko, A. Khudyakov
The analysis of etiological structure of spontaneous vitreous hemorrhage

A. Rusanovskaya
Results of the application of intraocular illumination at scleral buckling in the treatment of rhegmatogenous retinal detachment

K. Russkov, A. Zołotarev, I. Kazakov, D. Petrachkov
Subcutaneous emphysema following retinal surgery and fluid-air exchange in a case of ocular penetrating injury with intraorbital foreign body

F. Sabatino, A. Shalaby, S. Di Simplicio Cherubini
Postoperative endophthalmitis: causative microorganisms and visual outcomes, a case-series

A. Sachdev, C. Cristian, J. Pakiteeri, S. Trelore
An audit of diabetic macular oedema (dmo) patients treated with the iluvien 0.2 µg/day fluorocinolone acetonide (fac) intravitreal implant at the macclesfield district general hospital in the United Kingdom (UK)

T. Sakurai
3D digital visualization in vitreoretinal surgery: Technological features, efficiency, prospects

A. Sethia, A. Giridhar, M. Gopalakrishnan, J. Sheth
10 year long-term follow-up after vitreous surgery in eyes with advanced proliferative diabetic retinopathy

I. Shandurkov
What is the leading force for reduction of macular schisis in optic disc pit surgery?

S. Solonina, R. Troyanovsky, N. Malinovskaya, A. Baranov
Ocular toxocariasis: Treatment depending on localization of granulomas

S. Srivastava, V. Kolesnichenko, R. Cummings Kralik, B. McCary, N. Karthik, V. Gonzalez
The impact of gauge size, surgical volume, and cutter probe design on surgical efficiency

M. Stamenkovic, A. Bajic, V. Jaksic, B. Vukadinovic, N. Nikitovic, B. Trajkovic, M. Mavija
Premacular hemorrhage

S. Stebnev, V. Stebnev
Three-dimensional digital imaging system in the surgery of primary rhegmatogenous retinal detachment

V. Stebnev, S. Stebnev, N. Sladchikova
3D digital visualization in vitreoretinal surgery: Technological features, efficiency, prospects

M. Stopa, A. Gotz Więckowska
Heads-up vitreoretinal surgery for retinopathy of prematurity

Electroretinograms responses recorded using a handheld stimulating and recording system in eyes with silicone oil tamponade

Y. Toklu, M. Yorgun, B. Tanrıverdi
Temporal inverted internal limiting membrane flap technique for the treatment of macular holes

M. Tomioka, F. Okamoto, Y. Moriya, Y. Sugiuara, T. Murakami, S. Morikawa, T. Oshika
Vision related parameters which affect stereopsis in patients with macular hole

D. Tognetto, M. Pastore, G. Cirigliano, R. Merli, A. Gaggino, G. Guerin
Comparison of 25- and 27-gauge sutureless sclerotomy architecture using spectral-domain optical coherence tomography

N. Umanets
The results of surgical treatment of idiopathic epiretinal membranes (iERM) depends of initial visual acuity (VA) and OCT datas

D. Uthoff, J. Meister, R. Walker, N. Schrage
Efficiency of vitreous removal of using a novel diode-pumped, q-switched Nd: YAG laser compared to a mechanical cutter system: What is possible?

J. Uzzan
Intravitreal gas injection for the treatment of symptomatic vitreo-macular traction with or without macular hole: A retrospective analysis of 22 cases
G. Weigert, L. Aliyeva, K. Maccora, C. Abela Formanek, M. Georgopoulos, U. Schmidt Erfurth, S. Sacu AUSTRIA
Comparison of retinal oxygen saturation and central choroidal volume between epiretinal membrane surgery alone and in combination with cataract surgery

W. Wu, Y. Chang TAIWAN
Management of refractory large macular hole with autologous neurosensory retinal free flap transplantation

M. Yablokov, O. Fabrikantov RUSSIA
The influence of silicone tamponade on the macular status after endovitreal surgery for rhegmatogenous retinal detachment according to optical coherence tomography-angiography

S. Yang, W. Dong, J. Zhong CHINA
Successful management of retinopathy of prematurity with acute progression after anti-VEGF intravitreal injection

Z. Yazar, N. Ucgun, C. Zeki Fikret TURKEY
Evaluation of vitreoretinal surgery results in patients with epiretinal membrane associated with diabetic macular edema which is resistant to intravitreal treatment

G. Yılmaz, C. Ozurt, S. Akca Bayar, I. Akkoyun TURKEY
Reabsorption of acquired vitelliform lesions due to vitreomacular traction

V. Zaika, A. Iakimov, A. Shchuko RUSSIA
Extrusion and intrusion of silicone buckles after episcleral surgery of rhegmatogenous retinal detachment

Z. Zhang, S. Zhang, F. Li, L. Wang CHINA
A novel mobile app for risk estimation of volume expansion and IOP elevation in patients with intravitreous gas/air tamponade

Z. Zhang, S. Zhang CHINA
One critical lesson we should learn: The causative analysis and surgical management of retinal re-detachment under tamponade of silicone oil

K. Zhogolev, Y. Bayborodov, I. Panova RUSSIA
Clinical and instrumental monitoring in assessing the natural history of lamellar macular holes (preliminary results)

G. Zhurgumbayeva, A. Dzhapparkhanova, L. Tashtitova, D. Kyrykbayev KAZAKHSTAN
Long-term results of treatment of complete idiopathic macular hole

V. Zotov, N. Pashtaev RUSSIA
Subretinal injection platelet-rich plasma for highly myopic foveoschisis: technique and outcome
O. Abdelzaher QATAR
Subluxated crystalline lens, vitreoretinal point of view

K. Agarwal INDIA
Nightmare in surgery for stage 5 retinopathy of prematurity: save the day

V. Agrawal INDIA
The bug menace- surgical management techniques for live intravitreal cysticercosis

V. Agrawal INDIA
Giant retinal tears- The art of management

L. Akhundova AZERBAIJAN
Management of submacular haemorrhage with subretinal tissue plasminogen activator and pneumatic displacement

L. Akhundova AZERBAIJAN
Use what is at hand, and do not look for another if you are around the retina in eighty minutes

M. Al-Feky EGYPT
Using different surgical tools during lens sparing parsplanas vitrectomy in a case with bilateral stage 4b retinopathy of prematurity

K. Ananikas GREECE
Vitrectomy for epiretinal membrane following endogenous fungal endophthalmitis

K. Ananikas GREECE
Repair of a rhegmatogenous retinal detachment, caused by an 180° superior giant tear

K. Anastasilakis GREECE
Vitrectomy under air instead of heavy liquid use in retinal detachment surgery

T. Araújo PORTUGAL
Screen-DR: Innovation in diabetic retinopathy screening

J. Arias COLOMBIA
Plasma rich in growth factors (PRGF) for recurrent macular hole closure, a pilot study

J. Arias COLOMBIA
Optical coherence tomographic angiography (OCT-A): Guidance for intraocular tumours diagnosis

E. Arkhipov RUSSIA
Multimodal approaches to the correction of post-traumatic eye changes

D. Arsiutov RUSSIA
Rhegmatogenous retinal detachment surgery with the use of platelet rich plasma (prrp)

A. Aurora INDIA
Suprachoroidal drug injection simplified

E. Aydin TURKEY
Novel technique to reattach regmatogen retinal detachment: Tissue adhesive retinopexy

D. Balakrishnan INDIA
ACM assisted external drainage of subretinal fluid in Coats’ disease

D. Balakrishnan INDIA
Surgical pearls in FEVR surgery

C. Beckford SPAIN
Haemorrhagic retinal detachment associated with massive suprachoroidal hemorrhage. Combined drainage technique

J. Bermúdez Pío-Rendón SPAIN
Management of subfoveal perfluorocarbon liquid with 25G/38G cannula: About a new case

J. Bernardes PORTUGAL
A painstaking IOL rescue

P. Bhende INDIA
A lens, an IOL and a giant retinal tear (GRT) – The result of a fishing expedition

D. Bhojwani INDIA
Chandelier endoilluminator – The dark knight

R.K. Biswas INDIA
Do or die, save the eye

R.K. Biswas INDIA
It’s not the end, it’s the beginning

S. Boral INDIA
Mischievous foreign body: My ecstasy & agony

S. Boral INDIA
A new universal autograft for failed open macular holes

P. Bouzika GREECE
Implantation of a foldable capsular vitreous body in a phthisical eye

A. Brent UK
The use of silicone oil retention sutures in a post-traumatic aniridic patient requiring a combined penetrating keratoplasty and retinal detachment repair

B. Chanana INDIA
Management of giant retinal tear with sub-macular hemorrhage: A novel technique

D. Chow CANADA
Isolated ILM rug

A. D’Aponte SAUDI ARABIA
Surgical treatment of subretinal hemangioma in a case of Von Hippel-Lindau syndrome

S. Demirel TURKEY
Abnormal connection in between peripheric retina and anterior persistant hyperplastic vitreous: A finding that must be keep in mind before surgery
VIDEO COMPETITION

N. Doi JAPAN
A new endophotocoagulation technique for microaneurysms with diabetic macular edema

A. Dotan ISRAEL
What a P-V-R

A. Dotan ISRAEL
23G Pars plana vitrectomy for a posterior traumatic retinal incarceration

S. El Emam EGYPT
Triamcinolone assisted internal limiting membrane peeling

C. Florou GREECE
Comparative outcomes of sutureless implantation of carveal scleral IOL with a classic and a novel technique

M. Forlini ITALY
Il Gattopardo 2 (The leopard's second eye)

N. Fung HONG KONG
A series of dislocated 3 piece IOL repair with vitrectomy and scleral fixation using the original lenses

R. Gandhi INDIA
Diabetic vitrectomies: A step wise approach

J. Garza MEXICO
Packing technique with autologous internal limiting membrane in a non-resolved macular hole associated with retinal detachment

K. Ghasemi Falavarjani IRAN
Interface vitrectomy for retinal slippage associated with proliferative vitreoretinopathy

J. Giralt SPAIN
27-gauge vitrectomy for simultaneous rescue and sutureless intrascleral fixation of dislocated intraocular lens (IOL)

J.H. Gonzalez Cortes MEXICO
Efficacy of autologous anterior lens capsule graft in a non-resolved macular hole associated with retinal detachment

F. Gonzalez del Valle SPAIN
New vitreoretinal surgery to treat the complete luxation of the crystalline lens preserving the capsular bag

F. Gonzalez del Valle SPAIN
Biopsy and conservative surgical management of the ocular melanoma associated with cryotherapy

A. Goyal INDIA
Making of an artificial eye

A. Gupta INDIA
Oh my god ; Supra-choroidal silicone oil

M. Hasanreisoglu TURKEY
Metallic threat, out of sight, hidden behind the macula

M. Hasanreisoglu TURKEY
Take it all or leave it!

M. Hassani EGYPT
Subretinal proliferation: A nightmare

M. Hassani EGYPT
Epiretinal membranes: The most large & the most stick

M. Iglicki ARGENTINA
One day of the retina surgeon trying to relax on their day off when anterior segment complications will not let that happen

V. Kadri INDIA
Double Foveal Pathology - A catch 22 situation

A. Karamitsos GREECE
Introducing Ngenuity® 3D visualization system in vitreoretinal surgery: Recording our experience in clinical practice

V. Kazaykin RUSSIA
Surgical treatment of macular hole without postoperative vitreous cavity tamponade

M. Khalil EGYPT
Huge tie around the optic disc

M. Khalil EGYPT
A single retinotomy can do the job

H. Khaqan PAKISTAN
Plug the pit; novel surgical technique for closure of optic disc pit and treatment of associated maculopathy and macular hole

H. Khaqan PAKISTAN
Plug the giant refractory macular holes

A. Koytak TURKEY
Platelet-rich fibrin for the treatment of refractory macular holes

S.C. Kuo TAIWAN
The sling method to remove severe subluxated cataract in Marfan syndrome

R. Leszcynski POLAND
Inverted internal limiting membrane flap technique with limited chorioretinectomy for treatment perimacular large traumatic hole caused by intraocular foreign body

L. Lucatto BRAZIL
Scleral fixation technique using slip-knot sutures

S. Mabrouk TUNISIA
Techniques of the inverted flap in the idiopathic large macular hole: Which one is more effective?

S. Mabrouk TUNISIA
Intraocular foreign bodies: Different techniques of surgical removal

S. Mandal INDIA
Retinitis pigmentosa with macular hole - An untold story

S. Mano PORTUGAL
Management of an hourglass haemorrhage secondary to a retinal macroaneurysm

F. March De Ribot SPAIN
Natural chromovitrectomy in posterior capsule rupture

F. March De Ribot SPAIN
Dealing with UGH syndrome

Z. Michalewska POLAND
Flap closure techniques for refractory macular holes

M. Mikhail UK
Severe endophthalmitis post vitrectomy secondary to group C streptococcus

S. Mohamed HONG KONG
Mastering the giant: Retinal detachment secondary to giant retinal tear

142
L. Monje-Fernandez  SPAIN
Maneuvers during cortex aspiration when fundus reflex is not present

R. Muni  CANADA
No graft no flap technique for persistent macular hole

J. Nawrocki  POLAND
Managing Optic Pit: Know your stuff!

J. Olea Vallejo  SPAIN
Issues in the management of densiron 68 during vitrectomy

M. Oliveira  PORTUGAL
The Ring: A Vitreoretinal surgery horror story

I. Papandreou  GREECE
What to do in a sticky situation

F. Pichi  UAE
Pre-retinal and sub-retinal membranes removal in an acute retinal necrosis patient

M. Plakhontnyi  RUSSIA
Surgical treatment of idiopathic macular hole using a step-by-step method of forming a fragment of the inner limiting membrane

S.P. Prabhakar  INDIA
Management of rhegmatogenous retinal detachment with retinitis

J. Providência  PORTUGAL
The blind eye and the Invisible Guest

A. Qureshi  UK
The surgical repair of a penetrating ocular injury from a writing instrument in a child

A. Qureshi  UK
Transconjunctival scleral fixated intraocular lens technique: overcoming the surgical challenge

C. Rao  INDIA
Nuances of vitrectomy for rhegmatogenous retinal detachment repair in retinitis pigmentosa

M. Sagong  SOUTH KOREA
Management of submacular hemorrhage due to exudate AMD: Comparison of 3 treatment modalities

D. Shroff  INDIA
3 Ts for recurrent RD

M. Simunovic  AUSTRALIA
Retinal detachment repair in familial exudative vitreoretinopathy

J. Singh  INDIA
Management of retinal detachment with giant retinal tear in eyes with phakic intraocular lens

D.T. Ta Kim  CANADA
A technique for the intact removal of a nematode from the vitreous cavity

C. Tsang  HONG KONG
Techniques of autologous retinal transplant for persistent macular hole: A case series

D. Tsouris  GREECE
Aphakia restoration: The evolution

K. Turki  FRANCE
My first graft

S. Uupadhye  INDIA
Unusual complications following ozurdex injection

P.G. van Etten  THE NETHERLANDS
Vitreous wiping for vitreous cortex remnants removal in case of a suprachoroidal haemorrhage with total retinal detachment

W. Vasquez  PERU
Ocular trauma war

I. Velasque  FRANCE
Lasso technique for intrascleral iol fixation

J. Vieitez Vazquez  SPAIN
Vitrectomy with peeling of epiretinal membrane and laser in familial exudative vitreoretinopathy (FEVR) after trauma in a child

27-G Vitrectomy in a tractional retinal detachment in proliferative diabetic retinopathy

M. Viso  SPAIN
An evil lens

J. Zarranz-Ventura  SPAIN
Vitrectomy with peeling of epiretinal membrane and laser in familial exudative vitreoretinopathy (FEVR) after trauma in a child

OCT-A montages and 3D OCT-A reconstructions

Z. Zhang  CHINA
Systemic approach to prevent inadvertent perfusion in eyes with extensive choroidal detachment, suprachoroidal fluid, and hypotony during pars plana vitrectomy

Z. Zhang  CHINA
Reoperation for failed giant retinal tear surgery

A. Qureshi  UK
Retinal detachment repair in familial exudative vitreoretinopathy
A WORLD OF BENEFITS INCLUDING:

- Online CME Accredited Education Programme (EURETINA Insight)
- Observership Grant Scheme
- Annual Opportunities
- Young Retina Specialists Forum (YOURS)
- Online Session & Video Playback (EURETINA on Demand)
- Online Interviews & Panel Discussions with Experts (EURETINA Player)
- Membership Promotions including: 
  20% Discount for Members of National Societies 
  Free Membership for under 40s
Visit the Resource Centre to Discover our Membership Benefits

EURETINA InSight
CME accredited online interactive courses

EURETINA On Demand
Online library of presentations from EURETINA Congresses

Access to Ophthalmologica
The Official Journal of EURETINA

Reduced Congress Registration Fees

Get a demonstration at our booth today

Visit our website
www.euretina.org
Karger Publishers – your expert for retina publications

Ophthalmologica
The European Retina Journal
Editor: S. Wolf, Bern
www.karger.com/oph

New Editor as of 2019
H. Scholl
Basel
www.karger.com/ore

Ocular Oncology
and Pathology
Editors
A.D. Singh
Cleveland, Ohio
H.E. Grossniklaus
Atlanta, Ga.
www.karger.com/oop

Case Reports in
Ophthalmology
Editor
A. Loewenstein
Tel Aviv
www.karger.com/cop
General Information & Exhibition
GENERAL INFORMATION

Venue
Le Palais des congrès de Paris
METRO Line 1, Porte Maillot station – Exit 3
RER Line C, Neuilly Porte Maillot station

Opening Hours
Registration
Level 0
Wednesday 4 September 14.00 – 19.00
Thursday 5 September 07.00 – 18.30
Friday 6 September 07.00 – 18.30
Saturday 7 September 07.00 – 18.30
Sunday 8 September 07.30 – 12.30

Speaker Check-In
Room 242, Level 2
All speakers must check or upload their presentations 3 hours prior to their session.
Wednesday 4 September 14.00 – 18.00
Thursday 5 September 07.00 – 18.00
Friday 6 September 07.00 – 18.00
Saturday 7 September 07.00 – 18.00
Sunday 8 September 07.30 – 12.30

Exhibition
Hall Maillot, Level 2
Thursday 5 September 09.00 – 18.00
Friday 6 September 09.00 – 17.00
Saturday 7 September 09.00 – 17.00
Sunday 8 September 09.00 – 13.00

Speakers’ Corner
Arlequin Area, Level 3

Device Charging Stations, ATM, Cloakroom & Cafés
Refer to Congress Plans

First Aid
Registration Desk, Level 0

Kuoni Desk
Registration Area, Level 0

Multi-Faith Room
Room M271, Level 2.5

Lost & Found Items
Registration Desk, Level 0

Insurance
Delegates are advised to take out travel insurance to cover medical expenses, accidents, loss etc. No responsibility will be accepted by the Congress Organisers.

Wi-Fi
Wi-Fi is available free of charge throughout the venue.
Network Name: EURETINA2019
Password: EYL60:40

General Assembly
Friday 6 September 09.45, Room 351, Level 3

EURETINA Resource Centre
Exhibition Hall, Level 2, Booth 228

Receptions
Welcome Reception
Thursday 5 September 17.00, Exhibition Hall, Level 2

Closing Reception
Sunday 8 September 14.00, Foyer Bleu, Level 2

CME Credits
The 19th EURETINA Congress, Paris, France, 05/09/2019 08/09/2019 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits TM. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/education/earn-creditparticipation-international – activities.

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) a defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

Each participant can only receive the number of credits he/she is entitled to according to his/her actual participation at the event once he/she has completed the feedback form for each session. The EACCME® awards ECMEC®s on the basis of 1 ECMEC® for one hour of CME with a maximum of 8 ECMEC®s per day. Each delegate should contact his/her national CME body directly in order to claim their credits for the Congress.

Join the Conversation
#EURETINA19
Connect with EURETINA during the Congress by following us on:
Satellite Meeting
1pm Friday 06 September
Amphitheatre Havane

Take Another Look: Uncovering New Advances and Future Applications of Ultra-Widefield with Dr. Srinivas Sadda, Prof. Paulo Stanga & Prof. Tunde Peto

Join us to hear the panel discuss how ultra-widefield imaging technology facilitates the early detection, management and effective treatment of disorders and diseases evidenced in the retina.

Visit us at EURETINA 2019 Booth 238
Find out more optos.is/euretina2019
EURETINA would like to thank the following sponsors for their support:
ESASO ACTIVITIES 2020

ESASO Modules:

<table>
<thead>
<tr>
<th>Date</th>
<th>Module</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>JANUARY</td>
<td>Orbital, Lacrimal and Ophthalmic Plastic Surgery</td>
<td>Lugano, Switzerland</td>
</tr>
<tr>
<td>10 - 14</td>
<td>Intermediate - Advanced Surgical Retina</td>
<td>Lugano, Switzerland</td>
</tr>
<tr>
<td>MARCH</td>
<td>Medical Retina</td>
<td>Lugano, Switzerland</td>
</tr>
<tr>
<td>30 MARCH</td>
<td>Basic Surgical Retina</td>
<td>Lugano, Switzerland</td>
</tr>
<tr>
<td>01 MAY</td>
<td>Orbital, Lacrimal and Ophthalmic Plastic Surgery</td>
<td>Lugano, Switzerland</td>
</tr>
<tr>
<td>15 - 19</td>
<td>Intermediate - Advanced Surgical Retina</td>
<td>Lugano, Switzerland</td>
</tr>
<tr>
<td>21 - 25</td>
<td>Cornea and Corneal Refractive Surgery</td>
<td>Lugano, Switzerland</td>
</tr>
<tr>
<td>19 - 23</td>
<td>Glaucoma</td>
<td>Lugano, Switzerland</td>
</tr>
<tr>
<td>16 - 20</td>
<td>Basic Cataract and Intraocular Refractive Surgery</td>
<td>Lugano, Switzerland</td>
</tr>
<tr>
<td>11 - 15</td>
<td>Medical Retina</td>
<td>Lublin, Poland</td>
</tr>
</tbody>
</table>

Other educational activities of ESASO:

- Drylabs
- Simulator training 3D
- Preceptorships
- Certifications
- Wetlabs

For more information please visit www.esaso.org

WELCOME COUPON ESASO MODULES 2020

-10% Discount

VALIDITY
- Only for first-time attendees in the ESASO Modules
- Only for Europe Calendar 2020*
- Not applicable for sponsors
- Seats availability until maximum capacity reached
- Not valid for other educational activities
- Regular conditions for application, admission and regulations apply

HOW TO USE IT?
- Apply online on the ESASO Calendar and Application 2020 Europe’s page
- Quote the Euretina voucher within the “Remarks” field of the online application form
- Upload copy of the voucher in the “Additional documents” field

An application will be made to EACCME® for CME accreditation of each Lugano campus module
For more information write to info@esaso.org

*list of modules available at: www.esaso.org

EURETINA 2019
<table>
<thead>
<tr>
<th>Exhibitor</th>
<th>Booth Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>AL.CHI.MI.A. S.R.L.</td>
<td>203</td>
</tr>
<tr>
<td>Alcon</td>
<td>229</td>
</tr>
<tr>
<td>Alfa Intes</td>
<td>246</td>
</tr>
<tr>
<td>Alimera Sciences Limited</td>
<td>224a</td>
</tr>
<tr>
<td>Allergan</td>
<td>220</td>
</tr>
<tr>
<td>Altris, Inc.</td>
<td>200</td>
</tr>
<tr>
<td>Aprofol AG</td>
<td>240</td>
</tr>
<tr>
<td>ARCADOPHTA®</td>
<td>243</td>
</tr>
<tr>
<td>BAUSCH+LOMB</td>
<td>230</td>
</tr>
<tr>
<td>BAYER</td>
<td>227</td>
</tr>
<tr>
<td>BAYER Lounge</td>
<td>227a</td>
</tr>
<tr>
<td>Canon Medical Systems Europe</td>
<td>222</td>
</tr>
<tr>
<td>CenterVue S.p.A.</td>
<td>209</td>
</tr>
<tr>
<td>D.O.R.C.</td>
<td>201</td>
</tr>
<tr>
<td>DIAGNOSYS</td>
<td>232b</td>
</tr>
<tr>
<td>Diopsys, Inc.</td>
<td>218</td>
</tr>
<tr>
<td>Ellex</td>
<td>226</td>
</tr>
<tr>
<td>EURETINA Clinical Trends Survey</td>
<td>228a</td>
</tr>
<tr>
<td>EURETINA Resource Centre</td>
<td>228</td>
</tr>
<tr>
<td>Eyenuk, Inc.</td>
<td>245</td>
</tr>
<tr>
<td>FCI S.A.S.</td>
<td>221</td>
</tr>
<tr>
<td>GEUDER AG</td>
<td>213</td>
</tr>
<tr>
<td>HEIDELBERG ENGINEERING</td>
<td>211</td>
</tr>
<tr>
<td>HEINE Optotechnik GmbH &amp; Co.KG</td>
<td>250</td>
</tr>
<tr>
<td>HORUS PHARMA</td>
<td>224</td>
</tr>
<tr>
<td>Icare</td>
<td>209</td>
</tr>
<tr>
<td>Imagine Eyes</td>
<td>244a</td>
</tr>
<tr>
<td>IRIDEX</td>
<td>235</td>
</tr>
<tr>
<td>JP Medical Publishers</td>
<td>232c</td>
</tr>
<tr>
<td>Karger Publishers</td>
<td>217</td>
</tr>
<tr>
<td>Katalyst Surgical™, LLC.</td>
<td>202</td>
</tr>
<tr>
<td>kleine Rheinperle: Retina Ring</td>
<td>204b</td>
</tr>
<tr>
<td>Laboratoires Théa</td>
<td>223</td>
</tr>
<tr>
<td>LKC Technologies</td>
<td>204</td>
</tr>
<tr>
<td>LumiThera, Inc.</td>
<td>248</td>
</tr>
<tr>
<td>MacuLogix</td>
<td>232d</td>
</tr>
<tr>
<td>MEDIA MICE</td>
<td>244c</td>
</tr>
<tr>
<td>MedOne Surgical</td>
<td>208</td>
</tr>
<tr>
<td>NIDEK CO., LTD.</td>
<td>212</td>
</tr>
<tr>
<td>Novartis</td>
<td>225</td>
</tr>
<tr>
<td>OCULUS Surgical</td>
<td>247</td>
</tr>
<tr>
<td>OD-OS GmbH - Navilas</td>
<td>210</td>
</tr>
<tr>
<td>Oertli Instrumente AG</td>
<td>214</td>
</tr>
<tr>
<td>OPHTEC</td>
<td>242</td>
</tr>
<tr>
<td>OPTOPOL Technology</td>
<td>239</td>
</tr>
<tr>
<td>Optos plc</td>
<td>238</td>
</tr>
<tr>
<td>Optovue, Inc.</td>
<td>249</td>
</tr>
<tr>
<td>Oxurion NV</td>
<td>232</td>
</tr>
<tr>
<td>PHAKOS</td>
<td>213</td>
</tr>
<tr>
<td>Preceyes b.v.</td>
<td>237a</td>
</tr>
<tr>
<td>ProQR Therapeutics</td>
<td>236</td>
</tr>
<tr>
<td>QUANTEL MEDICAL</td>
<td>231</td>
</tr>
<tr>
<td>Retina Today</td>
<td>241</td>
</tr>
<tr>
<td>RetinaAI Medical AG</td>
<td>244b</td>
</tr>
<tr>
<td>Roche</td>
<td>207</td>
</tr>
<tr>
<td>RUMEX International Co.</td>
<td>216</td>
</tr>
<tr>
<td>Save Sight Registries</td>
<td>204a</td>
</tr>
<tr>
<td>SOOFT ITALIA SPA</td>
<td>232a</td>
</tr>
<tr>
<td>SUOER</td>
<td>235a</td>
</tr>
<tr>
<td>Thondar</td>
<td>241a</td>
</tr>
<tr>
<td>Tilak Healthcare</td>
<td>208a</td>
</tr>
<tr>
<td>Topcon Europe Medical B.V.</td>
<td>219</td>
</tr>
<tr>
<td>Vesber Biotechnology Co., Ltd.</td>
<td>244</td>
</tr>
<tr>
<td>Vitreocare</td>
<td>246</td>
</tr>
<tr>
<td>Vitreq B.V.</td>
<td>205</td>
</tr>
<tr>
<td>Volk Optical</td>
<td>234</td>
</tr>
<tr>
<td>Wisepress</td>
<td>233</td>
</tr>
<tr>
<td>ZEISS</td>
<td>215, 215a</td>
</tr>
</tbody>
</table>
RNA THERAPIES FOR INHERITED RETINAL DISEASES

Learn about our clinical pipeline at booth #236

www.proqr.com
EURETINA is delighted to host the 8th Retina Race

Date: Saturday 7 September 2019, 6.30am
Online & Onsite Registration Fee: €45 in Aid of Orbis*

*The registration fee includes €30 donation to Orbis, start number, chip, official race t-shirt, first aid, bag deposit service, changing location and refreshment points

Information at www.euretina.org
Thursday 5 September

LUNCHTIME SYMPOSIA
13.00 – 14.00
Amphithéâtre Bleu (Level 2)
Transforming DME Clinical Practice
Moderators: A. Loewenstein ISRAEL
B. Kuppermann USA
Sponsored by Allergan

Amphithéâtre Havane (Level 3)
Clinical Applications of Swept Source OCT & Angiography
Moderator: P. Keane UK
Sponsored by Topcon

Room 241 (Level 2)
Photobiomodulation: An Innovative, Mitochondria-targeted Therapy for Dry AMD and Other Ocular Diseases (An Update)
Moderators: J. Eells USA
M. Munk SWITZERLAND
Sponsored by Lumithera

Friday 6 September

MORNING SYMPOSIA
9.45 – 10.45
Amphithéâtre Bleu (Level 2)
Keeping a Step Ahead of the Disease: Proactive Treatment for nAMD
Moderator: L. Kodjikian FRANCE
Sponsored by Bayer

Salle Maillot (Level 2)
A New Vision in Retinal Gene Therapy: From Clinical Trials to Clinical Practice
Moderator: B. Leroy BELGIUM
Sponsored by Novartis

EURETINA Independent Medical Education Platform
Amphithéâtre Bordeaux (Level 3)
The Great Fluid Debate: Reviewing Treatment Outcome Goals for the AMD Patient
Moderators: S. Wolf SWITZERLAND
F.G. Holz GERMANY
Supported by:

Platinum: Novartis
Silver: Zeiss
Friday 6 September

MORNING SYMPOSIA
09.45 – 10.45
Room 251 (Level 2)

Seeing the Invisible - Transparent Subthreshold Treatment with Navigated Microsecond Pulsing Laser
Moderator: G. Staurenghi ITALY

Sponsored by NAVILAS®

Friday 6 September

LUNCHTIME SYMPOSIA
13.00 – 14.00
Salle Maillot (Level 2)

Ranibizumab; Retinal Care For all Ages: RIVAL (nAMD) to RAINBOW (ROP)
Moderator: R. Tadayoni FRANCE

Sponsored by Novartis

Friday 6 September

LUNCHTIME SYMPOSIA
13.00 – 14.00
Room 252 (Level 2)

Breaking the Cycle of Recurrence in DME: Where Research Meets Clinical Practice
Moderator: L. Kodjikian FRANCE

Sponsored by ALIMERA SCIENCES®

Amphithéâtre Havane (Level 3)

Take Another Look: Uncovering New Advances and Future Applications of Ultra-widefield
Moderator: T. Peto UK

Sponsored by Optos®

Amphithéâtre Bleu (Level 2)

Emerging Evidence: Molecular Properties and Patient Outcomes
Moderator: F. Behar-Cohen FRANCE

Sponsored by Bayer

Room 342 (Level 3)

Illuminating the Role of Angiopoietins in Retinal Diseases
Moderator: J-F. Korobelnik FRANCE

Sponsored by Roche
Friday 6 September

LUNCHTIME SYMPOSIA

13.00 – 14.00

Room 351 (Level 3)

New Mirante Multimodal Imaging and OCT-A Analytics can Help Breakthrough Tricky Cases of Retinal Disorders

Moderator: G. Staurenghi ITALY

Sponsored by NIDEK

Room 241 (Level 2)

Reimagine your Retina Surgery with Bausch + Lomb

Moderator: Y. Le Mer FRANCE

Sponsored by BAUSCH+LOMB

Saturday 7 September

MORNING SYMPOSIA

09.45 – 10.45

Amphithéâtre Bleu (Level 2)

Unsurpassed Vision Gains and Optimized Patient Outcomes in DME

Moderator: J-F. Korobelnik FRANCE

Sponsored by Bayer

Amphithéâtre Bordeaux (Level 3)

nAMD Management: Beyond the Horizon

Moderators: F. Bandello ITALY
A. García-Layana SPAIN

Sponsored by Allergan

Salle Maillot (Level 2)

Reimagine your Retina Surgery with Bausch + Lomb

Moderator: Y. Le Mer FRANCE

Sponsored by BAUSCH+LOMB

Saturday 7 September

MORNING SYMPOSIA

09.45 – 10.45

Room 252 (Level 2)

The Vitreoretinal Procedure - Integration, Stability, Speed

Moderator: R. Tadayoni FRANCE

Sponsored by Alcon

* Participation by Dr. Neil Bressler in this activity does not constitute or imply endorsement by the Johns Hopkins University, the Johns Hopkins Hospital, or the Johns Hopkins Health System

SATELLITE EDUCATION PROGRAMME

159
SATELLITE EDUCATION PROGRAMME

Saturday 7 September

MORNING SYMPOSIA
09.45 – 10.45
Room 351 (Level 3)
Complement C3 Inhibition in Geographic Atrophy
Moderator: F.G. Holz GERMANY

Sponsored by Apellis

Saturday 7 September

LUNCHTIME SYMPOSIA
13.00 – 14.00
Room 351 (Level 3)
Innovative Thinking in Théa Symposium Retinal Disease
Moderator: J. Seddon USA

Sponsored by Théa

Room 241 (Level 2)
Management of Retinal Diseases with Subliminal Laser Therapy
Moderator: V. Chong UK

Sponsored by Quantel Medical

Room 342 (Level 3)
Delivering the Future of nAMD Management
Moderator: R. Tadayoni FRANCE

Sponsored by Roche

Salle Maillot (Level 2)
Retinal Imaging Advancements
Moderator: J-F. Korobelnik FRANCE

Sponsored by ZEISS

Saturday 7 September

LUNCHTIME SYMPOSIA
13.00 – 14.00
Room 241 (Level 2)
Management of Retinal Diseases with Subliminal Laser Therapy
Moderator: V. Chong UK

Sponsored by Quantel Medical

Room 342 (Level 3)
Delivering the Future of nAMD Management
Moderator: R. Tadayoni FRANCE

Sponsored by Roche

Salle Maillot (Level 2)
Retinal Imaging Advancements
Moderator: J-F. Korobelnik FRANCE

Sponsored by ZEISS
THE ONLY
COMPLETE OCT SYSTEM
IN THE WORLD

VISIT US AT BOOTH
#239

The World’s first OCT Biometry | The World’s fastest OCT | The World’s first OCT Topography

OPTOPOL technology
manufacturer of the first Spectral Domain OCT in the world
optopol.com
INDEX

A

Aaberg, T. 76
Abdala, C. 88, 89, 96
Abdelmonem Abdou, Z. 60
Abdelzaher, O. 141
Abdin, A. 16
Abdolrahimzadeh, S. 15
Abreu González, R. 15, 27
Abrishami, M. 44, 95
Abu El Asrar, A. 12
Abulon, D. 72
Ach, T. 31
Agarwal, K. 141
Agarwal-Sinha, S. 15, 78, 107
Agrawal, V. 29, 141
Ah Moye, S. 30, 75
Airody, A. 16
Ajamil Rodanes, S. 52
Akdogan, M. 24
Akhundova, L. 141
Alfano, A. 41
Al-Feky, M. 141
Aljamaal, R. 13
Allen, P. 55
Almeida, A. 88
Almuina Varela, P. 95
Alotaibi, M. 71
Amin, A. 21
Amirkavi, M. 42
Amoroso, F. 43
Ananikas, K. 141
Anantharaman, G. 86
Anastasilakis, K. 141
Angguri Putri, C. 75
Arias Barquet, L. 141
Ardan, T. 34
Arias, J. 141
Armitage, R. 56
Arístodemou, P. 51
Arkhipov, E. 141
Arun, C. 61
Arsiutov, D. 141
Ascaso, F. 42
Aslam, T. 48, 74
Aslanis, S. 62
Asmus, F. 63
Audo, I. 15, 70
Augustin, A. 30
Au, L. 55
Aurora, A. 45, 141
Avic, R. 97
Awh, C. 50, 76, 91
Aydin, E. 27, 141
Aylward, B. 2, 17
Azzolini, C. 140

B

Baba, T. 25
Babiker, S. 71
Bacherini, D. 68
Baek, J. 69, 91
Bailey, C. 21
Bailiff, S. 102
Balakrishnan, D. 141
Balasubramanian, A. 16
Balalas, K. 48, 74
Bali, E. 66, 85, 104
Balios, B. 54
Balta, F. 66, 76
Bandello, F. 2, 34, 36, 47, 60, 70, 75, 82, 89, 94, 103, 105, 159
Banerjee, P. 78
Baradad Jurjo, M. 62
Barale, P. 72
Barbaro, L. 69
Barcat, G. 62
Barros Rodrigo, M. 38
Battaglia-Parodi, M. 41, 103
Batur, M. 62
Bechakis, N. 13, 45
Beckford, C. 141
Beets, K. 45
Behar-Cohen, F. 39, 47, 70, 82, 158
Bekkali, S. 76
Belkhadir, K. 52
Bell, S. Fraser 66
Berge, J. Ten 68
Bernardes, J. 102, 141
Bhende, P. 86, 141
Bhojwani, D. 52, 62, 141
Bikbov, M. 90
Bini, S. 21
Bisfora Gassendorf, L. 23
Biswas, R.K. 141
Blodi, B. 55
Bodagh, B. 157

Bodhankar, P. 105
Boeker, T. 18, 19
Boogunovic, H. 74
Boon, C.J. 15, 36, 67, 68, 98
Bopp, S. 61
Boral, S. 86, 141
Bornfeld, N. 13, 45
Borrelli, E. 70
Boscia, F. 85, 91
Bottoni, F. 47, 53
Bouzika, P. 141
Brancato, R. 2
Brent, A. 141
Bressler, N. 20, 36, 58, 159
Brinkmann, M. 56
Brinks, J. 68
Brizido, M. 75
Burggraaf Sánchez de las Matas, R. 69
Burgos-Blasco, B. 49
Busch, C. 30

C

Cahuzac, A. 90
Callegan, M. 22
Calzada, J. 33
Cano-Hidalgo, R. 87, 89, 94, 103
Capuano, V. 15
Carlos Pastor, J. 23
Carneiro, A. 31
Carpio, J.D. 88
Carreras, E. 100
Cassoux, N. 13
Castro Farias, D. 40
Cehofski, L. 68
Cervera Taulet, E. 47
Cha, D. 71
Chakravarty, U. 70, 102
Chamard, C. 105
Chanana, B. 29, 37, 77, 141
Chandra, A. 61, 78
Chandra, S. 102
Chang, A. 22, 42, 84
Chang, I. 42
Charles, S. 50
Charteris, D. 29
Chatziralli, I. 55, 56
Chaudhary, V. 72
Chawla, S. 37, 86
Chen, S-J. 29, 87
Chen, Y. 97
Cheung, G. 70, 73, 83
<table>
<thead>
<tr>
<th>Name</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gómez-Ulla, F.</td>
<td>83</td>
</tr>
<tr>
<td>Gomi, F.</td>
<td>86</td>
</tr>
<tr>
<td>Gonzalez Cortes, J.H.</td>
<td>87, 142</td>
</tr>
<tr>
<td>Gonzalez del Valle, F.</td>
<td>142</td>
</tr>
<tr>
<td>Gonzalez Saídvar, G.</td>
<td>25, 60,</td>
</tr>
<tr>
<td>Gotzaridis, S.</td>
<td>76, 89</td>
</tr>
<tr>
<td>Goyal, A.</td>
<td>32, 142</td>
</tr>
<tr>
<td>Granstam, E.</td>
<td>40</td>
</tr>
<tr>
<td>Graue, F.</td>
<td>87, 89, 94, 103</td>
</tr>
<tr>
<td>Grewal, D.</td>
<td>108</td>
</tr>
<tr>
<td>Grosso, A.</td>
<td>33</td>
</tr>
<tr>
<td>Grüb, M.</td>
<td>99</td>
</tr>
<tr>
<td>Grzybowski, A.</td>
<td>2, 53, 73, 82, 94</td>
</tr>
<tr>
<td>Gudsoorkar, S.</td>
<td>34, 99</td>
</tr>
<tr>
<td>Guenther, S.</td>
<td>97</td>
</tr>
<tr>
<td>Guerrero-Naranjo, J.L.</td>
<td>87</td>
</tr>
<tr>
<td>Gupta, A.</td>
<td>142</td>
</tr>
<tr>
<td>Gupta, S.</td>
<td>51</td>
</tr>
<tr>
<td>Gupta, V.</td>
<td>46</td>
</tr>
<tr>
<td>Guthoff, R.</td>
<td>107</td>
</tr>
<tr>
<td>Habib, M.</td>
<td>23</td>
</tr>
<tr>
<td>Habot Wilner, Z.</td>
<td>43</td>
</tr>
<tr>
<td>Hadjistilianou, D.</td>
<td>13</td>
</tr>
<tr>
<td>Hahn, L.</td>
<td>54, 67</td>
</tr>
<tr>
<td>Halim, S.</td>
<td>68</td>
</tr>
<tr>
<td>Hall, A.</td>
<td>99</td>
</tr>
<tr>
<td>Ham, D.I.</td>
<td>91</td>
</tr>
<tr>
<td>Hamza, H.</td>
<td>85</td>
</tr>
<tr>
<td>Haruta, M.</td>
<td>69</td>
</tr>
<tr>
<td>Hasan, H.</td>
<td>100</td>
</tr>
<tr>
<td>Hasanreisoglu, M.</td>
<td>142</td>
</tr>
<tr>
<td>Haskova, Z.</td>
<td>30</td>
</tr>
<tr>
<td>Hassanien, M.</td>
<td>142</td>
</tr>
<tr>
<td>Hassan, T.</td>
<td>50, 91</td>
</tr>
<tr>
<td>Hattenbach, L-O.</td>
<td>29, 61</td>
</tr>
<tr>
<td>Hatz, K.</td>
<td>66, 105</td>
</tr>
<tr>
<td>Hayashida, M.</td>
<td>21</td>
</tr>
<tr>
<td>Hazel, C.</td>
<td>71</td>
</tr>
<tr>
<td>Heimann, H.</td>
<td>13, 24, 29, 58, 77</td>
</tr>
<tr>
<td>Helbig, H.</td>
<td>89</td>
</tr>
<tr>
<td>He, M.</td>
<td>16</td>
</tr>
<tr>
<td>Henderson, R.</td>
<td>78</td>
</tr>
<tr>
<td>Herfort Jr, C.P.</td>
<td>12</td>
</tr>
<tr>
<td>Heriot, W.</td>
<td>17, 48</td>
</tr>
<tr>
<td>Hernandez-Da Mota, S.</td>
<td>87</td>
</tr>
<tr>
<td>Hess, K.</td>
<td>37</td>
</tr>
<tr>
<td>Hillenkamp, J.</td>
<td>48</td>
</tr>
<tr>
<td>Hillier, R.</td>
<td>24</td>
</tr>
<tr>
<td>Hoerauf, H.</td>
<td>53</td>
</tr>
<tr>
<td>Hogg, R.</td>
<td>50</td>
</tr>
<tr>
<td>Holz, F.G.</td>
<td>2, 24, 34, 43, 47, 57, 63, 67, 70, 86, 89, 160</td>
</tr>
<tr>
<td>Hoyng, C.</td>
<td>15, 24, 67, 98</td>
</tr>
<tr>
<td>Hubschman, J.P.</td>
<td>20</td>
</tr>
<tr>
<td>Huiskamp, C.</td>
<td>76</td>
</tr>
<tr>
<td>Humayun, M.</td>
<td>88</td>
</tr>
<tr>
<td>Hüning, G.M.</td>
<td>41</td>
</tr>
<tr>
<td>Husein, S.</td>
<td>99</td>
</tr>
<tr>
<td>Hussain, R.</td>
<td>15, 49</td>
</tr>
<tr>
<td>Hwang, D.</td>
<td>21, 87</td>
</tr>
<tr>
<td>Hykin, P.</td>
<td>36, 53</td>
</tr>
<tr>
<td>Iglicki, M.</td>
<td>27, 37, 97, 142</td>
</tr>
<tr>
<td>Ikuno, Y.</td>
<td>57</td>
</tr>
<tr>
<td>Invernizzi, A.</td>
<td>46, 83</td>
</tr>
<tr>
<td>Isanta Otal, C.</td>
<td>40</td>
</tr>
<tr>
<td>Islam, M.</td>
<td>99</td>
</tr>
<tr>
<td>Itoh, A.</td>
<td>86</td>
</tr>
<tr>
<td>Iturria Soler, J.</td>
<td>27</td>
</tr>
<tr>
<td>Iyer, S.</td>
<td>78</td>
</tr>
<tr>
<td>Jackson, T.</td>
<td>48, 51</td>
</tr>
<tr>
<td>Jacobsen, B.</td>
<td>60</td>
</tr>
<tr>
<td>Jaggi, D.</td>
<td>32, 100</td>
</tr>
<tr>
<td>Jaki, P.</td>
<td>90</td>
</tr>
<tr>
<td>Jansen, R.</td>
<td>22</td>
</tr>
<tr>
<td>Januschowski, K.</td>
<td>23, 37, 45, 51, 68</td>
</tr>
<tr>
<td>Jhinja, A.</td>
<td>51</td>
</tr>
<tr>
<td>Jimenez Santos, M.</td>
<td>71</td>
</tr>
<tr>
<td>Jonas, J.</td>
<td>43</td>
</tr>
<tr>
<td>Jones, L.</td>
<td>71</td>
</tr>
<tr>
<td>Jones, N.</td>
<td>12</td>
</tr>
<tr>
<td>Joussen, A.</td>
<td>13, 45, 58, 89, 108</td>
</tr>
<tr>
<td>Juncal, V.</td>
<td>107</td>
</tr>
<tr>
<td>Jürgens, I.</td>
<td>83</td>
</tr>
<tr>
<td>Kabanarou, S.</td>
<td>27, 99</td>
</tr>
<tr>
<td>Kabra, S.</td>
<td>30</td>
</tr>
<tr>
<td>Kacerik, E.</td>
<td>72</td>
</tr>
<tr>
<td>Kadayifcilar, S.</td>
<td>69</td>
</tr>
<tr>
<td>Kadonosono, K.</td>
<td>66, 76, 86</td>
</tr>
<tr>
<td>Kadri, V.</td>
<td>15, 142</td>
</tr>
<tr>
<td>Kaikkonen, O.</td>
<td>44</td>
</tr>
<tr>
<td>Kaiser, P.</td>
<td>91, 95</td>
</tr>
<tr>
<td>Kaluzny, J.</td>
<td>25</td>
</tr>
<tr>
<td>Kamar, S.</td>
<td>68</td>
</tr>
<tr>
<td>Kang, H.</td>
<td>47</td>
</tr>
<tr>
<td>Kapetanovic, J.</td>
<td>25</td>
</tr>
<tr>
<td>Karalezli, A.</td>
<td>69</td>
</tr>
<tr>
<td>Karaman Erdur, S.</td>
<td>105</td>
</tr>
<tr>
<td>Karamitsos, A.</td>
<td>142</td>
</tr>
<tr>
<td>Karpooor, M.</td>
<td>50</td>
</tr>
<tr>
<td>Kasbia, S.</td>
<td>69</td>
</tr>
<tr>
<td>Kashani, A.</td>
<td>87</td>
</tr>
<tr>
<td>Katz, G.</td>
<td>43</td>
</tr>
<tr>
<td>Kawasaki, R.</td>
<td>99</td>
</tr>
<tr>
<td>Kazaykin, V.</td>
<td>142</td>
</tr>
<tr>
<td>Keane, P.</td>
<td>26, 28, 48, 58, 88, 104, 157</td>
</tr>
<tr>
<td>Kertes, P.</td>
<td>24, 102</td>
</tr>
<tr>
<td>Keunen, J.</td>
<td>14, 90</td>
</tr>
<tr>
<td>Khairallah, M.</td>
<td>12</td>
</tr>
<tr>
<td>Khaled, E.R.</td>
<td>85</td>
</tr>
<tr>
<td>Khalid, H.</td>
<td>100</td>
</tr>
<tr>
<td>Khalil, M.</td>
<td>142</td>
</tr>
<tr>
<td>Khan, A.</td>
<td>54</td>
</tr>
<tr>
<td>Khan, H.</td>
<td>54</td>
</tr>
<tr>
<td>Khan, N.</td>
<td>73</td>
</tr>
<tr>
<td>Khaqan, H.</td>
<td>62, 142</td>
</tr>
<tr>
<td>Khattab, M.</td>
<td>68</td>
</tr>
<tr>
<td>Khorramnia, R.</td>
<td>106</td>
</tr>
<tr>
<td>Kiilgaard, J-F.</td>
<td>13, 58</td>
</tr>
<tr>
<td>Kilic, I.</td>
<td>47, 68</td>
</tr>
<tr>
<td>Kim, B.</td>
<td>72</td>
</tr>
<tr>
<td>Kim, E.</td>
<td>100</td>
</tr>
<tr>
<td>Kim, E.S.</td>
<td>91</td>
</tr>
<tr>
<td>Kim, J.</td>
<td>30, 54</td>
</tr>
<tr>
<td>Kim, K.</td>
<td>26</td>
</tr>
<tr>
<td>Kim, M.</td>
<td>21, 56,</td>
</tr>
<tr>
<td>Kim, S.</td>
<td>34</td>
</tr>
<tr>
<td>Kim, Y.</td>
<td>33, 50</td>
</tr>
<tr>
<td>Kinoshita, J.</td>
<td>27</td>
</tr>
<tr>
<td>Kiong Ngo, W.</td>
<td>83</td>
</tr>
<tr>
<td>Kitchens, J.</td>
<td>24</td>
</tr>
<tr>
<td>Kivela, T.</td>
<td>45, 58</td>
</tr>
<tr>
<td>Klaver, C.C.W.</td>
<td>2, 36, 67, 105</td>
</tr>
<tr>
<td>Klein, J.</td>
<td>26</td>
</tr>
<tr>
<td>Klepinina, O.</td>
<td>37</td>
</tr>
<tr>
<td>Klevering, J.</td>
<td>67</td>
</tr>
<tr>
<td>Kodikjian, L.</td>
<td>66, 157, 158,</td>
</tr>
<tr>
<td>Koelbi, P.</td>
<td>97</td>
</tr>
<tr>
<td>Koh, A.</td>
<td>31, 84, 86</td>
</tr>
<tr>
<td>Kohsuke, S.</td>
<td>72</td>
</tr>
<tr>
<td>Kolesnik, S.</td>
<td>107</td>
</tr>
<tr>
<td>Komuku, Y.</td>
<td>27</td>
</tr>
<tr>
<td>Kondo, H.</td>
<td>78</td>
</tr>
<tr>
<td>Korobelnik, J-F.</td>
<td>14, 40, 66, 75, 86, 158, 159</td>
</tr>
<tr>
<td>Koshy, Z.</td>
<td>48</td>
</tr>
<tr>
<td>P</td>
<td>Q</td>
</tr>
<tr>
<td>----------------</td>
<td>-----------------</td>
</tr>
<tr>
<td>Pacheco Soares Carneiro, I.</td>
<td>Querques, G.</td>
</tr>
<tr>
<td>Panchenko, I.</td>
<td>2, 15, 43, 70, 82, 98</td>
</tr>
<tr>
<td>Panova, I.</td>
<td>Qureshi, A. 143</td>
</tr>
<tr>
<td>Papadosioupolou, C.</td>
<td>85</td>
</tr>
<tr>
<td>Papandreou, I.</td>
<td>143</td>
</tr>
<tr>
<td>Papayannis, A.</td>
<td>32, 41</td>
</tr>
<tr>
<td>Paques, M.</td>
<td>84</td>
</tr>
<tr>
<td>Parikakis, E.</td>
<td>76</td>
</tr>
<tr>
<td>Paroikakis, E.</td>
<td>17, 49, 76</td>
</tr>
<tr>
<td>Parolini, B.</td>
<td>61, 73</td>
</tr>
<tr>
<td>Parrozzani, R.</td>
<td>62</td>
</tr>
<tr>
<td>Paruleher, M.</td>
<td>13</td>
</tr>
<tr>
<td>Pastore, M.</td>
<td>23</td>
</tr>
<tr>
<td>Patel, C.K.</td>
<td>100</td>
</tr>
<tr>
<td>Patell, F.</td>
<td>104</td>
</tr>
<tr>
<td>Patrao, N.</td>
<td>42</td>
</tr>
<tr>
<td>Pavloskioff, D.</td>
<td>89, 101</td>
</tr>
<tr>
<td>Pavesio, C.</td>
<td>12</td>
</tr>
<tr>
<td>Pavesio, E.</td>
<td>71</td>
</tr>
<tr>
<td>Pearce, I.</td>
<td>30, 44, 74</td>
</tr>
<tr>
<td>Peiretti, E.</td>
<td>25, 100</td>
</tr>
<tr>
<td>Pelayes, D.E.</td>
<td>45, 54, 68, 89, 94, 96, 103</td>
</tr>
<tr>
<td>Peng, L.</td>
<td>26</td>
</tr>
<tr>
<td>Pennesi, M.</td>
<td>72</td>
</tr>
<tr>
<td>Penwarden, A.</td>
<td>16</td>
</tr>
<tr>
<td>Pershin, B.</td>
<td>52</td>
</tr>
<tr>
<td>Pertile, G.</td>
<td>41, 57, 104</td>
</tr>
<tr>
<td>Pessoa, B.</td>
<td>49</td>
</tr>
<tr>
<td>Peto, T.</td>
<td>42, 108, 158</td>
</tr>
<tr>
<td>Pichi, F.</td>
<td>40, 46, 52, 143</td>
</tr>
<tr>
<td>Pignatuto, S.</td>
<td>15</td>
</tr>
<tr>
<td>Pilotto, E.</td>
<td>17, 36, 106</td>
</tr>
<tr>
<td>Plakhnotnyi, M.</td>
<td>143</td>
</tr>
<tr>
<td>Pleyer, U.</td>
<td>59</td>
</tr>
<tr>
<td>Poignet, B.</td>
<td>100</td>
</tr>
<tr>
<td>Polito, A.</td>
<td>41</td>
</tr>
<tr>
<td>Polkinghorne, P.J.</td>
<td>37</td>
</tr>
<tr>
<td>Pollreisz, A.</td>
<td>31</td>
</tr>
<tr>
<td>Pournaras, C.</td>
<td>82, 84</td>
</tr>
<tr>
<td>Pournaras, C.J.</td>
<td>84</td>
</tr>
<tr>
<td>Pournaras, J.</td>
<td>103</td>
</tr>
<tr>
<td>Pournaras, J.A.</td>
<td>39, 76</td>
</tr>
<tr>
<td>Prabhakar, S.P.</td>
<td>143</td>
</tr>
<tr>
<td>Praidou, A.</td>
<td>44</td>
</tr>
<tr>
<td>Prieto del Cura, M.</td>
<td>23, 69</td>
</tr>
<tr>
<td>Prigione, G.</td>
<td>41</td>
</tr>
<tr>
<td>Priglinger, S.</td>
<td>20, 30, 53, 66</td>
</tr>
<tr>
<td>Providência, J.</td>
<td>143</td>
</tr>
<tr>
<td>Prünte, C.</td>
<td>16</td>
</tr>
<tr>
<td>Puyo, L.</td>
<td>38</td>
</tr>
<tr>
<td>Mrejen, S.</td>
<td>104</td>
</tr>
<tr>
<td>Munier, F.</td>
<td>13</td>
</tr>
<tr>
<td>Muni, R.</td>
<td>24, 33, 143</td>
</tr>
<tr>
<td>Munk, M.</td>
<td>46, 71, 76, 104, 108, 157</td>
</tr>
<tr>
<td>Mura, M.</td>
<td>23, 28, 76</td>
</tr>
<tr>
<td>Murphy, G.</td>
<td>99</td>
</tr>
<tr>
<td>Murthy, H.</td>
<td>86</td>
</tr>
<tr>
<td>Mushtaq, B.</td>
<td>49</td>
</tr>
<tr>
<td>Nahen, K.</td>
<td>76</td>
</tr>
<tr>
<td>Nakamura, Y.</td>
<td>95</td>
</tr>
<tr>
<td>Nam, K.</td>
<td>69</td>
</tr>
<tr>
<td>Narayanan, R.</td>
<td>86</td>
</tr>
<tr>
<td>Nariai, Y.</td>
<td>56</td>
</tr>
<tr>
<td>Nasserallah, J.</td>
<td>99</td>
</tr>
<tr>
<td>Natarajan, S.</td>
<td>86, 96</td>
</tr>
<tr>
<td>Navase, H.</td>
<td>33</td>
</tr>
<tr>
<td>Neri, P.</td>
<td>12</td>
</tr>
<tr>
<td>Nguyen, Q.</td>
<td>157</td>
</tr>
<tr>
<td>Nguyen, T.</td>
<td>32</td>
</tr>
<tr>
<td>Ni Chen, S.</td>
<td>87</td>
</tr>
<tr>
<td>Nikolakopolous, A.</td>
<td>28, 76, 85</td>
</tr>
<tr>
<td>Nikolakopolous, K.</td>
<td>85</td>
</tr>
<tr>
<td>Nikolakopulos, T.</td>
<td>96</td>
</tr>
<tr>
<td>Noma, H.</td>
<td>33</td>
</tr>
<tr>
<td>Nourinia, R.</td>
<td>44</td>
</tr>
<tr>
<td>Numa, S.</td>
<td>68</td>
</tr>
<tr>
<td>Ocampo, H.</td>
<td>45, 95</td>
</tr>
<tr>
<td>O’Day, R.</td>
<td>106</td>
</tr>
<tr>
<td>Ogura, Y.</td>
<td>2, 73, 86, 102</td>
</tr>
<tr>
<td>Oh, J.</td>
<td>91</td>
</tr>
<tr>
<td>Ohji, M.</td>
<td>67, 84</td>
</tr>
<tr>
<td>Ohno-Matsui, K.</td>
<td>73</td>
</tr>
<tr>
<td>Olea Vallejo, J.</td>
<td>143</td>
</tr>
<tr>
<td>Oliveira Lopez, B.</td>
<td>75</td>
</tr>
<tr>
<td>Oliveira, M.</td>
<td>66, 143</td>
</tr>
<tr>
<td>Ong, T.</td>
<td>32</td>
</tr>
<tr>
<td>Oruc Dundar, S.</td>
<td>21</td>
</tr>
<tr>
<td>Oshima, Y.</td>
<td>76</td>
</tr>
<tr>
<td>Otsuka, Y.</td>
<td>32</td>
</tr>
<tr>
<td>Otto, T.</td>
<td>63</td>
</tr>
<tr>
<td>Oubraham, H.</td>
<td>82</td>
</tr>
<tr>
<td>Ozdogan Erkul, S.</td>
<td>71</td>
</tr>
<tr>
<td>Ozturk, M.</td>
<td>95</td>
</tr>
<tr>
<td>Ozturk Oner, A.</td>
<td>107</td>
</tr>
<tr>
<td>Otake, H.</td>
<td>79</td>
</tr>
<tr>
<td>Otsuka, T.</td>
<td>79</td>
</tr>
<tr>
<td>Ocana, J.</td>
<td>49</td>
</tr>
<tr>
<td>O’Day, R.</td>
<td>106</td>
</tr>
<tr>
<td>Ogura, Y.</td>
<td>2, 73, 85</td>
</tr>
<tr>
<td>Oh, J.</td>
<td>91</td>
</tr>
<tr>
<td>Ohji, M.</td>
<td>67, 84</td>
</tr>
<tr>
<td>Ohno-Matsui, K.</td>
<td>73</td>
</tr>
<tr>
<td>Olea Vallejo, J.</td>
<td>143</td>
</tr>
<tr>
<td>Oliveira Lopez, B.</td>
<td>75</td>
</tr>
<tr>
<td>Oliveira, M.</td>
<td>66, 143</td>
</tr>
<tr>
<td>Ong, T.</td>
<td>32</td>
</tr>
<tr>
<td>Oruc Dundar, S.</td>
<td>21</td>
</tr>
<tr>
<td>Oshima, Y.</td>
<td>76</td>
</tr>
<tr>
<td>Otsuka, Y.</td>
<td>32</td>
</tr>
<tr>
<td>Otto, T.</td>
<td>63</td>
</tr>
<tr>
<td>Oubraham, H.</td>
<td>82</td>
</tr>
<tr>
<td>Ozdogan Erkul, S.</td>
<td>71</td>
</tr>
<tr>
<td>Ozturk, M.</td>
<td>95</td>
</tr>
<tr>
<td>Ozturk Oner, A.</td>
<td>107</td>
</tr>
</tbody>
</table>
S
Sabti, K. 28
Sacconi, R. 70
Sadda, S. 27, 30, 31, 58, 70
Sadeghipour, A. 74
Sagriiotis, A. 42
Sagong, M. 143
Sagoo, M. 13
Sahel, J. 20
Saidkasimova, S. 44, 55, 61, 90
Sakamoto, T. 86, 87
Sakemi Fukuhara, P. 34
Sallo, F. 101
Salvanos, P. 100
Sand Sivertsen, M. 66
Santos, A.R. 75
Sarao, V. 95
Sato, T. 73
Sauer, L. 66, 68
Sawamura, H. 27
Scanlon, P. 30
Scannell, O. 62
Scarpa, G. 33
Schalenbourg, A. 13
Schauf, F. 89
Schlingemann, R. 22, 36, 103
Schmetterer, L. 53
Schmidt-Erfurth, U. 2, 28, 36, 48, 58, 72, 74, 75, 82, 105
Schmidt, J. 18, 19
Schmitz-Valckenberg, S. 24
Scholl, H. 63
Schroeder, W. 28, 96
Schumann, R. 53
Schwartz, R. 68
Schwertz, S. 43
Schworm, B. 60
Seidel, J. 160
Seibel, I. 62
Sennlaub, F. 70
Sen, P. 23
Sen, Y. Yew. 83
Sepetis, A. 40
Seregard, S. 2, 13, 45, 58, 89
Seres, A. 30
Serhiienko, A. 73
Shain, A. 58
Shahabutdinova, P. 97
Sharma, S. 108
Sheta, S. 85, 97
Sheth, S. 41
Sheu, S.J. 84, 87
Shibuya, M. 99
Shinoda, K. 72
Shinojima, A. 32
Shpak, A. 90
Shroff, D. 143
Shulman, S. 41
Siedlecki, J. 37
Sieving, P. 20
Sigler, E. 33
Silva, R. 31
Simakurthy, S. 102
Sim, D. 26
Simunovic, M. 32, 54, 143
Singer, M. 95
Singh, D. 51
Singh, J. 51, 143
Singh Jhinja, A. 51
Sinim Kahraman, N. 32, 54
Sivaprasad, S. 31, 36, 55, 70, 74, 108
Smith, J. 78
Solberg, Y. 100
Song, J.H. 91
Sorour, O. 49
Soubbrane, G. 82
Soudri, S. 43
Souied, E. 15, 16, 43, 70, 95
Spaide, R. 57, 73, 83, 105
Spitzer, M. 23
Sporer, K. 30, 66
Stalmans, P. 50, 160
Stanga, P. 38, 104
Stathopoulos, C. 13
Staurenghi, G. 14, 22, 24, 31, 70, 74, 83, 90, 96, 101, 158, 159
Stavvakas, P. 62, 104
Steel, D. 20, 23, 29, 48, 50, 61
Stewart, J. 47
Stingl, K. 54
Stolba, U. 8
Stopa, M. 23
Strang, N. 29
Streho, M. 17
Strong, S. 54, 69
Subhi, Y. 68
Sudhakar, A. 18, 19
Sullivan, P. 24, 28, 49, 59
Sundaram, N. 28
Sun, M. 33
Szepessy, Z. 33
Szniitman, R. 28
Szurman, P. 55, 97

T
Tabuchi, H. 86
Tadayoni, R. 2, 22, 28, 43, 53, 57, 66, 73, 86, 88, 104, 105, 158, 159, 160
Takagi, H. 56
Takano, S. 136
Takeyama, A. 25
Ta Kim, D.T. 143
Taki, Y. 27
Talks, J. 74, 99
Tan, C. 16, 17, 42, 83
Tan, G. 29, 53, 100, 106
Tatyan, C. 72
Tawfik, M. 85
Taylan Sekeroglu, H. 71
Taylor, D. 60
Tedja, M. 57
Teo, K. 66, 83
Terasaki, H. 84
Terashima, H. 56
Terheyden, J. 52
Tetsumoto, A. 56
Theelen, T. 98
Thiadens, A. 67
Thiele, S. 102
Thoguluva, V. 107
Tian, M. 37
Ting, D. 53, 58, 26
Tognetto, D. 18, 19
Tranos, P. 29
Trier, S. 42, 72
Trifanenko, I. 27
Tsai, D.C. 87
Tsen, C. 27
Tsouris, D. 143
Tucker, W. 108
Tufail, A. 22, 24, 48, 57, 91, 96, 101
Tugal-Tutkun, I. 12
Tunc, M. 62
Turki, K. 143

U
Ucgun, N. 49
Uppuluri, A. 33
Uptadhuye, S. 143
Uzzan, J. 82
INDEX

V
Vadalà, M.  42
Vagge, A.  69
Valdez Lopez, J.  105
van Dijk, E.  47, 68
van Etten, P.G.  143
van Meurs, J.  2, 22, 51, 53
van Rijssen, T.  15
Van Schooneveld, M.  90
Van Willekens, K.  51
Vartsakis, G.  25
Vasquez, W.  143
Veckeneer, M.  20, 44,
Velasque, I.  71, 143
Velastegui, E.  88
Velis, G.  33, 52,
Verhoekx, J.  56, 60
Verhoeven, V.  67
Verma, L.  37, 77
Vieira, M.  75
Vieitez Vazquez, J.  143
Vigues Jorba, L.  62
Vingerling, H.  57
Viso, M.  143
Vounotrypidis, E.  60
Vujosevic, S.  15, 57
Vutipongsatorn, K.  107

W
Wang, J.  47
Wang, Y.  69
Westcott, M.  12
Wickham, L.  17, 61
Willerslev, A.  21
Williams, K.M.  36
Williamson, T.  104
Wintergerst, M.  105
Wolf, A.  107
Wolfensberger, T.  17, 77, 96, 103
Wolf, S.  2, 17, 28, 34, 57, 101
Wolf, S. F.  22
Wong, C.  100
Wong, C.W.  106

X
Xiong, S.  33

Y
Yang, C.H.  87
Yang, C.M.  87
Yang, H.  56
Yan, H.  96
Yarmak, V.  56
Yasukawa, T.  86
Y. Koyanagi  32
Yoganathan, P.  42
Yorston, D.  17, 20, 29, 44, 48, 61,
Young, S.  102
Young Shin, J.  91
Yudina, N.  73
Yu, S.  21
Yu, S.Y.  84
Yzer, S.  98, 104, 107

Z
Zainullin, R.  99
Zalmay, P.  75
Zambrowski, O.  43
Zarbin, M.  75, 88
Zarranz-Ventura, J.  143
Zhang, H.  60
Zhang, Z.  143
Zhao, M.  47
Zhong, J.  25
Ziccardi, L.  34
Zikernagel, M.  57, 77
Zografos, L.  13, 39, 45, 70, 82, 84
Zola, M.  67
Zolotaryev, A.  90
Zouache, M.  98, 102
Zur, D.  40
Zweifel, S.  21, 103
A bright vision on illumination

Directional Chandelier system delivers illumination where you need it.

Patent Pending

29G Spotlight Directional Chandelier

A new generation chandelier with major improvements in functionality and ease of use.

- Directional Chandelier system designed to enhance illumination control
- Wide view fiber tip for global endo-illumination
- Easy insertion and fixation of the fiber with 29G valved entry system
- 29G minimal invasive incision

Please visit our booth # 205 at Euretina in Paris
OZURDEX® (dexamethasone 700 micrograms intravitreal implant in applicator) AstraZeneca provides prophylactic corticosteroid therapy for the treatment of retinal vein occlusion (RVO) to reduce the risk of neovascularisation.

Warnings/Precautions:
Intravitreous injections, including OZURDEX can be associated with complications such as endophthalmitis, glaucoma, retinal detachment, cataract, and vitreous haemorrhage.

Contraindications:
Intraocular injections of OZURDEX are contraindicated in the following conditions:
- Known hypersensitivity to dexamethasone, local and systemic medications.
- Inflammation of the eye.
- Active ocular herpes simplex keratitis.
- Active ocular herpes zoster.
- History of allergy to the drug.

Interactions:
Corticosteroids may impair wound healing, may delay ocular hypertension, may delay corneal healing.

Dosage:
OZURDEX can be administered to either eye, either simultaneously or sequentially. The recommended dose is one OZURDEX implant to each eye not more than 7 days apart. The implant is not recommended for use in one eye after use of the implant in the opposite eye.

Administration:
Before administration, the implant should be removed from the applicator and placed in the orbit in the inferior temporal quadrant of the eye. The needle should be inserted just below the limbus, and the medication released slowly over 10-15 seconds. The needle should not be inserted more than 2 mm past the limbus.

Injection:
The recommended dose is one OZURDEX implant to each eye not more than 7 days apart. The implant is not recommended for use in one eye after use of the implant in the opposite eye.

Adverse Events:
Adverse reactions considered to be related to the intravitreous injection procedure rather than the dexamethasone implant. Please refer to Summary of Product Characteristics for full information on adverse effects. Basic MDR Price: £70 (for VII) per pack containing 1 implant. Marketing Authorisation Number: EU/1/10/638/001. Marketing Authorisation Holder: Allergan Pharmaceuticals Ireland, Caltibridge Road, Westport, Co. Mayo, Ireland. Legal Category: POM. Date of Preparation: May 2019. UK/0288/2019

Reference: 1. Kodjikian L et al. Biomol Res Int 2018;8249253. Produced and funded by Allergan. License and Registrations may vary by country, please consult your local SNCP. Date of preparation: July 2019. INT-0ZU-1950006